{"items": "671", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "GeminiBio Appoints Steven Sandoval, Sr. to its Board of Directors", "url": "https://www.prnewswire.com/news-releases/geminibio-appoints-steven-sandoval-sr-to-its-board-of-directors-302037950.html", "time_published": "20240118T140000", "authors": ["BelHealth Investment Partners"], "summary": "* Senior biopharma and cell therapy engineering/operations executive with 30+ years of experience to help drive growth", "banner_image": "https://mma.prnewswire.com/media/959545/BelHealth_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.335412, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.073546", "ticker_sentiment_score": "0.107281", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tech Futures Rally Ahead Of Jobless Claims", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-nvidia-stock-set-to-hit-more-record-highs/", "time_published": "20240118T132000", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall Ahead Of Jobless Claims. Nvidia Set To Hit More Record Highs Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.744043"}], "overall_sentiment_score": 0.047556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AA", "relevance_score": "0.12165", "ticker_sentiment_score": "0.057898", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.129355", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.081276", "ticker_sentiment_score": "0.062072", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.201356", "ticker_sentiment_score": "0.114075", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.16171", "ticker_sentiment_score": "0.170372", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.040691", "ticker_sentiment_score": "0.117875", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.16171", "ticker_sentiment_score": "0.135664", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.201356", "ticker_sentiment_score": "0.091275", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.040691", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.16171", "ticker_sentiment_score": "0.118043", "ticker_sentiment_label": "Neutral"}, {"ticker": "FAST", "relevance_score": "0.12165", "ticker_sentiment_score": "0.057898", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.16171", "ticker_sentiment_score": "0.111091", "ticker_sentiment_label": "Neutral"}, {"ticker": "KEY", "relevance_score": "0.12165", "ticker_sentiment_score": "0.057898", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Ascends While Market Falls: Some Facts to Note", "url": "https://www.zacks.com/stock/news/2211768/amgen-amgn-ascends-while-market-falls-some-facts-to-note", "time_published": "20240117T230017", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) closed the most recent trading day at $304.08, moving +0.2% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default74.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.158408, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.553265", "ticker_sentiment_score": "0.17929", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen Options Trading: A Deep Dive into Market Sentiment - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/24/01/36666528/amgen-options-trading-a-deep-dive-into-market-sentiment", "time_published": "20240117T193057", "authors": ["Benzinga Insights"], "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 18 unusual trades. Delving into the details, we found 27% of traders were bullish, while 72% showed bearish tendencies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.150094, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.708432", "ticker_sentiment_score": "0.023286", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Drop Ahead Of Retail Sales", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-retail-sales-tesla-stock-slides-on-more-price-cuts/", "time_published": "20240117T131700", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones futures sank along with other major indexes early Wednesday, as markets continued to slide after failing to gain their footing on Tuesday. Meanwhile, Tesla stock struggled below critical benchmarks after the company lowered prices on its Model Y electric vehicles in Germany.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.059572, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.17179", "ticker_sentiment_score": "0.162926", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MELI", "relevance_score": "0.2138", "ticker_sentiment_score": "0.213082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.043264", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBKR", "relevance_score": "0.129284", "ticker_sentiment_score": "0.072138", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.173677", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPOT", "relevance_score": "0.2138", "ticker_sentiment_score": "0.144712", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.17179", "ticker_sentiment_score": "0.174547", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.17179", "ticker_sentiment_score": "0.081006", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.129284", "ticker_sentiment_score": "0.072138", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.043264", "ticker_sentiment_score": "0.010972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.17179", "ticker_sentiment_score": "0.144019", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.17179", "ticker_sentiment_score": "0.185633", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/equities/24/01/36653786/cathie-woods-ark-invest-liquidates-15-8m-worth-of-proshares-bitcoin-strategy-etf-units", "time_published": "20240117T033939", "authors": ["Benzinga Neuro"], "summary": "On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF BITO units. This trade comes amidst a dynamic period in the cryptocurrency market, reflecting Ark Invest's strategic adjustments in response to evolving market ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/cathie-wood-bz-ark_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990786"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.243933, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CRSP", "relevance_score": "0.224903", "ticker_sentiment_score": "0.579686", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.301824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.224903", "ticker_sentiment_score": "0.28065", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.224903", "ticker_sentiment_score": "0.439433", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.746902", "ticker_sentiment_score": "0.207969", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Osteoporosis Drugs Market is Projected to Develop at a CAGR of 3.5% from 2023 to 2033 | Persistence Market Research", "url": "https://www.benzinga.com/pressreleases/24/01/g36635069/osteoporosis-drugs-market-is-projected-to-develop-at-a-cagr-of-3-5-from-2023-to-2033-persistence-m", "time_published": "20240116T080000", "authors": ["Globe Newswire"], "summary": "New York, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Market Overview: The Osteoporosis Drugs Market is a rapidly evolving sector within the pharmaceutical industry, primarily driven by the growing aging population and the increasing prevalence of osteoporosis worldwide.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.322946, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.021797", "ticker_sentiment_score": "0.022673", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.021797", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.021797", "ticker_sentiment_score": "0.230828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.021797", "ticker_sentiment_score": "0.044643", "ticker_sentiment_label": "Neutral"}]}, {"title": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick", "url": "https://www.zacks.com/stock/news/2210202/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick", "time_published": "20240115T145007", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default59.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.40067, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.556576", "ticker_sentiment_score": "0.257667", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know", "url": "https://www.zacks.com/stock/news/2210094/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know", "time_published": "20240115T140006", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default261.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.235173, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.486627", "ticker_sentiment_score": "0.143592", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond", "url": "https://www.fool.com/investing/2024/01/15/5-biotech-stocks-that-could-be-big-winners-in-2024/", "time_published": "20240115T113000", "authors": ["George Budwell"], "summary": "These five biotech companies could have a lot of room to run.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F761232%2Fbiotech-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.348088, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMVT", "relevance_score": "0.282234", "ticker_sentiment_score": "0.395991", "ticker_sentiment_label": "Bullish"}, {"ticker": "BGNE", "relevance_score": "0.143415", "ticker_sentiment_score": "0.336585", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARGX", "relevance_score": "0.213674", "ticker_sentiment_score": "0.060262", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.143415", "ticker_sentiment_score": "0.169678", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and AstraZeneca", "url": "https://www.zacks.com/stock/news/2209905/the-zacks-analyst-blog-highlights-eli-lilly-novo-nordisk-amgen-and-astrazeneca", "time_published": "20240115T105000", "authors": ["Zacks Investment Research"], "summary": "Eli Lilly, Novo Nordisk, Amgen and AstraZeneca are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e5/1416.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.094253, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.261117", "ticker_sentiment_score": "0.085906", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.261117", "ticker_sentiment_score": "0.040358", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.210274", "ticker_sentiment_score": "0.07059", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.053153", "ticker_sentiment_score": "0.149079", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.261117", "ticker_sentiment_score": "0.241559", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Vera Therapeutics Stock Soared by 22% This Week", "url": "https://www.fool.com/investing/2024/01/12/why-vera-therapeutics-stock-soared-by-22-this-week/", "time_published": "20240112T234415", "authors": ["Eric Volkman"], "summary": "Executive changes and a bullish analyst take combined to boost sentiment on the company.", "banner_image": "https://g.foolcdn.com/editorial/images/761177/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.213119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.146916", "ticker_sentiment_score": "-0.11025", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.146916", "ticker_sentiment_score": "0.242507", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.146916", "ticker_sentiment_score": "-0.059967", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERA", "relevance_score": "0.421485", "ticker_sentiment_score": "0.465416", "ticker_sentiment_label": "Bullish"}]}, {"title": "Futures Lower Ahead Of Key Inflation Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-inflation-data-tesla-stock-dives-despite-cathie-wood-buys/", "time_published": "20240112T131700", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Drop Ahead Of Inflation Data. Tesla Stock Dives Despite Cathie Wood Buys Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.038073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.144491", "ticker_sentiment_score": "0.152901", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.03631", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.10863", "ticker_sentiment_score": "0.209181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.10863", "ticker_sentiment_score": "0.209181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.10863", "ticker_sentiment_score": "0.209181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.180056", "ticker_sentiment_score": "0.148814", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.03631", "ticker_sentiment_score": "0.010849", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.180056", "ticker_sentiment_score": "0.125872", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.072545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.10863", "ticker_sentiment_score": "-0.15628", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MELI", "relevance_score": "0.144491", "ticker_sentiment_score": "0.147904", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.250019", "ticker_sentiment_score": "-0.123804", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.10863", "ticker_sentiment_score": "0.209181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.144491", "ticker_sentiment_score": "0.111375", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.144491", "ticker_sentiment_score": "0.141657", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Finds No Link Between Obesity Drugs and Suicidal Thoughts", "url": "https://www.zacks.com/stock/news/2209351/fda-finds-no-link-between-obesity-drugs-and-suicidal-thoughts", "time_published": "20240112T124700", "authors": ["Kinjel Shah"], "summary": "The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.101797, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.227007", "ticker_sentiment_score": "0.104048", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.227007", "ticker_sentiment_score": "0.056869", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.171282", "ticker_sentiment_score": "0.110461", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.05749", "ticker_sentiment_score": "0.149399", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.227007", "ticker_sentiment_score": "0.250732", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ozempic not linked to suicidal thoughts, FDA report finds", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/ozempic-not-linked-to-suicidal-thoughts-fda-report-finds/3363168/", "time_published": "20240112T111249", "authors": ["Bloomberg"], "summary": "US regulators found no link between weight-loss drugs like Novo Nordisk A/S's Ozempic and suicidal thoughts, a positive sign for the popular medications as similar reviews in Europe remain ongoing.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2024/01/pills-384846_1280.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.082165, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.121037", "ticker_sentiment_score": "0.025567", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.121037", "ticker_sentiment_score": "0.025567", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.121037", "ticker_sentiment_score": "-0.009974", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Suffers a Larger Drop Than the General Market: Key Insights", "url": "https://www.zacks.com/stock/news/2209160/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights", "time_published": "20240111T225022", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) reachead $303.10 at the closing of the latest trading day, reflecting a -0.48% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default3.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.265452, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.699089", "ticker_sentiment_score": "0.363878", "ticker_sentiment_label": "Bullish"}]}, {"title": "Al Gore is officially too old to serve on Apple's board | Business", "url": "https://www.cnn.com/2024/01/11/tech/al-gore-is-officially-too-old-for-apple/index.html", "time_published": "20240111T223300", "authors": ["Ramishah Maruf"], "summary": "Al Gore is officially too old to serve on Apple's board ...", "banner_image": "https://media.cnn.com/api/v1/images/stellar/prod/240111164844-al-gore-011723.jpg?c=16x9&q=w_800,c_fill", "source": "CNN", "category_within_source": "Markets", "source_domain": "www.cnn.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.136055, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.151539", "ticker_sentiment_score": "0.059806", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.151539", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/24/01/36594746/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lillys-dominance", "time_published": "20240111T164037", "authors": ["Vandana Singh"], "summary": "Pharmaceutical companies, including Amgen Inc AMGN and Pfizer Inc PFE, are strategically positioning themselves to tap into the burgeoning obesity market. The pursuit involves developing innovative drugs or engaging in strategic acquisitions to compete with established players such as Novo ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/aapharma_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.164763, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.228073", "ticker_sentiment_score": "0.084786", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.115232", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.33628", "ticker_sentiment_score": "0.252282", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.33628", "ticker_sentiment_score": "0.252282", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALT", "relevance_score": "0.228073", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.531326", "ticker_sentiment_score": "0.077283", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.43789", "ticker_sentiment_score": "0.185632", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Xeris  ( XERS )  Up on Licensing Deal With Amgen to Develop Tepezza", "url": "https://www.zacks.com/stock/news/2208740/xeris-xers-up-on-licensing-deal-with-amgen-to-develop-tepezza", "time_published": "20240111T133000", "authors": ["Zacks Equity Research"], "summary": "Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.224431, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADMA", "relevance_score": "0.377142", "ticker_sentiment_score": "0.210134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.377142", "ticker_sentiment_score": "0.350647", "ticker_sentiment_label": "Bullish"}, {"ticker": "PBYI", "relevance_score": "0.256989", "ticker_sentiment_score": "0.195759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XERS", "relevance_score": "0.194242", "ticker_sentiment_score": "0.20057", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures Rise Ahead Of Imminent CPI Inflation Report", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-cpi-inflation-report-nvidia-stock-set-to-hit-record-high/", "time_published": "20240111T132200", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones futures were slightly higher in premarket trades Thursday, as Wall Street braced for a critical inflation report from the Labor Department. Among individual stocks, Nvidia stock rallied and set to hit another record high, while crypto stock Coinbase ( COIN ) jumped on SEC approval for ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.143159, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KBH", "relevance_score": "0.124809", "ticker_sentiment_score": "-0.031077", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.165883", "ticker_sentiment_score": "0.213819", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.206509", "ticker_sentiment_score": "0.027872", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.041755", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.206509", "ticker_sentiment_score": "0.210346", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.165883", "ticker_sentiment_score": "0.230009", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.041755", "ticker_sentiment_score": "0.200708", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.206509", "ticker_sentiment_score": "0.139379", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.165883", "ticker_sentiment_score": "0.158303", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.124809", "ticker_sentiment_score": "0.078085", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.124809", "ticker_sentiment_score": "0.078085", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is The Market Feeling About Amgen? - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/24/01/36582492/how-is-the-market-feeling-about-amgen", "time_published": "20240110T193022", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has risen 11.84% since its last report. The company recently reported that it has 9.06 million shares sold short, which is 1.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.11 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures Mixed As CPI Inflation Data Looms", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-goldman-sachs-downgraded-bitcoin-stock-coinbase-slides/", "time_published": "20240110T131400", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall As Goldman Sachs Downgraded. Bitcoin Stock Coinbase Slides Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/08/WallStreetFinance2-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.143114, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.138265", "ticker_sentiment_score": "0.102157", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.206099", "ticker_sentiment_score": "0.088336", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.138265", "ticker_sentiment_score": "0.071156", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.069394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.069394", "ticker_sentiment_score": "0.188027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAC", "relevance_score": "0.069394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.069394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.172342", "ticker_sentiment_score": "0.184649", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMCI", "relevance_score": "0.069394", "ticker_sentiment_score": "0.188027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.138265", "ticker_sentiment_score": "-0.161588", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.03473", "ticker_sentiment_score": "0.115549", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.172342", "ticker_sentiment_score": "0.120675", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.103927", "ticker_sentiment_score": "-0.231723", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PSMT", "relevance_score": "0.103927", "ticker_sentiment_score": "0.12371", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBH", "relevance_score": "0.103927", "ticker_sentiment_score": "0.12371", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.138265", "ticker_sentiment_score": "0.071156", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.172342", "ticker_sentiment_score": "0.077385", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGH", "relevance_score": "0.103927", "ticker_sentiment_score": "0.12371", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.069394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.138265", "ticker_sentiment_score": "0.210256", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GCT", "relevance_score": "0.069394", "ticker_sentiment_score": "0.188027", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.138265", "ticker_sentiment_score": "0.172429", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.103927", "ticker_sentiment_score": "-0.231723", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference - Amgen  ( NASDAQ:AMGN ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/24/01/36572344/is-ai-more-valuable-in-advertising-than-healthcare-jim-cramer-questions-wall-streets-preference", "time_published": "20240110T110256", "authors": ["Benzinga Neuro"], "summary": "In a recent revelation, CNBC's Mad Money host Jim Cramer disclosed that the financial market values artificial intelligence ( AI ) technology more for advertising than for healthcare. What Happened: Cramer shared his insights while attending JPMorgan's healthcare conference, reported CNBC on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/jim-cramer-shutterstock_1.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.317128, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MDT", "relevance_score": "0.213048", "ticker_sentiment_score": "0.175148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.213048", "ticker_sentiment_score": "0.175148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.213048", "ticker_sentiment_score": "0.123315", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.107495", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.213048", "ticker_sentiment_score": "0.175148", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 - Ambrx Biopharma  ( NASDAQ:AMAM ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36558906/global-oncology-cancer-drugs-market-revenue-projected-to-surpass-289-billion-by-2030", "time_published": "20240109T152500", "authors": ["Globe Newswire"], "summary": "PALM BEACH, Fla., Jan. 09, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - According to the report titled \"Aging in the United States,\" published by the Population Reference Bureau, \"the number of Americans aged 65 and older is projected to increase more than double over 95 million ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.998947"}], "overall_sentiment_score": 0.103242, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DNPUF", "relevance_score": "0.019474", "ticker_sentiment_score": "0.086828", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKTX", "relevance_score": "0.077782", "ticker_sentiment_score": "-0.066051", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAM", "relevance_score": "0.077782", "ticker_sentiment_score": "-0.065019", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.019474", "ticker_sentiment_score": "0.086828", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.058377", "ticker_sentiment_score": "0.166162", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELEV", "relevance_score": "0.097141", "ticker_sentiment_score": "0.001107", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.038937", "ticker_sentiment_score": "0.095682", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.097141", "ticker_sentiment_score": "-0.069713", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLYC", "relevance_score": "0.019474", "ticker_sentiment_score": "0.133755", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/24/01/36558676/looking-at-amgens-recent-unusual-options-activity", "time_published": "20240109T151623", "authors": ["Benzinga Insights"], "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 35 unusual trades. Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.121226, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.742397", "ticker_sentiment_score": "0.078821", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Lower As Netflix Slides On Downgrade", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-netflix-slides-on-downgrade-nvidia-set-to-hit-more-record-highs/", "time_published": "20240109T131200", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Fall As Netflix Slides On Downgrade. Nvidia To Hit More Record Highs Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.125108, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.212115", "ticker_sentiment_score": "0.025517", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.246404", "ticker_sentiment_score": "0.120353", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.142355", "ticker_sentiment_score": "0.087329", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.142355", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.071463", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.071463", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.17741", "ticker_sentiment_score": "0.19543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEOG", "relevance_score": "0.107016", "ticker_sentiment_score": "-0.03966", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.035768", "ticker_sentiment_score": "0.115999", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.17741", "ticker_sentiment_score": "0.125977", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.142355", "ticker_sentiment_score": "0.087329", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYI", "relevance_score": "0.107016", "ticker_sentiment_score": "-0.03966", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.212115", "ticker_sentiment_score": "0.110013", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.071463", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.142355", "ticker_sentiment_score": "0.146672", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.142355", "ticker_sentiment_score": "0.219761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.142355", "ticker_sentiment_score": "0.140471", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Magnificent Seven Stocks Lead Market Rally", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-magnificent-seven-stocks-rally-nvidia-breaks-out-past-buy-point/", "time_published": "20240108T215500", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures: Magnificent Seven Stocks Rally. Nvidia Breaks Out Past Buy Point Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-Chip-glows-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.208919, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.115232", "ticker_sentiment_score": "0.155184", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.076971", "ticker_sentiment_score": "0.086006", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.153226", "ticker_sentiment_score": "0.122934", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.228073", "ticker_sentiment_score": "0.270391", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.153226", "ticker_sentiment_score": "0.202159", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.153226", "ticker_sentiment_score": "0.123387", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.228073", "ticker_sentiment_score": "0.154061", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.153226", "ticker_sentiment_score": "0.113992", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.076971", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.153226", "ticker_sentiment_score": "0.155683", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.115232", "ticker_sentiment_score": "0.220472", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.190868", "ticker_sentiment_score": "0.251625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.115232", "ticker_sentiment_score": "0.014102", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships", "url": "https://www.marketwatch.com/story/nvidia-dives-deeper-into-ai-drug-development-with-amgen-recursion-partnerships-de481c8b", "time_published": "20240108T180000", "authors": ["Eleanor Laise"], "summary": "Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.", "banner_image": "https://images.mktw.net/im-608401/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.106715, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.545493", "ticker_sentiment_score": "0.144731", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.132004", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.26042", "ticker_sentiment_score": "0.185456", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.132004", "ticker_sentiment_score": "0.105235", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.132004", "ticker_sentiment_score": "0.123084", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/24/01/36537225/investigating-amgens-standing-in-biotechnology-industry-compared-to-competitors", "time_published": "20240108T160038", "authors": ["Benzinga Insights"], "summary": "Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Amgen AMGN in comparison to its major ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.24958, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.480056", "ticker_sentiment_score": "0.175875", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures Mixed As Boeing Dives On Groundings", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-boeing-dives-on-groundings-coinbase-rallies-on-price-target-hike/", "time_published": "20240108T130900", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall As Boeing Dives On Groundings. Coinbase Rallies On Price Hike Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-WallStreet-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.119998, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.141935", "ticker_sentiment_score": "0.115667", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.245693", "ticker_sentiment_score": "0.107766", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.141935", "ticker_sentiment_score": "0.080304", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.071251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.071251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.071251", "ticker_sentiment_score": "0.214688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.071251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.141935", "ticker_sentiment_score": "0.225583", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.035661", "ticker_sentiment_score": "0.128652", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.035661", "ticker_sentiment_score": "0.115954", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.141935", "ticker_sentiment_score": "0.054607", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.141935", "ticker_sentiment_score": "-0.02624", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.071251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.071251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.106699", "ticker_sentiment_score": "0.070375", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.245693", "ticker_sentiment_score": "0.11348", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.071251", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.141935", "ticker_sentiment_score": "0.152618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.17689", "ticker_sentiment_score": "0.211943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.106699", "ticker_sentiment_score": "-0.085498", "ticker_sentiment_label": "Neutral"}]}, {"title": "SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference - SpringWorks Therapeutics  ( NASDAQ:SWTX ) ", "url": "https://www.benzinga.com/pressreleases/24/01/g36529625/springworks-therapeutics-highlights-2023-accomplishments-and-anticipated-milestones-for-2024-at-th", "time_published": "20240108T113044", "authors": ["Globe Newswire"], "summary": "STAMFORD, Conn., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. SWTX, a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT ( 10:30 a.m.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.174151, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.017394", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.017394", "ticker_sentiment_score": "0.002709", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.017394", "ticker_sentiment_score": "0.003569", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.03478", "ticker_sentiment_score": "-0.029057", "ticker_sentiment_label": "Neutral"}]}, {"title": "SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2024/01/08/2805220/0/en/SpringWorks-Therapeutics-Highlights-2023-Accomplishments-and-Anticipated-Milestones-for-2024-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html", "time_published": "20240108T113000", "authors": ["SpringWorks Therapeutics", "Inc."], "summary": "STAMFORD, Conn., Jan. 08, 2024 ( GLOBE NEWSWIRE ) -- SpringWorks Therapeutics, Inc. ( Nasdaq: SWTX ) , a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, will present today at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT ( 10:30 a.m.", "banner_image": "https://ml.globenewswire.com/Resource/Download/89f6acc3-0fc3-4af1-84a4-f5b95d218eb8", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.178849, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.017769", "ticker_sentiment_score": "0.053152", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.017769", "ticker_sentiment_score": "0.053152", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.035529", "ticker_sentiment_score": "0.058092", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dogs Of The Dow 2024: 10 Blue-Chip Dividend Payers", "url": "https://www.forbes.com/sites/brettowens/2024/01/07/dogs-of-the-dow-2024-10-blue-chip-dividend-payers/", "time_published": "20240107T121500", "authors": ["Brett Owens"], "summary": "The 2024 Dogs of the Dow are particularly homely hounds-which means we're talking big dividends. This year's Dogs yield more than three-times the broader market's paltry payout. So, should we hold our noses and buy? Let's grab some peanut butter treats and investigate.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/5e0e14c60bf81b00072e5836/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "n/a", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.882182"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.917436"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.195231, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CSCO", "relevance_score": "0.077156", "ticker_sentiment_score": "0.156862", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVX", "relevance_score": "0.115509", "ticker_sentiment_score": "0.073793", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.077156", "ticker_sentiment_score": "-0.095558", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.096361", "ticker_sentiment_score": "0.106898", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.096361", "ticker_sentiment_score": "0.003278", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.115509", "ticker_sentiment_score": "0.087575", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.057907", "ticker_sentiment_score": "0.155125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KVUE", "relevance_score": "0.038623", "ticker_sentiment_score": "0.1006", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPLK", "relevance_score": "0.038623", "ticker_sentiment_score": "0.25476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.038623", "ticker_sentiment_score": "0.068065", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.096361", "ticker_sentiment_score": "0.107227", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOW", "relevance_score": "0.038623", "ticker_sentiment_score": "0.106423", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2206572/amgen-amgn-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20240105T225019", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $303, denoting a -0.06% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default285.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.241483, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.700945", "ticker_sentiment_score": "0.383645", "ticker_sentiment_label": "Bullish"}]}, {"title": "JPMorgan Healthcare, CES Show, Bank Earnings, Inflation Data", "url": "https://www.investors.com/research/investing-action-plan/jpmorgan-healthcare-ces-show-bank-earnings-inflation-data-investing-action-plan/", "time_published": "20240105T222900", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The big benchmarks launched the New Year by posting their first weekly slip since October. The Dow trimmed less than 1% while the Nasdaq lopped off 3%. Chips faltered, but solar stocks and auto retailers were the hardest hit industries. Big Pharma names had a good week, as Merck ( MRK ) led the ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/07/Stock-marketgrowth-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.173993, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CELH", "relevance_score": "0.123526", "ticker_sentiment_score": "0.144722", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.123526", "ticker_sentiment_score": "0.144722", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDFC", "relevance_score": "0.123526", "ticker_sentiment_score": "0.013892", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.123526", "ticker_sentiment_score": "0.021094", "ticker_sentiment_label": "Neutral"}, {"ticker": "WIT", "relevance_score": "0.082535", "ticker_sentiment_score": "0.064744", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.164188", "ticker_sentiment_score": "0.1163", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.123526", "ticker_sentiment_score": "0.144722", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.123526", "ticker_sentiment_score": "0.021094", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.123526", "ticker_sentiment_score": "0.144722", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.082535", "ticker_sentiment_score": "0.018562", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.082535", "ticker_sentiment_score": "0.133922", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.082535", "ticker_sentiment_score": "0.018562", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBH", "relevance_score": "0.164188", "ticker_sentiment_score": "0.107238", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYI", "relevance_score": "0.123526", "ticker_sentiment_score": "0.091327", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.082535", "ticker_sentiment_score": "0.088799", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.164188", "ticker_sentiment_score": "0.024866", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.164188", "ticker_sentiment_score": "0.109444", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.082535", "ticker_sentiment_score": "0.088799", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.082535", "ticker_sentiment_score": "0.133922", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFY", "relevance_score": "0.082535", "ticker_sentiment_score": "0.064744", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRLCF", "relevance_score": "0.041323", "ticker_sentiment_score": "0.084607", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.082535", "ticker_sentiment_score": "0.088799", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/24/01/36516275/looking-at-amgens-recent-unusual-options-activity", "time_published": "20240105T194609", "authors": ["Benzinga Insights"], "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 20 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.125529, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.738815", "ticker_sentiment_score": "0.089758", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Stock Of The Day: The Buying Opportunity In Weight Loss", "url": "https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/", "time_published": "20240105T180100", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/SOTD-1-4-2024NVO.png", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}], "overall_sentiment_score": 0.130124, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.404098", "ticker_sentiment_score": "0.232614", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.350564", "ticker_sentiment_score": "0.141762", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.120431", "ticker_sentiment_score": "0.106572", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.120431", "ticker_sentiment_score": "0.032569", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.060388", "ticker_sentiment_score": "0.337437", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "It's Been An Abysmal Two Years. But Biotech Is Looking Up.", "url": "https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/", "time_published": "20240105T140000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/01/A1-010824-biotech-Gash.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.12567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.035679", "ticker_sentiment_score": "0.069333", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.035679", "ticker_sentiment_score": "0.037838", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.02379", "ticker_sentiment_score": "0.084592", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.09495", "ticker_sentiment_score": "0.150269", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.153696", "ticker_sentiment_score": "0.053027", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.02379", "ticker_sentiment_score": "0.006781", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.079056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.008781", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.001871", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.035679", "ticker_sentiment_score": "0.017905", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRX", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.02379", "ticker_sentiment_score": "0.057997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRCL", "relevance_score": "0.02379", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.020246", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.035679", "ticker_sentiment_score": "0.08972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.02379", "ticker_sentiment_score": "0.14181", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.011896", "ticker_sentiment_score": "-0.115274", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.02379", "ticker_sentiment_score": "0.067127", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.02379", "ticker_sentiment_score": "-0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.035679", "ticker_sentiment_score": "0.064761", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.059429", "ticker_sentiment_score": "0.106048", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall Ahead Of Imminent Jobs Report", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobs-report-ai-leader-palantir-dives-on-downgrade/", "time_published": "20240105T131500", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Stocks jeopardized their weekly winning streak Friday as Dow Jones futures and other major indexes fell Friday morning ahead of the Labor Department's pivotal December jobs report. Meanwhile, artificial intelligence leader Palantir Technologies ( AI ) tumbled on a PLTR stock analyst's downgrade.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.07923, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.101869", "ticker_sentiment_score": "0.027297", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.135538", "ticker_sentiment_score": "0.156142", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CELH", "relevance_score": "0.168963", "ticker_sentiment_score": "0.174777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.234846", "ticker_sentiment_score": "0.039966", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.135538", "ticker_sentiment_score": "0.030941", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.234846", "ticker_sentiment_score": "0.043689", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.135538", "ticker_sentiment_score": "0.070193", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.135538", "ticker_sentiment_score": "0.096049", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.168963", "ticker_sentiment_score": "0.202744", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.034039", "ticker_sentiment_score": "0.010787", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.135538", "ticker_sentiment_score": "0.182724", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLTR", "relevance_score": "0.068016", "ticker_sentiment_score": "-0.056409", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why the Market Dipped But Amgen  ( AMGN )  Gained Today", "url": "https://www.zacks.com/stock/news/2205955/why-the-market-dipped-but-amgen-amgn-gained-today", "time_published": "20240104T230018", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) reachead $303.17 at the closing of the latest trading day, reflecting a +0.82% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default99.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.206602, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.571903", "ticker_sentiment_score": "0.276725", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's How Much a $1000 Investment in Amgen Made 10 Years Ago Would Be Worth Today", "url": "https://www.zacks.com/stock/news/2205532/heres-how-much-a-1000-investment-in-amgen-made-10-years-ago-would-be-worth-today", "time_published": "20240104T133005", "authors": ["Zacks Equity Research"], "summary": "Holding on to popular or trending stocks for the long-term can make your portfolio a winner.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default100.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.207553, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.668028", "ticker_sentiment_score": "0.318064", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.", "url": "https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets", "time_published": "20240104T123000", "authors": ["Globe Newswire"], "summary": "Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets\u2122.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.287429, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IMNM", "relevance_score": "0.039745", "ticker_sentiment_score": "0.095935", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.158", "ticker_sentiment_score": "0.04959", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.079392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2204932/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20240103T140006", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.233026, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.487546", "ticker_sentiment_score": "0.14691", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall Ahead Of Fed Minutes", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-fed-minutes-coindesk-nvidia-tesla-slide/", "time_published": "20240103T131100", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones futures dropped Wednesday morning ahead of minutes from the Federal Reserve's latest policy meeting. Meanwhile, market leaders Coindesk ( COIN ) and Nvidia ( NVDA ) , along with Tesla stock, fell sharply in early morning trading.", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-02-gov.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.014384, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.172404", "ticker_sentiment_score": "0.064478", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.172404", "ticker_sentiment_score": "0.137962", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.29689", "ticker_sentiment_score": "-0.065662", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.29689", "ticker_sentiment_score": "-0.017705", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.086713", "ticker_sentiment_score": "0.220191", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.172404", "ticker_sentiment_score": "0.172192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.214557", "ticker_sentiment_score": "0.136461", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.043421", "ticker_sentiment_score": "-0.093008", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.043421", "ticker_sentiment_score": "0.010974", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.172404", "ticker_sentiment_score": "0.127417", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2204768/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20240103T112007", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999994"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.279971, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.230782", "ticker_sentiment_score": "0.218856", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.116631", "ticker_sentiment_score": "0.066983", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2204769/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar", "time_published": "20240103T112006", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default326.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.237792, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.061631", "ticker_sentiment_score": "0.111021", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKG", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "STX", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall As Apple Slides On Downgrade", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-apple-stock-slides-on-downgrade-tesla-deliveries/", "time_published": "20240102T132100", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall 200 Points As Apple Slides On Downgrade. Tesla Deliveries Imminent Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.083282, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CALM", "relevance_score": "0.077719", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.192694", "ticker_sentiment_score": "0.068294", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.154703", "ticker_sentiment_score": "0.120018", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.038906", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.116348", "ticker_sentiment_score": "-0.07792", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.154703", "ticker_sentiment_score": "0.120635", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.038906", "ticker_sentiment_score": "0.008909", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.154703", "ticker_sentiment_score": "0.07912", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.038906", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.077719", "ticker_sentiment_score": "-0.148149", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.267245", "ticker_sentiment_score": "-0.023886", "ticker_sentiment_label": "Neutral"}, {"ticker": "V", "relevance_score": "0.154703", "ticker_sentiment_score": "0.160497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.154703", "ticker_sentiment_score": "0.211111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.077719", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.038906", "ticker_sentiment_score": "-0.079072", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar", "url": "https://www.fool.com/investing/2024/01/01/3-top-etfs-im-planning-to-buy-hand-over-fist-in-20/", "time_published": "20240101T111700", "authors": ["CFP\u00ae", "Matthew Frankel"], "summary": "I'm adding some ETFs to my retirement portfolio in 2024. here are the three I'm starting with.", "banner_image": "https://g.foolcdn.com/editorial/images/759690/stock-trader-2022.jpg", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.341417, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVGO", "relevance_score": "0.114682", "ticker_sentiment_score": "0.006707", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMT", "relevance_score": "0.114682", "ticker_sentiment_score": "0.089924", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCI", "relevance_score": "0.114682", "ticker_sentiment_score": "0.089924", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLD", "relevance_score": "0.114682", "ticker_sentiment_score": "0.089924", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.114682", "ticker_sentiment_score": "0.006707", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.114682", "ticker_sentiment_score": "0.006707", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.114682", "ticker_sentiment_score": "0.006707", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Stock Moves -0.15%: What You Should Know", "url": "https://www.zacks.com/stock/news/2203905/amgen-amgn-stock-moves--015-what-you-should-know", "time_published": "20231229T225020", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Amgen (AMGN) settling at $288.02, representing a -0.15% change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default19.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.163263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.588876", "ticker_sentiment_score": "0.182616", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "There Are Only 5 Dow Stocks I Wouldn't Buy in 2024", "url": "https://www.fool.com/investing/2023/12/29/there-are-only-5-dow-stocks-i-wouldnt-buy-in-2024/", "time_published": "20231229T150000", "authors": ["Daniel Foelber"], "summary": "There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F759306%2Fgettyimages-1413763041-1200x800-5b2df79.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999982"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.279781, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.23907", "ticker_sentiment_score": "0.182253", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSCO", "relevance_score": "0.144853", "ticker_sentiment_score": "0.061692", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.048523", "ticker_sentiment_score": "-0.087695", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.048523", "ticker_sentiment_score": "-0.087695", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.19231", "ticker_sentiment_score": "0.149396", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.048523", "ticker_sentiment_score": "0.088087", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMI", "relevance_score": "0.096866", "ticker_sentiment_score": "0.180141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.144853", "ticker_sentiment_score": "-0.064554", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.048523", "ticker_sentiment_score": "-0.087695", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.144853", "ticker_sentiment_score": "0.05482", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.144853", "ticker_sentiment_score": "0.025319", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.144853", "ticker_sentiment_score": "0.156924", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PG", "relevance_score": "0.048523", "ticker_sentiment_score": "-0.087695", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.096866", "ticker_sentiment_score": "0.005339", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPS", "relevance_score": "0.096866", "ticker_sentiment_score": "0.180141", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HD", "relevance_score": "0.048523", "ticker_sentiment_score": "0.129934", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.048523", "ticker_sentiment_score": "-0.087695", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Dip Ahead Of Final Session Of 2023", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-final-trading-session-of-2023-nvidia-rises-on-new-chip-for-china/", "time_published": "20231229T131800", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones futures took a dip along with other major indexes Friday morning as investors headed into the final trading session of 2023. But Nvidia battled the market tide and climbed after launching a gaming chip for China that will comply with U.S. export restrictions.", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.085022, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.046095", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.227432", "ticker_sentiment_score": "0.119238", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.182851", "ticker_sentiment_score": "0.133155", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.227432", "ticker_sentiment_score": "-0.039225", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.046095", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.182851", "ticker_sentiment_score": "0.264117", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.182851", "ticker_sentiment_score": "0.13872", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.092036", "ticker_sentiment_score": "0.222872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.046095", "ticker_sentiment_score": "0.10353", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.182851", "ticker_sentiment_score": "0.068266", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Sees Relative Strength Rating Improve To 74", "url": "https://www.investors.com/ibd-data-stories/amgen-sees-relative-strength-rating-improve-to-74/", "time_published": "20231229T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Amgen ( AMGN ) saw a positive improvement to its Relative Strength ( RS ) Rating on Friday, with an upgrade from 69 to 74. X When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.170425, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPRX", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.654522", "ticker_sentiment_score": "0.026115", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Near Record High As These 3 Dow Stocks Test Buy Points", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-sp-500-near-record-high-as-these-3-dow-components-test-buy-points/", "time_published": "20231228T200800", "authors": ["JUAN CARLOS ARANCIBIA", "Investor's Business Daily"], "summary": "The S&P 500 climbed within inches of a record high Thursday afternoon, as the stock market rose moderately but small caps broke a trend of outperformance. The S&P 500 climbed 0.2% to 4,791, leaving the index within 27 points of its prior record high 4,818, reached nearly two years ago.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-ChristmasTree-NYSE-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.052354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MARA", "relevance_score": "0.126119", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRA", "relevance_score": "0.188193", "ticker_sentiment_score": "0.12317", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.126119", "ticker_sentiment_score": "0.136737", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.063258", "ticker_sentiment_score": "-0.104416", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEO", "relevance_score": "0.188193", "ticker_sentiment_score": "-0.045948", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.123681", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.126119", "ticker_sentiment_score": "-0.123681", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's Options: A Look at What the Big Money is Thinking - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/12/36415244/amgens-options-a-look-at-what-the-big-money-is-thinking", "time_published": "20231228T174615", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.183685, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.666827", "ticker_sentiment_score": "0.188316", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Market Rally Continues; Dow Jones Hits Another Record High", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-keeps-continues-dow-jones-hits-another-record-high/", "time_published": "20231228T154900", "authors": ["KIMBERLEY KOENIG", "Investor's Business Daily"], "summary": "Stock Market Rally Continues. Dow Jones Hits Another Record High Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-bull-100-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.225469, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.212425", "ticker_sentiment_score": "0.238818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.142565", "ticker_sentiment_score": "0.141832", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.07157", "ticker_sentiment_score": "0.136899", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.142565", "ticker_sentiment_score": "-0.144126", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.142565", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data", "url": "https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmys-krtx-and-ryzb-acquisition-cytk-surges-on-study-data", "time_published": "20231228T133900", "authors": ["Ekta Bagri"], "summary": "Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/57/40404.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.189775, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KRTX", "relevance_score": "0.085324", "ticker_sentiment_score": "0.12637", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.127682", "ticker_sentiment_score": "0.205625", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CYTK", "relevance_score": "0.169676", "ticker_sentiment_score": "0.127713", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.127682", "ticker_sentiment_score": "0.112789", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.169676", "ticker_sentiment_score": "0.100268", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Mixed Ahead Of Jobless Claims", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-jobless-claims-cathie-wood-shakes-up-bitcoin-positions/", "time_published": "20231228T131600", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Fall Ahead Of Jobless Claims. Cathie Wood Shakes Up Bitcoin Positions Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.161963, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.168197", "ticker_sentiment_score": "0.115969", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.042346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.042346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.168197", "ticker_sentiment_score": "0.175275", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.168197", "ticker_sentiment_score": "0.119593", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.084572", "ticker_sentiment_score": "0.14144", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.209365", "ticker_sentiment_score": "0.127371", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.042346", "ticker_sentiment_score": "0.110498", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.168197", "ticker_sentiment_score": "0.140152", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.126561", "ticker_sentiment_score": "0.164746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.209365", "ticker_sentiment_score": "0.094649", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Surpasses Market Returns: Some Facts Worth Knowing", "url": "https://www.zacks.com/stock/news/2202891/amgen-amgn-surpasses-market-returns-some-facts-worth-knowing", "time_published": "20231227T230019", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $286.53, marking a +0.93% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default293.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.247479, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.531019", "ticker_sentiment_score": "0.320673", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FDA Rejects Amgen's  ( AMGN )  NDA Seeking Full Nod for Lumakras", "url": "https://www.zacks.com/stock/news/2202718/fda-rejects-amgens-amgn-nda-seeking-full-nod-for-lumakras", "time_published": "20231227T160900", "authors": ["Zacks Equity Research"], "summary": "Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.137035, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KRTX", "relevance_score": "0.067727", "ticker_sentiment_score": "0.034062", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYZB", "relevance_score": "0.067727", "ticker_sentiment_score": "0.034062", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.389889", "ticker_sentiment_score": "0.09105", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLPG", "relevance_score": "0.389889", "ticker_sentiment_score": "0.105513", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.201244", "ticker_sentiment_score": "0.183039", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Futures Dip After Nasdaq, S&P 500 Hit New Highs", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fed-manufacturing-data-tesla-stock-retakes-buy-point/", "time_published": "20231227T131100", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Dip Ahead Of Fed Data. Tesla Stock Retakes Buy Point Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/10/stock-wall-street-flags-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.106022, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.17879", "ticker_sentiment_score": "0.121033", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.045054", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.222429", "ticker_sentiment_score": "0.067083", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.17879", "ticker_sentiment_score": "0.18431", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.17879", "ticker_sentiment_score": "0.079899", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.17879", "ticker_sentiment_score": "0.087259", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.222429", "ticker_sentiment_score": "0.084675", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.045054", "ticker_sentiment_score": "0.103294", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.17879", "ticker_sentiment_score": "0.118582", "ticker_sentiment_label": "Neutral"}]}, {"title": "Santa Claus Rally In Gear For Dow, Other Indexes; Tesla Eyes New Record To Wrap Up The Year", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-gains-after-economic-data-tesla-eyes-new-record/", "time_published": "20231226T160600", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Gains After Economic Data. Tesla Eyes New Record Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/stock-homeSales-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999606"}, {"topic": "Manufacturing", "relevance_score": "0.2"}], "overall_sentiment_score": 0.203709, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.167709", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRO", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.369773", "ticker_sentiment_label": "Bearish"}, {"ticker": "CVX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.124747", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.112269", "ticker_sentiment_score": "0.191551", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RYZB", "relevance_score": "0.167709", "ticker_sentiment_score": "0.23572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDB", "relevance_score": "0.167709", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.112269", "ticker_sentiment_score": "0.124747", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.112269", "ticker_sentiment_score": "0.124747", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.112269", "ticker_sentiment_score": "0.191551", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNK", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.369773", "ticker_sentiment_label": "Bearish"}, {"ticker": "DHT", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.369773", "ticker_sentiment_label": "Bearish"}, {"ticker": "TSLA", "relevance_score": "0.222327", "ticker_sentiment_score": "0.220284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.112269", "ticker_sentiment_score": "0.003614", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.167709", "ticker_sentiment_score": "0.137038", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.112269", "ticker_sentiment_score": "-0.056081", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.167709", "ticker_sentiment_score": "0.153994", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TK", "relevance_score": "0.056275", "ticker_sentiment_score": "-0.333032", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MIST", "relevance_score": "0.112269", "ticker_sentiment_score": "0.003614", "ticker_sentiment_label": "Neutral"}]}, {"title": "Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36385381/full-approval-for-amgens-flagship-cancer-drug-lumakras-pushed-for-around-four-years", "time_published": "20231226T154556", "authors": ["Vandana Singh"], "summary": "Amgen Inc AMGN announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug Lumakras ( sotorasib ) . In October, the FDA advisers voted 10-2, expressing doubts about relying on the primary goal of the late-stage ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/26/amgn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.145551, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.524949", "ticker_sentiment_score": "0.07983", "ticker_sentiment_label": "Neutral"}]}, {"title": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks", "url": "https://www.zacks.com/stock/news/2202153/how-to-maximize-your-retirement-portfolio-with-these-top-ranked-dividend-stocks", "time_published": "20231226T141003", "authors": ["Zacks Equity Research"], "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.165293, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.214937", "ticker_sentiment_score": "0.119267", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.054359", "ticker_sentiment_score": "-0.036003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Rise Ahead Of Key Economic Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-ahead-of-economic-data-google-stock-leads-eight-stocks-to-buy-and-watch/", "time_published": "20231226T132300", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Rise Ahead Of Economic Data. Google Leads 8 Stocks To Buy And Watch Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}], "overall_sentiment_score": 0.131381, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.154951", "ticker_sentiment_score": "0.065533", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.038969", "ticker_sentiment_score": "0.076911", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.038969", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.038969", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.154951", "ticker_sentiment_score": "0.215094", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.154951", "ticker_sentiment_score": "0.113334", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.154951", "ticker_sentiment_score": "0.081249", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.193001", "ticker_sentiment_score": "0.12133", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.038969", "ticker_sentiment_score": "0.109411", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.154951", "ticker_sentiment_score": "0.103117", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analyzing Amgen In Comparison To Competitors In Biotechnology Industry - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/12/36379308/analyzing-amgen-in-comparison-to-competitors-in-biotechnology-industry", "time_published": "20231225T160035", "authors": ["Benzinga Insights"], "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Amgen AMGN in comparison to its major competitors within the Biotechnology ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.17521, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.492659", "ticker_sentiment_score": "0.123018", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech stocks set for a rebound in 2024, analysts say", "url": "https://www.marketwatch.com/story/biotech-stocks-set-for-a-rebound-in-2024-analysts-say-24df6236", "time_published": "20231222T160600", "authors": ["Eleanor Laise"], "summary": "A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.", "banner_image": "https://images.mktw.net/im-15783720/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.133016, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.089129", "ticker_sentiment_score": "0.156557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRUS", "relevance_score": "0.089129", "ticker_sentiment_score": "0.080617", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IRON", "relevance_score": "0.089129", "ticker_sentiment_score": "0.033685", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.17715", "ticker_sentiment_score": "0.070894", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.009465", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.089129", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.089129", "ticker_sentiment_score": "0.203569", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.085373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LLY", "relevance_score": "0.089129", "ticker_sentiment_score": "0.111772", "ticker_sentiment_label": "Neutral"}, {"ticker": "BPMC", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.1576", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SGEN", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.008934", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rallies 100 Points Despite Nike Carnage; Warren Buffett News Lifts This Oil Giant", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-holds-up-well-despite-nike-carnage-occidental-petroleum-jumps-warren-buffett-news/", "time_published": "20231222T155200", "authors": ["KEN SHREVE", "Investor's Business Daily"], "summary": "Dow Jones Rallies 100 Points Despite Nike Carnage. Warren Buffett News Lifts This Oil Giant Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.992549"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.012115, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.122393", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.061514", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.056674", "ticker_sentiment_score": "0.05711", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.11007", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.168884", "ticker_sentiment_score": "0.082373", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRTX", "relevance_score": "0.113062", "ticker_sentiment_score": "0.181989", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKE", "relevance_score": "0.168884", "ticker_sentiment_score": "-0.153291", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.168884", "ticker_sentiment_score": "0.070989", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.113062", "ticker_sentiment_score": "0.014915", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.113062", "ticker_sentiment_score": "-0.149794", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTES", "relevance_score": "0.168884", "ticker_sentiment_score": "-0.186585", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "OXY", "relevance_score": "0.168884", "ticker_sentiment_score": "0.220442", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANSS", "relevance_score": "0.113062", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.113062", "ticker_sentiment_score": "0.130643", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALTR", "relevance_score": "0.168884", "ticker_sentiment_score": "0.082373", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know", "url": "https://www.zacks.com/stock/news/2201494/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know", "time_published": "20231222T140006", "authors": ["Zacks Equity Research"], "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default162.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.206352, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.483888", "ticker_sentiment_score": "0.119284", "ticker_sentiment_label": "Neutral"}]}, {"title": "Spotlight on Amgen: Analyzing the Surge in Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/12/36350619/spotlight-on-amgen-analyzing-the-surge-in-options-activity", "time_published": "20231221T193137", "authors": ["Benzinga Insights"], "summary": "Investors with a lot of money to spend have taken a bullish stance on Amgen AMGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.183816, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.653008", "ticker_sentiment_score": "0.186475", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2200881/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now", "time_published": "20231221T112006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default312.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.27378, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.116631", "ticker_sentiment_score": "0.055779", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.116631", "ticker_sentiment_score": "0.055779", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.174167", "ticker_sentiment_score": "0.245846", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.116631", "ticker_sentiment_score": "0.055779", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Amgen's Recent Short Interest - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/12/36331858/looking-into-amgens-recent-short-interest", "time_published": "20231220T190023", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has risen 19.69% since its last report. The company recently reported that it has 8.10 million shares sold short, which is 1.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?", "url": "https://www.marketwatch.com/story/five-obesity-drug-trends-to-watch-in-2024-who-can-compete-with-eli-lilly-and-novo-nordisk-1dc62a7d", "time_published": "20231220T161700", "authors": ["Eleanor Laise"], "summary": "The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.", "banner_image": "https://images.mktw.net/im-80508866/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.119145, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VKTX", "relevance_score": "0.043778", "ticker_sentiment_score": "0.087169", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.043778", "ticker_sentiment_score": "-0.046832", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.087424", "ticker_sentiment_score": "0.081911", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.237288", "ticker_sentiment_score": "0.153064", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALT", "relevance_score": "0.043778", "ticker_sentiment_score": "0.083222", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.043778", "ticker_sentiment_score": "-0.018675", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.021897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.043778", "ticker_sentiment_score": "0.200504", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.065625", "ticker_sentiment_score": "-0.017049", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income", "url": "https://www.zacks.com/stock/news/2200487/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income", "time_published": "20231220T141002", "authors": ["Zacks Equity Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default181.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.168409, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.207571", "ticker_sentiment_score": "0.116065", "ticker_sentiment_label": "Neutral"}, {"ticker": "FITB", "relevance_score": "0.207571", "ticker_sentiment_score": "0.116065", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can Dogs of the Dow ETFs Snap Losing Trend in 2024?", "url": "https://www.zacks.com/stock/news/2200407/can-dogs-of-the-dow-etfs-snap-losing-trend-in-2024", "time_published": "20231220T122700", "authors": ["Sanghamitra Saha"], "summary": "The Dogs of the Dow underperformed the broader market in 2023. However, with the Fed likely to cut rates in 2024, can these dividend dogs roar next year?", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/124.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.063294, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CSCO", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.147818", "ticker_sentiment_score": "0.172629", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KO", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.196212", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.051376", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.147818", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOW", "relevance_score": "0.098862", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36310979/amgen-provides-exposure-to-obesity-drug-at-a-reasonable-price-says-bullish-analyst", "time_published": "20231219T194229", "authors": ["Priya Nigam"], "summary": "Amgen, Inc. AMGN shares have been in focus amid developments in the AI-powered healthcare space. The company's oral and injectable metabolic pipeline gives investors exposure to the obesity metabolic space at a much lower premium than peers, according to BMO Capital Markets.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/19/amgen.shutterstock_1940887285.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.197283, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.928849", "ticker_sentiment_score": "0.338288", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday - Cara Therapeutics  ( NASDAQ:CARA ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/12/36300674/uber-to-rally-over-13-here-are-10-top-analyst-forecasts-for-tuesday", "time_published": "20231219T123023", "authors": ["Avi Kapoor"], "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler boosted Itron, Inc. ITRI price target from $72 to $91.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/19/uber_-logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.752319"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.070307, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ITRI", "relevance_score": "0.236588", "ticker_sentiment_score": "0.206068", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CARA", "relevance_score": "0.236588", "ticker_sentiment_score": "-0.111025", "ticker_sentiment_label": "Neutral"}, {"ticker": "MIRM", "relevance_score": "0.236588", "ticker_sentiment_score": "0.003808", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRON", "relevance_score": "0.236588", "ticker_sentiment_score": "-0.224731", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JPM", "relevance_score": "0.159043", "ticker_sentiment_score": "0.007", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.236588", "ticker_sentiment_score": "0.009418", "ticker_sentiment_label": "Neutral"}, {"ticker": "RUN", "relevance_score": "0.236588", "ticker_sentiment_score": "-0.013277", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTNR", "relevance_score": "0.236588", "ticker_sentiment_score": "0.10923", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.236588", "ticker_sentiment_score": "0.354882", "ticker_sentiment_label": "Bullish"}, {"ticker": "UBER", "relevance_score": "0.236588", "ticker_sentiment_score": "-0.036144", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOOR", "relevance_score": "0.236588", "ticker_sentiment_score": "0.003802", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Advances But Underperforms Market: Key Facts", "url": "https://www.zacks.com/stock/news/2199629/amgen-amgn-advances-but-underperforms-market-key-facts", "time_published": "20231218T225020", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default131.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.189637, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.587962", "ticker_sentiment_score": "0.31776", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Amgen Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/12/17/is-amgen-stock-a-buy-now/", "time_published": "20231217T140000", "authors": ["Prosper Junior Bakiny"], "summary": "Boring businesses can be successful, too.", "banner_image": "https://media.ycharts.com/charts/7cad83689ad7550ccb0480a680c774cc.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.316726"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.204173, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.539641", "ticker_sentiment_score": "0.261984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.053509", "ticker_sentiment_score": "0.028078", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Whales and Their Recent Bets on AMGN Options - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/12/36241553/market-whales-and-their-recent-bets-on-amgn-options", "time_published": "20231214T164601", "authors": ["Benzinga Insights"], "summary": "Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen AMGN revealed 13 unusual trades. Delving into the details, we found 15% of traders were bullish, while 84% showed bearish tendencies.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.093253, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.712214", "ticker_sentiment_score": "-0.077029", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income", "url": "https://www.zacks.com/stock/news/2197926/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income", "time_published": "20231214T141003", "authors": ["Zacks Equity Research"], "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default101.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.150672, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.211191", "ticker_sentiment_score": "0.117636", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.05339", "ticker_sentiment_score": "-0.036", "ticker_sentiment_label": "Neutral"}, {"ticker": "RHP", "relevance_score": "0.211191", "ticker_sentiment_score": "0.191594", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen's  ( AMGN )  Tarlatamab BLA Gets FDA Priority Tag for SCLC", "url": "https://www.zacks.com/stock/news/2197836/amgens-amgn-tarlatamab-bla-gets-fda-priority-tag-for-sclc", "time_published": "20231214T132400", "authors": ["Zacks Equity Research"], "summary": "Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99489"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.09988, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DERM", "relevance_score": "0.272788", "ticker_sentiment_score": "0.07359", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRDA", "relevance_score": "0.324495", "ticker_sentiment_score": "0.086847", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.324495", "ticker_sentiment_score": "0.088958", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.272788", "ticker_sentiment_score": "0.147381", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vertex  ( VRTX )  Soars 13.2%: Is Further Upside Left in the Stock?", "url": "https://www.zacks.com/stock/news/2197712/vertex-vrtx-soars-132-is-further-upside-left-in-the-stock", "time_published": "20231214T111200", "authors": ["Zacks Equity Research"], "summary": "Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.238921, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.272788", "ticker_sentiment_score": "0.286913", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Biotech Stock That Could Be the Next Amgen", "url": "https://www.fool.com/investing/2023/12/13/1-biotech-stock-that-could-be-the-next-amgen/", "time_published": "20231213T151500", "authors": ["George Budwell"], "summary": "The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F758114%2Finnovation.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.282248, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.147818", "ticker_sentiment_score": "0.199185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.358669", "ticker_sentiment_score": "0.261825", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Upgraded to Strong-Buy by StockNews.com", "url": "https://www.defenseworld.net/2023/12/13/amgen-nasdaqamgn-upgraded-to-strong-buy-by-stocknews-com.html", "time_published": "20231213T074251", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Amgen ( NASDAQ:AMGN - Free Report ) from a buy rating to a strong-buy rating in a report released on Tuesday morning. Several other equities analysts have also commented on the company. Barclays increased their target price on Amgen from $210.00 to $230.00 in a ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.264702, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JEF", "relevance_score": "0.042196", "ticker_sentiment_score": "0.09467", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.042196", "ticker_sentiment_score": "0.09467", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.042196", "ticker_sentiment_score": "0.09467", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.126119", "ticker_sentiment_score": "0.12312", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.042196", "ticker_sentiment_score": "0.09467", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2197055/amgen-amgn-outpaces-stock-market-gains-what-you-should-know", "time_published": "20231212T225014", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) reachead $273.99 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default209.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.230529, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.472338", "ticker_sentiment_score": "0.339581", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?", "url": "https://www.fool.com/investing/2023/12/12/better-growth-stock-viking-therapeutics-or-iovance/", "time_published": "20231212T134500", "authors": ["George Budwell"], "summary": "Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F757942%2Fgrowth-stock.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.143186, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.060388", "ticker_sentiment_score": "0.120006", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.120431", "ticker_sentiment_score": "0.050158", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.120431", "ticker_sentiment_score": "0.050158", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.060388", "ticker_sentiment_score": "0.17028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.060388", "ticker_sentiment_score": "0.120006", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.060388", "ticker_sentiment_score": "0.17028", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:GBP", "relevance_score": "0.060388", "ticker_sentiment_score": "-0.073154", "ticker_sentiment_label": "Neutral"}]}, {"title": "PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Airbnb  ( NASDAQ:ABNB ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ", "url": "https://www.benzinga.com/news/23/12/36194642/pvh-to-rally-around-11-here-are-10-top-analyst-forecasts-for-tuesday", "time_published": "20231212T130033", "authors": ["Avi Kapoor"], "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised Velocity Financial, Inc. VEL price target from $14 to $17. BTIG analyst Sarah Barcomb ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/12/pvh_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.229243, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.166743", "ticker_sentiment_score": "0.160207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PVH", "relevance_score": "0.247838", "ticker_sentiment_score": "0.317667", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.326283", "ticker_sentiment_score": "0.22211", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GPRO", "relevance_score": "0.247838", "ticker_sentiment_score": "0.130235", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.166743", "ticker_sentiment_score": "0.165079", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.247838", "ticker_sentiment_score": "-0.111999", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.247838", "ticker_sentiment_score": "0.115328", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.247838", "ticker_sentiment_score": "0.462995", "ticker_sentiment_label": "Bullish"}, {"ticker": "ACHV", "relevance_score": "0.247838", "ticker_sentiment_score": "0.003951", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMR", "relevance_score": "0.247838", "ticker_sentiment_score": "0.078763", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.166743", "ticker_sentiment_score": "0.085376", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.247838", "ticker_sentiment_score": "0.215256", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VEL", "relevance_score": "0.247838", "ticker_sentiment_score": "0.231395", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Sanofi drops rare disease drug purchase after FTC files suit", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/sanofi-drops-rare-disease-drug-purchase-after-ftc-files-suit/3336644/", "time_published": "20231212T111733", "authors": ["Bloomberg"], "summary": "Sanofi SA said Monday it was canceling plans to license Maze Therapeutics Inc.'s treatment for a rare genetic disorder after the Federal Trade Commission sued to block the deal. The French drugmaker said it was disappointed with the FTC's actions, which it said would hold up bringing Maze's drug ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/08/syring.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.065933, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.103951", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.601928", "ticker_sentiment_score": "-0.192002", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Insights Into Amgen's Performance Versus Peers In Biotechnology Sector - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/12/36179137/insights-into-amgens-performance-versus-peers-in-biotechnology-sector", "time_published": "20231211T160037", "authors": ["Benzinga Insights"], "summary": "In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Amgen AMGN in comparison to its major competitors within the Biotechnology ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.179561, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.480056", "ticker_sentiment_score": "0.093233", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Amgen  ( AMGN )  is a Strong Value Stock", "url": "https://www.zacks.com/stock/news/2196159/heres-why-amgen-amgn-is-a-strong-value-stock", "time_published": "20231211T144006", "authors": ["Zacks Equity Research"], "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default85.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.38156, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.400265", "ticker_sentiment_score": "0.236939", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here is What to Know Beyond Why Amgen Inc.  ( AMGN )  is a Trending Stock", "url": "https://www.zacks.com/stock/news/2196075/here-is-what-to-know-beyond-why-amgen-inc-amgn-is-a-trending-stock", "time_published": "20231211T140007", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default48.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.228278, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.48028", "ticker_sentiment_score": "0.145514", "ticker_sentiment_label": "Neutral"}]}, {"title": "Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights", "url": "https://www.prnewswire.com/news-releases/red-biotechnology-market-to-reach-1-513-22-billion-globally-by-2030-at-10-7-cagr-coherent-market-insights-302009313.html", "time_published": "20231208T071400", "authors": ["Coherent Market Insights"], "summary": "BURLINGAME, Calif., Dec. 8, 2023 /PRNewswire/ -- According to Coherent Market Insights, The global red biotechnology market was valued at US$ 742.80 Billion in 2023 and is forecast to reach a value of US$ 1,513.22 Billion by 2030 at a CAGR of 10.7% between 2023 and 2030.", "banner_image": "https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.196644, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.028833", "ticker_sentiment_score": "0.001897", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Registers a Bigger Fall Than the Market: Important Facts to Note", "url": "https://www.zacks.com/stock/news/2194481/amgen-amgn-registers-a-bigger-fall-than-the-market-important-facts-to-note", "time_published": "20231206T225015", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $269.35, marking a -0.56% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default14.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.158302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.523451", "ticker_sentiment_score": "0.107323", "ticker_sentiment_label": "Neutral"}]}, {"title": "P/E Ratio Insights for Amgen - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/12/36113823/pe-ratio-insights-for-amgen", "time_published": "20231206T144602", "authors": ["Benzinga Insights"], "summary": "In the current market session, Amgen Inc. AMGN price is at $271.31, after a 0.16% increase. However, over the past month, the stock decreased by 0.58%, and in the past year, by 4.86%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": -0.063556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.433523", "ticker_sentiment_score": "-0.005784", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/fallopian-tube-cancer-therapeutics-market-size-to-grow-by-usd-832-01-million-from-2023-2028-abbvie-inc-amgen-inc-arrien-pharmaceuticals-llc-and-more-among-the-key-companies-in-the-market---technavio-302006567.html", "time_published": "20231205T221500", "authors": [], "summary": "Fallopian Tube Cancer Therapeutics Market size to grow by USD 832.01 million from 2023-2028| AbbVie Inc., Amgen ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.026585, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.114956", "ticker_sentiment_score": "-0.045307", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMGN", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMHF", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVSQ", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Dividend Stocks to Maximize Your Retirement Income", "url": "https://www.zacks.com/stock/news/2192894/3-top-dividend-stocks-to-maximize-your-retirement-income", "time_published": "20231204T141004", "authors": ["Zacks Equity Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default271.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.298841, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.21258", "ticker_sentiment_score": "0.118241", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRBK", "relevance_score": "0.107255", "ticker_sentiment_score": "0.078038", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer  ( PFE )  Stock Down 5% as Obesity Drug Fails in Phase II", "url": "https://www.zacks.com/stock/news/2192689/pfizer-pfe-stock-down-5-as-obesity-drug-fails-in-phase-ii", "time_published": "20231204T103200", "authors": ["Zacks Equity Research"], "summary": "The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.127847, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.114137", "ticker_sentiment_score": "0.08737", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.170475", "ticker_sentiment_score": "0.109247", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.22595", "ticker_sentiment_score": "0.229561", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.333257", "ticker_sentiment_score": "-0.002375", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Diversified Portfolio Is Geared for Market-Beating Gains Over the Next 20 Years", "url": "https://www.fool.com/investing/2023/12/03/this-diversified-portfolio-is-geared-for-market-be/", "time_published": "20231203T153000", "authors": ["George Budwell"], "summary": "Modern portfolio theory is a helpful guide to choosing winning investments.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756898%2Fgrowth.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.714479"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.374721, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ACHR", "relevance_score": "0.096477", "ticker_sentiment_score": "0.092597", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.096477", "ticker_sentiment_score": "0.190224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PH", "relevance_score": "0.096477", "ticker_sentiment_score": "0.201939", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNC", "relevance_score": "0.096477", "ticker_sentiment_score": "0.201939", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSA", "relevance_score": "0.096477", "ticker_sentiment_score": "0.201939", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.096477", "ticker_sentiment_score": "0.190224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.096477", "ticker_sentiment_score": "0.201939", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/laryngeal-cancer-therapeutics-market-size-to-grow-by-usd-575-25-million-from-2022-2027-accord-healthcare-ltd-amgen-inc-astrazeneca-plc-athenex-inc-and-more-among-the-major-companies-in-the-market--technavio-302002789.html", "time_published": "20231201T223500", "authors": [], "summary": "Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.054932, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CLDX", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.132368", "ticker_sentiment_score": "-0.053456", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNXQ", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANL", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.066414", "ticker_sentiment_score": "-0.02104", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is BioMarin  ( BMRN )  Up 14.3% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2192385/why-is-biomarin-bmrn-up-143-since-last-earnings-report", "time_published": "20231201T163156", "authors": ["Zacks Equity Research"], "summary": "BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default197.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.106036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.048036", "ticker_sentiment_score": "0.176791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.190417", "ticker_sentiment_score": "0.053491", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2191965/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20231201T112006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.284941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061315", "ticker_sentiment_score": "0.071003", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122269", "ticker_sentiment_score": "0.068311", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Clears Technical Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/ibd-data-stories/amgen-clears-technical-benchmark-hitting-80-plus-rs-rating/", "time_published": "20231201T080000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "On Friday, Amgen ( AMGN ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 79 to 82. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.367522, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.762438", "ticker_sentiment_score": "0.579129", "ticker_sentiment_label": "Bullish"}, {"ticker": "IMGN", "relevance_score": "0.363388", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.363388", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html", "time_published": "20231201T073500", "authors": [], "summary": "Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.290604, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "GIC", "relevance_score": "0.048523", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.048523", "ticker_sentiment_score": "0.017903", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Amgen's Recent Short Interest - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/11/36028089/looking-into-amgens-recent-short-interest", "time_published": "20231130T170020", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has risen 5.83% since its last report. The company recently reported that it has 6.77 million shares sold short, which is 1.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.97 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( AMGN )  Up 2.2% Since Last Earnings Report: Can It Continue?", "url": "https://www.zacks.com/stock/news/2191630/amgen-amgn-up-22-since-last-earnings-report-can-it-continue", "time_published": "20231130T163055", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default240.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}, {"topic": "Earnings", "relevance_score": "0.999483"}], "overall_sentiment_score": 0.121309, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DCPH", "relevance_score": "0.092213", "ticker_sentiment_score": "0.019827", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.31482", "ticker_sentiment_score": "0.253954", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVS", "relevance_score": "0.023102", "ticker_sentiment_score": "0.01825", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software", "url": "https://www.zacks.com/stock/news/2191553/the-zacks-analyst-blog-highlights-mcdonalds-amgen-nextera-energy-general-mills-and-take-two-interactive-software", "time_published": "20231130T151600", "authors": ["Zacks Investment Research"], "summary": "McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9f/16064.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": 0.145367, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GIS", "relevance_score": "0.150592", "ticker_sentiment_score": "0.041782", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.150592", "ticker_sentiment_score": "0.041782", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.364987", "ticker_sentiment_score": "0.227421", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCD", "relevance_score": "0.22421", "ticker_sentiment_score": "0.055676", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEE", "relevance_score": "0.431065", "ticker_sentiment_score": "0.094803", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTWO", "relevance_score": "0.150592", "ticker_sentiment_score": "0.041782", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amazon  ( AMZN )  Teams Up With Amgen, Expands Customer Base", "url": "https://www.zacks.com/stock/news/2191357/amazon-amzn-teams-up-with-amgen-expands-customer-base", "time_published": "20231130T134400", "authors": ["Zacks Equity Research"], "summary": "Amazon's (AMZN) AWS gets selected by Amgen. This highlights the efficiency and reliability of AWS' innovative cloud products and services.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/a4/1882.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.209636, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.180685", "ticker_sentiment_score": "0.194723", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.180685", "ticker_sentiment_score": "0.120587", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKAHF", "relevance_score": "0.060694", "ticker_sentiment_score": "0.031113", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.060694", "ticker_sentiment_score": "0.098452", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.296582", "ticker_sentiment_score": "0.214205", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MUFG", "relevance_score": "0.180685", "ticker_sentiment_score": "0.147758", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.506832", "ticker_sentiment_score": "0.449705", "ticker_sentiment_label": "Bullish"}]}, {"title": "Top Stock Reports for McDonald's, Amgen & NextEra Energy", "url": "https://www.zacks.com/research-daily/2190730/top-stock-reports-for-mcdonalds-amgen-nextera-energy", "time_published": "20231129T195200", "authors": ["Sheraz Mian"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Amgen Inc. (AMGN) and NextEra Energy, Inc. (NEE).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default203.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.168495, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.213048", "ticker_sentiment_score": "0.25453", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEE", "relevance_score": "0.31482", "ticker_sentiment_score": "0.076941", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Trending Stock Amgen Inc.  ( AMGN )  a Buy Now?", "url": "https://www.zacks.com/stock/news/2190248/is-trending-stock-amgen-inc-amgn-a-buy-now", "time_published": "20231128T140005", "authors": ["Zacks Equity Research"], "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default252.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.217531, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.488469", "ticker_sentiment_score": "0.123059", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Spectacular Dividend Stock Every Investor Should Consider", "url": "https://www.fool.com/investing/2023/11/28/1-spectacular-dividend-stock-every-investor-should/", "time_published": "20231128T140000", "authors": ["George Budwell"], "summary": "This biotech pioneer has been an exceptional growth and income stock.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756238%2Fgrowth-graph.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.327923, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.405651", "ticker_sentiment_score": "0.406091", "ticker_sentiment_label": "Bullish"}]}, {"title": "This Stock Hasn't Split Since 1999 - $1,000 Invested Then Would Be Worth A Boatload Today", "url": "https://www.benzinga.com/general/23/11/35977573/this-stock-hasnt-split-since-1999-1-000-invested-then-would-be-worth-a-boatload-today", "time_published": "20231128T133617", "authors": ["Chris Bibey"], "summary": "When investing in the stock market, a history of strong returns should be high on your priority list. Combine this with a positive outlook on the future, and you may have a winner to add to your portfolio. Amgen Inc., an American multinational biopharmaceutical company, fits this mold.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Financial-Stock-Market-Numbers-And-City-_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.341614, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.112008", "ticker_sentiment_score": "0.068225", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?", "url": "https://www.zacks.com/stock/news/2190100/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp", "time_published": "20231128T112006", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default176.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.184982, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.129866", "ticker_sentiment_score": "0.063182", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.129866", "ticker_sentiment_score": "0.063182", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.256314", "ticker_sentiment_score": "0.095388", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.129866", "ticker_sentiment_score": "0.063182", "ticker_sentiment_label": "Neutral"}]}, {"title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks", "url": "https://www.zacks.com/stock/news/2189650/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks", "time_published": "20231127T141003", "authors": ["Zacks Equity Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default136.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.184204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.216376", "ticker_sentiment_score": "0.119894", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRBK", "relevance_score": "0.109206", "ticker_sentiment_score": "0.078512", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Rating Lowered to Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/11/25/amgen-nasdaqamgn-rating-lowered-to-buy-at-stocknews-com.html", "time_published": "20231125T071048", "authors": ["Defense World Staff"], "summary": "Amgen ( NASDAQ:AMGN - Get Free Report ) was downgraded by stock analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued on Thursday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.237967, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.040691", "ticker_sentiment_score": "0.017321", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.040691", "ticker_sentiment_score": "0.017321", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.040691", "ticker_sentiment_score": "0.071438", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.040691", "ticker_sentiment_score": "0.017321", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENV", "relevance_score": "0.081276", "ticker_sentiment_score": "0.175689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JBARF", "relevance_score": "0.081276", "ticker_sentiment_score": "0.175689", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.759392", "ticker_sentiment_score": "0.383184", "ticker_sentiment_label": "Bullish"}]}, {"title": "Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/11/35941406/investigating-amgens-standing-in-biotechnology-industry-compared-to-competitors", "time_published": "20231124T160016", "authors": ["Benzinga Insights"], "summary": "In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices. In this article, we will undertake a comprehensive industry comparison, evaluating Amgen AMGN vis-\u00e0-vis its key ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.257361, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.571381", "ticker_sentiment_score": "0.327785", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should Schwab U.S. Dividend Equity ETF  ( SCHD )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2188831/should-schwab-us-dividend-equity-etf-schd-be-on-your-investing-radar", "time_published": "20231124T112007", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default218.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.233542, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCHW", "relevance_score": "0.060541", "ticker_sentiment_score": "0.117007", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.120733", "ticker_sentiment_score": "0.067941", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.120733", "ticker_sentiment_score": "0.067941", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.120733", "ticker_sentiment_score": "0.067941", "ticker_sentiment_label": "Neutral"}]}, {"title": "P/E Ratio Insights for Amgen - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/11/35919857/pe-ratio-insights-for-amgen", "time_published": "20231122T161512", "authors": ["Benzinga Insights"], "summary": "In the current session, Amgen Inc. AMGN is trading at $262.34, after a 0.18% drop. Over the past month, the stock decreased by 3.61%, and in the past year, by 7.54%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.144495, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.364275", "ticker_sentiment_score": "-0.125831", "ticker_sentiment_label": "Neutral"}]}, {"title": "New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade", "url": "https://www.marketwatch.com/story/new-etf-invested-in-ozempic-maker-and-exposed-to-other-obesity-drugs-falls-in-first-day-of-trade-a489a9b0", "time_published": "20231122T130100", "authors": ["Christine Idzelis"], "summary": "The new Tema Cardiovascular and Metabolic ETF fell in its first day of trade. It is exposed to weight-loss drugs including Ozempic.", "banner_image": "https://images.mktw.net/im-75709773/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.297411, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.690822", "ticker_sentiment_score": "0.056772", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.690822", "ticker_sentiment_score": "0.056772", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.690822", "ticker_sentiment_score": "0.056772", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.388879", "ticker_sentiment_score": "0.04038", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income", "url": "https://www.zacks.com/stock/news/2186558/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income", "time_published": "20231120T141003", "authors": ["Zacks Equity Research"], "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default4.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.252575, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.215415", "ticker_sentiment_score": "0.119475", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRBK", "relevance_score": "0.108712", "ticker_sentiment_score": "0.07839", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBAN", "relevance_score": "0.215415", "ticker_sentiment_score": "0.124388", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2186419/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20231120T112007", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.159934, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.068112", "ticker_sentiment_score": "0.034069", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.135729", "ticker_sentiment_score": "0.071814", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know", "url": "https://www.zacks.com/stock/news/2185899/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know", "time_published": "20231117T140005", "authors": ["Zacks Equity Research"], "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default197.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.226698, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.488469", "ticker_sentiment_score": "0.083439", "ticker_sentiment_label": "Neutral"}]}, {"title": "The War In Alzheimer's Treatment Is Just Beginning", "url": "https://www.investors.com/news/technology/biotech-stocks-the-war-in-alzheimers-treatment-is-just-beginning-why-there-is-still-hope/", "time_published": "20231117T131500", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks: The Race For An Alzheimer's Cure Takes Off Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/A1jump2c-112023-1024x384.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.123012, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VAXX", "relevance_score": "0.067871", "ticker_sentiment_score": "-0.096986", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMB", "relevance_score": "0.033966", "ticker_sentiment_score": "-0.089096", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.067871", "ticker_sentiment_score": "0.189791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NHPEF", "relevance_score": "0.016987", "ticker_sentiment_score": "-0.009199", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.05093", "ticker_sentiment_score": "0.057996", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABOS", "relevance_score": "0.033966", "ticker_sentiment_score": "0.068935", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.05093", "ticker_sentiment_score": "-0.09242", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.135252", "ticker_sentiment_score": "0.103934", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033966", "ticker_sentiment_score": "-0.088133", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.21806", "ticker_sentiment_score": "0.140978", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is First Trust Dow 30 Equal Weight ETF  ( EDOW )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2185775/is-first-trust-dow-30-equal-weight-etf-edow-a-strong-etf-right-now", "time_published": "20231117T112006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default64.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999992"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.248038, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.11894", "ticker_sentiment_score": "0.060738", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.11894", "ticker_sentiment_score": "0.060738", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.11894", "ticker_sentiment_score": "0.060738", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: 3 Biotech Stocks Beating BioMarin Pharmaceutical  ( BMRN ) ", "url": "https://stocknews.com/news/amgn-vrtx-jazz-bmrn-3-biotech-stocks-beating-biomarin-pharmaceutical-bmrn/", "time_published": "20231116T134724", "authors": ["StockNews.com Staff"], "summary": "AMGN: 3 Biotech Stocks Beating BioMarin Pharmaceutical ...", "banner_image": "https://stocknews.com/wp-content/uploads/2021/11/Dipanjan-Banchur_headshots_3.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999967"}], "overall_sentiment_score": 0.255388, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.217834", "ticker_sentiment_score": "0.209854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.1372", "ticker_sentiment_score": "0.173495", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.244245", "ticker_sentiment_score": "0.246887", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.164282", "ticker_sentiment_score": "0.159799", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The Difficult-To-Express Proteins Market Is Expected To Grow At A Rate Of More Than 11% Through 2023-2027 As Per The Business Research Company's Difficult-To-Express Proteins Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/11/g35755379/the-difficult-to-express-proteins-market-is-expected-to-grow-at-a-rate-of-more-than-11-through-202", "time_published": "20231113T163000", "authors": ["Globe Newswire"], "summary": "LONDON, Nov. 13, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Difficult-To-Express Proteins Global Market Report 2023, the global difficult-to-express proteins market is set to experience significant growth, with a projected increase from $3.65 billion in 2022 to $4.11 ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.334442, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.065685", "ticker_sentiment_score": "0.166065", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TECH", "relevance_score": "0.065685", "ticker_sentiment_score": "0.159347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.065685", "ticker_sentiment_score": "0.159347", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Top Dividend Stocks to Maximize Your Retirement Income", "url": "https://www.zacks.com/stock/news/2183228/3-top-dividend-stocks-to-maximize-your-retirement-income", "time_published": "20231113T141004", "authors": ["Zacks Equity Research"], "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default332.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.209441, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.217346", "ticker_sentiment_score": "0.118668", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRBK", "relevance_score": "0.109705", "ticker_sentiment_score": "0.08083", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.054983", "ticker_sentiment_score": "0.044035", "ticker_sentiment_label": "Neutral"}]}, {"title": "IO Biotech Announces 2023 Third Quarter Results - IO Biotech  ( NASDAQ:IOBT ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35747830/io-biotech-announces-2023-third-quarter-results", "time_published": "20231113T131216", "authors": ["Globe Newswire"], "summary": "Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA\u00ae ( pembrolizumab ) , in patients with advanced melanoma", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.038109, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.025873", "ticker_sentiment_score": "-0.030459", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.254307", "ticker_sentiment_score": "0.019633", "ticker_sentiment_label": "Neutral"}, {"ticker": "KURA", "relevance_score": "0.025873", "ticker_sentiment_score": "-0.00548", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.025873", "ticker_sentiment_score": "-0.00548", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELVN", "relevance_score": "0.025873", "ticker_sentiment_score": "-0.00548", "ticker_sentiment_label": "Neutral"}]}, {"title": "IO Biotech Announces 2023 Third Quarter Results", "url": "https://www.globenewswire.com/news-release/2023/11/13/2779042/0/en/IO-Biotech-Announces-2023-Third-Quarter-Results.html", "time_published": "20231113T131200", "authors": ["IO Biotech"], "summary": "\u2022 Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA\u00ae ( pembrolizumab ) , in patients with advanced melanoma \u2022 Presented encouraging preliminary data from Phase 2 basket trial of IO102-IO103 at the IASLC 2023 ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/21813ca0-5b16-4fc8-94c7-b620f00bc20a", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.04053, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.026299", "ticker_sentiment_score": "0.00542", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.233307", "ticker_sentiment_score": "0.030976", "ticker_sentiment_label": "Neutral"}, {"ticker": "KURA", "relevance_score": "0.026299", "ticker_sentiment_score": "0.042", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.026299", "ticker_sentiment_score": "0.042", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELVN", "relevance_score": "0.026299", "ticker_sentiment_score": "0.042", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/11/35728436/investigating-amgens-standing-in-biotechnology-industry-compared-to-competitors", "time_published": "20231110T160014", "authors": ["Benzinga Insights"], "summary": "In today's rapidly changing and fiercely competitive business landscape, it is vital for investors and industry enthusiasts to carefully evaluate companies. In this article, we will perform a comprehensive industry comparison, evaluating Amgen AMGN against its key competitors in the Biotechnology ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.275268, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.500995", "ticker_sentiment_score": "0.238117", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Top Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/11/10/2-top-biotech-stocks-to-buy-right-now/", "time_published": "20231110T151500", "authors": ["Prosper Junior Bakiny"], "summary": "Don't give up on these stocks too fast.", "banner_image": "https://media.ycharts.com/charts/23bb3db224d5e90f0f2ad5eb3a2c68b0.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.186111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.380426", "ticker_sentiment_score": "0.253569", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.521812", "ticker_sentiment_score": "0.388976", "ticker_sentiment_label": "Bullish"}, {"ticker": "JNJ", "relevance_score": "0.05654", "ticker_sentiment_score": "0.084917", "ticker_sentiment_label": "Neutral"}]}, {"title": "Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research", "url": "https://www.prnewswire.com/news-releases/oncology-drugs-market-worth-520-billion-by-2033---exclusive-report-by-we-market-research-301984776.html", "time_published": "20231110T150100", "authors": ["We Market Research"], "summary": "CHICAGO, Nov. 10, 2023 /PRNewswire/ -- According to the latest findings from We Market Research, the oncology drug market is on track to achieve a value of USD 205 billion by the year 2023.", "banner_image": "https://mma.prnewswire.com/media/2267296/We_Market_Research_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.227297, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.081138", "ticker_sentiment_score": "0.083483", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040622", "ticker_sentiment_score": "0.029936", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.081138", "ticker_sentiment_score": "0.046543", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.040622", "ticker_sentiment_score": "0.059987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2182112/is-spdr-portfolio-sp-500-high-dividend-etf-spyd-a-strong-etf-right-now", "time_published": "20231110T112006", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default291.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999994"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.257004, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.057767", "ticker_sentiment_score": "0.078963", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.115232", "ticker_sentiment_score": "0.06109", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKG", "relevance_score": "0.115232", "ticker_sentiment_score": "0.06109", "ticker_sentiment_label": "Neutral"}, {"ticker": "STX", "relevance_score": "0.115232", "ticker_sentiment_score": "0.06109", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Dives As Powell Gives This Inflation Warning; Tesla Stock Gets Hammered", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-dives-as-fed-chair-jerome-powell-gives-this-inflation-warning-tesla-stock-gets-hammered-apple-stock-microsoft-stock/", "time_published": "20231109T202300", "authors": ["Investor's Business Daily", "MICHAEL LARKIN"], "summary": "Dow Jones Dives As Powell Gives This Inflation Warning. Tesla ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-03-gov.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.890401"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.967321"}], "overall_sentiment_score": -0.024365, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.041975", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.07293", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.12546", "ticker_sentiment_score": "-0.008742", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.166743", "ticker_sentiment_score": "-0.176527", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WWD", "relevance_score": "0.12546", "ticker_sentiment_score": "0.144554", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.12546", "ticker_sentiment_score": "-0.241261", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.12546", "ticker_sentiment_score": "-0.083747", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.166743", "ticker_sentiment_score": "-0.209552", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TDG", "relevance_score": "0.166743", "ticker_sentiment_score": "0.280583", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.233983", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HD", "relevance_score": "0.12546", "ticker_sentiment_score": "-0.241261", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JXNFL", "relevance_score": "0.083833", "ticker_sentiment_score": "0.019876", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRVL", "relevance_score": "0.083833", "ticker_sentiment_score": "-0.10929", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should First Trust Dow 30 Equal Weight ETF  ( EDOW )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2181404/should-first-trust-dow-30-equal-weight-etf-edow-be-on-your-investing-radar", "time_published": "20231109T112006", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default289.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.177476, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.130217", "ticker_sentiment_score": "0.070327", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.130217", "ticker_sentiment_score": "0.070327", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.130217", "ticker_sentiment_score": "0.070327", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sj\u00f6gren's Syndrome - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/11/35667804/amgens-rare-autoimmune-disease-candidate-shows-improvement-in-disease-burden-in-treating-sj-grens", "time_published": "20231108T164315", "authors": ["Vandana Singh"], "summary": "Amgen Inc AMGN released new data from its Phase 2 study of dazodalibep for Sj\u00f6gren's, a chronic ( long-lasting ) autoimmune disorder that happens when the immune system attacks the glands that make moisture in the eyes, mouth, and other parts of the body.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/08/amgn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.117707, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.2872", "ticker_sentiment_score": "-0.149925", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the Invesco Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2180608/should-you-invest-in-the-invesco-biotechnology-genome-etf-pbe", "time_published": "20231108T112004", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default262.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.175411, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.254973", "ticker_sentiment_score": "0.091126", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.129168", "ticker_sentiment_score": "0.070052", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio", "url": "https://www.zacks.com/stock/news/2180122/why-this-1-momentum-stock-could-be-a-great-addition-to-your-portfolio", "time_published": "20231107T145008", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default303.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.378675, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.195348", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks", "url": "https://www.zacks.com/stock/news/2179993/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks", "time_published": "20231107T141003", "authors": ["Zacks Equity Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.240695, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAT", "relevance_score": "0.206245", "ticker_sentiment_score": "0.185017", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.206245", "ticker_sentiment_score": "0.113906", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRX", "relevance_score": "0.206245", "ticker_sentiment_score": "0.188164", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Jones Up As Yields Spike; Berkshire Slumps As Warren Buffett Snaps Up These Assets", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-up-as-yields-spike-berkshire-slumps-as-warren-buffett-snaps-up-these-assets/", "time_published": "20231106T203300", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Up As Yields Spike. Berkshire Slumps As Warren Buffett ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/SMT-warrenbuffett3-110623-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.133333, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.114137", "ticker_sentiment_score": "0.288122", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.038162", "ticker_sentiment_score": "0.281024", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.076236", "ticker_sentiment_score": "0.290665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.076236", "ticker_sentiment_score": "0.290665", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.189076", "ticker_sentiment_score": "0.136807", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEG", "relevance_score": "0.076236", "ticker_sentiment_score": "0.261004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.114137", "ticker_sentiment_score": "0.114174", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.076236", "ticker_sentiment_score": "0.076805", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.189076", "ticker_sentiment_score": "0.058265", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.347", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MRNA", "relevance_score": "0.076236", "ticker_sentiment_score": "-0.121419", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.076236", "ticker_sentiment_score": "0.210969", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DELL", "relevance_score": "0.151778", "ticker_sentiment_score": "0.31566", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CWCO", "relevance_score": "0.114137", "ticker_sentiment_score": "0.170672", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman - and Martin Shkreli", "url": "https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a", "time_published": "20231106T203200", "authors": ["Eleanor Laise"], "summary": "Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades-the kind of drugs that should be cheap.", "banner_image": "https://images.mktw.net/im-871045?width=700&height=393", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.066744, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.055848", "ticker_sentiment_score": "-0.013012", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027941", "ticker_sentiment_score": "0.088489", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027941", "ticker_sentiment_score": "0.024774", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.027941", "ticker_sentiment_score": "0.088489", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.027941", "ticker_sentiment_score": "0.007658", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.041901", "ticker_sentiment_score": "0.007958", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.027941", "ticker_sentiment_score": "0.007658", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.027941", "ticker_sentiment_score": "0.007658", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.027941", "ticker_sentiment_score": "0.024774", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.027941", "ticker_sentiment_score": "-0.042172", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: November Buy Alert: 3 Biotech Stocks Making Gains", "url": "https://stocknews.com/news/amgn-inva-orgo-november-buy-alert-3-biotech-stocks-making-gains/", "time_published": "20231106T184115", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is well-positioned for steady growth, owing to rapid advancements in drug developments and the growing impact of chronic diseases.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.269705, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.278618", "ticker_sentiment_score": "0.29423", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INVA", "relevance_score": "0.244987", "ticker_sentiment_score": "0.331012", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORGO", "relevance_score": "0.141517", "ticker_sentiment_score": "0.274202", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2179089/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20231106T140006", "authors": ["Zacks Equity Research"], "summary": "Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default186.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.221961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.482982", "ticker_sentiment_score": "0.113008", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html", "time_published": "20231103T223500", "authors": [], "summary": "Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.217263, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GBIO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VYGR", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.148731", "ticker_sentiment_score": "0.045255", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Back In Force As Yields Plunge: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-back-in-force-as-treasury-yields-plunge-arista-palantir-are-winners/", "time_published": "20231103T165559", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally took off this past week as Treasury yields plunged on generally weak economic data and soothing words from Fed Chief Jerome Powell Nasdaq staged a follow-through day to confirm the market rally on Wednesday, with the S&P 500 and Dow Jones following through on Thursday.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-bullfightingbear-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999897"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.004916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.070882", "ticker_sentiment_score": "0.015254", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.070882", "ticker_sentiment_score": "-0.061816", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.040029", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.053192", "ticker_sentiment_score": "0.124905", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.053192", "ticker_sentiment_score": "0.078879", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.044243", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.352867", "ticker_sentiment_label": "Bearish"}, {"ticker": "ALGM", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.070882", "ticker_sentiment_score": "-0.040517", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.158635", "ticker_sentiment_score": "-0.062061", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRUS", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.044087", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.088537", "ticker_sentiment_score": "0.057142", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.053192", "ticker_sentiment_score": "0.078879", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.028361", "ticker_sentiment_label": "Neutral"}, {"ticker": "HMC", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.022873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.017742", "ticker_sentiment_score": "0.107", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.088537", "ticker_sentiment_score": "-0.014717", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.024925", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.106148", "ticker_sentiment_score": "-0.0443", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.017742", "ticker_sentiment_score": "-0.021613", "ticker_sentiment_label": "Neutral"}, {"ticker": "RELY", "relevance_score": "0.053192", "ticker_sentiment_score": "0.006008", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.035476", "ticker_sentiment_score": "0.147308", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.053192", "ticker_sentiment_score": "0.167262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.035476", "ticker_sentiment_score": "0.15563", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ORCL", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.001911", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBOE", "relevance_score": "0.035476", "ticker_sentiment_score": "0.13248", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.035476", "ticker_sentiment_score": "0.16532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCJ", "relevance_score": "0.088537", "ticker_sentiment_score": "0.001072", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.019707", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.035476", "ticker_sentiment_score": "0.16532", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ETSY", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.020024", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.136003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "TM", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.022873", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.053192", "ticker_sentiment_score": "-0.136003", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.035476", "ticker_sentiment_score": "0.11532", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.035476", "ticker_sentiment_score": "0.043443", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.035476", "ticker_sentiment_score": "-0.060946", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.017742", "ticker_sentiment_score": "-0.021613", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Wins Big With FDA, Analyst Sees Soaring Potential - Johnson & Johnson  ( NYSE:JNJ ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35571081/amgen-wins-big-with-fda-analyst-sees-soaring-potential", "time_published": "20231102T190103", "authors": ["Priya Nigam"], "summary": "The FDA approval of Amgen, Inc's AMGN biosimilar version of Johnson & Johnson's JNJ psoriasis treatment, Stelara, for multiple inflammatory diseases sent shares climbing in early trading on Thursday. Amgen has exhibited the ability \"to grow mid-cycle assets, despite underwhelming initial ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/02/amgen_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.270374, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.94121", "ticker_sentiment_score": "0.514615", "ticker_sentiment_label": "Bullish"}]}, {"title": "SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights", "url": "https://www.globenewswire.com/news-release/2023/11/02/2772053/0/en/SpringWorks-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Business-Highlights.html", "time_published": "20231102T103000", "authors": ["SpringWorks Therapeutics", "Inc."], "summary": "- PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/03870757-75d0-4869-a7a0-98e8d7ffbc21", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.118245, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.017862", "ticker_sentiment_score": "-0.000905", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.035714", "ticker_sentiment_score": "0.049302", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.017862", "ticker_sentiment_score": "0.044986", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.053549", "ticker_sentiment_score": "0.043991", "ticker_sentiment_label": "Neutral"}]}, {"title": "These Analysts Revise Their Forecasts On Amgen After Q3 Results - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35545825/these-analysts-revise-their-forecasts-on-amgen-after-q3-results", "time_published": "20231101T181832", "authors": ["Lisa Levin"], "summary": "Amgen Inc AMGN reported mixed third-quarter financial results. Amgen reported quarterly sales of $6.90 billion, slightly missing the consensus of $6.94 billion. Adjusted EPS increased 6% to $4.96, driven by increased revenues, beating the consensus of $4.66.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/amgen_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.095123, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.970877", "ticker_sentiment_score": "0.232021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.414559", "ticker_sentiment_score": "-0.256355", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income", "url": "https://www.zacks.com/stock/news/2176198/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income", "time_published": "20231101T131003", "authors": ["Zacks Equity Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default360.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.209201, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BRX", "relevance_score": "0.220809", "ticker_sentiment_score": "0.198287", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.055881", "ticker_sentiment_score": "-0.036014", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAT", "relevance_score": "0.220809", "ticker_sentiment_score": "0.194981", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.220809", "ticker_sentiment_score": "0.12016", "ticker_sentiment_label": "Neutral"}]}, {"title": "Company News for Nov 01, 2023", "url": "https://www.zacks.com/stock/news/2176192/company-news-for-nov-01-2023", "time_published": "20231101T120500", "authors": ["Zacks Equity Research"], "summary": "Companies In The Article Are: AMGN, NVDA, RGEN, COCO ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ec/8343.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.103963, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RGEN", "relevance_score": "0.582526", "ticker_sentiment_score": "0.602183", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVDA", "relevance_score": "0.582526", "ticker_sentiment_score": "-0.34945", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.582526", "ticker_sentiment_score": "-0.31296", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COCO", "relevance_score": "0.582526", "ticker_sentiment_score": "0.460374", "ticker_sentiment_label": "Bullish"}]}, {"title": "Should SPDR Portfolio S&P 500 High Dividend ETF  ( SPYD )  Be on Your Investing Radar?", "url": "https://www.zacks.com/stock/news/2176036/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar", "time_published": "20231101T102006", "authors": ["Zacks Equity Research"], "summary": "Style Box ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default232.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.235444, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.061631", "ticker_sentiment_score": "0.111021", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKG", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "STX", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "USFDA approves Amgen's biosimilar for multiple inflammatory diseases", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/usfda-approves-amgens-biosimilar-for-multiple-inflammatory-diseases/3293732/", "time_published": "20231101T075343", "authors": ["Sushmita Panda"], "summary": "The U.S. Food and Drug Administration ( USFDA ) on Wednesday approved Wezlana ( ustekinumab-auub ) as a biosimilar to and interchangeable with Stelara ( ustekinumab ) for multiple inflammatory diseases. The FDA granted the approval of Wezlana to Amgen, Inc.", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/11/pill-g3fe14fdf6_1920.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.098953, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.087503", "ticker_sentiment_score": "0.133526", "ticker_sentiment_label": "Neutral"}]}, {"title": "Fear & Greed Index Remains In 'Fear' Zone Ahead Of Fed's Decision - Caterpillar  ( NYSE:CAT ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/11/35529691/fear-greed-index-remains-in-fear-zone-ahead-of-feds-decision", "time_published": "20231101T061130", "authors": ["Lisa Levin"], "summary": "The CNN Money Fear and Greed index remained in the \"Fear\" zone on Tuesday. U.S. stocks closed higher on Tuesday, ahead of the Federal Reserve's monetary policy decision. The central bank is widely projected to keep interest rates unchanged on Wednesday. Data on jobs report for October will be ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/01/image22.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": -0.131451, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.232439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.232439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.232439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.232439", "ticker_sentiment_score": "0.01923", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.232439", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBD", "relevance_score": "0.117486", "ticker_sentiment_score": "-0.473673", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.232439", "ticker_sentiment_score": "0.01923", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen gets FDA approval for its inflammatory diseases treatment Wezlana", "url": "https://www.marketwatch.com/story/amgen-gets-fda-approval-for-inflammatory-diseases-treatment-d4d01c80", "time_published": "20231031T222200", "authors": ["Ben Glickman"], "summary": "Amgen has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.", "banner_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.080386, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.659096", "ticker_sentiment_score": "0.019039", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's stock hit by expectations its obesity pipeline is facing a longer wait", "url": "https://www.marketwatch.com/story/amgens-stock-jumps-premarket-after-earnings-beat-and-company-again-raises-guidance-d4015936", "time_published": "20231031T155900", "authors": ["Ciara Linnane"], "summary": "Amgen Inc.'s stock fell 3.3% Tuesday despite an earnings beat and raised guidance. Obesity drugs were to blame.", "banner_image": "https://images.mktw.net/im-814193/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.104098, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.146469", "ticker_sentiment_score": "0.114297", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.146469", "ticker_sentiment_score": "-0.199329", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.288044", "ticker_sentiment_score": "-0.031612", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.073546", "ticker_sentiment_score": "0.091052", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.146469", "ticker_sentiment_score": "0.114297", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Beats on Q3 Earnings Beat, Lags Sales, Ups View", "url": "https://www.zacks.com/stock/news/2175771/amgen-amgn-beats-on-q3-earnings-beat-lags-sales-ups-view", "time_published": "20231031T153000", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999813"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.074095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.07948", "ticker_sentiment_score": "0.095988", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.053035", "ticker_sentiment_score": "0.062929", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.334529", "ticker_sentiment_score": "0.181836", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.132077", "ticker_sentiment_score": "0.256652", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Amgen  ( AMGN )  Shares Are Trading Lower Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35514314/amgen-lifts-annual-outlook-after-q3-performance-but-stock-still-falls-heres-why", "time_published": "20231031T135536", "authors": ["Vandana Singh"], "summary": "Amgen Inc AMGN reported Q3 FY23 sales of $6.90 billion, slightly missing the consensus of $6.94 billion. Total revenues increased 4% Y/Y, resulting from a 5% increase in product sales.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/31/amgen-6391.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.065239, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.561184", "ticker_sentiment_score": "0.27822", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.301315", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Boosts Guidance, But Sales Of Its Biggest Blockbuster Lag", "url": "https://www.investors.com/news/technology/amgen-stock-amgen-earnings-q3-2023/", "time_published": "20231031T130528", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Amgen Stock Dips As Blockbuster Enbrel Lags. Boosts Outlook ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/08/stock-amgen-05-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.164144, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.904419", "ticker_sentiment_score": "0.354858", "ticker_sentiment_label": "Bullish"}]}, {"title": "Amgen  ( AMGN )  Q3 Earnings Top Estimates", "url": "https://www.zacks.com/stock/news/2175197/amgen-amgn-q3-earnings-top-estimates", "time_published": "20231031T122506", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) delivered earnings and revenue surprises of 6.67% and 0.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default190.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999997"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.148374, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.399204", "ticker_sentiment_score": "0.145279", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIP", "relevance_score": "0.206392", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Rise Ahead Of Key Housing Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-ahead-of-key-housing-data-tesla-stock-continues-to-slide/", "time_published": "20231031T122257", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures rose Tuesday morning, as Wall Street braces for the start of the Federal Reserve's two-day meeting. Meanwhile, Tesla stock continued to fall Tuesday, with solid losses, after Monday's dive below the 200 price level.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.169422, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.101154", "ticker_sentiment_score": "0.118205", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.13459", "ticker_sentiment_score": "0.133378", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.101154", "ticker_sentiment_score": "0.002219", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.067536", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSW", "relevance_score": "0.167787", "ticker_sentiment_score": "0.058684", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.033799", "ticker_sentiment_score": "0.107376", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.101154", "ticker_sentiment_score": "0.002219", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.067536", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.13459", "ticker_sentiment_score": "0.126703", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.13459", "ticker_sentiment_score": "0.133378", "ticker_sentiment_label": "Neutral"}, {"ticker": "LULU", "relevance_score": "0.101154", "ticker_sentiment_score": "0.093772", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.13459", "ticker_sentiment_score": "0.104528", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNW", "relevance_score": "0.167787", "ticker_sentiment_score": "0.134902", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.101154", "ticker_sentiment_score": "0.002219", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.101154", "ticker_sentiment_score": "0.002219", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.101154", "ticker_sentiment_score": "0.118205", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.200688", "ticker_sentiment_score": "0.127641", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. Stocks Poised To Extend Gains As Fed Meeting Gets Underway; Why This Analyst Expects 'Young Bull Market' To Remain Alive - Meritage Homes  ( NYSE:MTH ) , Arista Networks  ( NYSE:ANET ) , JetBlue Airways  ( NASDAQ:JBLU ) , Chesapeake Energy  ( NASDAQ:CHK ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35510696/u-s-stocks-poised-to-extend-gains-as-fed-meeting-gets-underway-why-this-analyst-expects-young-bull-", "time_published": "20231031T114444", "authors": ["Shanthi Rexaline"], "summary": "Early indications suggest U.S. stock could strive to retain the winning momentum intact, although key catalysts scheduled for the next couple of sessions could leave investors cautious. Some of the Smid-cap earnings have come in better than expected, triggering a strong upward move in the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stocks_Photo_by_Jirapong_Manustrong_on_Shutterstock_28.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.100096, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MTH", "relevance_score": "0.084423", "ticker_sentiment_score": "0.086021", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBLU", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIRI", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.042271", "ticker_sentiment_score": "0.147128", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BP", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BUD", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.084423", "ticker_sentiment_score": "0.086021", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.084423", "ticker_sentiment_score": "-0.383301", "ticker_sentiment_label": "Bearish"}, {"ticker": "UNM", "relevance_score": "0.084423", "ticker_sentiment_score": "0.086021", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.084423", "ticker_sentiment_score": "0.086021", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.042271", "ticker_sentiment_score": "0.162038", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LPLA", "relevance_score": "0.042271", "ticker_sentiment_score": "-0.192933", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WOLF", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.084423", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUMC", "relevance_score": "0.084423", "ticker_sentiment_score": "0.086021", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2175072/is-invesco-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20231031T102005", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default285.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999986"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.216666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.175433", "ticker_sentiment_score": "0.221938", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.117486", "ticker_sentiment_score": "0.060435", "ticker_sentiment_label": "Neutral"}]}, {"title": "Charlie Munger says not much 'low-hanging fruit left' as he discusses Apple, Costco vs. Walmart and EVs.", "url": "https://www.marketwatch.com/story/charlie-munger-says-not-much-low-hanging-fruit-left-as-he-discusses-apple-costco-vs-walmart-and-evs-105a3ff0", "time_published": "20231031T100400", "authors": ["Barbara Kollmeyer"], "summary": "Our call of the day comes from a podcast interview with the legendary Charlie Munger, who discusses a range of investing topics.", "banner_image": "https://images.mktw.net/im-878368?width=700&height=462", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999997"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.142676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.233837", "ticker_sentiment_score": "0.094219", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.136", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.029654", "ticker_sentiment_score": "-0.059073", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.059268", "ticker_sentiment_score": "0.102346", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITOCF", "relevance_score": "0.029654", "ticker_sentiment_score": "0.0647", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.040454", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.040454", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.044077", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.176502", "ticker_sentiment_score": "0.089471", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.040454", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.044077", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARUF", "relevance_score": "0.029654", "ticker_sentiment_score": "0.0647", "ticker_sentiment_label": "Neutral"}, {"ticker": "MITSF", "relevance_score": "0.029654", "ticker_sentiment_score": "0.0647", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.029654", "ticker_sentiment_score": "0.0647", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.040454", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.029654", "ticker_sentiment_score": "0.0647", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZR", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.040454", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOLF", "relevance_score": "0.059268", "ticker_sentiment_score": "-0.136", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.059268", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.118209", "ticker_sentiment_score": "0.029684", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.029654", "ticker_sentiment_score": "-0.008786", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 futures steady as lower Treasury yields support sentiment", "url": "https://www.marketwatch.com/story/s-p-500-futures-steady-as-lower-treasury-yields-support-sentiment-7e463e27", "time_published": "20231031T074900", "authors": ["Jamie Chisholm"], "summary": "U.S. stock futures were mildly mixed early Tuesday, holding most of the previous day's rally as Treasury yields moved lower.", "banner_image": "https://images.mktw.net/im-872378/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.062525, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SWQGF", "relevance_score": "0.098659", "ticker_sentiment_score": "0.075769", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZR", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYC", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.098659", "ticker_sentiment_score": "-0.042642", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cram Session: Week Ahead Packed with Earnings, Fed Meeting, Jobs Data as Markets Attempt Rebound - Apple  ( NASDAQ:AAPL ) ", "url": "https://www.benzinga.com/markets/23/10/35497918/cram-session-week-ahead-packed-with-earnings-fed-meeting-jobs-data-as-markets-attempt-rebound", "time_published": "20231030T182525", "authors": ["Schwab Center for Financial Research"], "summary": "( Monday market open ) This week offers something for everyone as Wall Street licks its wounds after Friday's plunge to fresh five-month lows. Major indexes bounced in premarket trading early Monday, helped by technical buying and a drop in crude oil prices, but remain squarely in correction mode ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/30/shutterstock_1016430565_11.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.047707, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.089378", "ticker_sentiment_score": "-0.005172", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.04476", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.089378", "ticker_sentiment_score": "-0.005172", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.089378", "ticker_sentiment_score": "-0.005172", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.133717", "ticker_sentiment_score": "0.028904", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.089378", "ticker_sentiment_score": "0.050195", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.04476", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.089378", "ticker_sentiment_score": "-0.005172", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.04476", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.089378", "ticker_sentiment_score": "0.024916", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.089378", "ticker_sentiment_score": "0.024916", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.04476", "ticker_sentiment_score": "-0.099261", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.04476", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.04476", "ticker_sentiment_score": "-0.008837", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.089378", "ticker_sentiment_score": "-0.005172", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.089378", "ticker_sentiment_score": "0.024916", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.089378", "ticker_sentiment_score": "0.024916", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.022389", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.155738", "ticker_sentiment_score": "0.157643", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NUE", "relevance_score": "0.04476", "ticker_sentiment_score": "0.097281", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.022389", "ticker_sentiment_score": "-0.021317", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drug, Biotech Stocks' Q3 Earnings Due on Oct 31: AMGN, PFE, INCY", "url": "https://www.zacks.com/stock/news/2174650/drug-biotech-stocks-q3-earnings-due-on-oct-31-amgn-pfe-incy", "time_published": "20231030T153700", "authors": ["Zacks Equity Research"], "summary": "Let's take a look at three biotech/drug companies, AMGN, PFE and INCY, slated to release quarterly results on Oct 31.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/12/31139.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.142261, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.388879", "ticker_sentiment_score": "0.136578", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.050679", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.297061", "ticker_sentiment_score": "0.089505", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.474958", "ticker_sentiment_score": "0.283441", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.050679", "ticker_sentiment_score": "-0.162331", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNY", "relevance_score": "0.050679", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: Amgen  ( AMGN )  Earnings Watch: Buy or Sell?", "url": "https://stocknews.com/news/amgn-gild-jazz-alks-amgen-amgn-earnings-watch-buy-or-sell/", "time_published": "20231030T153404", "authors": ["StockNews.com Staff"], "summary": "Pharmaceutical major Amgen Inc. ( AMGN ) is scheduled to report its third-quarter earnings on October 31. In this piece, I have discussed why it could be wise to buy the stock now. Wall Street expects a year-over-year decline in earnings on higher revenues when AMGN reports results for the ...", "banner_image": "https://stocknews.com/wp-content/uploads/2017/02/amgen-logo-amgn.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}], "overall_sentiment_score": 0.183455, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.072108", "ticker_sentiment_score": "0.071115", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.072108", "ticker_sentiment_score": "0.071115", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.558244", "ticker_sentiment_score": "0.259511", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.072108", "ticker_sentiment_score": "0.071115", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises As Apple Climbs Ahead Of Earnings; GM Reportedly Settles With UAW", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-as-apple-climbs-ahead-of-earnings-gm-settles-with-uaw/", "time_published": "20231030T150805", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Dow Jones Rises As Apple Climbs Ahead Of Earnings. GM ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/stock-WallStreet-06-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999896"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.069208, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.158868", "ticker_sentiment_score": "-0.073442", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSCC", "relevance_score": "0.106305", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.053271", "ticker_sentiment_score": "0.142686", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.210731", "ticker_sentiment_score": "0.050436", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.106305", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBS", "relevance_score": "0.106305", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.106305", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.158868", "ticker_sentiment_score": "-0.073442", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.053271", "ticker_sentiment_score": "-0.047015", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.106305", "ticker_sentiment_score": "0.076727", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.158868", "ticker_sentiment_score": "-0.073442", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDC", "relevance_score": "0.106305", "ticker_sentiment_score": "-0.052684", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.106305", "ticker_sentiment_score": "0.076727", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.106305", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOLF", "relevance_score": "0.106305", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.053271", "ticker_sentiment_score": "0.032999", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient", "url": "https://www.fool.com/investing/2023/10/30/gene-therapy-could-be-on-the-cusp-of-major-breakth/", "time_published": "20231030T123000", "authors": ["George Budwell"], "summary": "This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F752824%2Fpharma-researcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.12974, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.051999", "ticker_sentiment_score": "0.013965", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.155118", "ticker_sentiment_score": "0.002808", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081572", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.051999", "ticker_sentiment_score": "0.081572", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Rise Ahead Of Fed Meeting; Apple Earnings Loom", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-fed-meeting-apple-earnings-jobs-report-loom/", "time_published": "20231030T121151", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Futures Rise Ahead Of Fed Meeting. Apple Earnings Loom Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/02/stock-wallStreet-1-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.139911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.105141", "ticker_sentiment_score": "0.173131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.208464", "ticker_sentiment_score": "0.218158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.070207", "ticker_sentiment_score": "-0.031528", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSW", "relevance_score": "0.174335", "ticker_sentiment_score": "0.109425", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.035138", "ticker_sentiment_score": "0.184458", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.070207", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.070207", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.139872", "ticker_sentiment_score": "0.129308", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.105141", "ticker_sentiment_score": "0.173131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LULU", "relevance_score": "0.105141", "ticker_sentiment_score": "0.094863", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.105141", "ticker_sentiment_score": "0.173131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LNW", "relevance_score": "0.174335", "ticker_sentiment_score": "0.162305", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.070207", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.105141", "ticker_sentiment_score": "0.173131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ON", "relevance_score": "0.035138", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.139872", "ticker_sentiment_score": "0.124485", "ticker_sentiment_label": "Neutral"}]}, {"title": "Beat the Market the Zacks Way: Novo Nordisk, Lifeway Foods, Casey's in Focus", "url": "https://www.zacks.com/stock/news/2174326/beat-the-market-the-zacks-way-novo-nordisk-lifeway-foods-caseys-in-focus", "time_published": "20231030T115200", "authors": ["Abhinab Dasgupta"], "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/1383.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.17717, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LWAY", "relevance_score": "0.068112", "ticker_sentiment_score": "0.174446", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SKM", "relevance_score": "0.068112", "ticker_sentiment_score": "0.083224", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.102013", "ticker_sentiment_score": "0.107965", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.068112", "ticker_sentiment_score": "0.023136", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCFS", "relevance_score": "0.068112", "ticker_sentiment_score": "0.213013", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CASY", "relevance_score": "0.068112", "ticker_sentiment_score": "0.023136", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDRE", "relevance_score": "0.068112", "ticker_sentiment_score": "0.174446", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.068112", "ticker_sentiment_score": "0.060308", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.068112", "ticker_sentiment_score": "0.060308", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANTX", "relevance_score": "0.068112", "ticker_sentiment_score": "0.201922", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.068112", "ticker_sentiment_score": "0.1013", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Dow Jones Dividend Stocks to Buy Hand Over Fist Right Now", "url": "https://www.fool.com/investing/2023/10/29/2-dow-jones-dividend-stocks-to-buy-hand-over-fist/", "time_published": "20231029T103000", "authors": ["George Budwell"], "summary": "These two defensive dividend stocks sport compelling valuations and attractive yields.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F752477%2Fdividends.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.370022, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "VZ", "relevance_score": "0.263231", "ticker_sentiment_score": "0.361141", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.38588", "ticker_sentiment_score": "0.549143", "ticker_sentiment_label": "Bullish"}, {"ticker": "VOD", "relevance_score": "0.06697", "ticker_sentiment_score": "0.215834", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Five Dow Stocks Near Buy Points", "url": "https://www.investors.com/news/microsoft-leads-5-dow-jones-stocks-near-buy-points/", "time_published": "20231028T154300", "authors": ["JED GRAHAM", "Investor's Business Daily"], "summary": "Microsoft Leads These 5 Dow Jones Stocks Near Buy Points Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/05/Stock-microsoft-sign-04-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.138585, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.289652", "ticker_sentiment_score": "0.220363", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.032916", "ticker_sentiment_score": "0.096266", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.258694", "ticker_sentiment_score": "0.068822", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.065775", "ticker_sentiment_score": "0.100531", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.289652", "ticker_sentiment_score": "0.189716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.195551", "ticker_sentiment_score": "0.125386", "ticker_sentiment_label": "Neutral"}]}, {"title": "Apple, Fed Meeting, Caterpillar, Jobs Report; Investing Action Plan", "url": "https://www.investors.com/research/investing-action-plan/apple-fed-meeting-caterpillar-jobs-report-investing-action-plan/", "time_published": "20231027T215300", "authors": ["ALAN R. ELLIOTT", "Investor's Business Daily"], "summary": "Apple, Fed Meeting, Caterpillar, Jobs Report. Investing Action Plan Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/Stock-mannequinapple-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.99999"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.100088, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.052493", "ticker_sentiment_score": "0.008988", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.052493", "ticker_sentiment_score": "0.075", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.069951", "ticker_sentiment_score": "0.015119", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANET", "relevance_score": "0.052493", "ticker_sentiment_score": "0.003991", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.017509", "ticker_sentiment_score": "0.117232", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.035009", "ticker_sentiment_score": "0.066673", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.104759", "ticker_sentiment_score": "0.056462", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.069951", "ticker_sentiment_score": "0.019329", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.052493", "ticker_sentiment_score": "0.093934", "ticker_sentiment_label": "Neutral"}, {"ticker": "BUD", "relevance_score": "0.035009", "ticker_sentiment_score": "0.121518", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.104759", "ticker_sentiment_score": "0.069871", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.035009", "ticker_sentiment_score": "0.012525", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.035009", "ticker_sentiment_score": "0.176478", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.035009", "ticker_sentiment_score": "-0.017404", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.052493", "ticker_sentiment_score": "-0.048998", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.035009", "ticker_sentiment_score": "0.01861", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHEN", "relevance_score": "0.035009", "ticker_sentiment_score": "-0.004844", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.052493", "ticker_sentiment_score": "0.152599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PAYC", "relevance_score": "0.035009", "ticker_sentiment_score": "0.055611", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.035009", "ticker_sentiment_score": "0.02226", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.035009", "ticker_sentiment_score": "0.045334", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.052493", "ticker_sentiment_score": "0.003991", "ticker_sentiment_label": "Neutral"}, {"ticker": "CF", "relevance_score": "0.052493", "ticker_sentiment_score": "0.016038", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.035009", "ticker_sentiment_score": "0.055832", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.052493", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBOE", "relevance_score": "0.035009", "ticker_sentiment_score": "0.250018", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAH", "relevance_score": "0.052493", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWKS", "relevance_score": "0.035009", "ticker_sentiment_score": "0.071169", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.052493", "ticker_sentiment_score": "0.006", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.052493", "ticker_sentiment_score": "0.092997", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.035009", "ticker_sentiment_score": "0.080794", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.104759", "ticker_sentiment_score": "0.012288", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.052493", "ticker_sentiment_score": "0.093934", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.017509", "ticker_sentiment_score": "0.020325", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets - CVS Health  ( NYSE:CVS ) , Enphase Energy  ( NASDAQ:ENPH ) , Alphabet  ( NASDAQ:GOOGL ) , Apple  ( NASDAQ:AAPL ) ", "url": "https://www.benzinga.com/news/earnings/23/10/35474151/bears-roam-wall-street-as-middle-east-conflict-earnings-outlook-raise-concerns-despite-strong-q3-us", "time_published": "20231027T203357", "authors": ["Piero Cingari"], "summary": "It has been another week of volatility in the stock market, characterized by mounting fears of a wider Middle East conflict and a more cautious fourth-quarter earnings outlook announced by U.S. corporations.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Bearish_stock_chart..jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.995921"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.151583, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.046816", "ticker_sentiment_score": "0.123827", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDLZ", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.09347", "ticker_sentiment_score": "-0.055253", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.046816", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.09347", "ticker_sentiment_score": "0.057667", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.046816", "ticker_sentiment_score": "0.094925", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDD", "relevance_score": "0.09347", "ticker_sentiment_score": "0.204728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SBUX", "relevance_score": "0.09347", "ticker_sentiment_score": "-0.055253", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.09347", "ticker_sentiment_score": "-0.055253", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.09347", "ticker_sentiment_score": "-0.055253", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTW", "relevance_score": "0.09347", "ticker_sentiment_score": "0.204728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BKNG", "relevance_score": "0.09347", "ticker_sentiment_score": "-0.055253", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHR", "relevance_score": "0.09347", "ticker_sentiment_score": "0.057667", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.139804", "ticker_sentiment_score": "0.004048", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.09347", "ticker_sentiment_score": "-0.119207", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.09347", "ticker_sentiment_score": "-0.055253", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROL", "relevance_score": "0.09347", "ticker_sentiment_score": "0.204728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCD", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.09347", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.09347", "ticker_sentiment_score": "0.233308", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.27535", "ticker_sentiment_score": "0.25509", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Apple Headlines Earnings Calendar With Chip Titan AMD, Amgen Also Set To Report", "url": "https://www.investors.com/research/earnings-preview/apple-headlines-earnings-calendar-with-chip-titan-amd-health-giant-amgen/", "time_published": "20231027T185200", "authors": ["Investor's Business Daily", "VIDYA RAMAKRISHNAN"], "summary": "Apple Headlines Earnings Calendar With Chip Titan AMD, Amgen ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/EARNwatch103023-300x171.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.996675"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.080895, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.072987", "ticker_sentiment_score": "0.024625", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.036532", "ticker_sentiment_score": "0.023689", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.216537", "ticker_sentiment_score": "-0.046513", "ticker_sentiment_label": "Neutral"}, {"ticker": "FORM", "relevance_score": "0.251495", "ticker_sentiment_score": "-0.050655", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.072987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLS", "relevance_score": "0.072987", "ticker_sentiment_score": "0.123966", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.145364", "ticker_sentiment_score": "0.181628", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.319817", "ticker_sentiment_score": "0.020985", "ticker_sentiment_label": "Neutral"}]}, {"title": "Performance Comparison: Amgen And Competitors In Biotechnology Industry - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/10/35467984/performance-comparison-amgen-and-competitors-in-biotechnology-industry", "time_published": "20231027T160018", "authors": ["Benzinga Insights"], "summary": "In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Amgen AMGN in relation to its major competitors in the ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}], "overall_sentiment_score": 0.220905, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.441424", "ticker_sentiment_score": "0.141169", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie  ( ABBV )  Q3 Earnings Beat, Shares Down Despite Raised View", "url": "https://www.zacks.com/stock/news/2173886/abbvie-abbv-q3-earnings-beat-shares-down-despite-raised-view", "time_published": "20231027T145100", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d5/8276.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993856"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.121556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CHRS", "relevance_score": "0.037213", "ticker_sentiment_score": "-0.05635", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.291038", "ticker_sentiment_score": "0.312919", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.148045", "ticker_sentiment_score": "-0.029829", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.037213", "ticker_sentiment_score": "0.285488", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.074345", "ticker_sentiment_score": "0.131252", "ticker_sentiment_label": "Neutral"}]}, {"title": "Weight-Loss Beating Continues For Devices Makers; Why It's Overdone", "url": "https://www.investors.com/news/technology/weight-loss-drugs-spook-medical-device-stocks-an-overreaction/", "time_published": "20231027T130000", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/10/IT2c103023-300x171.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.093424, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INSP", "relevance_score": "0.034907", "ticker_sentiment_score": "-0.017925", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBH", "relevance_score": "0.034907", "ticker_sentiment_score": "0.125221", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.017458", "ticker_sentiment_score": "-0.108231", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.087122", "ticker_sentiment_score": "0.080517", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMD", "relevance_score": "0.034907", "ticker_sentiment_score": "0.125221", "ticker_sentiment_label": "Neutral"}, {"ticker": "MASI", "relevance_score": "0.034907", "ticker_sentiment_score": "0.23697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.034907", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.087122", "ticker_sentiment_score": "0.002112", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.034907", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EW", "relevance_score": "0.034907", "ticker_sentiment_score": "0.23697", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSNUF", "relevance_score": "0.017458", "ticker_sentiment_score": "0.047327", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.069748", "ticker_sentiment_score": "0.111489", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.034907", "ticker_sentiment_score": "0.099119", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLNO", "relevance_score": "0.017458", "ticker_sentiment_score": "0.014131", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.05234", "ticker_sentiment_score": "0.026937", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.121738", "ticker_sentiment_score": "0.072049", "ticker_sentiment_label": "Neutral"}]}, {"title": "A large international study of migraine reveals new biological pathways for treatment", "url": "https://www.newswire.ca/news-releases/a-large-international-study-of-migraine-reveals-new-biological-pathways-for-treatment-816056881.html", "time_published": "20231026T150000", "authors": ["deCODE genetics"], "summary": "REYKJAVIK, Iceland , Oct. 26, 2023 /CNW/ -- A large international study led by deCODE Genetics on the genetics of migraine provides novel insights into the biology of migraine enabling detection of rare variants protecting against migraine, opening an avenue for potential development of novel ...", "banner_image": "https://mma.prnewswire.com/media/2256118/deCode_genetics.mp4?p=medium", "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.059185, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.07031", "ticker_sentiment_score": "0.071295", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income", "url": "https://www.zacks.com/stock/news/2172536/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income", "time_published": "20231026T131003", "authors": ["Zacks Equity Research"], "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default184.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.220442, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MPX", "relevance_score": "0.203215", "ticker_sentiment_score": "0.117314", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.203215", "ticker_sentiment_score": "0.11418", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Pharma Stocks That Are Screaming Buys in October", "url": "https://www.fool.com/investing/2023/10/26/3-pharma-stocks-that-are-screaming-buys-in-october/", "time_published": "20231026T113000", "authors": ["Jim Halley"], "summary": "Each company delivers an above-average dividend and revenue growth.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.109768, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.076115", "ticker_sentiment_score": "0.002043", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.076115", "ticker_sentiment_score": "-0.044986", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.151539", "ticker_sentiment_score": "0.035847", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.188781", "ticker_sentiment_score": "0.100446", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wearable Injectors Market Share Worth $13.88 Billion by 2027 - Exclusive Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35435683/wearable-injectors-market-share-worth-13-88-billion-by-2027-exclusive-report-by-the-insight-partne", "time_published": "20231026T111847", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- Wearable injectors are drug delivery devices that adhere to the body to deliver larger volumes of drugs subcutaneously. Several pharmaceutical and medical device companies have developed wearable injectors.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.159252, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TNDM", "relevance_score": "0.075516", "ticker_sentiment_score": "0.075724", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.0378", "ticker_sentiment_score": "0.069057", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.075516", "ticker_sentiment_score": "0.089892", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.113062", "ticker_sentiment_score": "0.103738", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.0378", "ticker_sentiment_score": "0.069057", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRRMF", "relevance_score": "0.0378", "ticker_sentiment_score": "0.069057", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZLDPF", "relevance_score": "0.075516", "ticker_sentiment_score": "0.094955", "ticker_sentiment_label": "Neutral"}]}, {"title": "UniQure  ( QURE )  Expected to Beat Earnings Estimates: Should You Buy?", "url": "https://www.zacks.com/stock/news/2171738/uniqure-qure-expected-to-beat-earnings-estimates-should-you-buy", "time_published": "20231025T140219", "authors": ["Zacks Equity Research"], "summary": "UniQure (QURE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default294.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.154308, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.176502", "ticker_sentiment_score": "-0.002866", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna  ( MRNA )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2171770/moderna-mrna-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231025T131000", "authors": ["Zacks Equity Research"], "summary": "Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/db/3160.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.03106, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.593341", "ticker_sentiment_score": "0.07016", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.201523", "ticker_sentiment_score": "0.055846", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.201523", "ticker_sentiment_score": "-0.006354", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.050894", "ticker_sentiment_score": "0.04899", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  to Report Q3 Earnings: Will It Beat Estimates?", "url": "https://www.zacks.com/stock/news/2171289/amgen-amgn-to-report-q3-earnings-will-it-beat-estimates", "time_published": "20231025T112600", "authors": ["Zacks Equity Research"], "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5d/2633.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.203947, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.219312", "ticker_sentiment_score": "0.114532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.219312", "ticker_sentiment_score": "0.215777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.272181", "ticker_sentiment_score": "0.030414", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.272181", "ticker_sentiment_score": "0.036737", "ticker_sentiment_label": "Neutral"}]}, {"title": "USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2171221/usa-compression-and-disney-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20231025T084900", "authors": ["Zacks Equity Research"], "summary": "Chicago, IL - October 25, 2023 - Zacks Equity Research shares USA Compression Partners ( USAC Quick QuoteUSAC - ) as the Bull of the Day and Disney ( DIS Quick QuoteDIS - ) as the Bear of the Day.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9d/53642.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.155371, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.220558", "ticker_sentiment_score": "0.315034", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.273705", "ticker_sentiment_score": "0.255919", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.193575", "ticker_sentiment_score": "0.174337", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DIS", "relevance_score": "0.111358", "ticker_sentiment_score": "0.040294", "ticker_sentiment_label": "Neutral"}, {"ticker": "USAC", "relevance_score": "0.138943", "ticker_sentiment_score": "0.079014", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Outperforms Broader Market: What You Need to Know", "url": "https://www.zacks.com/stock/news/2171081/amgen-amgn-outperforms-broader-market-what-you-need-to-know", "time_published": "20231024T215018", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $276.12, marking a +1.12% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default2.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99246"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.161042, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.608634", "ticker_sentiment_score": "0.225467", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( AMGN )  Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release", "url": "https://www.zacks.com/stock/news/2170849/amgen-amgn-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q3-release", "time_published": "20231024T140052", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default200.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.154111, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.262522", "ticker_sentiment_score": "0.16165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INSM", "relevance_score": "0.176825", "ticker_sentiment_score": "-0.001436", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Biotech Stocks With Decent Dividend for a Steady Return", "url": "https://www.zacks.com/stock/news/2170733/3-biotech-stocks-with-decent-dividend-for-a-steady-return", "time_published": "20231024T131500", "authors": ["Indrajit Bandyopadhyay"], "summary": "Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.301538, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.406197", "ticker_sentiment_score": "0.344854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.359262", "ticker_sentiment_score": "0.524882", "ticker_sentiment_label": "Bullish"}, {"ticker": "GILD", "relevance_score": "0.451494", "ticker_sentiment_score": "0.422583", "ticker_sentiment_label": "Bullish"}]}, {"title": "GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?", "url": "https://www.zacks.com/stock/news/2170671/gsk-gears-up-for-q3-earnings-will-it-surpass-estimates", "time_published": "20231024T112500", "authors": ["Zacks Equity Research"], "summary": "We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.131683, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.231773", "ticker_sentiment_score": "0.060659", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.231773", "ticker_sentiment_score": "-0.005316", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.404201", "ticker_sentiment_score": "0.26663", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/10/35383209/looking-at-amgens-recent-unusual-options-activity", "time_published": "20231023T203050", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.141141, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.802099", "ticker_sentiment_score": "0.286965", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.102449", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk", "url": "https://www.zacks.com/stock/news/2170092/the-zacks-analyst-blog-highlights-apple-amgen-becton-dickinson-unitedhealth-and-verisk", "time_published": "20231023T103200", "authors": ["Zacks Investment Research"], "summary": "Apple, Amgen, Becton, Dickinson, UnitedHealth and Verisk are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/24/52.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.219572, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.530253", "ticker_sentiment_score": "0.326822", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRSK", "relevance_score": "0.143415", "ticker_sentiment_score": "0.039373", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.348592", "ticker_sentiment_score": "0.215181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.143415", "ticker_sentiment_score": "0.039373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.282234", "ticker_sentiment_score": "0.206647", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Take the Zacks Approach to Beat the Market: Novo Nordisk, Amgen, Fabrinet in Focus", "url": "https://www.zacks.com/stock/news/2170088/take-the-zacks-approach-to-beat-the-market-novo-nordisk-amgen-fabrinet-in-focus", "time_published": "20231023T092300", "authors": ["Abhinab Dasgupta"], "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.998682"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.14354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LULU", "relevance_score": "0.066139", "ticker_sentiment_score": "0.023094", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.099066", "ticker_sentiment_score": "0.107081", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOH", "relevance_score": "0.066139", "ticker_sentiment_score": "0.083127", "ticker_sentiment_label": "Neutral"}, {"ticker": "FN", "relevance_score": "0.066139", "ticker_sentiment_score": "0.212679", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRP", "relevance_score": "0.066139", "ticker_sentiment_score": "0.137099", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.066139", "ticker_sentiment_score": "0.061217", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.066139", "ticker_sentiment_score": "0.061217", "ticker_sentiment_label": "Neutral"}, {"ticker": "FICO", "relevance_score": "0.066139", "ticker_sentiment_score": "0.101176", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICFI", "relevance_score": "0.066139", "ticker_sentiment_score": "0.023094", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMYT", "relevance_score": "0.066139", "ticker_sentiment_score": "0.137099", "ticker_sentiment_label": "Neutral"}]}, {"title": "Asthma Biologics Market Predicted to Reach USD 19.2 billion by 2031, Growing at a 12.5% CAGR | Exclusive Report by Transparency Market Research", "url": "https://www.prnewswire.com/news-releases/asthma-biologics-market-predicted-to-reach-usd-19-2-billion-by-2031--growing-at-a-12-5-cagr--exclusive-report-by-transparency-market-research-301964281.html", "time_published": "20231023T091400", "authors": ["Transparency Market Research"], "summary": "Asthma Biologics Market Predicted to Reach USD 19.2 billion by 2031, Growing at a 12.5% CAGR | Exclusive Report ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.405759, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.046273", "ticker_sentiment_score": "0.278548", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.09239", "ticker_sentiment_score": "0.274714", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AbbVie  ( ABBV )  to Report Q3 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2170056/abbvie-abbv-to-report-q3-earnings-whats-in-the-cards", "time_published": "20231023T083200", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.202745, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.043264", "ticker_sentiment_score": "0.029734", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.412523", "ticker_sentiment_score": "0.324419", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.2138", "ticker_sentiment_score": "0.05686", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.2138", "ticker_sentiment_score": "-0.004984", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.043264", "ticker_sentiment_score": "0.115711", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Stock Reports for Apple, Amgen & Becton, Dickinson", "url": "https://www.zacks.com/research-daily/2169481/top-stock-reports-for-apple-amgen-becton-dickinson", "time_published": "20231020T184100", "authors": ["Sheraz Mian"], "summary": "Today's Research Daily features new research reports on 12 major stocks, including Apple Inc. (AAPL), Amgen Inc. (AMGN) and Becton, Dickinson and Company (BDX).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.263212, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.239195", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.464633", "ticker_sentiment_score": "0.551641", "ticker_sentiment_label": "Bullish"}, {"ticker": "BDX", "relevance_score": "0.098659", "ticker_sentiment_score": "0.294338", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Stock Market Erases Gains And Here Comes Powell; Tesla Stock Has This Problem", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-erases-gains-here-comes-powell-teslas-chart-becomes-deformed/", "time_published": "20231019T144700", "authors": ["JUAN CARLOS ARANCIBIA", "Investor's Business Daily"], "summary": "Stock Market Erases Gains And Here Comes Powell. Tesla Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/06/Stock-jeromepowell2022-03-gov.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.055338, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.175009", "ticker_sentiment_score": "0.326468", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.175009", "ticker_sentiment_score": "-0.021979", "ticker_sentiment_label": "Neutral"}, {"ticker": "BX", "relevance_score": "0.1172", "ticker_sentiment_score": "-0.076821", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.1172", "ticker_sentiment_score": "-0.089813", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.175009", "ticker_sentiment_score": "0.012121", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVS", "relevance_score": "0.1172", "ticker_sentiment_score": "0.244611", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.1172", "ticker_sentiment_score": "-0.089813", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.1172", "ticker_sentiment_score": "-0.089813", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco Pharmaceuticals ETF  ( PJP )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2168544/is-invesco-pharmaceuticals-etf-pjp-a-strong-etf-right-now", "time_published": "20231019T102005", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default265.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.258671, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.115509", "ticker_sentiment_score": "0.055568", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.115509", "ticker_sentiment_score": "0.055568", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.172507", "ticker_sentiment_score": "0.240144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.115509", "ticker_sentiment_score": "0.055568", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Stock Moves -0.3%: What You Should Know", "url": "https://www.zacks.com/stock/news/2168393/amgen-amgn-stock-moves--03-what-you-should-know", "time_published": "20231018T215017", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) closed the most recent trading day at $283.58, moving -0.3% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default10.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.103347, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.531019", "ticker_sentiment_score": "0.111033", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Biotech Stocks Set to Outpace Q3 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2168288/5-biotech-stocks-set-to-outpace-q3-earnings-estimates", "time_published": "20231018T152000", "authors": ["Zacks Equity Research"], "summary": "Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.170488, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.30569", "ticker_sentiment_score": "0.052098", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTA", "relevance_score": "0.353418", "ticker_sentiment_score": "-0.064866", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.353418", "ticker_sentiment_score": "0.073833", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.399734", "ticker_sentiment_score": "0.11986", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.353418", "ticker_sentiment_score": "0.115454", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Unusual Options Activity For October 17 - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/10/35296672/amgen-unusual-options-activity-for-october-17", "time_published": "20231017T193101", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 16 strange trades. If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.096878, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.862496", "ticker_sentiment_score": "0.222202", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PBYI vs. AMGN: Which Stock Is the Better Value Option?", "url": "https://www.zacks.com/stock/news/2167363/pbyi-vs-amgn-which-stock-is-the-better-value-option", "time_published": "20231017T154011", "authors": ["Zacks Equity Research"], "summary": "Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech ( PBYI Quick QuotePBYI - ) or Amgen ( AMGN Quick QuoteAMGN - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default344.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.443748, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.753462", "ticker_sentiment_score": "0.523296", "ticker_sentiment_label": "Bullish"}]}, {"title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know", "url": "https://www.zacks.com/stock/news/2167043/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know", "time_published": "20231017T130006", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default343.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.239771, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.488469", "ticker_sentiment_score": "0.104632", "ticker_sentiment_label": "Neutral"}]}, {"title": "USFDA gives final nod to Glenmark's psoriasis drug", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/usfda-gives-final-nod-to-glenmarks-psoriasis-drug/3275095/lite/", "time_published": "20231017T065529", "authors": ["Health Desk"], "summary": "Glenmark Pharmaceuticals Ltd. on Tuesday announced that it has received final approval from the United States Food & Drug Administration ( U.S. FDA ) for Apremilast Tablets, 10 mg, 20 mg and 30 mg. According to the company's statement, it is the generic version of Otezla Tablets, 10 mg, 20 mg ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/10/thermometer-g9932653d8_1920-2.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.199303, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.266828", "ticker_sentiment_score": "0.106946", "ticker_sentiment_label": "Neutral"}]}, {"title": "USFDA gives final nod to Glenmark's psoriasis drug", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/usfda-gives-final-nod-to-glenmarks-psoriasis-drug/3275095/", "time_published": "20231017T065529", "authors": ["Health Desk"], "summary": "Glenmark Pharmaceuticals Ltd. on Tuesday announced that it has received final approval from the United States Food & Drug Administration ( U.S. FDA ) for Apremilast Tablets, 10 mg, 20 mg and 30 mg. According to the company's statement, it is the generic version of Otezla Tablets, 10 mg, 20 mg ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/10/thermometer-g9932653d8_1920-2.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.199303, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.266828", "ticker_sentiment_score": "0.106946", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will Amgen  ( AMGN )  Beat Estimates Again in Its Next Earnings Report?", "url": "https://www.zacks.com/stock/news/2166638/will-amgen-amgn-beat-estimates-again-in-its-next-earnings-report", "time_published": "20231016T161010", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default276.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999953"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.301659, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.409171", "ticker_sentiment_score": "0.40694", "ticker_sentiment_label": "Bullish"}]}, {"title": "$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/10/35270975/100-invested-in-amgen-15-years-ago-would-be-worth-this-much-today", "time_published": "20231016T160026", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 1.38% on an annualized basis producing an average annual return of 12.0%. Currently, Amgen has a market capitalization of $153.28 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "AMGN: Exploring the Upside Potential of 3 Biotech Stocks", "url": "https://stocknews.com/news/amgn-incy-alks-exploring-the-upside-potential-of-3-biotech-stocks/", "time_published": "20231016T130843", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is well-positioned for steady growth, owing to rapid advancements in drug developments and the growing demand to treat chronic diseases.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_517925923-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.165837, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALKS", "relevance_score": "0.339638", "ticker_sentiment_score": "0.201078", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.310451", "ticker_sentiment_score": "0.213649", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INCY", "relevance_score": "0.189422", "ticker_sentiment_score": "0.232294", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings", "url": "https://www.zacks.com/stock/news/2166333/want-better-returns-dont-ignore-these-2-medical-stocks-set-to-beat-earnings", "time_published": "20231016T125006", "authors": ["Zacks Equity Research"], "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default120.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.351038, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.268294", "ticker_sentiment_score": "0.238624", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXSM", "relevance_score": "0.392948", "ticker_sentiment_score": "0.338081", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Beat the Market the Zacks Way: Novo Nordisk, MakeMyTrip, Fastenal in Focus", "url": "https://www.zacks.com/stock/news/2166368/beat-the-market-the-zacks-way-novo-nordisk-makemytrip-fastenal-in-focus", "time_published": "20231016T120800", "authors": ["Abhinab Dasgupta"], "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.928139"}], "overall_sentiment_score": 0.134156, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CELH", "relevance_score": "0.065238", "ticker_sentiment_score": "0.212549", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CORT", "relevance_score": "0.065238", "ticker_sentiment_score": "0.079085", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.097721", "ticker_sentiment_score": "0.106695", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.065238", "ticker_sentiment_score": "0.047169", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSN", "relevance_score": "0.065238", "ticker_sentiment_score": "0.173751", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FAST", "relevance_score": "0.065238", "ticker_sentiment_score": "0.061177", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADP", "relevance_score": "0.065238", "ticker_sentiment_score": "0.061177", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.065238", "ticker_sentiment_score": "0.10113", "ticker_sentiment_label": "Neutral"}, {"ticker": "SP", "relevance_score": "0.065238", "ticker_sentiment_score": "0.173751", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMYT", "relevance_score": "0.065238", "ticker_sentiment_score": "0.205531", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio Announces Appointment of David Meline to Board of Directors", "url": "https://www.prnewswire.com/news-releases/pacbio-announces-appointment-of-david-meline-to-board-of-directors-301957110.html", "time_published": "20231016T120500", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board MENLO PARK, Calif., Oct. 16, 2023 /PRNewswire/ -- PacBio ( NASDAQ: PACB ) , a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to ...", "banner_image": "https://mma.prnewswire.com/media/1861430/PacBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.313974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABLZF", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.317869", "ticker_sentiment_score": "0.28883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.081552", "ticker_sentiment_score": "0.058019", "ticker_sentiment_label": "Neutral"}]}, {"title": "Which Is A Better Pick - Abbott Stock Or Amgen?", "url": "https://www.forbes.com/sites/greatspeculations/2023/10/16/which-is-a-better-pick--abbott-stock-or-amgen/", "time_published": "20231016T120006", "authors": ["Trefis Team"], "summary": "There is more to the comparison, and in the sections below, we discuss why we believe ABT will offer better returns than AMGN in the next three years.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/61efad4cf236864124c99299/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.16289, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.704675", "ticker_sentiment_score": "0.299984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.046363", "ticker_sentiment_score": "0.027888", "ticker_sentiment_label": "Neutral"}]}, {"title": "In-Depth Analysis: Amgen Versus Competitors In Biotechnology Industry - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/10/35244136/in-depth-analysis-amgen-versus-competitors-in-biotechnology-industry", "time_published": "20231013T160022", "authors": ["Benzinga Insights"], "summary": "In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Amgen AMGN and its primary competitors in the Biotechnology ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.202246, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.464844", "ticker_sentiment_score": "0.079048", "ticker_sentiment_label": "Neutral"}]}, {"title": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics", "url": "https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html", "time_published": "20231013T154500", "authors": ["Research and Markets"], "summary": "Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.144187, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.073209", "ticker_sentiment_score": "0.139168", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.073209", "ticker_sentiment_score": "0.08925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.036643", "ticker_sentiment_score": "0.067285", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sanofi reaps rewards of immunology investment with eczema results", "url": "https://www.marketwatch.com/story/sanofi-reaps-rewards-of-immunology-investment-with-eczema-results-9ce642b0", "time_published": "20231013T140000", "authors": ["Eleanor Laise"], "summary": "Pharmaceutical giant set to take on Amgen with atopic dermatitis treatment.", "banner_image": "https://images.mktw.net/im-867618/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.24028, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KNBWF", "relevance_score": "0.112008", "ticker_sentiment_score": "0.099052", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.151207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.221819", "ticker_sentiment_score": "0.151207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KYKOF", "relevance_score": "0.112008", "ticker_sentiment_score": "0.099052", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.675825", "ticker_sentiment_score": "0.369096", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is This Dividend Stock a Screaming Buy After Its Latest Acquisition?", "url": "https://www.fool.com/investing/2023/10/13/is-this-dividend-stock-screaming-buy-after-latest/", "time_published": "20231013T123000", "authors": ["Prosper Junior Bakiny"], "summary": "The biotech is ending the year with a bang.", "banner_image": "https://media.ycharts.com/charts/b04931307482007b59a716282b8aab98.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.163735, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.554365", "ticker_sentiment_score": "0.282728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.388879", "ticker_sentiment_score": "0.321891", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Amgen Stock a Buy Now?", "url": "https://www.fool.com/investing/2023/10/13/is-amgen-stock-a-buy-now/", "time_published": "20231013T092500", "authors": ["David Jagielski"], "summary": "The company recently closed its acquisition of Horizon Therapeutics.", "banner_image": "https://media.ycharts.com/charts/d51cec1f5f59aa9bba0777623c46640b.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993856"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.153724, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.602879", "ticker_sentiment_score": "0.226083", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.19117", "ticker_sentiment_score": "0.057753", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.04823", "ticker_sentiment_score": "0.082354", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( AMGN )  Rises As Market Takes a Dip: Key Facts", "url": "https://www.zacks.com/stock/news/2165200/amgn-rises-as-market-takes-a-dip-key-facts", "time_published": "20231012T215020", "authors": ["Zacks Equity Research"], "summary": "In the closing of the recent trading day, Amgen (AMGN) stood at $285.04, denoting a +0.51% change from the preceding trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default169.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.125128, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.517534", "ticker_sentiment_score": "0.113451", "ticker_sentiment_label": "Neutral"}]}, {"title": "GILD: How to Enhance Your Own Strategies with POWR Ratings", "url": "https://stocknews.com/news/gild-amgn-uthr-biib-regn-how-to-enhance-your-own-strategies-with-powr-ratings/", "time_published": "20231012T162947", "authors": ["StockNews.com Staff"], "summary": "One thing Wall Street is never short of is ideas. Technical strategies, fundamental strategies, seasonal investing, and the list goes on and on and on.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/06/shutterstock_530971462-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998333"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}], "overall_sentiment_score": 0.16666, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AWON", "relevance_score": "0.035035", "ticker_sentiment_score": "0.006888", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.139467", "ticker_sentiment_score": "0.121564", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.173832", "ticker_sentiment_score": "0.036379", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.241512", "ticker_sentiment_score": "0.114", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.207868", "ticker_sentiment_score": "0.139319", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/10/35224311/check-out-what-whales-are-doing-with-amgn", "time_published": "20231012T160148", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.174125, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.76367", "ticker_sentiment_score": "0.19683", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen's  ( AMGN )  Stock Rallies Almost 5% on Broker Upgrade", "url": "https://www.zacks.com/stock/news/2165040/amgens-amgn-stock-rallies-almost-5-on-broker-upgrade", "time_published": "20231012T155500", "authors": ["Zacks Equity Research"], "summary": "A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/96/702.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976671"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.186288, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.114682", "ticker_sentiment_score": "0.058752", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.281584", "ticker_sentiment_score": "0.130771", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.613172", "ticker_sentiment_score": "0.289195", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.227007", "ticker_sentiment_score": "0.172129", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALPN", "relevance_score": "0.227007", "ticker_sentiment_score": "0.183207", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations - Cardiol Therapeutics  ( NASDAQ:CRDL ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35220787/cardiol-therapeutics-fights-heart-inflammation-with-novel-formulations", "time_published": "20231012T135319", "authors": ["Beau Sharpe"], "summary": "697,000 people die from heart disease every year in the United States - that is one in every five deaths. In fact, cardiovascular disease is the number one killer for most Americans per the CDC. Everyday life choices play an essential role in heart health, and sometimes unfortunate accidents can ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/12/shutterstock_1381636952.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.096094, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CRDL", "relevance_score": "0.323927", "ticker_sentiment_score": "0.140733", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.066598", "ticker_sentiment_score": "-0.014349", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.033328", "ticker_sentiment_score": "-0.01534", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033328", "ticker_sentiment_score": "-0.056748", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032", "url": "https://investingnews.com/global-car-t-cell-therapy-market-projected-to-reach-83-billion-by-2032/", "time_published": "20231012T133921", "authors": ["Investing News Network"], "summary": "FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.976913"}], "overall_sentiment_score": 0.106971, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.084796", "ticker_sentiment_score": "0.028337", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.084796", "ticker_sentiment_score": "0.055474", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.105883", "ticker_sentiment_score": "0.065147", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGBP", "relevance_score": "0.105883", "ticker_sentiment_score": "0.04808", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.084796", "ticker_sentiment_score": "0.054363", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.021237", "ticker_sentiment_score": "0.135143", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises After Fed Minutes As House Vote On New Speaker Looms; Meta Breaks Out", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-after-fed-minutes-as-house-vote-on-new-speaker-looms-meta-breaks-out/", "time_published": "20231011T195200", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Rises After Fed Minutes As House Vote On New ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/01/stock-FederalReserve-snow-11-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999981"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.062531, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.100308", "ticker_sentiment_score": "0.04817", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAVA", "relevance_score": "0.100308", "ticker_sentiment_score": "-0.081807", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.050254", "ticker_sentiment_score": "0.236385", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.100308", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.050254", "ticker_sentiment_score": "-0.076389", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.100308", "ticker_sentiment_score": "0.197599", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.149966", "ticker_sentiment_score": "0.235216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FAST", "relevance_score": "0.100308", "ticker_sentiment_score": "0.032902", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.199037", "ticker_sentiment_score": "0.209207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.100308", "ticker_sentiment_score": "0.04772", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade", "url": "https://www.investors.com/news/technology/amgen-stock-surges-to-10-month-high-after-snagging-an-unexpected-upgrade/", "time_published": "20231011T194900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/stock-Amgen-03-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.038583, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AKRO", "relevance_score": "0.074926", "ticker_sentiment_score": "-0.07799", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.653008", "ticker_sentiment_score": "-0.007515", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.149192", "ticker_sentiment_score": "0.123004", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.149192", "ticker_sentiment_score": "0.006356", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.149192", "ticker_sentiment_score": "-0.121467", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's cancer-drug pipeline looks promising despite FDA setback, analysts say", "url": "https://www.marketwatch.com/story/amgens-cancer-drug-pipeline-looks-promising-despite-fda-setback-analysts-say-70339525", "time_published": "20231011T124700", "authors": ["Eleanor Laise"], "summary": "Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade ...", "banner_image": "https://images.mktw.net/im-428023/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.147073, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.866386", "ticker_sentiment_score": "0.249245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.148731", "ticker_sentiment_score": "0.116523", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2164069/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20231011T102006", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default245.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.09889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Still Buy the Nasdaq's Best-Performing September Stocks?", "url": "https://www.fool.com/investing/2023/10/10/should-you-still-buy-the-nasdaqs-best-performing-o/", "time_published": "20231010T105300", "authors": ["Jeremy Bowman"], "summary": "Tech stocks sold off last month, but these three were gainers.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F749789%2Fstock-market-chart.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999956"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.191799, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVDA", "relevance_score": "0.05387", "ticker_sentiment_score": "0.10102", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.213048", "ticker_sentiment_score": "0.235254", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.213048", "ticker_sentiment_score": "0.112066", "ticker_sentiment_label": "Neutral"}, {"ticker": "GFS", "relevance_score": "0.213048", "ticker_sentiment_score": "0.119139", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.05387", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.05387", "ticker_sentiment_score": "0.145753", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Magnificent Dividend Stocks to Buy Hand Over Fist in October", "url": "https://www.fool.com/investing/2023/10/09/2-magnificent-dividend-stocks-to-buy-hand-over-fis/", "time_published": "20231009T141500", "authors": ["George Budwell"], "summary": "These two healthcare stocks are reliable passive income vehicles.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F750190%2Fgrowth.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}], "overall_sentiment_score": 0.482856, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.374714", "ticker_sentiment_score": "0.58081", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.324495", "ticker_sentiment_score": "0.477298", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABT", "relevance_score": "0.055621", "ticker_sentiment_score": "0.202953", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mirati  ( MRTX )  Gets Buyout Offer From Bristol Myers for $4.8B", "url": "https://www.zacks.com/stock/news/2162730/mirati-mrtx-gets-buyout-offer-from-bristol-myers-for-48b", "time_published": "20231009T140100", "authors": ["Zacks Equity Research"], "summary": "Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.209608, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.116631", "ticker_sentiment_score": "0.053482", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.286193", "ticker_sentiment_score": "0.272283", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.116631", "ticker_sentiment_score": "0.207933", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.230782", "ticker_sentiment_score": "0.171532", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why Mirati Stock Tumbled On A $5.8 Billion Takeover Bid", "url": "https://www.investors.com/news/technology/mrtx-stock-takes-a-hit-after-receiving-a-lowball-takeover-bid/", "time_published": "20231009T135200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "MRTX Stock Takes A Hit After Receiving A Lowball Takeover Bid Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/stock-Bristol-Myers-Squibb-08-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999701"}], "overall_sentiment_score": 0.120117, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.105897", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.706282", "ticker_sentiment_score": "0.093412", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.452244", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNY", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.105897", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coherus  ( CHRS )  Stock Rises on BLA Re-Filing for Udenyca Onbody", "url": "https://www.zacks.com/stock/news/2162656/coherus-chrs-stock-rises-on-bla-re-filing-for-udenyca-onbody", "time_published": "20231009T134900", "authors": ["Zacks Equity Research"], "summary": "Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.033567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CHRS", "relevance_score": "0.275091", "ticker_sentiment_score": "0.111618", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHJBF", "relevance_score": "0.070105", "ticker_sentiment_score": "0.215437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANVS", "relevance_score": "0.339978", "ticker_sentiment_score": "0.062909", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.139669", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.208166", "ticker_sentiment_score": "-0.014858", "ticker_sentiment_label": "Neutral"}]}, {"title": "Beat the Market the Zacks Way: UnitedHealth, Novo Nordisk, Check Point Software in Focus", "url": "https://www.zacks.com/stock/news/2162451/beat-the-market-the-zacks-way-unitedhealth-novo-nordisk-check-point-software-in-focus", "time_published": "20231009T112000", "authors": ["Santanu Roy"], "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/16/2258.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.972193"}], "overall_sentiment_score": 0.14879, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LINC", "relevance_score": "0.059268", "ticker_sentiment_score": "0.025021", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOVO", "relevance_score": "0.059268", "ticker_sentiment_score": "0.117456", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTU", "relevance_score": "0.088799", "ticker_sentiment_score": "0.109614", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHKP", "relevance_score": "0.059268", "ticker_sentiment_score": "0.105999", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.059268", "ticker_sentiment_score": "0.023008", "ticker_sentiment_label": "Neutral"}, {"ticker": "FN", "relevance_score": "0.059268", "ticker_sentiment_score": "0.128", "ticker_sentiment_label": "Neutral"}, {"ticker": "HURN", "relevance_score": "0.059268", "ticker_sentiment_score": "0.153806", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.059268", "ticker_sentiment_score": "0.094033", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.059268", "ticker_sentiment_score": "0.094033", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.059268", "ticker_sentiment_score": "0.023008", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTRX", "relevance_score": "0.059268", "ticker_sentiment_score": "0.153806", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( AMGN )  Increases Yet Falls Behind Market: What Investors Need to Know", "url": "https://www.zacks.com/stock/news/2161867/amgen-amgn-increases-yet-falls-behind-market-what-investors-need-to-know", "time_published": "20231006T215021", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) closed at $267.47 in the latest trading session, marking a +0.9% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default244.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.201287, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.582526", "ticker_sentiment_score": "0.31273", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts - Mirati Therapeutics  ( NASDAQ:MRTX ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35129164/amgens-adcomm-meeting-paves-way-to-launch-boost-for-mirati-therapeutics-lung-cancer", "time_published": "20231006T164432", "authors": ["Vandana Singh"], "summary": "According to a report on Thursday, French pharma company Sanofi SA SNY is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc MRTX. The deal would potentially bolster Sanofi's drug pipeline, helping the company to reduce its reliance on the blockbuster asthma ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/mrtx_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.257917, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.219809", "ticker_sentiment_score": "-0.061312", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.423251", "ticker_sentiment_score": "0.011502", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.219809", "ticker_sentiment_score": "-0.275856", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "FDA AdCom Gives Thumbs Down To Late-Stage Data For Amgen's Lumakras In Advanced Form Of Lung Cancer  ( UPDATED )  - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35122196/fda-adcomm-gives-thumbs-down-to-late-stage-data-amgens-lumakras", "time_published": "20231006T161800", "authors": ["Vandana Singh"], "summary": "Editor's note: The headline of this story has been updated to make clearer the FDA vote is on late-stage Lumakras data. FDA advisers concluded that the data from a late-stage trial lacks the requisite reliability to endorse the traditional approval of Amgen Inc's AMGN Lumakras for patients ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/mrtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.127154, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.454174", "ticker_sentiment_score": "0.22044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRTX", "relevance_score": "0.454174", "ticker_sentiment_score": "0.253616", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mirati  ( MRTX )  Surges 45% as Sanofi Reportedly Eyes Buyout", "url": "https://www.zacks.com/stock/news/2161744/mirati-mrtx-surges-45-as-sanofi-reportedly-eyes-buyout", "time_published": "20231006T153400", "authors": ["Zacks Equity Research"], "summary": "A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.132004", "ticker_sentiment_score": "0.075841", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.322233", "ticker_sentiment_score": "0.218182", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.381949", "ticker_sentiment_score": "0.18426", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC", "url": "https://investingnews.com/amgen-completes-acquisition-of-horizon-therapeutics-plc/", "time_published": "20231006T132132", "authors": ["Investing News Network"], "summary": "Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines Amgen ( NASDAQ: AMGN ) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion .", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.024436, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.251464", "ticker_sentiment_score": "0.153688", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.021312", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.042609", "ticker_sentiment_score": "0.174114", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know", "url": "https://www.zacks.com/stock/news/2161430/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know", "time_published": "20231006T130006", "authors": ["Zacks Equity Research"], "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default277.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.212624, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.484798", "ticker_sentiment_score": "0.116051", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35122196/fda-adcomm-gives-thumbs-down-to-amgens-lumakras-for-advanced-form-of-lung-cancer", "time_published": "20231006T125914", "authors": ["Vandana Singh"], "summary": "FDA advisers concluded that the data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's AMGN Lumakras for patients afflicted with an advanced form of lung cancer.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/06/mrtx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.123231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.48268", "ticker_sentiment_score": "0.136274", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.48268", "ticker_sentiment_score": "0.263222", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen to continue to seek full approval of Lumakras cancer drug after FDA panel votes against it", "url": "https://www.marketwatch.com/story/amgen-to-continue-to-seek-full-approval-of-lumakras-cancer-drug-after-fda-panel-votes-against-it-b5148d82", "time_published": "20231006T123600", "authors": ["Ciara Linnane"], "summary": "Amgen will continue to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer.", "banner_image": "https://images.mktw.net/im-863830/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.058443, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.116348", "ticker_sentiment_score": "-0.13534", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC", "url": "https://www.prnewswire.com/news-releases/amgen-completes-acquisition-of-horizon-therapeutics-plc-301949517.html", "time_published": "20231006T123000", "authors": ["Amgen"], "summary": "Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen ( NASDAQ: AMGN ) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a ...", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.029274, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.020758", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.020758", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.303675", "ticker_sentiment_score": "0.155416", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.020758", "ticker_sentiment_score": "0.10592", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Research Coverage Started at StockNews.com", "url": "https://www.defenseworld.net/2023/10/06/amgen-nasdaqamgn-research-coverage-started-at-stocknews-com.html", "time_published": "20231006T061652", "authors": ["Defense World Staff"], "summary": "Amgen ( NASDAQ:AMGN ) Research Coverage Started at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.273594, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.080728", "ticker_sentiment_score": "0.174831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TFC", "relevance_score": "0.040416", "ticker_sentiment_score": "0.086328", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.040416", "ticker_sentiment_score": "0.086328", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.080728", "ticker_sentiment_score": "0.174831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.040416", "ticker_sentiment_score": "0.061427", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.080728", "ticker_sentiment_score": "0.174831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.040416", "ticker_sentiment_score": "0.086328", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBARF", "relevance_score": "0.080728", "ticker_sentiment_score": "0.174831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.7562", "ticker_sentiment_score": "0.435048", "ticker_sentiment_label": "Bullish"}]}, {"title": "The Zacks Analyst Blog Highlights Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City", "url": "https://www.zacks.com/stock/news/2160567/the-zacks-analyst-blog-highlights-amgen-servicenow-rtx-automatic-data-processing-and-canadian-pacific-kansas-city", "time_published": "20231005T111600", "authors": ["Zacks Investment Research"], "summary": "Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City are included in this Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/74/11868.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.244559, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.072435", "ticker_sentiment_score": "-0.050429", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.072435", "ticker_sentiment_score": "0.233776", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.28387", "ticker_sentiment_score": "0.077776", "ticker_sentiment_label": "Neutral"}, {"ticker": "RTX", "relevance_score": "0.532941", "ticker_sentiment_score": "0.266364", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.144275", "ticker_sentiment_score": "0.035794", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.350564", "ticker_sentiment_score": "0.205907", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CP", "relevance_score": "0.144275", "ticker_sentiment_score": "0.035794", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.072435", "ticker_sentiment_score": "0.043113", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Surpasses Market Returns: Some Facts Worth Knowing", "url": "https://www.zacks.com/stock/news/2160368/amgen-amgn-surpasses-market-returns-some-facts-worth-knowing", "time_published": "20231004T220019", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) reachead $265.44 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default335.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.123549, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.585687", "ticker_sentiment_score": "0.213652", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Top Research Reports for Amgen, ServiceNow & RTX", "url": "https://www.zacks.com/research-daily/2159999/top-research-reports-for-amgen-servicenow-rtx", "time_published": "20231004T195500", "authors": ["Sheraz Mian"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), ServiceNow, Inc. (NOW) and RTX Corporation (RTX).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default61.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.306211, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.103778", "ticker_sentiment_score": "-0.056166", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.103778", "ticker_sentiment_score": "0.253705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.103778", "ticker_sentiment_score": "0.253705", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.205807", "ticker_sentiment_score": "0.077719", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.103778", "ticker_sentiment_score": "0.047215", "ticker_sentiment_label": "Neutral"}]}, {"title": "Large-scale proteomics in population-based studies from UK and Iceland", "url": "https://investingnews.com/large-scale-proteomics-in-population-based-studies-from-uk-and-iceland/", "time_published": "20231004T153810", "authors": ["Investing News Network"], "summary": "In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.122618, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.284696", "ticker_sentiment_score": "0.070225", "ticker_sentiment_label": "Neutral"}]}, {"title": "Large-scale proteomics in population-based studies from UK and Iceland - Canada NewsWire", "url": "https://www.newswire.ca/news-releases/large-scale-proteomics-in-population-based-studies-from-uk-and-iceland-804037245.html", "time_published": "20231004T150000", "authors": [], "summary": "Large-scale proteomics in population-based studies from UK and Iceland Canada ...", "banner_image": null, "source": "Canada Newswire", "category_within_source": "n/a", "source_domain": "www.newswire.ca", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.113394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.279015", "ticker_sentiment_score": "0.06909", "ticker_sentiment_label": "Neutral"}]}, {"title": "Breast Cancer Therapeutics Market to Hit $63.96 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/10/g35082720/breast-cancer-therapeutics-market-to-hit-63-96-billion-globally-by-2030-exclusive-report-by-the-in", "time_published": "20231004T095703", "authors": ["Globe Newswire"], "summary": "Pune, India, Oct. 04, 2023 ( GLOBE NEWSWIRE ) -- Breast cancer is one of the most common types of cancer and has a sizable market for therapies. According to the Centers for Disease Control and Prevention, in 2020, in the US, 239,612 new cases of breast cancer were reported among women, of which ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.334725, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.073209", "ticker_sentiment_score": "-0.060171", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.036643", "ticker_sentiment_score": "-0.119027", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Still Buy the Dow Jones' Best-Performing September Stocks?", "url": "https://www.fool.com/investing/2023/10/04/should-you-buy-dow-best-performing-stocks/", "time_published": "20231004T091000", "authors": ["James Brumley"], "summary": "A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy.", "banner_image": "https://media.ycharts.com/charts/3c611a71157ae042544b002dd7f4b588.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.173347, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.042953", "ticker_sentiment_score": "0.004927", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.212301", "ticker_sentiment_score": "0.108813", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.253426", "ticker_sentiment_score": "0.143911", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.085782", "ticker_sentiment_score": "0.036786", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.372139", "ticker_sentiment_score": "0.187911", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35069802/is-amgens-lung-cancer-drug-lumakras-up-to-the-mark-fda-briefing-raises-concerns", "time_published": "20231003T193041", "authors": ["Vandana Singh"], "summary": "The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's AMGN supplemental application for complete approval of Lumakras ( sotorasib ) for previously treated locally advanced or metastatic KRAS G12C-mutated non-small ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/amgn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.029354, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.544495", "ticker_sentiment_score": "-0.003381", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration - Novo Nordisk  ( NYSE:NVO ) ", "url": "https://www.benzinga.com/general/biotech/23/10/35068559/drugmakers-agree-to-participate-for-medicare-drug-price-negotiation-with-biden-administration", "time_published": "20231003T173519", "authors": ["Vandana Singh"], "summary": "All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration to halt the process.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/10/03/pills-image_by_steve_buissinne_from_pixabay.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.08438, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.262522", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: Top 3 Biotech Stocks Leading the Way This October", "url": "https://stocknews.com/news/amgn-gild-jazz-top-3-biotech-stocks-leading-the-way-this-october/", "time_published": "20231003T164408", "authors": ["StockNews.com Staff"], "summary": "The biotech industry is thriving, driven by innovation and stable demand, positioning it for sustained growth. Despite macroeconomic challenges, this positive outlook is supported by an aging population and the demand for quality treatments for both rare and common diseases.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.256922, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.308742", "ticker_sentiment_score": "0.115153", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAZZ", "relevance_score": "0.121404", "ticker_sentiment_score": "0.150495", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.169335", "ticker_sentiment_score": "0.147264", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Intuit Stock Is A Better Pick Over Amgen", "url": "https://www.forbes.com/sites/greatspeculations/2023/10/03/heres-why-intuit-stock-is-a-better-pick-over-amgen/", "time_published": "20231003T130000", "authors": ["Trefis Team"], "summary": "Looking at stock returns, INTU has fared better.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/651af26283b9cce150738c7b/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Earnings", "relevance_score": "0.99999"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.242731, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INTU", "relevance_score": "0.769861", "ticker_sentiment_score": "0.392116", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.652336", "ticker_sentiment_score": "0.36686", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.04161", "ticker_sentiment_score": "0.079246", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Mixed After Government Shutdown Averted", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-tesla-stock-q3-deliveries/", "time_published": "20231002T121700", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Fall After Shutdown Averted. Tesla Stock Awaits ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/02/stock-wallStreet-1-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.150541, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.160365", "ticker_sentiment_score": "0.099082", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.120632", "ticker_sentiment_score": "0.048337", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.120632", "ticker_sentiment_score": "0.04078", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.080593", "ticker_sentiment_score": "0.092592", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.160365", "ticker_sentiment_score": "0.08168", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.120632", "ticker_sentiment_score": "0.005873", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.160365", "ticker_sentiment_score": "0.168655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.040348", "ticker_sentiment_score": "0.010933", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.120632", "ticker_sentiment_score": "0.079292", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.160365", "ticker_sentiment_score": "-0.046586", "ticker_sentiment_label": "Neutral"}]}, {"title": "Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus", "url": "https://www.zacks.com/stock/news/2158593/take-the-zacks-approach-to-beat-the-market-shopify-caterpillar-amgen-in-focus", "time_published": "20231002T114400", "authors": ["Abhinab Dasgupta"], "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/2120.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.132218, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.065957", "ticker_sentiment_score": "0.132265", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNK", "relevance_score": "0.065957", "ticker_sentiment_score": "0.173915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WEIGF", "relevance_score": "0.033006", "ticker_sentiment_score": "0.188096", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FDS", "relevance_score": "0.065957", "ticker_sentiment_score": "0.10618", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTU", "relevance_score": "0.098794", "ticker_sentiment_score": "0.112328", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.065957", "ticker_sentiment_score": "0.027159", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.065957", "ticker_sentiment_score": "-0.002005", "ticker_sentiment_label": "Neutral"}, {"ticker": "TK", "relevance_score": "0.033006", "ticker_sentiment_score": "0.168528", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAMT", "relevance_score": "0.065957", "ticker_sentiment_score": "0.173915", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.065957", "ticker_sentiment_score": "0.061209", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.065957", "ticker_sentiment_score": "0.061209", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.033006", "ticker_sentiment_score": "-0.007925", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/09/35009267/check-out-what-whales-are-doing-with-amgn", "time_published": "20230929T180333", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 14 strange trades. If we consider the specifics of each trade, it is accurate to state that 21% of the investors opened trades with bullish expectations and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.106173, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.815149", "ticker_sentiment_score": "0.199026", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment", "url": "https://www.marketwatch.com/story/as-merck-astrazeneca-and-other-drugmakers-sign-on-medicare-price-negotiations-face-critical-moment-9d85879f", "time_published": "20230929T142000", "authors": ["Eleanor Laise"], "summary": "A deadline looms to sign drug-price negotiation agreements as industry watches for legal reprieve.", "banner_image": "https://images.mktw.net/im-860220/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.004787, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.149656", "ticker_sentiment_score": "0.138204", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.100099", "ticker_sentiment_score": "-0.006512", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.100099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Stocks to Focus on as Demand for Obesity Drugs Booms", "url": "https://www.zacks.com/stock/news/2157743/3-stocks-to-focus-on-as-demand-for-obesity-drugs-booms", "time_published": "20230929T133500", "authors": ["Kinjel Shah"], "summary": "With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/82/41137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.14477, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.087185", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.043658", "ticker_sentiment_score": "0.169787", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.298437", "ticker_sentiment_score": "0.153741", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.215702", "ticker_sentiment_score": "0.061785", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Rise Ahead Of Key Inflation Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-key-inflation-data-nike-surges-on-earnings/", "time_published": "20230929T120700", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Rise Ahead Of Imminent Inflation Data. Nike ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/03/stock-wallstreet-031317-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.928139"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.199916, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.146469", "ticker_sentiment_score": "0.092464", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.110124", "ticker_sentiment_score": "0.048819", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.110124", "ticker_sentiment_score": "0.05756", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.073546", "ticker_sentiment_score": "0.091703", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.146469", "ticker_sentiment_score": "0.011954", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.218161", "ticker_sentiment_score": "0.16905", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.146469", "ticker_sentiment_score": "0.200655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKE", "relevance_score": "0.073546", "ticker_sentiment_score": "0.129651", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.036812", "ticker_sentiment_score": "0.112523", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.110124", "ticker_sentiment_score": "0.076543", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.146469", "ticker_sentiment_score": "0.028112", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2157520/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230929T102005", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default17.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.239238, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061631", "ticker_sentiment_score": "0.074005", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.122894", "ticker_sentiment_score": "0.068464", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2157352/amgen-amgn-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230928T215017", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $270.82, marking a +0.68% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default140.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.215515, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.624172", "ticker_sentiment_score": "0.352375", "ticker_sentiment_label": "Bullish"}]}, {"title": "Futures Fall Ahead Of Jobless Claims", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobless-claims-carmax-dives-on-earnings/", "time_published": "20230928T120400", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones futures turned higher Thursday morning, along with S&P 500 futures, while Nasdaq futures dipped, ahead of initial unemployment claims and GDP data. Meanwhile, CarMax ( KMX ) dived on weak earnings results. The Labor Department's first-time jobless claims are due out at 8:30 a.m.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-wallstreetflag-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.091405, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.151064", "ticker_sentiment_score": "0.168445", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.068035", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.075874", "ticker_sentiment_score": "-0.104119", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.086309", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.188193", "ticker_sentiment_score": "0.042169", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.03798", "ticker_sentiment_score": "0.008893", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.113597", "ticker_sentiment_score": "0.082966", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.114092", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.224903", "ticker_sentiment_score": "-0.088391", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBL", "relevance_score": "0.03798", "ticker_sentiment_score": "-0.049397", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.151064", "ticker_sentiment_score": "0.20173", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KMX", "relevance_score": "0.113597", "ticker_sentiment_score": "-0.133317", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.151064", "ticker_sentiment_score": "0.034007", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2156616/amgen-amgn-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230927T220020", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $268.98, marking a -0.02% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default26.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.136906, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.613743", "ticker_sentiment_score": "0.170172", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average", "url": "https://markets.businessinsider.com/news/etf/september-s-shakeout-s-p-500-nasdaq-100-see-just-13-of-stocks-above-50-day-average-1032660395", "time_published": "20230927T160452", "authors": ["Piero Cingari"], "summary": "In a month marked by volatility, the stock market is sending out distress signals like never before. The S&P 500 and Nasdaq 100 have both hit yearly lows in terms of the percentage of stocks trading below their 50-day moving averages.", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2023/Stock.wance-paleri-NnRIrQ1USyw-unsplash.jpeg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": -0.048329, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LMT", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.25646", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DG", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.133425", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.158583", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "WBA", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.158583", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VLO", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PODD", "relevance_score": "0.105604", "ticker_sentiment_score": "-0.133425", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.158098", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.105604", "ticker_sentiment_score": "0.158098", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics", "url": "https://www.marketwatch.com/story/amgen-discloses-more-than-400-million-stake-in-recent-ipo-neumora-therapeutics-6e46f0d7", "time_published": "20230927T123600", "authors": ["Tomi Kilgore"], "summary": "An Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.", "banner_image": "https://images.mktw.net/im-858603/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.838487"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.200084, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.777888", "ticker_sentiment_score": "0.373627", "ticker_sentiment_label": "Bullish"}]}, {"title": "Futures Rise Ahead Of Key Data", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-economic-data-costco-stock-slides-on-earnings/", "time_published": "20230927T121000", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures Rise Ahead Of Economic Data. Costco Slides ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.167788, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.155201", "ticker_sentiment_score": "0.080154", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.155201", "ticker_sentiment_score": "0.036097", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.077972", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.155201", "ticker_sentiment_score": "0.053198", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.19331", "ticker_sentiment_score": "0.0506", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.039033", "ticker_sentiment_score": "0.117291", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.116725", "ticker_sentiment_score": "0.135646", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.116725", "ticker_sentiment_score": "-0.009098", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.116725", "ticker_sentiment_score": "0.086089", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.230965", "ticker_sentiment_score": "0.092303", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYX", "relevance_score": "0.039033", "ticker_sentiment_score": "0.169638", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.155201", "ticker_sentiment_score": "0.216715", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBER", "relevance_score": "0.155201", "ticker_sentiment_score": "-0.001349", "ticker_sentiment_label": "Neutral"}]}, {"title": "Protein Engineering Market size to grow by USD 2.37 billion from 2022-2027| Agilent Technologies Inc., Amgen Inc ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/protein-engineering-market-size-to-grow-by-usd-2-37-billion-from-2022-2027-agilent-technologies-inc-amgen-inc-bio-rad-laboratories-inc-are-emerging-companies-in-the-market--technavio-301939213.html", "time_published": "20230926T234500", "authors": [], "summary": "Protein Engineering Market size to grow by USD 2.37 billion from 2022-2027| Agilent Technologies Inc., Amgen Inc ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.358109, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNNSF", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRKR", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAT", "relevance_score": "0.138863", "ticker_sentiment_score": "0.121471", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.069697", "ticker_sentiment_score": "0.06925", "ticker_sentiment_label": "Neutral"}]}, {"title": "Which Is A Better Pick - PepsiCo Stock Or Amgen?", "url": "https://www.forbes.com/sites/greatspeculations/2023/09/26/which-is-a-better-pick--pepsico-stock-or-amgen/", "time_published": "20230926T100038", "authors": ["Trefis Team"], "summary": "We believe that PepsiCo stock (NYSE: PEP) is a better pick over Amgen stock (NASDAQ: AMGN).", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f6c313c868255bca85cc97/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999767"}], "overall_sentiment_score": 0.222119, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.76367", "ticker_sentiment_score": "0.358854", "ticker_sentiment_label": "Bullish"}, {"ticker": "PEP", "relevance_score": "0.805366", "ticker_sentiment_score": "0.365747", "ticker_sentiment_label": "Bullish"}, {"ticker": "AWON", "relevance_score": "0.04497", "ticker_sentiment_score": "0.067133", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Key Inflation Data Looms As Stocks Bounce", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-key-inflation-data-looms-tesla-stock-in-focus-ahead-of-deliveries/", "time_published": "20230925T211500", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones Futures: Inflation Data Looms As Yields Spike. Tesla ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/10/stock-WallStreet-03-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.154677, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.105604", "ticker_sentiment_score": "0.070068", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.175094", "ticker_sentiment_score": "0.077395", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.105604", "ticker_sentiment_score": "0.049527", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.070517", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.175094", "ticker_sentiment_score": "0.005727", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.209365", "ticker_sentiment_score": "0.035849", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.140485", "ticker_sentiment_score": "0.145607", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.105604", "ticker_sentiment_score": "0.014906", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.175094", "ticker_sentiment_score": "0.033516", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.044129", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.140485", "ticker_sentiment_score": "0.048688", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Coherus BioSciences'  ( CHRS )  Shares Are Falling Today - Coherus BioSciences  ( NASDAQ:CHRS ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34870927/fda-strikes-off-coherus-biosciences-new-injector-biosimilar-treatment-for-cancer-patients", "time_published": "20230925T193507", "authors": ["Vandana Singh"], "summary": "The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's CHRS on-body injector ( OBI ) presentation of Udenyca ( pegfilgrastim-cbqv ) , solely due to an ongoing review of inspection findings at a third-party ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/25/chrs.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.153391, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.308891", "ticker_sentiment_score": "0.056872", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.448842", "ticker_sentiment_score": "0.106912", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2154769/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20230925T130007", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default16.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.213225, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.483888", "ticker_sentiment_score": "0.098006", "ticker_sentiment_label": "Neutral"}]}, {"title": "Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus", "url": "https://www.zacks.com/stock/news/2154739/beat-the-market-like-zacks-elementis-novo-nordisk-amgen-in-focus", "time_published": "20230925T115000", "authors": ["Abhinab Dasgupta"], "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.163831, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BR", "relevance_score": "0.066047", "ticker_sentiment_score": "-0.002005", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.066047", "ticker_sentiment_score": "0.132272", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCC", "relevance_score": "0.066047", "ticker_sentiment_score": "0.150343", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PAYX", "relevance_score": "0.066047", "ticker_sentiment_score": "0.060206", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMSOF", "relevance_score": "0.033052", "ticker_sentiment_score": "0.168547", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.066047", "ticker_sentiment_score": "-0.002005", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.066047", "ticker_sentiment_score": "0.060206", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSCI", "relevance_score": "0.066047", "ticker_sentiment_score": "0.106185", "ticker_sentiment_label": "Neutral"}, {"ticker": "SABR", "relevance_score": "0.066047", "ticker_sentiment_score": "0.173936", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EMNSF", "relevance_score": "0.033052", "ticker_sentiment_score": "0.183194", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.09893", "ticker_sentiment_score": "0.11237", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?", "url": "https://www.zacks.com/stock/news/2154633/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp", "time_published": "20230925T102006", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default85.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.164233, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.132004", "ticker_sentiment_score": "0.063692", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.196877", "ticker_sentiment_score": "0.100763", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.132004", "ticker_sentiment_score": "0.063692", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.132004", "ticker_sentiment_score": "0.063692", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Thyroid Gland Disorder Treatment Market to grow by USD 868.87 million from 2022 to 2027 | Abbott Laboratories ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/the-thyroid-gland-disorder-treatment-market-to-grow-by-usd-868-87-million-from-2022-to-2027--abbott-laboratories-abbvie-inc-alvogen-iceland-ehf-and-more-among-key-companies--technavio-301936306.html", "time_published": "20230925T021500", "authors": [], "summary": "The Thyroid Gland Disorder Treatment Market to grow by USD 868.87 million from 2022 to 2027 | Abbott Laboratories ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.194182, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSNUF", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAYNF", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCINQ", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.077845", "ticker_sentiment_score": "0.027652", "ticker_sentiment_label": "Neutral"}]}, {"title": "Innovative Gelatin Capsules Transforming Pharmaceutical Industry: A Look into the Future", "url": "https://www.prnewswire.com/news-releases/innovative-gelatin-capsules-transforming-pharmaceutical-industry-a-look-into-the-future-301936082.html", "time_published": "20230922T214500", "authors": ["Research and Markets"], "summary": "DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The \"Pharmaceutical Gelatin Market Share, Size, Trends, Industry Analysis Report, By Source, By Function, By End Use, By Regions, Segment Forecast, 2023-2032\" report has been added to ResearchAndMarkets.com's offering.", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.269668, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.060236", "ticker_sentiment_score": "-0.055999", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Dermatology Drugs Market Set to Skyrocket, Anticipated Valuation of $50.47 Billion by 2032", "url": "https://www.prnewswire.com/news-releases/global-dermatology-drugs-market-set-to-skyrocket-anticipated-valuation-of-50-47-billion-by-2032--301936081.html", "time_published": "20230922T213000", "authors": ["Research and Markets"], "summary": "DUBLIN, Sept. 22, 2023 /PRNewswire/ -- The \"Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Segment Forecast, 2023-2032\" report has been added to ResearchAndMarkets.com's ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.263166, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.056", "ticker_sentiment_label": "Neutral"}]}, {"title": "Diving Back Into A Correction: Watchlists, Nike Earnings, Coal Stocks, Housing Data", "url": "https://www.investors.com/research/investing-action-plan/diving-back-into-a-correction-watchlists-nike-earnings-coal-stocks-housing-data/", "time_published": "20230922T212100", "authors": ["ALAN R. ELLIOTT", "Investor's Business Daily"], "summary": "Diving Back Into A Correction: Watchlists, Nike Earnings, Coal ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/02/FIFTY1-021616-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.099065, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.146916", "ticker_sentiment_score": "0.118412", "ticker_sentiment_label": "Neutral"}, {"ticker": "BG", "relevance_score": "0.218817", "ticker_sentiment_score": "0.180572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCH", "relevance_score": "0.146916", "ticker_sentiment_score": "0.169497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRTX", "relevance_score": "0.146916", "ticker_sentiment_score": "0.118412", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACGL", "relevance_score": "0.218817", "ticker_sentiment_score": "0.180572", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NKE", "relevance_score": "0.541149", "ticker_sentiment_score": "0.087704", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.218817", "ticker_sentiment_score": "-0.169165", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GE", "relevance_score": "0.146916", "ticker_sentiment_score": "0.118412", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.218817", "ticker_sentiment_score": "-0.169165", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "AI To Revolutionize Clinical Trials And Diagnostics - Mainz Biomed  ( NASDAQ:MYNZ ) ", "url": "https://www.benzinga.com/markets/penny-stocks/23/09/34828759/ai-to-revolutionize-clinical-trials-and-diagnostics", "time_published": "20230922T165108", "authors": ["Upwallstreet"], "summary": "With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics. For example, Mainz Biomed MYNZ has developled ColoAlert, an affordable test for early ...", "banner_image": "https://cdn.benzinga.com/files/female-scientist-lab-with-notepad.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.107581, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.129516", "ticker_sentiment_score": "0.077811", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.129516", "ticker_sentiment_score": "0.077811", "ticker_sentiment_label": "Neutral"}]}, {"title": "Glioma Treatment Market worth $8.29 Billion by 2030 - Exclusive Report by The Insight Partners", "url": "https://www.benzinga.com/pressreleases/23/09/g34822634/glioma-treatment-market-worth-8-29-billion-by-2030-exclusive-report-by-the-insight-partners", "time_published": "20230922T125442", "authors": ["Globe Newswire"], "summary": "Pune, India, Sept. 22, 2023 ( GLOBE NEWSWIRE ) -- Glioma is a condition that covers a broad category of brain and spinal cord tumors that concern the glial cells in the brain function and can be fatal depending on the location and severity of the tumor.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.041116, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KPTI", "relevance_score": "0.023418", "ticker_sentiment_score": "0.087173", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.023418", "ticker_sentiment_score": "0.153913", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEVA", "relevance_score": "0.023418", "ticker_sentiment_score": "0.087173", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRX", "relevance_score": "0.023418", "ticker_sentiment_score": "0.087173", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDMO", "relevance_score": "0.023418", "ticker_sentiment_score": "0.153913", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.023418", "ticker_sentiment_score": "0.087173", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023418", "ticker_sentiment_score": "0.087173", "ticker_sentiment_label": "Neutral"}]}, {"title": "From Years to Months: How AI is Shaping the Landscape of Clinical Trials - Novartis  ( NYSE:NVS ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34818722/from-years-to-months-how-ai-is-shaping-the-landscape-of-clinical-trials", "time_published": "20230922T114907", "authors": ["Vandana Singh"], "summary": "Pharmaceutical companies are harnessing artificial intelligence ( AI ) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These human studies, crucial to drug development, can take years and accrue costs in the billions.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/22/laboratory-g420324b5c_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.261679, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.360752", "ticker_sentiment_score": "0.172304", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.245339", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.245339", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Neumora Therapeutics Slumped This Week", "url": "https://www.fool.com/investing/2023/09/21/why-shares-of-neumora-therapeutics-slumped-this-we/", "time_published": "20230921T220604", "authors": ["Jim Halley"], "summary": "The clinical-stage biotech just had its IPO last week.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.137723, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.126784", "ticker_sentiment_score": "0.095482", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.126784", "ticker_sentiment_score": "0.134813", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Stock Moves -0.76%: What You Should Know", "url": "https://www.zacks.com/stock/news/2153920/amgen-amgn-stock-moves--076-what-you-should-know", "time_published": "20230921T215020", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $269.41, marking a -0.76% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default156.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.162742, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.670305", "ticker_sentiment_score": "0.206665", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Dividend Growth Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/09/21/2-dividend-growth-stocks-to-buy-right-now/", "time_published": "20230921T133700", "authors": ["Prosper Junior Bakiny"], "summary": "A wise man once said, be greedy when others are fearful.", "banner_image": "https://media.ycharts.com/charts/432f23a2346e3a885a16e79ac83635b0.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.222236, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.045655", "ticker_sentiment_score": "0.016991", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.54329", "ticker_sentiment_score": "0.329071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.045655", "ticker_sentiment_score": "0.10641", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.225321", "ticker_sentiment_score": "0.010819", "ticker_sentiment_label": "Neutral"}]}, {"title": "HP Inc. Names David Meline to Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/09/21/2747292/0/en/HP-Inc-Names-David-Meline-to-Board-of-Directors.html", "time_published": "20230921T123500", "authors": ["HP Inc."], "summary": "PALO ALTO, Calif., Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- HP Inc. ( NYSE: HPQ ) today announced the appointment of David Meline to its Board of Directors. Meline is the former Chief Financial Officer for Moderna Inc., a global biotechnology and pharmaceutical leader. His appointment is effective ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/37c4d49c-63cd-4ba2-9a1a-c89d07424eb9", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.303015, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HPQ", "relevance_score": "0.493128", "ticker_sentiment_score": "0.574569", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABLZF", "relevance_score": "0.105604", "ticker_sentiment_score": "0.071151", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.209365", "ticker_sentiment_score": "0.065542", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.105604", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Dividend Stocks: Amgen Hits Buy Point, Offers Solid Dividend Growth", "url": "https://www.investors.com/research/the-income-investor/dividend-stocks-amgen-outperforms-hitting-buypoint-offers-solid-dividend-growth/", "time_published": "20230920T175700", "authors": ["STEVEN BELL", "Investor's Business Daily"], "summary": "Best Dividend Stocks: Amgen Hits Buy Point, Offers Solid Dividend ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/stock-amgen-04-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.18286, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.708701", "ticker_sentiment_score": "0.084686", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.11983", "ticker_sentiment_score": "-0.195612", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HZNP", "relevance_score": "0.236972", "ticker_sentiment_score": "0.103142", "ticker_sentiment_label": "Neutral"}]}, {"title": "INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc's Directors and Officers for Breach of Fiduciary Duties - AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34769377/investigation-alert-scott-scott-attorneys-at-law-llp-investigates-amgen-incs-directors-and-officer", "time_published": "20230920T171628", "authors": ["Globe Newswire"], "summary": "NEW YORK, Sept. 20, 2023 ( GLOBE NEWSWIRE ) -- Scott+Scott Attorneys at Law LLP ( \"Scott+Scott\" ) , an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. ( \"Amgen\" ) AMGN breached their fiduciary duties to Amgen and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.13568, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.950503", "ticker_sentiment_score": "0.179173", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/09/34768132/check-out-what-whales-are-doing-with-amgn", "time_published": "20230920T161632", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.150512, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.729067", "ticker_sentiment_score": "0.144704", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2152870/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230920T102005", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default165.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18723, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.069294", "ticker_sentiment_score": "0.034094", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.138066", "ticker_sentiment_score": "0.072464", "ticker_sentiment_label": "Neutral"}]}, {"title": "JNJ: 3 Healthcare Stocks to Buy Today", "url": "https://stocknews.com/news/jnj-abbv-amgn-3-healthcare-stocks-to-buy-today/", "time_published": "20230918T161805", "authors": ["StockNews.com Staff"], "summary": "Johnson & Johnson ( JNJ ) , Amgen ( AMGN ) and AbbVie ( ABBV ) are healthcare sector leaders with their company specific transformative catalysts in the fray. All three stocks are rated a strong buy by the propriety POWR Rating, ranking above the 95th percentile.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/07/shutterstock_1006149949-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.204143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.075161", "ticker_sentiment_score": "-0.031981", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.258743", "ticker_sentiment_score": "0.158904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.328819", "ticker_sentiment_score": "0.221508", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.075161", "ticker_sentiment_score": "0.054204", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.396147", "ticker_sentiment_score": "0.21806", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Beat the Market the Zacks Way: Automatic Data Processing, Casey's, Paysafe in Focus", "url": "https://www.zacks.com/stock/news/2151789/beat-the-market-the-zacks-way-automatic-data-processing-caseys-paysafe-in-focus", "time_published": "20230918T120200", "authors": ["Abhinab Dasgupta"], "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/84/1383.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.164045, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ESRT", "relevance_score": "0.06471", "ticker_sentiment_score": "0.252698", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.06471", "ticker_sentiment_score": "0.101106", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRM", "relevance_score": "0.06471", "ticker_sentiment_score": "0.138195", "ticker_sentiment_label": "Neutral"}, {"ticker": "WWD", "relevance_score": "0.06471", "ticker_sentiment_score": "0.236342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.096932", "ticker_sentiment_score": "0.106473", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSFE", "relevance_score": "0.06471", "ticker_sentiment_score": "0.236342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CASY", "relevance_score": "0.06471", "ticker_sentiment_score": "0.062045", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADP", "relevance_score": "0.06471", "ticker_sentiment_score": "0.061155", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.06471", "ticker_sentiment_score": "0.061155", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBB", "relevance_score": "0.06471", "ticker_sentiment_score": "0.132178", "ticker_sentiment_label": "Neutral"}]}, {"title": "Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html", "time_published": "20230918T091500", "authors": [], "summary": "Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.019617, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNX", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLDX", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.08609", "ticker_sentiment_score": "-0.093515", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.043108", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/large-molecule-injectable-drugs-market-to-grow-by-usd-191-45-billion-from-2022-2027--north-america-to-account-for-45-of-market-growth---technavio-301929312.html", "time_published": "20230918T083500", "authors": [], "summary": "Large Molecule Injectable Drugs Market to grow by USD 191.45 billion from 2022-2027 | North America to account for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.157274, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAX", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.052685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/09/34623014/amgen-unusual-options-activity", "time_published": "20230915T164755", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.148456, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.703874", "ticker_sentiment_score": "0.164878", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( AMGN )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2149176/amgen-amgn-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230914T215017", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $262.30, marking a +1.97% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default308.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.219121, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.689912", "ticker_sentiment_score": "0.402702", "ticker_sentiment_label": "Bullish"}]}, {"title": "MRNA: Moderna  ( MRNA )  Stock Analysis: Is the Biotech Stock a Buy at This Time?", "url": "https://stocknews.com/news/mrna-jazz-otsky-amgn-moderna-mrna-stock-analysis-is-the-biotech-stock-a-buy/", "time_published": "20230914T165016", "authors": ["StockNews.com Staff"], "summary": "MRNA: Moderna ( MRNA ) Stock Analysis: Is the Biotech Stock a Buy ... ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/Biotech-Lg_FB.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.131754, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MRNA", "relevance_score": "0.595794", "ticker_sentiment_score": "0.219381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.045874", "ticker_sentiment_score": "0.171212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.045874", "ticker_sentiment_score": "0.171212", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/09/34547484/1000-invested-in-this-stock-15-years-ago-would-be-worth-4-200-today", "time_published": "20230913T183021", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 1.11% on an annualized basis producing an average annual return of 10.27%. Currently, Amgen has a market capitalization of $138.98 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "2 Top Dividend Stocks to Buy in September", "url": "https://www.fool.com/investing/2023/09/13/2-top-dividend-stocks-to-buy-in-september/", "time_published": "20230913T143000", "authors": ["George Budwell"], "summary": "These two blue-chip dividend stocks have stood the test of time.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F747174%2Fdividends.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.455157, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.365166", "ticker_sentiment_score": "0.52113", "ticker_sentiment_label": "Bullish"}, {"ticker": "AXP", "relevance_score": "0.473427", "ticker_sentiment_score": "0.566949", "ticker_sentiment_label": "Bullish"}]}, {"title": "AbbVie's  ( ABBV )  Skyrizi Crohn's Disease Study Meets Goals", "url": "https://www.zacks.com/stock/news/2148368/abbvies-abbv-skyrizi-crohns-disease-study-meets-goals", "time_published": "20230913T140200", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cc/389.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.245804, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.202932", "ticker_sentiment_score": "0.210757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHRS", "relevance_score": "0.068306", "ticker_sentiment_score": "0.133832", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.559547", "ticker_sentiment_score": "0.328597", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - CVS Health  ( NYSE:CVS ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/09/34530435/these-3-health-care-stocks-with-over-3-dividend-yields-are-recommended-by-wall-streets-m", "time_published": "20230913T113521", "authors": ["Lisa Levin"], "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/13/image11.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.080874, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.306627", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MDT", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.049605", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.104228", "ticker_sentiment_score": "0.111909", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.104228", "ticker_sentiment_score": "-0.014336", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.206685", "ticker_sentiment_score": "0.164796", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "NVS: 3 Pharma Stocks Surpassing Johnson & Johnson  ( JNJ ) ", "url": "https://stocknews.com/news/nvs-hznp-rdy-jnj-amgn-3-pharma-stocks-surpassing-johnson-johnson-jnj/", "time_published": "20230912T163807", "authors": ["StockNews.com Staff"], "summary": "NVS: 3 Pharma Stocks Surpassing Johnson & Johnson ...", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_745024336-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.23135, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.393241", "ticker_sentiment_score": "0.301748", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.087824", "ticker_sentiment_score": "0.171752", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.231332", "ticker_sentiment_score": "0.124567", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.058615", "ticker_sentiment_score": "0.11319", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.029327", "ticker_sentiment_score": "0.198322", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know", "url": "https://www.zacks.com/stock/news/2147660/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know", "time_published": "20230912T130006", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.230788, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.488469", "ticker_sentiment_score": "0.134943", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold", "url": "https://www.investors.com/research/amgen-stock-earns-relative-strength-rating-upgrade-hits-key-threshold/", "time_published": "20230911T183700", "authors": ["INVESTOR'S BUSINESS DAILY", "JULIE MAK", "Investor's Business Daily"], "summary": "Amgen Stock Earns Relative Strength Rating Upgrade. Hits Key ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU5.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.300024, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.592095", "ticker_sentiment_score": "0.341341", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.320974", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.320974", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis - Novartis  ( NYSE:NVS ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34440622/another-arthritis-blockbuster-drug-faces-generic-competition-novartis-sandoz-inks-pact-with-samsu", "time_published": "20230911T133200", "authors": ["Vandana Singh"], "summary": "Sandoz, a generic and biosimilar medicines unit of Novartis AG NVS, has entered a development and commercialization agreement with Samsung Bioepis. The agreement provides Sandoz exclusive rights to commercialize the biosimilar SB17 ustekinumab in the US, Canada, EEA, Switzerland, and the U.K.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/nvs.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185087, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.252987", "ticker_sentiment_score": "0.163659", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVS", "relevance_score": "0.252987", "ticker_sentiment_score": "0.244215", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.252987", "ticker_sentiment_score": "0.265849", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.252987", "ticker_sentiment_score": "0.094961", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.065606", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.101034", "ticker_sentiment_label": "Neutral"}]}, {"title": "Which Is A Better Pick - Honeywell Stock Or Amgen?", "url": "https://www.forbes.com/sites/greatspeculations/2023/09/11/which-is-a-better-pick--honeywell-stock-or-amgen/", "time_published": "20230911T130057", "authors": ["Trefis Team"], "summary": "We believe that Honeywell stock (NYSE: HON) and Amgen stock (NASDAQ: AMGN) will offer little returns in the next three years.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64feb5650dc6b1324873b638/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.998682"}], "overall_sentiment_score": 0.124103, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.665853", "ticker_sentiment_score": "0.264988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HON", "relevance_score": "0.795061", "ticker_sentiment_score": "0.207078", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Longeveron  ( NASDAQ: LGVN )  Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS  ( Compared To 80% Survival In Historical Trials )  To Market - Longeveron  ( NASDAQ:LGVN ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34436783/longeveron-nasdaq-lgvn-reports-100-5-year-survival-in-trial-for-rare-pediatric-disease-hlhs-compa", "time_published": "20230911T120509", "authors": ["David Willey"], "summary": "Advancements in healthcare and medicine have helped contribute to the reduction in child mortality rates, plummeting from 185 per 1,000 births a century ago to just 7 per 1,000 births in 2020. However, some serious pediatric conditions continue to pose a threat.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/11/screenshot_2023-09-11_at_5.33.52_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.223302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGVN", "relevance_score": "0.254307", "ticker_sentiment_score": "0.328893", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.128822", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.128822", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus", "url": "https://www.zacks.com/stock/news/2147094/take-the-zacks-approach-to-beat-the-market-shopify-novo-nordisk-amgen-in-focus", "time_published": "20230911T120100", "authors": ["Abhinab Dasgupta"], "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/1179.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.170879, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.067347", "ticker_sentiment_score": "0.132382", "ticker_sentiment_label": "Neutral"}, {"ticker": "BZH", "relevance_score": "0.067347", "ticker_sentiment_score": "0.260272", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HQY", "relevance_score": "0.067347", "ticker_sentiment_score": "0.279454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OFG", "relevance_score": "0.067347", "ticker_sentiment_score": "0.279454", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRS", "relevance_score": "0.067347", "ticker_sentiment_score": "0.142432", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYX", "relevance_score": "0.067347", "ticker_sentiment_score": "0.060269", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.067347", "ticker_sentiment_score": "0.06212", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.067347", "ticker_sentiment_score": "0.06212", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.067347", "ticker_sentiment_score": "0.060269", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADP", "relevance_score": "0.067347", "ticker_sentiment_score": "0.106267", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.10087", "ticker_sentiment_score": "0.112974", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Reports Positive Data From Phase 1 Study Of Lumakras Combination In Non-small Cell Lung Cancer", "url": "https://markets.businessinsider.com/news/stocks/amgen-reports-positive-data-from-phase-1-study-of-lumakras-combination-in-non-small-cell-lung-cancer-1032618038", "time_published": "20230910T151635", "authors": ["markets.businessinsider.com"], "summary": "( RTTNews ) - Amgen ( AMGN ) announced positive data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating Lumakras ( sotorasib ) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer or NSCLC.", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.033824, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.44622", "ticker_sentiment_score": "-0.143554", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2146847/amgen-amgn-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230908T215017", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $259.43, marking a +1.98% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default221.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.19136, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.666827", "ticker_sentiment_score": "0.363312", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Jones Rises 100 Points, Led By Microsoft, Apple Stock; High-Flying Adobe Upgraded Ahead Of Earnings", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-edges-higher-led-by-apple-stock-adobe-snares-upgrade-ahead-of-earnings-while-nvidia-tests-key-level/", "time_published": "20230908T144800", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Dow Jones Rises 100 Points, Led By Microsoft, Apple Stock. High ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.980509"}], "overall_sentiment_score": 0.050999, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.035362", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.195051", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AAPL", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.113737", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.190417", "ticker_sentiment_score": "0.184818", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RH", "relevance_score": "0.095899", "ticker_sentiment_score": "0.087326", "ticker_sentiment_label": "Neutral"}, {"ticker": "KR", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.210029", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADBE", "relevance_score": "0.236742", "ticker_sentiment_score": "0.151675", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.143415", "ticker_sentiment_score": "-0.035362", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.095899", "ticker_sentiment_score": "0.161928", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MANH", "relevance_score": "0.095899", "ticker_sentiment_score": "0.126156", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUOL", "relevance_score": "0.095899", "ticker_sentiment_score": "0.363605", "ticker_sentiment_label": "Bullish"}, {"ticker": "IOT", "relevance_score": "0.095899", "ticker_sentiment_score": "0.068212", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is The Market Feeling About Amgen? - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/09/34363275/how-is-the-market-feeling-about-amgen", "time_published": "20230908T143023", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has risen 8.2% since its last report. The company recently reported that it has 7.03 million shares sold short, which is 1.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.43 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More", "url": "https://www.zacks.com/stock/news/2146657/biotech-stock-roundup-mrnas-vaccine-update-amgn-hznp-clear-ftc-lawsuit-more", "time_published": "20230908T135800", "authors": ["Zacks Equity Research"], "summary": "Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default115.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.136858, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALNY", "relevance_score": "0.090816", "ticker_sentiment_score": "0.039966", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHVN", "relevance_score": "0.224487", "ticker_sentiment_score": "0.180294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRNA", "relevance_score": "0.310283", "ticker_sentiment_score": "0.018387", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.224487", "ticker_sentiment_score": "0.133694", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.18046", "ticker_sentiment_score": "0.113277", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Fall As Stock Market Rally Struggles", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stock-market-rally-struggles-cathie-wood-sells-nvidia-stock/", "time_published": "20230908T121100", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "Dow Jones futures dropped Friday morning, along with S&P 500 and Nasdaq futures, as the stock market headed for a losing week. Cathie Wood's Ark Invest ETFs sold more than 13,500 shares of Nvidia stock. Ahead of Friday's opening bell, Dow Jones futures dropped 0.2%, while S&P 500 futures lost ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.095911, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NFLX", "relevance_score": "0.0864", "ticker_sentiment_score": "0.067795", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.043264", "ticker_sentiment_score": "-0.002972", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.129284", "ticker_sentiment_score": "-0.016358", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKR", "relevance_score": "0.0864", "ticker_sentiment_score": "0.047211", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.043264", "ticker_sentiment_score": "0.110761", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.0864", "ticker_sentiment_score": "-0.222127", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.043264", "ticker_sentiment_score": "0.006948", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.0864", "ticker_sentiment_score": "-0.049308", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.2138", "ticker_sentiment_score": "0.020868", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.129284", "ticker_sentiment_score": "-0.158354", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "V", "relevance_score": "0.0864", "ticker_sentiment_score": "-0.075008", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.129284", "ticker_sentiment_score": "0.068312", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.0864", "ticker_sentiment_score": "0.062646", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Rating Increased to Strong-Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/09/08/amgen-nasdaqamgn-rating-increased-to-strong-buy-at-stocknews-com.html", "time_published": "20230908T071245", "authors": ["Defense World Staff"], "summary": "Amgen ( NASDAQ:AMGN ) Rating Increased to Strong-Buy at ... Defense World ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.22492, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.794423", "ticker_sentiment_score": "0.369276", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.050465", "ticker_sentiment_score": "0.076415", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.050465", "ticker_sentiment_score": "0.076415", "ticker_sentiment_label": "Neutral"}]}, {"title": "IBD Rating Upgrades: Amgen Flashes Improved Price Strength", "url": "https://www.investors.com/ibd-data-stories/ibd-rating-upgrades-amgen-flashes-improved-price-strength-2/", "time_published": "20230908T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "In a welcome move, Amgen ( AMGN ) saw its Relative Strength Rating rise from 70 to 75 on Friday. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.337301, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.605266", "ticker_sentiment_score": "0.375862", "ticker_sentiment_label": "Bullish"}, {"ticker": "HZNP", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNSA", "relevance_score": "0.329551", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC Settles Suit, Potentially Averting Further Hurdles", "url": "https://www.investorideas.com/news/2023/biotech/09072FTC-Settles-Suit.asp", "time_published": "20230907T173823", "authors": [], "summary": "Last week, the U.S. Federal Trade Commission ( FTC ) suspended its legal challenge to Amgen Inc. ( AMGN:NASDAQ ) 's proposed acquisition of Horizon Therapeutics Plc ( HZNP:NASDAQ ) , 2022's largest deal announcement in the biopharma space.", "banner_image": "https://www.streetwisereports.com/images/national-cancer-institute-PP5nO5gcLdA-unsplash_1.jpg", "source": "Investor Ideas", "category_within_source": "n/a", "source_domain": "www.investorideas.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.19758, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.246549", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.061949", "ticker_sentiment_score": "0.033094", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.061949", "ticker_sentiment_score": "0.033094", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.359014", "ticker_sentiment_score": "0.315656", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( AMGN )  Stock Outperforms Industry YTD: Here's Why", "url": "https://www.zacks.com/stock/news/2145372/amgen-amgn-stock-outperforms-industry-ytd-heres-why", "time_published": "20230906T134000", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998626"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.26083, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CORT", "relevance_score": "0.113597", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.279015", "ticker_sentiment_score": "0.214655", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.608634", "ticker_sentiment_score": "0.314452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.224903", "ticker_sentiment_score": "0.462142", "ticker_sentiment_label": "Bullish"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Wednesday", "url": "https://www.cnbc.com/2023/09/06/jim-cramers-top-10-things-to-watch-in-the-stock-market-wednesday-.html", "time_published": "20230906T130822", "authors": ["Jim Cramer"], "summary": "Equities are lower in premarket trading Wednesday, while Arm Holdings' roadshow ahead of a planned initial public offering is impressive.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107290745-1692802098753-gettyimages-1619153799-ARM_IPO.jpeg?v=1694005702&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.076538, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TJX", "relevance_score": "0.136113", "ticker_sentiment_score": "0.161328", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "D", "relevance_score": "0.068306", "ticker_sentiment_score": "0.112032", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.136113", "ticker_sentiment_score": "0.024715", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.068306", "ticker_sentiment_score": "0.078215", "ticker_sentiment_label": "Neutral"}, {"ticker": "STZ", "relevance_score": "0.136113", "ticker_sentiment_score": "0.17828", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHTR", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.3583", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.136113", "ticker_sentiment_score": "0.028359", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations - Horizon Therapeutics  ( NASDAQ:HZNP ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34245963/amgens-horizon-acquisition-offers-multiple-advantages-tax-breaks-shield-from-drug-pricing-negotia", "time_published": "20230905T175220", "authors": ["Vandana Singh"], "summary": "On Friday, the U.S. Federal Trade Commission ( FTC ) gave a green light to Amgen Inc's AMGN acquisition of Horizon Therapeutics Plc HZNP, which contradicts its earlier commitment to tighter antitrust checks.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/05/amgn-hznp.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.043211, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.582526", "ticker_sentiment_score": "0.348526", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.213048", "ticker_sentiment_score": "0.008489", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Still Buy the Dow Jones' Best-Performing August Stocks?", "url": "https://www.fool.com/investing/2023/09/05/should-you-still-buy-the-dow-jones-best-performing/", "time_published": "20230905T131300", "authors": ["James Brumley"], "summary": "They're rolling now, but this market has been too hot-and-cold of late to ignore any company's -- or company's stock's -- underlying bigger picture.", "banner_image": "https://media.ycharts.com/charts/d47ef694f29c2cf606f55c63edc8dbe5.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.278634, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CSCO", "relevance_score": "0.281307", "ticker_sentiment_score": "0.294289", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.319414", "ticker_sentiment_score": "0.227248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.041039", "ticker_sentiment_score": "0.051347", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.203045", "ticker_sentiment_score": "0.248142", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus", "url": "https://www.zacks.com/stock/news/2144752/beat-the-market-the-zacks-way-nvidia-novo-nordisk-matson-in-focus", "time_published": "20230905T120600", "authors": ["Abhinab Dasgupta"], "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/93/98.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.226287, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BR", "relevance_score": "0.067158", "ticker_sentiment_score": "0.063116", "ticker_sentiment_label": "Neutral"}, {"ticker": "CELH", "relevance_score": "0.067158", "ticker_sentiment_score": "0.212844", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.067158", "ticker_sentiment_score": "0.063116", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCC", "relevance_score": "0.067158", "ticker_sentiment_score": "0.279407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.100588", "ticker_sentiment_score": "0.107531", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.067158", "ticker_sentiment_score": "0.101236", "ticker_sentiment_label": "Neutral"}, {"ticker": "CME", "relevance_score": "0.067158", "ticker_sentiment_score": "0.135379", "ticker_sentiment_label": "Neutral"}, {"ticker": "MATX", "relevance_score": "0.067158", "ticker_sentiment_score": "0.260229", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.067158", "ticker_sentiment_score": "0.061268", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.067158", "ticker_sentiment_score": "0.061268", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVT", "relevance_score": "0.067158", "ticker_sentiment_score": "0.279407", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-expands-executive-leadership-team-with-appointment-of-industry-veterans-scott-burrows-and-heidy-abreu-king-jones-301917249.html", "time_published": "20230905T110000", "authors": [], "summary": "Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.999921"}], "overall_sentiment_score": 0.264247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AGLE", "relevance_score": "0.121445", "ticker_sentiment_score": "0.10459", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARQT", "relevance_score": "0.121445", "ticker_sentiment_score": "0.071439", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXLA", "relevance_score": "0.040622", "ticker_sentiment_score": "0.125346", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.040622", "ticker_sentiment_score": "0.064589", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.040622", "ticker_sentiment_score": "0.125346", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.040622", "ticker_sentiment_score": "0.125346", "ticker_sentiment_label": "Neutral"}]}, {"title": "GSK: 3 Pharma Stocks for Value Investors", "url": "https://stocknews.com/news/gsk-hznp-nbix-amgn-pph-3-pharma-stocks-for-value-investors/", "time_published": "20230904T185844", "authors": ["StockNews.com Staff"], "summary": "The pharmaceutical industry is well-positioned to witness solid long-term growth thanks to the fast-expanding market for drugs and therapies. Moreover, given the consistent product demand, the pharma business is less susceptible to economic cycles.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/11/shutterstock_1289565157-1-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.246907, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.098524", "ticker_sentiment_score": "0.176628", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GSK", "relevance_score": "0.22731", "ticker_sentiment_score": "0.24603", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.163465", "ticker_sentiment_score": "0.089455", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBIX", "relevance_score": "0.131105", "ticker_sentiment_score": "0.121667", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC Allows Amgen  ( AMGN )  to Proceed With $28B Horizon Buyout", "url": "https://www.zacks.com/stock/news/2144523/ftc-allows-amgen-amgn-to-proceed-with-28b-horizon-buyout", "time_published": "20230904T161400", "authors": ["Zacks Equity Research"], "summary": "Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.021584, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DVAX", "relevance_score": "0.399204", "ticker_sentiment_score": "0.121577", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANVS", "relevance_score": "0.272788", "ticker_sentiment_score": "0.073955", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.704675", "ticker_sentiment_score": "0.00382", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.616842", "ticker_sentiment_score": "-0.032461", "ticker_sentiment_label": "Neutral"}]}, {"title": "Addressing the Fragile: 2023 Global Osteogenesis Imperfecta Treatment Market's Growth Driven by Research and Collaboration", "url": "https://www.prnewswire.com/news-releases/addressing-the-fragile-2023-global-osteogenesis-imperfecta-treatment-markets-growth-driven-by-research-and-collaboration-301916828.html", "time_published": "20230904T154500", "authors": ["Research and Markets"], "summary": "Addressing the Fragile: 2023 Global Osteogenesis Imperfecta Treatment Market's Growth Driven by Research and ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.048854, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MREO", "relevance_score": "0.074001", "ticker_sentiment_score": "0.048716", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.074001", "ticker_sentiment_score": "0.048716", "ticker_sentiment_label": "Neutral"}, {"ticker": "RARE", "relevance_score": "0.074001", "ticker_sentiment_score": "0.048716", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.074001", "ticker_sentiment_score": "0.048716", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIDS", "relevance_score": "0.074001", "ticker_sentiment_score": "0.048716", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.074001", "ticker_sentiment_score": "0.048716", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  is a Top-Ranked Momentum Stock: Should You Buy?", "url": "https://www.zacks.com/stock/news/2144314/amgen-amgn-is-a-top-ranked-momentum-stock-should-you-buy", "time_published": "20230904T135007", "authors": ["Zacks Equity Research"], "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default290.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": 0.365221, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.451494", "ticker_sentiment_score": "0.202113", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "As Medicare drug-price negotiations inch forward, some states are flexing new powers to cut costs for a broader swath of drugs", "url": "https://www.marketwatch.com/story/as-medicare-drug-price-negotiations-inch-forward-some-states-are-flexing-new-powers-to-cut-costs-for-a-broader-swath-of-drugs-a4ca7f3e", "time_published": "20230901T153000", "authors": ["Eleanor Laise"], "summary": "States like Colorado are looking to set upper payment limits on certain drugs as soon as next year.", "banner_image": "https://images.mktw.net/im-837664/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.035458, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.063678", "ticker_sentiment_score": "-0.049016", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.063678", "ticker_sentiment_score": "-0.03203", "ticker_sentiment_label": "Neutral"}]}, {"title": "Market Rally Gains Momentum As Yields Slide: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-gains-momentum-as-treasury-yields-slide-tesla-unveils-model-3-upgrade/", "time_published": "20230901T145800", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "The stock market rally staged a follow-through day Tuesday, with the major indexes running above the 50-day line in higher volume. Tame labor and inflation data sent Treasury yields sharply lower, giving stocks a lift.", "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-BullHead-91-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.009644, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.089129", "ticker_sentiment_score": "0.024048", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.044634", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.034831", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.084877", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPQ", "relevance_score": "0.044634", "ticker_sentiment_score": "0.051761", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDB", "relevance_score": "0.089129", "ticker_sentiment_score": "-0.027884", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.030841", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.111281", "ticker_sentiment_score": "0.020489", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.044634", "ticker_sentiment_score": "0.016724", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDD", "relevance_score": "0.044634", "ticker_sentiment_score": "0.014985", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIVE", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.084877", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTG", "relevance_score": "0.044634", "ticker_sentiment_score": "0.03125", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.082416", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.155308", "ticker_sentiment_score": "0.027029", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBL", "relevance_score": "0.044634", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBY", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.066627", "ticker_sentiment_label": "Neutral"}, {"ticker": "DELL", "relevance_score": "0.044634", "ticker_sentiment_score": "0.070764", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIG", "relevance_score": "0.066908", "ticker_sentiment_score": "-0.086213", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.111281", "ticker_sentiment_score": "0.005718", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.089129", "ticker_sentiment_score": "0.014921", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTNX", "relevance_score": "0.066908", "ticker_sentiment_score": "-0.035198", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMBA", "relevance_score": "0.066908", "ticker_sentiment_score": "-0.035336", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYDIY", "relevance_score": "0.022326", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.030841", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPE", "relevance_score": "0.044634", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.022326", "ticker_sentiment_score": "-0.018816", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.01906", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLLI", "relevance_score": "0.044634", "ticker_sentiment_score": "-0.084877", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.089129", "ticker_sentiment_score": "0.084766", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's $27.8 Billion Purchase Of Horizon Therapeutics On After FTC Settlement", "url": "https://www.forbes.com/sites/tylerroush/2023/09/01/amgens-278-billion-purchase-of-horizon-therapeutics-on-after-ftc-settlement/", "time_published": "20230901T145309", "authors": ["Ty Roush"], "summary": "The agency previously argued the merger could harm patients who are prescribed Horizon's two fastest-growing drugs.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64f1fa63063fd220ce1e813e/0x0.jpg?format=jpg&crop=2203,1238,x0,y119,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.045387, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.164441", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HZNP", "relevance_score": "0.204936", "ticker_sentiment_score": "-0.194922", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.078932", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.103331", "ticker_sentiment_score": "-0.078932", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal - Horizon Therapeutics  ( NASDAQ:HZNP ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/09/34172813/amgen-horizon-therapeutics-28b-acquisition-federal-trade-commission-gives-green-signal", "time_published": "20230901T144738", "authors": ["Vandana Singh"], "summary": "The U.S. Federal Trade Commission ( FTC ) has approved drug manufacturer Amgen Inc AMGN to proceed with its $27.8 billion acquisition of Horizon Therapeutics Plc HZNP. This decision reverses the FTC's earlier objections to the deal.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/09/01/amgn-hznp.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.045737, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.690822", "ticker_sentiment_score": "0.181075", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.388879", "ticker_sentiment_score": "0.272658", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/anti-rheumatic-market-to-grow-exponentially-by-2029--brandessence-market-research-301915970.html", "time_published": "20230901T143400", "authors": ["Brandessence Market Research And Consulting Private Limited"], "summary": "LONDON, Sept. 1, 2023 /PRNewswire/ -- Rheumatoid arthritis ( RA ) is a highly prevalent auto-immune ailment. This disease predominantly affects our joints, mainly that of hands and feet. It occurs when the immune system begins attacking the healthy tissues.", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.110872, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CPIX", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.027382", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.054732", "ticker_sentiment_score": "0.131821", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027382", "ticker_sentiment_score": "0.060193", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. FTC allows Amgen to go ahead with $27.8 bln Horizon deal", "url": "https://www.reuters.com/markets/deals/us-ftc-allows-amgen-move-forward-with-278-bln-horizon-deal-cnbc-2023-09-01/", "time_published": "20230901T130800", "authors": ["Manas Mishra", "David Shepardson"], "summary": "An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013. REUTERS/Robert Galbraith/Files Acquire Licensing Rights Sept 1 ( Reuters ) - The U.S.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/LM23T4TJARKYVBE3LV24IMDCNY.jpg", "source": "Reuters", "category_within_source": "Markets", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.057929, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.129516", "ticker_sentiment_score": "-0.061926", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.129516", "ticker_sentiment_score": "-0.061926", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here is What to Know Beyond Why Amgen Inc.  ( AMGN )  is a Trending Stock", "url": "https://www.zacks.com/stock/news/2143497/here-is-what-to-know-beyond-why-amgen-inc-amgn-is-a-trending-stock", "time_published": "20230901T130006", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.233334, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.482078", "ticker_sentiment_score": "0.106902", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Downgraded by StockNews.com to \"Buy\"", "url": "https://www.defenseworld.net/2023/09/01/amgen-nasdaqamgn-downgraded-by-stocknews-com-to-buy.html", "time_published": "20230901T093449", "authors": ["Defense World Staff"], "summary": "StockNews.com downgraded shares of Amgen ( NASDAQ:AMGN - Free Report ) from a strong-buy rating to a buy rating in a research note released on Thursday. Other equities research analysts have also recently issued research reports about the stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}, {"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.234174, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JEF", "relevance_score": "0.049732", "ticker_sentiment_score": "0.055545", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.049732", "ticker_sentiment_score": "0.055545", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.049732", "ticker_sentiment_score": "0.055545", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.049732", "ticker_sentiment_score": "0.075", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is This the Green Light Biotech Stocks Have Been Waiting For?", "url": "https://www.fool.com/investing/2023/08/31/is-this-the-green-light-biotech-stocks-have-been-w/", "time_published": "20230831T115300", "authors": ["Cory Renauer"], "summary": "It looks like the Federal Trade Commission will give up on its attempt to block Amgen's acquisition of Horizon Therapeutics.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745808%2F3-frowning-people-looking-at-a-laptop.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.093955, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.368091", "ticker_sentiment_score": "0.120528", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.095327", "ticker_sentiment_score": "-0.110783", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.047749", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicare's First Price Negotiation List Targets Expensive Drugs  ( Revised ) ", "url": "https://www.zacks.com/stock/news/2142728/medicares-first-price-negotiation-list-targets-expensive-drugs-revised", "time_published": "20230831T065300", "authors": ["Zacks Equity Research"], "summary": "The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.021558, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.011416", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.008722", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.077816", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/08/30/2734798/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230830T201500", "authors": ["Alvotech"], "summary": "Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.122774, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.013868", "ticker_sentiment_score": "0.054786", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.041586", "ticker_sentiment_score": "0.027392", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.45704", "ticker_sentiment_score": "0.250081", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.013868", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.013868", "ticker_sentiment_score": "0.054786", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.013868", "ticker_sentiment_score": "0.054786", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.013868", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013868", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/08/30/2734797/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230830T201500", "authors": ["Alvotech"], "summary": "REYKJAVIK, Iceland, Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.122757, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.013819", "ticker_sentiment_score": "0.054766", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.041442", "ticker_sentiment_score": "0.02738", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.455642", "ticker_sentiment_score": "0.249568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.013819", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.013819", "ticker_sentiment_score": "0.054766", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.013819", "ticker_sentiment_score": "0.054766", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.013819", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013819", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicare's First Price Negotiation List Targets Expensive Drugs", "url": "https://www.zacks.com/stock/news/2142358/medicares-first-price-negotiation-list-targets-expensive-drugs", "time_published": "20230830T131900", "authors": ["Kinjel Shah"], "summary": "The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.033457, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.208166", "ticker_sentiment_score": "0.008424", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.139669", "ticker_sentiment_score": "0.006387", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.139669", "ticker_sentiment_score": "-0.065949", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicare's First Price Negotiation List Targets Expensive Drugs  ( Revised ) ", "url": "https://www.zacks.com/stock/news/2142728/medicares-first-price-negotiation-list-targets-expensive-drugs-revised", "time_published": "20230830T131900", "authors": ["Zacks Equity Research"], "summary": "The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default145.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.021558, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.011416", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.008722", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.13459", "ticker_sentiment_score": "-0.077816", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eliquis, Jardiance among first 10 drugs selected for Medicare price negotiations", "url": "https://www.marketwatch.com/story/merck-amgen-abbvie-products-among-first-10-drugs-selected-for-medicare-price-negotiations-556c2484", "time_published": "20230829T192200", "authors": ["Eleanor Laise"], "summary": "Merck, Johnson & Johnson and Amgen are among the first drugmakers to have products chosen for a contentious initiative to rein in prescription-drug costs.", "banner_image": "https://images.mktw.net/im-810517/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.012021, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.058188", "ticker_sentiment_score": "0.011008", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.058188", "ticker_sentiment_score": "0.015135", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.058188", "ticker_sentiment_score": "0.049067", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.058188", "ticker_sentiment_score": "0.047971", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.058188", "ticker_sentiment_score": "0.047971", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.058188", "ticker_sentiment_score": "0.047971", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.116067", "ticker_sentiment_score": "-0.026232", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: 3 Best Biotech Stocks for Health and Wealth", "url": "https://stocknews.com/news/amgn-vrtx-incy-repl-sndx-3-best-biotech-stocks-for-health-and-wealth/", "time_published": "20230829T175651", "authors": ["StockNews.com Staff"], "summary": "Innovative biotech companies are making remarkable progress in creating novel medications and therapies for a diverse array of conditions, such as cancer, heart disease, and rare ailments. Encouraging trial outcomes and enhanced patient well-being are spurring the demand for continuous medical ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999995"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.33801, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.141034", "ticker_sentiment_score": "0.136199", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.164228", "ticker_sentiment_score": "0.13575", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.047231", "ticker_sentiment_score": "0.108521", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.047231", "ticker_sentiment_score": "0.026781", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.232885", "ticker_sentiment_score": "0.232763", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "10 Drugs Selected for Medicare Price Reduction", "url": "https://www.zacks.com/stock/news/2141961/10-drugs-selected-for-medicare-price-reduction", "time_published": "20230829T145500", "authors": ["Zacks Equity Research"], "summary": "We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these. Pre-market indices are in the red currently, albeit marginally. Investors cool their heels early after back-to-back ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f1/466.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.154535, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BBY", "relevance_score": "0.238913", "ticker_sentiment_score": "0.312403", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPQ", "relevance_score": "0.160633", "ticker_sentiment_score": "0.095204", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.160633", "ticker_sentiment_score": "0.041728", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.160633", "ticker_sentiment_score": "0.041728", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.160633", "ticker_sentiment_score": "0.041728", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medicare Drugs Targeted Under Inflation Reduction Act", "url": "https://www.zacks.com/stock/news/2141940/medicare-drugs-targeted-under-inflation-reduction-act", "time_published": "20230829T142100", "authors": ["Mark Vickery"], "summary": "Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b8/1573.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.983605"}], "overall_sentiment_score": 0.147494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BBY", "relevance_score": "0.228431", "ticker_sentiment_score": "0.282311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HPQ", "relevance_score": "0.15347", "ticker_sentiment_score": "0.095083", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.15347", "ticker_sentiment_score": "0.041855", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.15347", "ticker_sentiment_score": "0.041855", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.15347", "ticker_sentiment_score": "0.041855", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle - Wants To Cut Billions In Costs. Here Are The Stocks Affected - Johnson & Johnson  ( NYSE:JNJ ) ", "url": "https://www.benzinga.com/general/biotech/23/08/34087337/biden-targets-cancer-diabetes-drugs-in-controversial-medicare-price-battle-wants-to-cut-billions-", "time_published": "20230829T133050", "authors": ["Vandana Singh"], "summary": "The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: Bristol Myers Squibb Co's BMS blood thinner, Eliquis Eli Lilly And Co's LLY diabetes treatment, Jardiance.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/29/joe_biden_shutter.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.040665, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.227007", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.227007", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.334762", "ticker_sentiment_score": "-0.098769", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.227007", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.114682", "ticker_sentiment_score": "0.320043", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AbbVie, Merck, Lilly Highlight Biden List For Price Cuts", "url": "https://www.investors.com/news/technology/pharmaceutical-stocks-biden-administration-unveils-10-drugs-subject-to-price-cuts/", "time_published": "20230829T132800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Pharmaceutical Stocks: Biden Administration Unveils 10 Drugs ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/02/Stock-Biden-07-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": 0.011944, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.290607", "ticker_sentiment_score": "0.311341", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.423843", "ticker_sentiment_score": "0.053971", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.008377", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.423843", "ticker_sentiment_score": "0.138684", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.147818", "ticker_sentiment_score": "0.03379", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.290607", "ticker_sentiment_score": "0.311341", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AbbVie  ( ABBV )  Seeks Approval for Skyrizi for Ulcerative Colitis", "url": "https://www.zacks.com/stock/news/2141813/abbvie-abbv-seeks-approval-for-skyrizi-for-ulcerative-colitis", "time_published": "20230829T132100", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.21863, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.20997", "ticker_sentiment_score": "0.217881", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHRS", "relevance_score": "0.070725", "ticker_sentiment_score": "0.135208", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.575603", "ticker_sentiment_score": "0.286017", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Horizon  ( HZNP )  Up as FTC Pauses Acquisition by Amgen Lawsuit", "url": "https://www.zacks.com/stock/news/2141403/horizon-hznp-up-as-ftc-pauses-acquisition-by-amgen-lawsuit", "time_published": "20230828T151100", "authors": ["Zacks Equity Research"], "summary": "The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises 5.8% in response.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.062834, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.594159", "ticker_sentiment_score": "-0.127118", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORT", "relevance_score": "0.179343", "ticker_sentiment_score": "0.165541", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.34974", "ticker_sentiment_score": "-0.316586", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Top Stories: Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal - Bayer  ( OTC:BAYRY ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/08/34069633/hawaiian-electric-says-power-lines-not-responsible-for-deadly-lahaina-fire-china-targets-stock-marke", "time_published": "20230828T143708", "authors": ["Vandana Singh"], "summary": "Walmart Inc WMT has reportedly resolved the University of California's light-bulb patent lawsuit. The university accused the retail behemoth of infringing its patents associated with \"filament\" LED light bulbs ( invented at the Santa Barbara-based school system ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/28/china_money-938269_1920.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.1191, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.101869", "ticker_sentiment_score": "0.081093", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYDDF", "relevance_score": "0.068016", "ticker_sentiment_score": "-0.014083", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.068016", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDC", "relevance_score": "0.101869", "ticker_sentiment_score": "0.189831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.068016", "ticker_sentiment_score": "0.076907", "ticker_sentiment_label": "Neutral"}, {"ticker": "BZUN", "relevance_score": "0.068016", "ticker_sentiment_score": "0.062686", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAWEL", "relevance_score": "0.034039", "ticker_sentiment_score": "0.002973", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNSDF", "relevance_score": "0.101869", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BV", "relevance_score": "0.068016", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBL", "relevance_score": "0.101869", "ticker_sentiment_score": "-0.008576", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYDIY", "relevance_score": "0.034039", "ticker_sentiment_score": "-0.013381", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.068016", "ticker_sentiment_score": "0.076907", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFTBF", "relevance_score": "0.068016", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.068016", "ticker_sentiment_score": "0.09125", "ticker_sentiment_label": "Neutral"}, {"ticker": "HE", "relevance_score": "0.034039", "ticker_sentiment_score": "0.002973", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.068016", "ticker_sentiment_score": "-0.015336", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Amgen  ( AMGN )  is a Top Value Stock for the Long-Term", "url": "https://www.zacks.com/stock/news/2141322/why-amgen-amgn-is-a-top-value-stock-for-the-long-term", "time_published": "20230828T134004", "authors": ["Zacks Equity Research"], "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default121.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.353668, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.488777", "ticker_sentiment_score": "0.236702", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Wall Street Thinks This Tiny Biotech Company Could Soar Soon", "url": "https://www.fool.com/investing/2023/08/28/wall-street-thinks-this-tiny-biotech-company-could/", "time_published": "20230828T123000", "authors": ["George Budwell"], "summary": "An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F745581%2Fresearcher.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.204223, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.055621", "ticker_sentiment_score": "0.157909", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLUE", "relevance_score": "0.110973", "ticker_sentiment_score": "0.079156", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.055621", "ticker_sentiment_score": "0.022997", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields - CVS Health  ( NYSE:CVS ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/08/34066469/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields", "time_published": "20230828T122153", "authors": ["Lisa Levin"], "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/28/image10.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.071231, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.104683", "ticker_sentiment_score": "0.395144", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.104683", "ticker_sentiment_score": "0.250298", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.207571", "ticker_sentiment_score": "-0.095361", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.075275", "ticker_sentiment_label": "Neutral"}]}, {"title": "Beat the Market Like Zacks: Hubbell, Adobe, Nikola in Focus", "url": "https://www.zacks.com/stock/news/2141268/beat-the-market-like-zacks-hubbell-adobe-nikola-in-focus", "time_published": "20230828T120200", "authors": ["Abhinab Dasgupta"], "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/4052.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.197789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NTES", "relevance_score": "0.064973", "ticker_sentiment_score": "0.260795", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APAM", "relevance_score": "0.064973", "ticker_sentiment_score": "0.142225", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYX", "relevance_score": "0.064973", "ticker_sentiment_score": "0.061166", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKLA", "relevance_score": "0.064973", "ticker_sentiment_score": "0.19543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.064973", "ticker_sentiment_score": "0.062051", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.064973", "ticker_sentiment_score": "0.062051", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSCI", "relevance_score": "0.064973", "ticker_sentiment_score": "0.106129", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICE", "relevance_score": "0.064973", "ticker_sentiment_score": "0.061166", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.097325", "ticker_sentiment_score": "0.111888", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBB", "relevance_score": "0.064973", "ticker_sentiment_score": "0.212513", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "US Stocks Seen Opening Firmer In New Week's 1st Session As Traders Look To Week's Key Data; Analyst Constructive Despite Bearish Signals - Alibaba Gr Holding  ( NYSE:BABA ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , XPeng  ( NYSE:XPEV ) , NVIDIA  ( NASDAQ:NVDA ) , Horizon Therapeutics  ( NASDAQ:HZNP ) , Baidu  ( NASDAQ:BIDU ) , Amgen  ( NASDAQ:AMGN ) , Hawaiian Electric Indus  ( NYSE:HE ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/markets/equities/23/08/34065176/us-stocks-seen-opening-firmer-in-new-weeks-1st-session-as-traders-look-to-weeks-key-data-analyst", "time_published": "20230828T112219", "authors": ["Shanthi Rexaline"], "summary": "Stocks appear to be on track for a cautious start on Monday as the Jack Hole Symposium is now in the rearview. The major averages had a mixed close in the week ended Aug. 25, with the Nasdaq Composite and the S&P 500 indices carving out noteworthy gains.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Share_market_Photo_by_AshDesign_on_Shutterstock_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.125395, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.135729", "ticker_sentiment_score": "-0.08864", "ticker_sentiment_label": "Neutral"}, {"ticker": "XPEV", "relevance_score": "0.135729", "ticker_sentiment_score": "0.208244", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.135729", "ticker_sentiment_score": "0.029862", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.135729", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.135729", "ticker_sentiment_score": "-0.08864", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.068112", "ticker_sentiment_score": "0.221082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.135729", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC Takes A Rare Step Back, Pauses Legal Battle With Amgen Over $28B Horizon Deal - Horizon Therapeutics  ( NASDAQ:HZNP ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/08/34056018/ftc-takes-a-rare-step-back-pauses-legal-battle-with-amgen-over-28b-horizon-deal", "time_published": "20230826T162847", "authors": ["Bibhu Pattnaik"], "summary": "The Federal Trade Commission ( FTC ) decided to momentarily halt its challenge against pharmaceutical giant Amgen, Inc AMGN, concerning its proposed acquisition of Horizon Therapeutics PLC HZNP valued at $27.8 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/26/amgen.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.16672, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ATVI", "relevance_score": "0.169676", "ticker_sentiment_score": "0.033637", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.169676", "ticker_sentiment_score": "0.033637", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.169676", "ticker_sentiment_score": "0.157957", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.546745", "ticker_sentiment_score": "0.25893", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.169676", "ticker_sentiment_score": "0.097323", "ticker_sentiment_label": "Neutral"}]}, {"title": "An Update On The Amgen-Horizon Battle Just Sent The Latter Flying", "url": "https://www.investors.com/news/technology/hznp-stock-jumps-on-a-new-ftc-development-in-the-amgen-takeover-battle/", "time_published": "20230825T213200", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "HZNP Stock Jumps On A New FTC Development In The Amgen ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/02/Stock-HorizonPharma-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.085594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.364275", "ticker_sentiment_score": "0.064558", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.570165", "ticker_sentiment_score": "0.123473", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.12546", "ticker_sentiment_score": "0.150375", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "As Medicare picks 10 drugs for price negotiations, 50 million people stand to benefit - even if their drugs aren't on the list", "url": "https://www.marketwatch.com/story/as-medicare-picks-10-drugs-for-price-negotiations-50-million-people-stand-to-benefit-even-if-their-drugs-arent-on-the-list-aceec7e", "time_published": "20230825T145400", "authors": ["Eleanor Laise"], "summary": "Government negotiations with drugmakers are set to launch amid a growing number of legal challenges.", "banner_image": "https://images.mktw.net/im-462100/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.035789, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.062843", "ticker_sentiment_score": "-0.034042", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.062843", "ticker_sentiment_score": "-0.034042", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.062843", "ticker_sentiment_score": "-0.071167", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.062843", "ticker_sentiment_score": "-0.034042", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.062843", "ticker_sentiment_score": "-0.034042", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock buybacks spur wealth inequality and stifle innovation. Should they be banned?", "url": "https://www.marketwatch.com/story/stock-buybacks-spur-wealth-inequality-and-stifle-innovation-but-should-they-be-banned-13e963c0", "time_published": "20230824T215600", "authors": ["Ciara Linnane"], "summary": "Stock buybacks have become a major source of wealth inequality and have stifled innovation in the U.S., according to this academic.", "banner_image": "https://images.mktw.net/im-841345?width=700&height=554", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.769861"}], "overall_sentiment_score": 0.178846, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.140076", "ticker_sentiment_score": "0.170483", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSCO", "relevance_score": "0.105295", "ticker_sentiment_score": "0.07433", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.07031", "ticker_sentiment_score": "0.146063", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.105295", "ticker_sentiment_score": "0.087187", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.105295", "ticker_sentiment_score": "0.087187", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.105295", "ticker_sentiment_score": "-0.05102", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNLF", "relevance_score": "0.07031", "ticker_sentiment_score": "0.165721", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.07031", "ticker_sentiment_score": "0.106509", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.105295", "ticker_sentiment_score": "0.157777", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.07031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.07031", "ticker_sentiment_score": "0.080602", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.105295", "ticker_sentiment_score": "0.181737", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GE", "relevance_score": "0.07031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.07031", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.105295", "ticker_sentiment_score": "0.181737", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Can AbbVie  ( ABBV )  Protect Revenues After Humira Patent Loss?", "url": "https://www.zacks.com/stock/news/2140301/can-abbvie-abbv-protect-revenues-after-humira-patent-loss", "time_published": "20230824T145300", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/52/873.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.21974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CHRS", "relevance_score": "0.052455", "ticker_sentiment_score": "0.056914", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.642977", "ticker_sentiment_score": "0.354671", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.156461", "ticker_sentiment_score": "0.075563", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.052455", "ticker_sentiment_score": "0.10994", "ticker_sentiment_label": "Neutral"}]}, {"title": "Blanchard\u00ae and Amgen Win Bronze Brandon Hall Group Excellence Award for Best Unique or Innovative Learning and Development Program", "url": "https://www.prnewswire.com/news-releases/blanchard-and-amgen-win-bronze-brandon-hall-group-excellence-award-for-best-unique-or-innovative-learning-and-development-program-301908833.html", "time_published": "20230824T140500", "authors": ["Blanchard"], "summary": "Blanchard\u00ae and Amgen Win Bronze Brandon Hall Group Excellence Award for Best Unique or Innovative Learning ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2076256/Blanchard_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.499637, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.099066", "ticker_sentiment_score": "0.249748", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "4 Surefire Stocks to Buy in the Next Bear Market", "url": "https://www.fool.com/investing/2023/08/24/4-surefire-stocks-to-buy-in-the-next-bear-market/", "time_published": "20230824T140000", "authors": ["James Brumley"], "summary": "Not all companies struggle when economic weakness takes hold.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.103676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADBE", "relevance_score": "0.149656", "ticker_sentiment_score": "0.042577", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRON", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.149656", "ticker_sentiment_score": "0.056024", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.222838", "ticker_sentiment_score": "-0.023437", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.149656", "ticker_sentiment_score": "0.142178", "ticker_sentiment_label": "Neutral"}]}, {"title": "GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus - AstraZeneca  ( NASDAQ:AZN ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/34022293/gri-bio-is-bringing-hope-to-patients-with-idiopathic-pulmonary-fibrosis-and-lupus", "time_published": "20230824T122359", "authors": ["Faith Ashmore"], "summary": "Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that are more widely known are Idiopathic Pulmonary Fibrosis ( IPF ) and Lupus.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/24/screenshot_2023-08-24_at_5.52.33_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.064169, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.051125", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.051125", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.110973", "ticker_sentiment_score": "0.051125", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRI", "relevance_score": "0.423251", "ticker_sentiment_score": "0.114231", "ticker_sentiment_label": "Neutral"}]}, {"title": "This Is What Whales Are Betting On Amgen - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/34012223/this-is-what-whales-are-betting-on-amgen", "time_published": "20230823T200102", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.172948, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.815635", "ticker_sentiment_score": "0.261222", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "George Soros Bets Big On Electric Vehicles, Bitcoin, Pharmaceuticals And Consumer Internet Providers, According To Latest Filings", "url": "https://www.benzinga.com/markets/cryptocurrency/23/08/33990235/george-soros-bets-big-on-electric-vehicles-bitcoin-pharmaceuticals-and-consumer-internet-p", "time_published": "20230822T170942", "authors": ["Caleb Naysmith"], "summary": "Billionaire philanthropist George Soros, while polarizing, has made some of the most successful trades in history. His fund has averaged a roughly 30% yearly return since inception. Soros made bets on Tesla Inc. as early as 2018 and ventured into cryptocurrency the same year.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/George_Soros_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.099065, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSTR", "relevance_score": "0.079656", "ticker_sentiment_score": "-0.001018", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.079656", "ticker_sentiment_score": "0.073105", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.079656", "ticker_sentiment_score": "0.088379", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.079656", "ticker_sentiment_score": "-0.087901", "ticker_sentiment_label": "Neutral"}, {"ticker": "LBRDP", "relevance_score": "0.158519", "ticker_sentiment_score": "0.139216", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.158519", "ticker_sentiment_score": "0.139216", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHTR", "relevance_score": "0.079656", "ticker_sentiment_score": "0.107747", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.079656", "ticker_sentiment_score": "-0.087901", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.310843", "ticker_sentiment_score": "-0.002229", "ticker_sentiment_label": "Neutral"}]}, {"title": "Peering Into Amgen's Recent Short Interest - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33968954/peering-into-amgens-recent-short-interest", "time_published": "20230821T174525", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has fallen 8.96% since its last report. The company recently reported that it has 6.51 million shares sold short, which is 1.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.241618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Trending Stock Amgen Inc.  ( AMGN )  a Buy Now?", "url": "https://www.zacks.com/stock/news/2138583/is-trending-stock-amgen-inc-amgn-a-buy-now", "time_published": "20230821T130005", "authors": ["Zacks Equity Research"], "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default342.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.220115, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.487546", "ticker_sentiment_score": "0.095612", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Amgen Stock a Top Buy and Hold?", "url": "https://www.fool.com/investing/2023/08/21/is-amgen-stock-a-top-buy-and-hold/", "time_published": "20230821T121500", "authors": ["George Budwell"], "summary": "The biotech checks several important boxes for long-term shareholders.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.330859, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.764699", "ticker_sentiment_score": "0.537904", "ticker_sentiment_label": "Bullish"}, {"ticker": "HZNP", "relevance_score": "0.1568", "ticker_sentiment_score": "0.192245", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Beat the Market the Zacks Way: Caterpillar, Amgen, Broadridge Financial Solutions in Focus", "url": "https://www.zacks.com/stock/news/2138501/beat-the-market-the-zacks-way-caterpillar-amgen-broadridge-financial-solutions-in-focus", "time_published": "20230821T104200", "authors": ["Santanu Roy"], "summary": "Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d8/1060.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999612"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.18498, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BR", "relevance_score": "0.064276", "ticker_sentiment_score": "0.097082", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTES", "relevance_score": "0.064276", "ticker_sentiment_score": "0.312013", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHOP", "relevance_score": "0.064276", "ticker_sentiment_score": "0.212424", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTU", "relevance_score": "0.064276", "ticker_sentiment_score": "0.106097", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.064276", "ticker_sentiment_score": "0.097082", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIT", "relevance_score": "0.064276", "ticker_sentiment_score": "0.132152", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.064276", "ticker_sentiment_score": "0.060133", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADP", "relevance_score": "0.096283", "ticker_sentiment_score": "0.111584", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.064276", "ticker_sentiment_score": "0.060133", "ticker_sentiment_label": "Neutral"}, {"ticker": "URBN", "relevance_score": "0.064276", "ticker_sentiment_score": "0.233525", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CWCO", "relevance_score": "0.064276", "ticker_sentiment_score": "0.233525", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/33898106/looking-at-amgens-recent-unusual-options-activity", "time_published": "20230817T163302", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen AMGN we detected 23 strange trades. If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.148349, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.82082", "ticker_sentiment_score": "0.036263", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Now Covered by StockNews.com", "url": "https://www.defenseworld.net/2023/08/17/amgen-nasdaqamgn-now-covered-by-stocknews-com.html", "time_published": "20230817T072242", "authors": ["Defense World Staff"], "summary": "Equities researchers at StockNews.com assumed coverage on shares of Amgen ( NASDAQ:AMGN - Get Free Report ) in a report released on Thursday. The brokerage set a \"strong-buy\" rating on the medical research company's stock.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.23179, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.803061", "ticker_sentiment_score": "0.387953", "ticker_sentiment_label": "Bullish"}, {"ticker": "RBCPF", "relevance_score": "0.051441", "ticker_sentiment_score": "0.070546", "ticker_sentiment_label": "Neutral"}, {"ticker": "TJX", "relevance_score": "0.051441", "ticker_sentiment_score": "0.039004", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "url": "https://www.investors.com/research/amgen-stock-scores-relative-strength-rating-upgrade-hits-key-benchmark/", "time_published": "20230816T182500", "authors": ["JULIE MAK", "Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "Amgen Stock Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.339253, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPRX", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.549581", "ticker_sentiment_score": "0.286188", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSA", "relevance_score": "0.294093", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Could Amgen Stock Help You Become a Millionaire?", "url": "https://www.fool.com/investing/2023/08/16/could-amgen-stock-help-you-become-a-millionaire/", "time_published": "20230816T140753", "authors": ["David Jagielski"], "summary": "Its pending acquisition of Horizon Therapeutics could make the company much bigger.", "banner_image": "https://media.ycharts.com/charts/e214eb1f2ee4a9af632887f3f5472b58.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}], "overall_sentiment_score": 0.220503, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.649187", "ticker_sentiment_score": "0.351304", "ticker_sentiment_label": "Bullish"}, {"ticker": "HZNP", "relevance_score": "0.114137", "ticker_sentiment_score": "-0.012543", "ticker_sentiment_label": "Neutral"}]}, {"title": "U.S. retailers lose their appetite for SlimFast, owner says", "url": "https://www.reuters.com/business/retail-consumer/us-retailers-lose-their-appetite-slimfast-owner-says-2023-08-16/", "time_published": "20230816T132300", "authors": ["Reuters"], "summary": "DUBLIN, Aug 16 ( Reuters ) - Sales of SlimFast plunged further in the three months to mid-July, prompting key U.S. retailers to stock fewer of the meal replacement shakes, the brand's owner said on Wednesday as weight-loss drugs shake up the diet market.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=152", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.151768, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.108466", "ticker_sentiment_score": "0.205766", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GLAPF", "relevance_score": "0.504646", "ticker_sentiment_score": "0.276007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.108466", "ticker_sentiment_score": "0.205766", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen Scores Relative Strength Rating Upgrade; Hits Key Benchmark", "url": "https://www.investors.com/ibd-data-stories/amgen-scores-relative-strength-rating-upgrade-hits-key-benchmark/", "time_published": "20230816T070000", "authors": ["INVESTOR'S BUSINESS DAILY", "Investor's Business Daily"], "summary": "Amgen Scores Relative Strength Rating Upgrade. Hits Key Benchmark Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.311611, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CPRX", "relevance_score": "0.366061", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.659096", "ticker_sentiment_score": "0.310131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSA", "relevance_score": "0.366061", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotechnology Market to Worth Around USD 3,995.22 Billion by 2032", "url": "https://www.benzinga.com/pressreleases/23/08/g33835844/biotechnology-market-to-worth-around-usd-3-995-22-billion-by-2032", "time_published": "20230814T150000", "authors": ["Globe Newswire"], "summary": "Ottawa, Aug. 14, 2023 ( GLOBE NEWSWIRE ) -- The global biotechnology market size accounted for USD 1,224.31 billion in 2022, a study published by Towards Healthcare a sister firm of Precedence Research.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.318732, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CASBF", "relevance_score": "0.013202", "ticker_sentiment_score": "0.050568", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMXHF", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.013202", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDS", "relevance_score": "0.026401", "ticker_sentiment_score": "0.128473", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.013202", "ticker_sentiment_score": "0.226716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.013202", "ticker_sentiment_score": "0.172021", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Amgen Stock Fully Valued After A 17% Rise In A Month?", "url": "https://www.forbes.com/sites/greatspeculations/2023/08/14/is-amgen-stock-fully-valued-after-a-17-rise-in-a-month/", "time_published": "20230814T130021", "authors": ["Trefis Team"], "summary": "Amgen stock (NASDAQ: AMGN) has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64d9b893ddc590d941b1ea41/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Markets", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.162931, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.79415", "ticker_sentiment_score": "0.271901", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.072", "ticker_sentiment_score": "0.105021", "ticker_sentiment_label": "Neutral"}]}, {"title": "QUALCOMM, AIG And 2 Other Stocks Insiders Are Selling - Amgen  ( NASDAQ:AMGN ) , American Intl Gr  ( NYSE:AIG ) ", "url": "https://www.benzinga.com/news/23/08/33828098/qualcomm-aig-and-2-other-stocks-insiders-are-selling", "time_published": "20230814T120805", "authors": ["Lisa Levin"], "summary": "The Nasdaq 100 closed lower on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/14/qualcomm_-_log.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.086171, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANF", "relevance_score": "0.45634", "ticker_sentiment_score": "0.368935", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.45634", "ticker_sentiment_score": "-0.176536", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "QCOM", "relevance_score": "0.45634", "ticker_sentiment_score": "0.134714", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIG", "relevance_score": "0.45634", "ticker_sentiment_score": "0.248743", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Take the Zacks Approach to Beat the Markets: Celsius, Adobe, Curtiss-Wright in Focus", "url": "https://www.zacks.com/stock/news/2136155/take-the-zacks-approach-to-beat-the-markets-celsius-adobe-curtiss-wright-in-focus", "time_published": "20230814T115700", "authors": ["Santanu Roy"], "summary": "Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2b/4052.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.9545"}], "overall_sentiment_score": 0.134546, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CELH", "relevance_score": "0.063008", "ticker_sentiment_score": "0.212284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DE", "relevance_score": "0.063008", "ticker_sentiment_score": "0.097042", "ticker_sentiment_label": "Neutral"}, {"ticker": "CW", "relevance_score": "0.063008", "ticker_sentiment_score": "0.201248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PAYX", "relevance_score": "0.063008", "ticker_sentiment_score": "0.061094", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLDR", "relevance_score": "0.063008", "ticker_sentiment_score": "0.196233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADBE", "relevance_score": "0.063008", "ticker_sentiment_score": "0.097042", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.227511", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSCI", "relevance_score": "0.063008", "ticker_sentiment_score": "0.106052", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPH", "relevance_score": "0.063008", "ticker_sentiment_score": "0.245411", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JHX", "relevance_score": "0.063008", "ticker_sentiment_score": "0.245411", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADP", "relevance_score": "0.063008", "ticker_sentiment_score": "0.061094", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.09439", "ticker_sentiment_score": "0.11105", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.131325", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Suffers Second Straight Week of Losses, Breaks Key Support Level As Tech Bears Return: Is This Time Different? - PayPal Holdings  ( NASDAQ:PYPL ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Constellation Energy  ( NASDAQ:CEG ) , Fortinet  ( NASDAQ:FTNT ) , Datadog  ( NASDAQ:DDOG ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/23/08/33760613/nasdaq-suffers-second-straight-week-of-losses-breaks-key-support-level-as-tech-bears-return-is-this", "time_published": "20230811T200117", "authors": ["Piero Cingari"], "summary": "The Nasdaq 100 Index finds itself in a rare bind as it stares down a second consecutive week of losses and hovers at the lowest level in a month. This troubling downturn, an unexpected twist in the 2023 tale, sent ripples of concern through the markets, with investors now fearing that a trend ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/NASDAQ.Shutterstock.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.061567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.22595", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEG", "relevance_score": "0.22595", "ticker_sentiment_score": "0.200187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.114137", "ticker_sentiment_score": "0.224181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.22595", "ticker_sentiment_score": "0.200187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTNT", "relevance_score": "0.22595", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDOG", "relevance_score": "0.22595", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2135485/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20230811T102008", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.184085, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.13459", "ticker_sentiment_score": "0.071501", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Off Session Lows As Disney Jumps; Cathie Wood Loads Up On This Stock Despite 23% Plunge", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-reverses-as-walt-disney-stock-jumps-cathie-wood-loads-up-on-this-stock-despite-23-plunge/", "time_published": "20230810T192000", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Off Session Lows As Disney Jumps. Cathie Wood Loads Up On This Stock Despite 23% Plunge Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.168815, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.160901", "ticker_sentiment_score": "0.134359", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.080865", "ticker_sentiment_score": "0.013525", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.080865", "ticker_sentiment_score": "0.148897", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.080865", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPR", "relevance_score": "0.080865", "ticker_sentiment_score": "-0.224896", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RBLX", "relevance_score": "0.277658", "ticker_sentiment_score": "0.029485", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRI", "relevance_score": "0.080865", "ticker_sentiment_score": "-0.224896", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PRGS", "relevance_score": "0.121037", "ticker_sentiment_score": "0.036698", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.080865", "ticker_sentiment_score": "0.148897", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.040484", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIPS", "relevance_score": "0.080865", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Dow Jones Stocks To Watch In August 2023", "url": "https://stockmarket.com/featured/3-dow-jones-stocks-to-watch-in-august-2023-2023-08-10", "time_published": "20230810T152637", "authors": ["Jonathan Phillip"], "summary": "The Dow Jones Industrial Average, often just called \"the Dow,\" is a bit like the all-star team of the stock market. It's made up of 30 big, reputable American companies from various industries. Think of it as a snapshot of how the U.S. economy is doing.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/08/amgen-stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.997902"}], "overall_sentiment_score": 0.214542, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.329992", "ticker_sentiment_score": "0.296931", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HON", "relevance_score": "0.329992", "ticker_sentiment_score": "0.179225", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.390904", "ticker_sentiment_score": "0.285984", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen Inc.  ( AMGN )  is Attracting Investor Attention: Here is What You Should Know", "url": "https://www.zacks.com/stock/news/2134910/amgen-inc-amgn-is-attracting-investor-attention-here-is-what-you-should-know", "time_published": "20230810T130006", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default104.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.217481, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.484798", "ticker_sentiment_score": "0.128536", "ticker_sentiment_label": "Neutral"}]}, {"title": "Want Rising Dividend Income? Buy Amgen Stock", "url": "https://www.fool.com/investing/2023/08/10/want-rising-dividend-income-buy-amgen-stock/", "time_published": "20230810T095900", "authors": ["Kody Kester"], "summary": "The drugmaker possesses a solid medicine portfolio and pipeline.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743291%2Fa-patient-attends-a-doctor-appointment.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}, {"topic": "Earnings", "relevance_score": "0.999975"}], "overall_sentiment_score": 0.303702, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.254973", "ticker_sentiment_score": "0.308754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.064797", "ticker_sentiment_score": "0.182354", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.129168", "ticker_sentiment_score": "0.112317", "ticker_sentiment_label": "Neutral"}]}, {"title": "Blockchain technology in the healthcare market to grow by USD 1,939.31 million from 2022 to 2027; The growing ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/blockchain-technology-in-the-healthcare-market-to-grow-by-usd-1-939-31-million-from-2022-to-2027-the-growing-inclination-toward-data-security-to-boost-the-market---technavio-301895959.html", "time_published": "20230809T233000", "authors": [], "summary": "Blockchain technology in the healthcare market to grow by USD 1,939.31 million from 2022 to 2027. The growing ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.999989"}], "overall_sentiment_score": 0.255403, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBM", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:PTOY", "relevance_score": "0.04882", "ticker_sentiment_score": "0.041477", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/33673916/looking-at-amgens-recent-unusual-options-activity", "time_published": "20230809T173042", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.209542, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.804025", "ticker_sentiment_score": "0.357288", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Horizon  ( HZNP )  Q2 Earnings Top, Krystexxa & Uplizna Boost Sales", "url": "https://www.zacks.com/stock/news/2134466/horizon-hznp-q2-earnings-top-krystexxa-uplizna-boost-sales", "time_published": "20230809T160900", "authors": ["Zacks Equity Research"], "summary": "Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors being Krystexxa and Uplizna.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.021598, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.201944", "ticker_sentiment_score": "0.038221", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.29887", "ticker_sentiment_score": "-0.075796", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.250902", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "65% Profit On Eli Lilly - 20% Reduction In Heart Attacks And Strokes With Weight Loss Drug - Raising The Target - Novo Nordisk  ( NYSE:NVO ) ", "url": "https://www.benzinga.com/23/08/33670747/65-profit-on-eli-lilly-20-reduction-in-heart-attacks-and-strokes-with-weight-loss-drug-raising-the-t", "time_published": "20230809T150956", "authors": ["The Arora Report"], "summary": "Signal Limited is a Signal ( s ) with a great record in similar situations but does not meet all of the stringent criteria for a Signal. Typically Signal Limited has higher risk-reward compared to a Signal over the short term.", "banner_image": "https://cdn.benzinga.com/files/640px-eli_lilly_corporate_center_indianapolis_indiana_usa.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.012093, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.554014", "ticker_sentiment_score": "0.143412", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.110209", "ticker_sentiment_score": "0.015962", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.110209", "ticker_sentiment_score": "0.117806", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.270973", "ticker_sentiment_score": "-0.004059", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.110209", "ticker_sentiment_score": "0.117806", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.110209", "ticker_sentiment_score": "0.015962", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Heavyweights - Caterpillar & Amgen Beat The Street", "url": "https://www.forbes.com/sites/johnbuckingham/2023/08/09/dow-jones-heavyweightscaterpillar--amgen-beat-the-street/", "time_published": "20230809T135400", "authors": ["John Buckingham"], "summary": "Unlike most market indexes, the Dow Jones Industrial Average is price-weighted, meaning that high-price stocks like Caterpillar (CAT) and Amgen (AMGN) are heavyweights...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/64d2d0439615cbe9abd9eed6/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.999174"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.271137, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VZ", "relevance_score": "0.045743", "ticker_sentiment_score": "-0.04056", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.045743", "ticker_sentiment_score": "0.024742", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.181477", "ticker_sentiment_score": "0.1254", "ticker_sentiment_label": "Neutral"}, {"ticker": "WBA", "relevance_score": "0.091335", "ticker_sentiment_score": "-0.042957", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.045743", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.091335", "ticker_sentiment_score": "-0.042957", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.091335", "ticker_sentiment_score": "-0.042957", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.22574", "ticker_sentiment_score": "0.137455", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.091335", "ticker_sentiment_score": "-0.042957", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies", "url": "https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/", "time_published": "20230809T120600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/05/Stock-TargetDollarSign-02-adobe-300x170.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.083353, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.381253", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.549433", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNY", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Rating Increased to Strong-Buy at StockNews.com", "url": "https://www.defenseworld.net/2023/08/09/amgen-nasdaqamgn-rating-increased-to-strong-buy-at-stocknews-com.html", "time_published": "20230809T095213", "authors": ["Defense World Staff"], "summary": "Amgen ( NASDAQ:AMGN - Get Free Report ) was upgraded by StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report released on Monday. A number of other research firms have also weighed in on AMGN. Jefferies Financial Group lowered their price objective on Amgen from $325.00 to ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999365"}, {"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.223969, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JEF", "relevance_score": "0.055881", "ticker_sentiment_score": "0.052966", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.055881", "ticker_sentiment_score": "0.052966", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.055881", "ticker_sentiment_score": "0.052966", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.858969", "ticker_sentiment_score": "0.376762", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Off, Datadog Plunges 21%; These IPOs Buck Weak Market", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-down-datadog-plunges-21-at-lows-2-new-ipo-stocks-buck-stock-market-weakness/", "time_published": "20230808T192100", "authors": ["Investor's Business Daily", "DAVID SAITO-CHUNG"], "summary": "Dow Jones Down, Datadog Plunges 21% At Lows. 2 New IPO Stocks Buck Stock Market Weakness Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-Cloud74-adobe-768x434.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999966"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.154523, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "IVZ", "relevance_score": "0.057628", "ticker_sentiment_score": "-0.023176", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.227538", "ticker_sentiment_score": "0.231588", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DDOG", "relevance_score": "0.282234", "ticker_sentiment_score": "-0.151787", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FWRG", "relevance_score": "0.114956", "ticker_sentiment_score": "0.188762", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Growth Priced Into Amgen Stock After Earnings Beat? - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/08/33623812/is-growth-priced-into-amgen-stock-after-earnings-beat", "time_published": "20230808T145052", "authors": ["MarketBeat"], "summary": "Amgen Inc. AMGN delivered a solid earnings report after the market closed on August 3. Shareholders hope the results will be enough to reverse the fortunes of AMGN stock, down 12% in 2023. But heading into earnings, analyst sentiment suggests that all the growth may already be priced into the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/08/640px-amgen.svg_.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": -0.004808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.809093", "ticker_sentiment_score": "-0.020358", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.129866", "ticker_sentiment_score": "-0.199386", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABBV", "relevance_score": "0.129866", "ticker_sentiment_score": "-0.020694", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/08/33631109/100-invested-in-this-stock-15-years-ago-would-be-worth-400-today", "time_published": "20230808T140103", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 9.9%. Currently, Amgen has a market capitalization of $139.70 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Is AbbVie Still a Good Dividend Stock to Buy?", "url": "https://www.fool.com/investing/2023/08/08/is-abbvie-still-a-good-dividend-stock-to-buy/", "time_published": "20230808T093700", "authors": ["Cory Renauer"], "summary": "Find out if AbbVie can overcome sinking sales of its top-selling product.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F741720%2Fa-person-delivering-a-presentation-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.149643, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.64741", "ticker_sentiment_score": "0.266308", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.067347", "ticker_sentiment_score": "0.118317", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.067347", "ticker_sentiment_score": "-0.032292", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.067347", "ticker_sentiment_score": "0.072149", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Today: Dow Outperforms as Amgen, Boeing Gain Ground", "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-dow-outperforms-as-amgen-boeing-gain-ground", "time_published": "20230807T201320", "authors": ["Karee Venema"], "summary": "Stock started the week on a positive note, with the main benchmarks closing higher Monday. Blue chip stocks outperformed thanks to strong gains for drugmaker Amgen ( AMGN ) and aircraft manufacturer Boeing ( BA ) , while Warren Buffett's Berkshire Hathaway ( BRK.B ) put in an impressive ...", "banner_image": "https://cdn.mos.cms.futurecdn.net/nYBu5KzjaySPp84ye64oBK-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.890401"}], "overall_sentiment_score": 0.321781, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UPS", "relevance_score": "0.153961", "ticker_sentiment_score": "-0.02669", "ticker_sentiment_label": "Neutral"}, {"ticker": "CME", "relevance_score": "0.077343", "ticker_sentiment_score": "0.203146", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.153961", "ticker_sentiment_score": "0.064509", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.229149", "ticker_sentiment_score": "0.451056", "ticker_sentiment_label": "Bullish"}, {"ticker": "BA", "relevance_score": "0.229149", "ticker_sentiment_score": "0.451056", "ticker_sentiment_label": "Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.153961", "ticker_sentiment_score": "0.203356", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Jones Gains As Apple Crumbles; These Warren Buffett Stocks Are Near Buy Points", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-gains-as-apple-stock-crumbles-these-warren-buffett-stocks-are-near-buy-points-berkshire-hathaway-earnings-tesla-stock-falls-management-change-cfo-quits/", "time_published": "20230807T191400", "authors": ["Investor's Business Daily", "MICHAEL LARKIN"], "summary": "Dow Jones Gains As Apple Crumbles. These Warren Buffett Stocks Are Near Buy Points Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/11/Stock-WarrenBuffett-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.999346"}], "overall_sentiment_score": 0.240247, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OZK", "relevance_score": "0.17813", "ticker_sentiment_score": "0.284904", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.221616", "ticker_sentiment_score": "-0.075128", "ticker_sentiment_label": "Neutral"}, {"ticker": "GL", "relevance_score": "0.13409", "ticker_sentiment_score": "0.278908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MNST", "relevance_score": "0.089629", "ticker_sentiment_score": "0.331878", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.13409", "ticker_sentiment_score": "-0.028211", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.089629", "ticker_sentiment_score": "0.11606", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.13409", "ticker_sentiment_score": "0.184357", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.221616", "ticker_sentiment_score": "-0.156182", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "V", "relevance_score": "0.13409", "ticker_sentiment_score": "-0.024894", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPAR", "relevance_score": "0.17813", "ticker_sentiment_score": "0.105642", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHTR", "relevance_score": "0.089629", "ticker_sentiment_score": "0.133774", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.089629", "ticker_sentiment_score": "0.052385", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.13409", "ticker_sentiment_score": "0.133663", "ticker_sentiment_label": "Neutral"}]}, {"title": "Company News for Aug 7, 2023", "url": "https://www.zacks.com/stock/news/2133112/company-news-for-aug-7-2023", "time_published": "20230807T134100", "authors": ["Zacks Equity Research"], "summary": "Companies in The News Are: ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.189826, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.546745", "ticker_sentiment_score": "0.307255", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PAA", "relevance_score": "0.546745", "ticker_sentiment_score": "0.445304", "ticker_sentiment_label": "Bullish"}, {"ticker": "TU", "relevance_score": "0.546745", "ticker_sentiment_score": "0.138528", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ligand  ( LGND )  to Post Q2 Earnings: What's in Store?", "url": "https://www.zacks.com/stock/news/2133134/ligand-lgnd-to-post-q2-earnings-whats-in-store", "time_published": "20230807T130200", "authors": ["Zacks Equity Research"], "summary": "Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8b/382.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99915"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.108546, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KOD", "relevance_score": "0.1172", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.231884", "ticker_sentiment_score": "0.09543", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.1172", "ticker_sentiment_score": "0.161884", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.1172", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.058759", "ticker_sentiment_score": "-0.028035", "ticker_sentiment_label": "Neutral"}]}, {"title": "Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions - Longeveron  ( NASDAQ:LGVN ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33598342/longeveron-announces-key-additions-to-its-leadership-team-and-board-as-it-gears-up-for-phase-2-tr", "time_published": "20230807T120215", "authors": ["David Willey"], "summary": "Longeveron, Inc. LGVN is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. Longeveron's primary drug is Lomecel-B\u2122, which is being developed as a potential therapy for Alzheimer's disease, Aging-Frailty, and a rare pediatric disease, ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/07/screenshot_2023-08-07_at_5.27.21_pm.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.182708, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGVN", "relevance_score": "0.624973", "ticker_sentiment_score": "0.300767", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.19117", "ticker_sentiment_score": "0.044686", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRMD", "relevance_score": "0.064276", "ticker_sentiment_score": "0.050025", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.128135", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "1 Top Dividend Growth Stock to Buy on the Dip", "url": "https://www.fool.com/investing/2023/08/05/1-top-dividend-growth-stock-to-buy-on-the-dip/", "time_published": "20230805T124500", "authors": ["Prosper Junior Bakiny"], "summary": "Investors' patience will be rewarded.", "banner_image": "https://media.ycharts.com/charts/fb7b37d077c02b7d5016b3ae0b9f743a.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.213128, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.119532", "ticker_sentiment_score": "0.0693", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.740604", "ticker_sentiment_score": "0.326042", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.007019", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.059935", "ticker_sentiment_score": "-0.033995", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Reverses Lower On Reports Of Cyberattack; Fortinet Slammed After Earnings", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-reverses-lower-on-reports-of-cyberattack-fortinet-slammed-after-earnings/", "time_published": "20230804T191200", "authors": ["Investor's Business Daily", "KEN SHREVE"], "summary": "Dow Jones Reverses Lower On Reports Of Cyberattack. Fortinet Slammed After Earnings Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-dow-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.99676"}, {"topic": "Earnings", "relevance_score": "0.99994"}], "overall_sentiment_score": 0.021879, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.108222", "ticker_sentiment_score": "-0.028521", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.002774", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.108222", "ticker_sentiment_score": "-0.187944", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FTNT", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.266008", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SHAK", "relevance_score": "0.16171", "ticker_sentiment_score": "0.047467", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEAM", "relevance_score": "0.108222", "ticker_sentiment_score": "0.152652", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.260728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.002774", "ticker_sentiment_label": "Neutral"}, {"ticker": "BKNG", "relevance_score": "0.108222", "ticker_sentiment_score": "0.167076", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.16171", "ticker_sentiment_score": "0.242209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.108222", "ticker_sentiment_score": "-0.218832", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FOREX:USD", "relevance_score": "0.054236", "ticker_sentiment_score": "-0.142687", "ticker_sentiment_label": "Neutral"}]}, {"title": "Looking Into Amgen's Recent Short Interest - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/08/33580802/looking-into-amgens-recent-short-interest", "time_published": "20230804T184541", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has risen 3.08% since its last report. The company recently reported that it has 7.18 million shares sold short, which is 1.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.21 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( AMGN )  Q2 Earnings Beat Estimates, 2023 View Raised", "url": "https://www.zacks.com/stock/news/2132815/amgen-amgn-q2-earnings-beat-estimates-2023-view-raised", "time_published": "20230804T161200", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/905.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.993781"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.151969, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.045482", "ticker_sentiment_score": "0.05258", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.450733", "ticker_sentiment_score": "0.259966", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.090816", "ticker_sentiment_score": "0.220122", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.090816", "ticker_sentiment_score": "0.115644", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bioprocess Validation Market to grow at a CAGR of 11.39% from 2022 to 2027|Increasing demand for ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/bioprocess-validation-market-to-grow-at-a-cagr-of-11-39-from-2022-to-2027increasing-demand-for-biopharmaceuticals-to-boost-market-growth---technavio-301892736.html", "time_published": "20230804T151500", "authors": [], "summary": "Bioprocess Validation Market to grow at a CAGR of 11.39% from 2022 to 2027|Increasing demand for ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.244667, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PVARF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "A", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHKSF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.031119", "ticker_sentiment_score": "0.104281", "ticker_sentiment_label": "Neutral"}, {"ticker": "GEAGF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.031119", "ticker_sentiment_score": "0.104281", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.031119", "ticker_sentiment_score": "0.113286", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTR", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHHLF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.093168", "ticker_sentiment_score": "0.12168", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLW", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUVPF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRL", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "LH", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.062191", "ticker_sentiment_score": "0.045003", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.062191", "ticker_sentiment_score": "0.120072", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Rises Despite Apple's Hard Fall; Cybersecurity Stocks Tumble On This Warning", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-as-apple-fallsdow-jones-rises-cybersecurity-stocks-tumble/", "time_published": "20230804T150600", "authors": ["VIDYA RAMAKRISHNAN", "Investor's Business Daily"], "summary": "Dow Jones Rises Despite Apple's Hard Fall. Cybersecurity Stocks Tumble On This Warning Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/04/Stock-nowhiringsign-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999921"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": -0.029204, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.194763", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.181714", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.503078", "ticker_sentiment_label": "Bearish"}, {"ticker": "FSR", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.503078", "ticker_sentiment_label": "Bearish"}, {"ticker": "FTNT", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.20047", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TEAM", "relevance_score": "0.130571", "ticker_sentiment_score": "0.128344", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.15561", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BKNG", "relevance_score": "0.130571", "ticker_sentiment_score": "0.125114", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.194763", "ticker_sentiment_score": "-0.193496", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PANW", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.193581", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "If You Had Invested $5,000 in Amgen in 2013, This Is How Much You Would Have Today", "url": "https://www.fool.com/investing/2023/08/04/if-you-invested-5000-in-amgen-in-2013-this-is-how/", "time_published": "20230804T134500", "authors": ["Kody Kester"], "summary": "The pharmaceutical company has significantly enriched shareholders over the past 10 years.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F742219%2Fa-doctor-takes-a-patients-blood-pressure.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990893"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.282064, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.636698", "ticker_sentiment_score": "0.441149", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.080458", "ticker_sentiment_score": "0.088491", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.080458", "ticker_sentiment_score": "0.267965", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen Raises FY23 Outlook, Discloses Brief Readout From Tarlatamab Lung Cancer, Lumakras Colorectal Cancer Studies - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33569920/amgen-raises-fy23-outlook-discloses-brief-readout-from-tarlatamab-lung-cancer-lumakras-colorectal", "time_published": "20230804T132044", "authors": ["Vandana Singh"], "summary": "Amgen Inc AMGN reported Q2 FY23 sales of $6.99 billion, up 7% Y/Y, beating the consensus of $6.63 billion. Product sales increased 6%, driven by 11% volume growth, partially offset by a 2% lower net selling price, 1% lower inventory levels, and 1% negative impact from foreign exchange.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/04/amgn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.072567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.716023", "ticker_sentiment_score": "-0.187343", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Jim Cramer's top 10 things to watch in the stock market Friday", "url": "https://www.cnbc.com/2023/08/04/jim-cramers-top-10-things-to-watch-in-the-stock-market-friday.html", "time_published": "20230804T130854", "authors": ["Jim Cramer"], "summary": "Amazon's (AMZN) second-quarter results Thursday gave investors exactly what they wanted, while Apple (AAPL) showed the power of its services business.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107265539-1688143825419-gettyimages-1445219528-0j5a5924_aa9d9f31-1b4a-4dd0-89b5-44fb3851622c.jpeg?v=1691154534&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.998682"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.127525, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.109206", "ticker_sentiment_score": "0.11033", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVR", "relevance_score": "0.054732", "ticker_sentiment_score": "-0.125997", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.16317", "ticker_sentiment_score": "-0.172133", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AAPL", "relevance_score": "0.109206", "ticker_sentiment_score": "0.00454", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.109206", "ticker_sentiment_score": "0.11033", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMR", "relevance_score": "0.109206", "ticker_sentiment_score": "0.11033", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.16317", "ticker_sentiment_score": "0.094841", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.16317", "ticker_sentiment_score": "0.254229", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.054732", "ticker_sentiment_score": "0.042022", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.109206", "ticker_sentiment_score": "-0.13985", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.16317", "ticker_sentiment_score": "-0.014892", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.109206", "ticker_sentiment_score": "0.077416", "ticker_sentiment_label": "Neutral"}, {"ticker": "W", "relevance_score": "0.109206", "ticker_sentiment_score": "0.04744", "ticker_sentiment_label": "Neutral"}, {"ticker": "PH", "relevance_score": "0.109206", "ticker_sentiment_score": "0.11033", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.109206", "ticker_sentiment_score": "0.087519", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.216376", "ticker_sentiment_score": "0.205583", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ETN", "relevance_score": "0.109206", "ticker_sentiment_score": "0.11033", "ticker_sentiment_label": "Neutral"}, {"ticker": "PANW", "relevance_score": "0.216376", "ticker_sentiment_score": "-0.018349", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures Mixed Ahead Of Imminent Jobs Report", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-jobs-report-amazon-surges-on-earnings-apple-stock-falls/", "time_published": "20230804T122109", "authors": ["SCOTT LEHTONEN", "Investor's Business Daily"], "summary": "Dow Jones Futures Drops Ahead Of Jobs Report. Amazon Surges On Earnings, But Apple Falls Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/04/stock-wallstreet-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.17216, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.093775", "ticker_sentiment_score": "0.17306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.062597", "ticker_sentiment_score": "0.099033", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.186259", "ticker_sentiment_score": "0.013763", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBKR", "relevance_score": "0.124809", "ticker_sentiment_score": "0.08637", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.124809", "ticker_sentiment_score": "0.140729", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNST", "relevance_score": "0.062597", "ticker_sentiment_score": "0.06101", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.093775", "ticker_sentiment_score": "0.093022", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.031322", "ticker_sentiment_score": "0.110092", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.093775", "ticker_sentiment_score": "0.093022", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.124809", "ticker_sentiment_score": "0.046774", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.186259", "ticker_sentiment_score": "0.093371", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.093775", "ticker_sentiment_score": "0.17306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.124809", "ticker_sentiment_score": "0.139568", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPLK", "relevance_score": "0.124809", "ticker_sentiment_score": "0.15699", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEAM", "relevance_score": "0.093775", "ticker_sentiment_score": "0.17306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NET", "relevance_score": "0.093775", "ticker_sentiment_score": "0.17306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SQ", "relevance_score": "0.093775", "ticker_sentiment_score": "0.17306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.155652", "ticker_sentiment_score": "0.029471", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/the-pulmonary-embolism-therapeutics-market-size-to-grow-at-a-cagr-of-9-52-from-2022-to-2027the-advancement-in-the-healthcare-and-medical-sector-is-a-major-trend-technavio-301892623.html", "time_published": "20230804T093000", "authors": [], "summary": "The Pulmonary Embolism Therapeutics Market size to grow at a CAGR of 9.52% from 2022 to 2027|The advancement ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.05773, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAYZF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "NARI", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.045569", "ticker_sentiment_score": "0.139204", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hywin Holdings, Leonteq AG, and Arta TechFin jointly launch \"Global Mega-Trends Series\" principal-protected notes", "url": "https://www.globenewswire.com/news-release/2023/08/04/2718711/0/en/Hywin-Holdings-Leonteq-AG-and-Arta-TechFin-jointly-launch-Global-Mega-Trends-Series-principal-protected-notes.html", "time_published": "20230804T010000", "authors": ["HYWIN WEALTH MANAGEMENT CO.", "LTD"], "summary": "HONG KONG, Aug. 04, 2023 ( GLOBE NEWSWIRE ) -- Hywin Holdings Ltd. ( \"Hywin Wealth\" or \"Hywin\" ) ( NASDAQ: HYW ) , a leading independent wealth management service provider in China, Leonteq Securities AG ( \"Leonteq\" ) , a Swiss fintech company with a leading marketplace for structured investment ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/3902d648-f31d-4755-bf64-9369e18a1d19", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999696"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.337564, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADI", "relevance_score": "0.029078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.029078", "ticker_sentiment_score": "-0.042423", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.029078", "ticker_sentiment_score": "0.126195", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.029078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRCOF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.291496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TCTZF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.129078", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.029078", "ticker_sentiment_score": "0.129078", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.074831", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.029078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.029078", "ticker_sentiment_score": "0.126195", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDG", "relevance_score": "0.029078", "ticker_sentiment_score": "0.074831", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAFRF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.074831", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.029078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLAC", "relevance_score": "0.029078", "ticker_sentiment_score": "0.126195", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOELF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.291496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.029078", "ticker_sentiment_score": "0.129078", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYW", "relevance_score": "0.390178", "ticker_sentiment_score": "0.381795", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.029078", "ticker_sentiment_score": "0.126195", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNTQF", "relevance_score": "0.058117", "ticker_sentiment_score": "0.113002", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.029078", "ticker_sentiment_score": "0.074831", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTTF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.291496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALB", "relevance_score": "0.029078", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "THLEF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.074831", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.029078", "ticker_sentiment_score": "0.126195", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKILF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.291496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FANUF", "relevance_score": "0.029078", "ticker_sentiment_score": "0.291496", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.029078", "ticker_sentiment_score": "0.074831", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hywin Holdings, Leonteq AG, and Arta TechFin jointly launch \"Global Mega-Trends Series\" principal-protected notes - Hywin Holdings  ( NASDAQ:HYW ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33564916/hywin-holdings-leonteq-ag-and-arta-techfin-jointly-launch-global-mega-trends-series-principal-prot", "time_published": "20230804T010000", "authors": ["Globe Newswire"], "summary": "HONG KONG, Aug. 04, 2023 ( GLOBE NEWSWIRE ) -- Hywin Holdings Ltd. ( \"Hywin Wealth\" or \"Hywin\" ) HYW, a leading independent wealth management service provider in China, Leonteq Securities AG ( \"Leonteq\" ) , a Swiss fintech company with a leading marketplace for structured investment solutions, ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999896"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.330991, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADI", "relevance_score": "0.028355", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLP", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.042278", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028355", "ticker_sentiment_score": "0.125769", "ticker_sentiment_label": "Neutral"}, {"ticker": "STM", "relevance_score": "0.028355", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRCOF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.29085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TCTZF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.128646", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.028355", "ticker_sentiment_score": "0.128646", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.074546", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.028355", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.028355", "ticker_sentiment_score": "0.125769", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDG", "relevance_score": "0.028355", "ticker_sentiment_score": "0.074546", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAFRF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.074546", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.028355", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLAC", "relevance_score": "0.028355", "ticker_sentiment_score": "0.125769", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOELF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.29085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.028355", "ticker_sentiment_score": "0.128646", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYW", "relevance_score": "0.406088", "ticker_sentiment_score": "0.379542", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABBV", "relevance_score": "0.028355", "ticker_sentiment_score": "0.125769", "ticker_sentiment_label": "Neutral"}, {"ticker": "LNTQF", "relevance_score": "0.056674", "ticker_sentiment_score": "0.111995", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.028355", "ticker_sentiment_score": "0.074546", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADTTF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.29085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALB", "relevance_score": "0.028355", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "THLEF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.074546", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.028355", "ticker_sentiment_score": "0.125769", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKILF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.29085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FANUF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.29085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.028355", "ticker_sentiment_score": "0.074546", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Q2 Earnings and Revenues Top Estimates", "url": "https://www.zacks.com/stock/news/2132276/amgen-amgn-q2-earnings-and-revenues-top-estimates", "time_published": "20230803T213516", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) delivered earnings and revenue surprises of 12.61% and 5.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default5.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.150743, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.40348", "ticker_sentiment_score": "0.143722", "ticker_sentiment_label": "Neutral"}, {"ticker": "STTK", "relevance_score": "0.208764", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Raises Outlook With Horizon Still Waiting In The Wings", "url": "https://www.investors.com/news/technology/amgen-stock-amgen-earnings-q2-2023/", "time_published": "20230803T201700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Amgen ( AMGN ) stock rose moderately late Thursday after the biotech company reported adjusted profit of $5 per share on $6.99 billion in second-quarter sales. On average, analysts polled by FactSet expected Amgen to report $4.49 per share on $6.66 billion in sales.", "banner_image": "https://www.investors.com/wp-content/uploads/2022/11/Stock-amgen-08-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.272227, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.975103", "ticker_sentiment_score": "0.531045", "ticker_sentiment_label": "Bullish"}, {"ticker": "HZNP", "relevance_score": "0.42503", "ticker_sentiment_score": "0.325551", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen stock jumps after record earnings beat expectations, and biotech raises full-year outlook", "url": "https://www.marketwatch.com/story/amgen-stock-jumps-after-the-biotechs-record-earnings-beats-expectations-and-full-year-outlook-is-raised-e90cb53a", "time_published": "20230803T201300", "authors": ["Tomi Kilgore"], "summary": "Amgen's stock jumped in after-hours trading Thursday, after the biotechnology giant reported record second-quarter earnings that rose above expectations.", "banner_image": "https://images.mktw.net/im-829522/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.081618, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.318897", "ticker_sentiment_score": "0.035312", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS", "url": "https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-financial-results-301893066.html", "time_published": "20230803T200100", "authors": ["Amgen"], "summary": "Positive Top-Line Results for LUMAKRAS\u00ae ( Sotorasib ) Plus Vectibix\u00ae ( Panitumumab ) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Aug. 3, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the second quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.118881, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.014941", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.014941", "ticker_sentiment_score": "0.174477", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.029876", "ticker_sentiment_score": "0.11085", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.014941", "ticker_sentiment_score": "-0.017107", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.014941", "ticker_sentiment_score": "0.094737", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.014941", "ticker_sentiment_score": "-0.017107", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014941", "ticker_sentiment_score": "-0.017107", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Regeneron Pharmaceuticals Moving Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ", "url": "https://www.benzinga.com/general/biotech/23/08/33549371/why-is-regeneron-pharmaceuticals-moving-higher-today", "time_published": "20230803T143542", "authors": ["Vandana Singh"], "summary": "Regeneron Pharmaceuticals Inc REGN earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Street estimate. Revenues increased 11% Y/Y to $3.16 billion, beating the consensus of $3.01 billion. Dupixent global net sales ( recorded by Sanofi ) increased 33% to $2.79 billion ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/03/regn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.061925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.401331", "ticker_sentiment_score": "-0.066489", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.27432", "ticker_sentiment_score": "0.029797", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTLT", "relevance_score": "0.401331", "ticker_sentiment_score": "0.484263", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNY", "relevance_score": "0.139265", "ticker_sentiment_score": "0.126556", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Dividend Stocks That Hiked Payouts by 60% in Just 5 Years", "url": "https://www.fool.com/investing/2023/08/03/3-dividend-stocks-that-hiked-payouts-by-60-in-just/", "time_published": "20230803T120000", "authors": ["David Jagielski"], "summary": "Can these stocks keep the rate hikes coming?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F741902%2Fstock-certificate-investment-retire-heirloom-donate-capital-gains-tax-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.340497, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ATVI", "relevance_score": "0.06211", "ticker_sentiment_score": "0.124369", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.244723", "ticker_sentiment_score": "0.209209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDLZ", "relevance_score": "0.303175", "ticker_sentiment_score": "0.403302", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.466963", "ticker_sentiment_score": "0.37637", "ticker_sentiment_label": "Bullish"}, {"ticker": "HZNP", "relevance_score": "0.06211", "ticker_sentiment_score": "-0.097022", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month - Cars.com  ( NYSE:CARS ) , DraftKings  ( NASDAQ:DKNG ) , PayPal Holdings  ( NASDAQ:PYPL ) , Cheesecake Factory  ( NASDAQ:CAKE ) , Expedia Group  ( NASDAQ:EXPE ) , Hyatt Hotels  ( NYSE:H ) , Kellogg  ( NYSE:K ) , Amgen  ( NASDAQ:AMGN ) , DoorDash  ( NYSE:DASH ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Occidental Petroleum  ( NYSE:OXY ) , Etsy  ( NASDAQ:ETSY ) , Qualcomm  ( NASDAQ:QCOM ) , Warner Bros. Discovery  ( NASDAQ:WBD ) , EVgo  ( NASDAQ:EVGO ) , Atlassian  ( NASDAQ:TEAM ) , Gilead Sciences  ( NASDAQ:GILD ) , Hasbro  ( NASDAQ:HAS ) , Bausch Health Companies  ( NYSE:BHC ) , Moderna  ( NASDAQ:MRNA ) , Qorvo  ( NASDAQ:QRVO ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , SPDR S&P 500  ( ARCA:SPY ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/markets/equities/23/08/33543176/us-stock-futures-dip-as-apple-amazon-earnings-loom-analyst-warns-of-perfectly-normal-5-pullback-", "time_published": "20230803T105308", "authors": ["Shanthi Rexaline"], "summary": "As Fitch's U.S. ratings downgrade overhang persists and earnings new flow turns negative, stock futures are pulling back yet again on Thursday. Traders may find caution a virtue as a few profile tech names, including Apple, Inc. AAPL, are scheduled to report their quarterly results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/WallStreet.NYSE_2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.98396"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.048216, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.106541", "ticker_sentiment_score": "-0.191391", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AAPL", "relevance_score": "0.159218", "ticker_sentiment_score": "0.035669", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAKE", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.05339", "ticker_sentiment_score": "0.063035", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETSY", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVGO", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEAM", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring, Novartis, Merck, Amgen, Ionis , BioMarin, AstraZeneca", "url": "https://www.prnewswire.com/news-releases/atherosclerosis-market-to-witness-growth-by-2032-estimates-delveinsight--leading-companies---csl-behring-novartis-merck-amgen-ionis--biomarin-astrazeneca-301891245.html", "time_published": "20230802T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.114748, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HUMA", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.028868", "ticker_sentiment_score": "-0.085973", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.057698", "ticker_sentiment_score": "0.015995", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.028868", "ticker_sentiment_score": "0.121734", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKXJF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSKYF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028868", "ticker_sentiment_score": "0.037471", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.028868", "ticker_sentiment_score": "0.037471", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESPR", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNUGF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHGCF", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.057698", "ticker_sentiment_score": "0.11102", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.028868", "ticker_sentiment_score": "0.121734", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABIO", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.028868", "ticker_sentiment_score": "-0.085973", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.028868", "ticker_sentiment_score": "0.037471", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHX", "relevance_score": "0.028868", "ticker_sentiment_score": "0.000924", "ticker_sentiment_label": "Neutral"}, {"ticker": "NAMS", "relevance_score": "0.028868", "ticker_sentiment_score": "0.121734", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.028868", "ticker_sentiment_score": "0.027341", "ticker_sentiment_label": "Neutral"}]}, {"title": "Risk-Off Mood Pervades Following Surprise Downgrade Of U.S. Treasuries By Fitch Ratings - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/markets/23/08/33523169/risk-off-mood-pervades-following-surprise-downgrade-of-u-s-treasuries-by-fitch-ratings", "time_published": "20230802T142423", "authors": ["Alex Coffey"], "summary": "( Wednesday market open ) A defensive, \"risk-off\" mood gripped global markets early Wednesday after Fitch Ratings' surprise downgrade of its rating for U.S. Treasuries to AA+ from AAA. The move sparked a rapid retreat from riskier assets, but the bond market saw little initial reaction.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/02/shutterstock_444525001.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999993"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.041163, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.039516", "ticker_sentiment_score": "0.323005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.252584", "ticker_sentiment_score": "-0.005781", "ticker_sentiment_label": "Neutral"}, {"ticker": "DG", "relevance_score": "0.039516", "ticker_sentiment_score": "0.029494", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.019764", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.039516", "ticker_sentiment_score": "0.004886", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.019764", "ticker_sentiment_score": "0.026687", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBG", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "K", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.019764", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.039516", "ticker_sentiment_score": "0.144099", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.039516", "ticker_sentiment_score": "0.004886", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.039516", "ticker_sentiment_score": "0.027982", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.019764", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.059243", "ticker_sentiment_score": "0.168349", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENB", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.039516", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.233743", "ticker_sentiment_score": "-0.02732", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.039516", "ticker_sentiment_score": "0.029494", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.019764", "ticker_sentiment_score": "-0.068344", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intercept Pharmaceuticals  ( ICPT )  Reports Q2 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2130946/intercept-pharmaceuticals-icpt-reports-q2-loss-tops-revenue-estimates", "time_published": "20230802T122511", "authors": ["Zacks Equity Research"], "summary": "Intercept (ICPT) delivered earnings and revenue surprises of 75% and 6.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default233.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.109979, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ICPT", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.064105", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.139265", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Best Dow Jones Stocks To Watch In August 2023", "url": "https://www.investors.com/research/dow-jones-stocks/", "time_published": "20230801T192800", "authors": ["Investor's Business Daily", "SCOTT LEHTONEN"], "summary": "The Dow Jones Industrial Average remains in rally mode through the end of July, with the stock market at its 2023 highs. The best Dow Jones stocks to buy and watch in August 2023 are Apple ( AAPL ) , Boeing ( BA ) , Caterpillar ( CAT ) , Microsoft ( MSFT ) and Salesforce ( CRM ) .", "banner_image": "https://www.investors.com/wp-content/uploads/2021/09/Stock-apple-streamingevent-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.259288, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.338582", "ticker_sentiment_score": "0.273713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.390613", "ticker_sentiment_score": "0.319222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VZ", "relevance_score": "0.116067", "ticker_sentiment_score": "-0.175962", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CAT", "relevance_score": "0.229691", "ticker_sentiment_score": "0.160072", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WBA", "relevance_score": "0.116067", "ticker_sentiment_score": "-0.175962", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.116067", "ticker_sentiment_score": "-0.175962", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BA", "relevance_score": "0.229691", "ticker_sentiment_score": "0.209569", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Looking At Amgen's Recent Unusual Options Activity - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/08/33502959/looking-at-amgens-recent-unusual-options-activity", "time_published": "20230801T191601", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.227868, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.774013", "ticker_sentiment_score": "0.389802", "ticker_sentiment_label": "Bullish"}, {"ticker": "BCS", "relevance_score": "0.107016", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Mixed Brew: Pfizer, Merck Earnings Head Opposite Ways, But Uber And Caterpillar Slug Line Drives - Alaska Air Gr  ( NYSE:ALK ) , Apple  ( NASDAQ:AAPL ) ", "url": "https://www.benzinga.com/markets/23/08/33501240/mixed-brew-pfizer-merck-earnings-head-opposite-ways-but-uber-and-caterpillar-slug-line-drives", "time_published": "20230801T173623", "authors": ["Alex Coffey"], "summary": "( Tuesday market open ) The new month starts with stocks tinted red, but this week's main events are just getting underway. A rise in Treasury yields might have investors nervous early Tuesday as the 10-year yield popped back above 4% ahead of key U.S. economic data.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/01/shutterstock_306271739_8.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.682689"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.999995"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.012069, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.077156", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.019317", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "K", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.077156", "ticker_sentiment_score": "-0.033955", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.038623", "ticker_sentiment_score": "0.143726", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.096361", "ticker_sentiment_score": "0.033233", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.038623", "ticker_sentiment_score": "-0.109184", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.096361", "ticker_sentiment_score": "0.038798", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.057907", "ticker_sentiment_score": "0.076226", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.038623", "ticker_sentiment_score": "0.020817", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBLU", "relevance_score": "0.038623", "ticker_sentiment_score": "0.073541", "ticker_sentiment_label": "Neutral"}, {"ticker": "YELL", "relevance_score": "0.019317", "ticker_sentiment_score": "-0.102643", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBG", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOX", "relevance_score": "0.019317", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUM", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.019317", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.077156", "ticker_sentiment_score": "0.113864", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENB", "relevance_score": "0.038623", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.077156", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAR", "relevance_score": "0.038623", "ticker_sentiment_score": "0.213208", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Earnings Extravaganza: Another One-Third of S&P 500 Companies Report this Week, Including Amazon, Apple - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33474441/earnings-extravaganza-another-one-third-of-s-p-500-companies-report-this-week-including-amazon-appl", "time_published": "20230731T161315", "authors": ["Alex Coffey"], "summary": "( Monday market open ) It's \"tech week\" on Wall Street. No, wait, it's \"pharma week.\" Or is it \"employment week?\" How about all three?", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/31/shutterstock_156562427_12.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.992549"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.04301, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.15347", "ticker_sentiment_score": "0.03614", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.038592", "ticker_sentiment_score": "-0.004921", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.019302", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "K", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.17237", "ticker_sentiment_score": "-0.07387", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.038592", "ticker_sentiment_score": "0.143713", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.077094", "ticker_sentiment_score": "0.035379", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.096283", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.05786", "ticker_sentiment_score": "0.104522", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.05786", "ticker_sentiment_score": "0.041286", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.038592", "ticker_sentiment_score": "-0.004921", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBG", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUM", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.038592", "ticker_sentiment_score": "-0.004921", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENB", "relevance_score": "0.038592", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.15347", "ticker_sentiment_score": "0.03614", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  to Report Q2 Earnings: Here's What to Expect", "url": "https://www.zacks.com/stock/news/2129960/amgen-amgn-to-report-q2-earnings-heres-what-to-expect", "time_published": "20230731T150900", "authors": ["Zacks Equity Research"], "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998917"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.111736, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.105836", "ticker_sentiment_score": "0.033037", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.450607", "ticker_sentiment_score": "0.15337", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.105836", "ticker_sentiment_score": "-0.069034", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.209819", "ticker_sentiment_score": "0.037442", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rising Stars, Falling Trends: July's Industry ETF Winners and Losers - Invesco Solar ETF  ( ARCA:TAN ) , Deere  ( NYSE:DE ) , SLB  ( NYSE:SLB ) , Archer-Daniels Midland  ( NYSE:ADM ) , Mueller Industries  ( NYSE:MLI ) , Amgen  ( NASDAQ:AMGN ) , Ferguson  ( NYSE:FERG ) , Vanguard Real Estate ETF  ( ARCA:VNQ ) , VanEck Gold Miners ETF  ( ARCA:GDX ) , SPDR S&P 500  ( ARCA:SPY ) , American Tower  ( NYSE:AMT ) , SMA Solar Tech  ( OTC:SMTGF ) , VanEck Oil Services ETF  ( ARCA:OIH ) , VanEck Semiconductor ETF  ( NASDAQ:SMH ) , Taiwan Semiconductor  ( NYSE:TSM ) , Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Antero Resources  ( NYSE:AR ) , First Solar  ( NASDAQ:FSLR ) , SPDR S&P Oil & Gas Explor & Product  ( ARCA:XOP ) , Biogen  ( NASDAQ:BIIB ) , SPDR S&P Regional Banking ETF  ( ARCA:KRE ) , Enphase Energy  ( NASDAQ:ENPH ) , Broadcom  ( NASDAQ:AVGO ) , Western Alliance  ( NYSE:WAL ) , CoStar Gr  ( NASDAQ:CSGP ) , iShares Biotechnology ETF  ( NASDAQ:IBB ) , Prologis  ( NYSE:PLD ) , Waters  ( NYSE:WAT ) , Ovintiv  ( NYSE:OVV ) , Danaher  ( NYSE:DHR ) , Invesco Water Resources ETF  ( NASDAQ:PHO ) , U.S. Global Jets ETF  ( ARCA:JETS ) , Lam Research  ( NASDAQ:LRCX ) , Zoetis  ( NYSE:ZTS ) , SM Energy  ( NYSE:SM ) , SPDR Dow Jones Industrial Average ETF  ( ARCA:DIA ) , iShares Russell 2000 ETF  ( ARCA:IWM ) , NVIDIA  ( NASDAQ:NVDA ) , Zions Bancorp  ( NASDAQ:ZION ) , Apellis Pharmaceuticals  ( NASDAQ:APLS ) , Crown Castle  ( NYSE:CCI ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) , Southwest Airlines  ( NYSE:LUV ) , VanEck Agribusiness ETF  ( ARCA:MOO ) , Pinnacle Finl Partners  ( NASDAQ:PNFP ) , Delta Air Lines  ( NYSE:DAL ) , Ecolab  ( NYSE:ECL ) , APA  ( NASDAQ:APA ) , Halliburton  ( NYSE:HAL ) , SolarEdge Technologies  ( NASDAQ:SEDG ) , Valmont Industries  ( NYSE:VMI ) , Intel  ( NASDAQ:INTC ) ", "url": "https://www.benzinga.com/markets/equities/23/07/33471902/rising-stars-falling-trends-julys-industry-etf-winners-and-losers", "time_published": "20230731T145922", "authors": ["Piero Cingari"], "summary": "As July comes to an end, it's time to take a look at the best- and worst-performing industry ETFs for the month. Among the largest ETFs that represent major U.S. stock indices, the SPDR S&P 500 ETF Trust SPY returned 3.1% in July, marking its fifth consecutive month of gains.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Spanish,Bull,Running,In,The,Bullring,With,Big,Horns,On_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.166243, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DE", "relevance_score": "0.110209", "ticker_sentiment_score": "0.050232", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.056323", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSGP", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLD", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADM", "relevance_score": "0.110209", "ticker_sentiment_score": "0.050232", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLI", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.164656", "ticker_sentiment_score": "0.180471", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "OVV", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "FERG", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.164656", "ticker_sentiment_score": "0.061707", "ticker_sentiment_label": "Neutral"}, {"ticker": "SM", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.164656", "ticker_sentiment_score": "-0.031505", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMT", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCI", "relevance_score": "0.110209", "ticker_sentiment_score": "0.048041", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIONL", "relevance_score": "0.055236", "ticker_sentiment_score": "0.041883", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.054977", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMTGF", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNFP", "relevance_score": "0.110209", "ticker_sentiment_score": "0.045851", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.110209", "ticker_sentiment_score": "0.040379", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "AR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.041473", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAL", "relevance_score": "0.164656", "ticker_sentiment_score": "0.057668", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEDG", "relevance_score": "0.110209", "ticker_sentiment_score": "0.044757", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.110209", "ticker_sentiment_score": "-0.025482", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.110209", "ticker_sentiment_score": "0.049137", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investing Action Plan: Apple, Amazon And An Upturn In Optimism", "url": "https://www.investors.com/research/investing-action-plan/stock-market-action-plan-apple-amazon-and-an-upturn-in-optimism/", "time_published": "20230728T222500", "authors": ["Investor's Business Daily", "IBD STAFF"], "summary": "A good week for optimism left the stock market in strong standing as it heads into early August. Chips showed strength, riding the rising trend in AI computing. Department stores also soared as markets begin to look toward the back-to-school and holiday shopping seasons.", "banner_image": "https://www.investors.com/wp-content/uploads/2021/08/Stock-BullPaintedRushing-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.150949, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CVS", "relevance_score": "0.06515", "ticker_sentiment_score": "0.077233", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.086791", "ticker_sentiment_score": "0.167143", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANET", "relevance_score": "0.04346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.04346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.06515", "ticker_sentiment_score": "0.099257", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABNB", "relevance_score": "0.06515", "ticker_sentiment_score": "0.099257", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.04346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNKO", "relevance_score": "0.04346", "ticker_sentiment_score": "-0.114905", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.04346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "THC", "relevance_score": "0.06515", "ticker_sentiment_score": "-0.036363", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.04346", "ticker_sentiment_score": "0.014851", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.06515", "ticker_sentiment_score": "0.112516", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.04346", "ticker_sentiment_score": "0.085123", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.04346", "ticker_sentiment_score": "0.00594", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDG", "relevance_score": "0.04346", "ticker_sentiment_score": "0.083325", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.086791", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.06515", "ticker_sentiment_score": "0.084501", "ticker_sentiment_label": "Neutral"}, {"ticker": "EA", "relevance_score": "0.04346", "ticker_sentiment_score": "0.057574", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.04346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.04346", "ticker_sentiment_score": "0.024659", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.04346", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.04346", "ticker_sentiment_score": "-0.035863", "ticker_sentiment_label": "Neutral"}, {"ticker": "MELI", "relevance_score": "0.04346", "ticker_sentiment_score": "0.073301", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.06515", "ticker_sentiment_score": "0.05805", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.04346", "ticker_sentiment_score": "0.003966", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENB", "relevance_score": "0.06515", "ticker_sentiment_score": "0.071468", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.06515", "ticker_sentiment_score": "0.089474", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.108368", "ticker_sentiment_score": "0.184585", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MAR", "relevance_score": "0.06515", "ticker_sentiment_score": "0.099257", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRVL", "relevance_score": "0.04346", "ticker_sentiment_score": "0.083325", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.021738", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Dow Breaks 13-Day Winning Streak, Fed Raises Interest Rates To 2001 Levels And AI Is The Buzzword For Big Tech Earnings: The Week In The Markets - PacWest Banc  ( NASDAQ:PACW ) , CVS Health  ( NYSE:CVS ) , JPMorgan Chase  ( NYSE:JPM ) , Merck & Co  ( NYSE:MRK ) , Amgen  ( NASDAQ:AMGN ) , Pfizer  ( NYSE:PFE ) , Peoples Trust Company  ( OTC:PPAL ) , Anheuser-Busch InBev  ( NYSE:BUD ) , Microsoft  ( NASDAQ:MSFT ) , Shopify  ( NYSE:SHOP ) , Starbucks  ( NASDAQ:SBUX ) , Qualcomm  ( NASDAQ:QCOM ) , Advanced Micro Devices  ( NASDAQ:AMD ) , Alibaba Gr Holding  ( NYSE:BABA ) , PayPal Holdings  ( NASDAQ:PYPL ) , Alphabet  ( NASDAQ:GOOG ) , Meta Platforms  ( NASDAQ:META ) , Bank of America  ( NYSE:BAC ) , ConocoPhillips  ( NYSE:COP ) , Banc of California  ( NYSE:BANC ) , HSBC Holdings  ( NYSE:HSBC ) , Intel  ( NASDAQ:INTC ) , Caterpillar  ( NYSE:CAT ) , Toyota Motor  ( NYSE:TM ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/markets/equities/23/07/33449979/the-dow-breaks-13-day-winning-streak-fed-raises-interest-rates-to-2001-levels-and-ai-is-the-buzz", "time_published": "20230728T200647", "authors": ["Natan Ponieman"], "summary": "The S&P 500 and other major indexes slid on Thursday but recovered on Friday to wrap up the week to the upside. The Dow Jones broke a 13-day winning streak Thursday, its best since 1987, and was up 0.65% on a weekly basis Friday. The Nasdaq Composite posted a weekly gain of 1.67%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Artificial,Intelligence,(ai),machine,Learning,With,Data,Mining,Technology,On,Virtual_8.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.103139, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACW", "relevance_score": "0.114956", "ticker_sentiment_score": "0.196637", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PYPL", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.114956", "ticker_sentiment_score": "0.083342", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.114956", "ticker_sentiment_score": "0.08371", "ticker_sentiment_label": "Neutral"}, {"ticker": "COP", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.114956", "ticker_sentiment_score": "0.08371", "ticker_sentiment_label": "Neutral"}, {"ticker": "BANC", "relevance_score": "0.114956", "ticker_sentiment_score": "0.196637", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.227538", "ticker_sentiment_score": "0.005545", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QCOM", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.114956", "ticker_sentiment_score": "0.240528", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.114956", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen  ( NASDAQ:BIIB ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33444357/reatas-acquisition-fits-biogens-strategy-despite-high-cost-analyst-says-high-level-", "time_published": "20230728T155617", "authors": ["Vandana Singh"], "summary": "Earlier today, Biogen Inc BIIB agreed to acquire Reata Pharmaceuticals Inc RETA for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/28/aapharma_5.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.162687, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SLDB", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSGN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.280615", "ticker_sentiment_score": "0.481365", "ticker_sentiment_label": "Bullish"}, {"ticker": "LRMR", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.280615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.718897", "ticker_sentiment_score": "0.314394", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Price Pressure Eased In June, Fueling Early Wall Street Gains, But BoJ Rate Policy Move Rattles Market - Ford Motor  ( NYSE:F ) , Intel  ( NASDAQ:INTC ) ", "url": "https://www.benzinga.com/markets/23/07/33445247/price-pressure-eased-in-june-fueling-early-wall-street-gains-but-boj-rate-policy-move-rattles-market", "time_published": "20230728T152733", "authors": ["Alex Coffey"], "summary": "( Friday market open ) Welcome signs of easing U.S. inflation propelled Wall Street to early gains Friday, but the market remains rattled following a policy tweak earlier from the Bank of Japan ( BoJ ) and worries about the Federal Reserve potentially tightening further.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/28/shutterstock_306271739_7.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.990678"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.002439, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "D", "relevance_score": "0.01957", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "K", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "THC", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.039128", "ticker_sentiment_score": "-0.17116", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRBG", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUM", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.097615", "ticker_sentiment_score": "0.16207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CAT", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNA", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENB", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.039128", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Things About Johnson & Johnson Every Smart Investor Knows", "url": "https://www.fool.com/investing/2023/07/28/3-things-about-johnson-johnson-every-smart-investo/", "time_published": "20230728T123700", "authors": ["Jim Halley"], "summary": "The company has been a strong value stock but faces big changes this year.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}, {"topic": "Earnings", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.092916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.256089", "ticker_sentiment_score": "0.003796", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICNB", "relevance_score": "0.043421", "ticker_sentiment_score": "0.102889", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.043421", "ticker_sentiment_score": "0.168413", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GMAB", "relevance_score": "0.043421", "ticker_sentiment_score": "0.053643", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.413878", "ticker_sentiment_score": "0.028474", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/07/33429061/check-out-what-whales-are-doing-with-amgn", "time_published": "20230727T193130", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bearish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.152527, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.837089", "ticker_sentiment_score": "0.335426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.110973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Begin Day With Strength, Propelled By Solid Earnings And Economic Data Including GDP - Bank of America  ( NYSE:BAC ) , Boeing  ( NYSE:BA ) ", "url": "https://www.benzinga.com/markets/23/07/33427159/stocks-begin-day-with-strength-propelled-by-solid-earnings-and-economic-data-including-gdp", "time_published": "20230727T175126", "authors": ["Alex Coffey"], "summary": "( Thursday market open ) Major indexes turned green in premarket trading on Thursday following solid earnings from Meta Platforms META and McDonald's MCD, accompanied by a host of price target increases from Wall Street analysts.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/27/shutterstock_1049641082_13.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.999326"}, {"topic": "Economy - Fiscal", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.07214, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DD", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.02135", "ticker_sentiment_score": "0.057075", "ticker_sentiment_label": "Neutral"}, {"ticker": "KHC", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "H", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "K", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLX", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "THC", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBUX", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AON", "relevance_score": "0.042685", "ticker_sentiment_score": "0.060382", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.06399", "ticker_sentiment_score": "0.146169", "ticker_sentiment_label": "Neutral"}, {"ticker": "MO", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.042685", "ticker_sentiment_score": "-0.119739", "ticker_sentiment_label": "Neutral"}, {"ticker": "CL", "relevance_score": "0.06399", "ticker_sentiment_score": "-0.038126", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUM", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNA", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.042685", "ticker_sentiment_score": "0.060382", "ticker_sentiment_label": "Neutral"}, {"ticker": "XOM", "relevance_score": "0.042685", "ticker_sentiment_score": "0.060382", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.042685", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.042685", "ticker_sentiment_score": "-0.119739", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.06399", "ticker_sentiment_score": "0.017184", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.042685", "ticker_sentiment_score": "0.01695", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie  ( ABBV )  Beats on Q2 Earnings & Sales, Raises '23 View", "url": "https://www.zacks.com/stock/news/2128992/abbvie-abbv-beats-on-q2-earnings-sales-raises-23-view", "time_published": "20230727T170500", "authors": ["Zacks Equity Research"], "summary": "AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.116199, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.036869", "ticker_sentiment_score": "0.003882", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.073659", "ticker_sentiment_score": "-0.029303", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.182782", "ticker_sentiment_score": "0.156185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.182782", "ticker_sentiment_score": "-0.019419", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.073659", "ticker_sentiment_score": "0.131144", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie Earnings, Revenue Fall Less Than Expected", "url": "https://www.investors.com/news/technology/abbvie-stock-abbvie-earnings-q22023/", "time_published": "20230727T122700", "authors": ["Investor's Business Daily", "REINHARDT KRAUSE"], "summary": "AbbVie Stock: AbbVie Earnings, Revenue Fall But Top Expectations Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/04/Stock-abbvie-04-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}], "overall_sentiment_score": 0.026648, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.255641", "ticker_sentiment_score": "-0.039924", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.949596", "ticker_sentiment_score": "0.072879", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Winning Strategy to Fade the Crowd Before Earnings", "url": "https://moneymorning.com/investing/the-winning-strategy-to-fade-the-crowd-before-earnings/", "time_published": "20230726T183129", "authors": ["Tom Gentile"], "summary": "Last week, we discussed how I turn earnings season into the most lucrative time of the year by trading ahead of the crowd. If you missed that conversation, you can still catch the replay here. And while the focus was mostly on profiting from the run up into earnings announcements, a few traders ...", "banner_image": "https://powerprofittrades.com/wp-content/uploads/2023/07/23-07-26-condors1-2-1024x577.png", "source": "Money Morning", "category_within_source": "GoogleRSS", "source_domain": "moneymorning.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.9545"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.177138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.18046", "ticker_sentiment_score": "0.049989", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.18046", "ticker_sentiment_score": "0.049989", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.18046", "ticker_sentiment_score": "0.049989", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie's Skyrizi Achieves Superiority Versus Amgen's Drug In Head-to-Head Study In Moderate Plaque Psoriasis - AbbVie  ( NYSE:ABBV ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33397063/abbvies-skyrizi-achieves-superiority-versus-amgens-drug-in-head-to-head-study-in-moderate-plaque-", "time_published": "20230726T162549", "authors": ["Vandana Singh"], "summary": "AbbVie Inc ABBV announced that the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of Skyrizi ( risankizumab ) compared to Amgen Inc's AMGN Otezla ( apremilast ) for moderate plaque psoriasis eligible for ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/26/abbv.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.033043, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.2872", "ticker_sentiment_score": "0.12175", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.642555", "ticker_sentiment_score": "0.293333", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AbbVie may see less pain from Humira sales decline as rival lags", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-may-see-less-pain-humira-sales-decline-rival-lags-2023-07-26/", "time_published": "20230726T160600", "authors": ["Leroy Leo"], "summary": "July 26 ( Reuters ) - AbbVie Inc ( ABBV.N ) is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.", "banner_image": "https://graphics.reuters.com/ABBVIE-RESULTS/HUMIRA-US/akpeazmdapr/chart.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.00239, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.061609", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.09402", "ticker_sentiment_score": "0.164714", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.521465", "ticker_sentiment_score": "-0.06581", "ticker_sentiment_label": "Neutral"}]}, {"title": "Seven Humira Biosimilars: Increased Competition In Arthritis Drug Market Sparks Need For Reform Of Drug Pricing Intermediaries - AbbVie  ( NYSE:ABBV ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33386891/seven-humira-biosimilars-increased-competition-in-arthritis-drug-market-sparks-need-for-reform-of", "time_published": "20230726T130634", "authors": ["Vandana Singh"], "summary": "Seven pharmaceutical companies recently launched their biosimilars of AbbVie Inc's ABBV top-selling arthritis drug Humira.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/26/abbvie.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.157595, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.328819", "ticker_sentiment_score": "0.168786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.328819", "ticker_sentiment_score": "0.265693", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "2 Cheap High-Yield Dividend Stocks to Buy Now", "url": "https://www.fool.com/investing/2023/07/25/2-cheap-high-yield-dividend-stocks-to-buy-now/", "time_published": "20230725T151500", "authors": ["George Budwell"], "summary": "These two pharma stocks are top-notch passive income vehicles.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F741054%2Fdividends.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.803643"}], "overall_sentiment_score": 0.371704, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.342487", "ticker_sentiment_score": "0.223808", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.175433", "ticker_sentiment_score": "0.168718", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the Invesco Dynamic Pharmaceuticals ETF  ( PJP ) ?", "url": "https://www.zacks.com/stock/news/2126629/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp", "time_published": "20230725T102008", "authors": ["Zacks Equity Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.185606, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.131643", "ticker_sentiment_score": "0.063605", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.131643", "ticker_sentiment_score": "0.063605", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.196344", "ticker_sentiment_score": "0.130316", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.131643", "ticker_sentiment_score": "0.063605", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2126475/amgen-amgn-gains-but-lags-market-what-you-should-know", "time_published": "20230724T215021", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) closed the most recent trading day at $235.42, moving +0.26% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.193246, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.608634", "ticker_sentiment_score": "0.246374", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Mirati  ( MRTX )  Down 7% on CHMP's Opinion on Krazati Filing", "url": "https://www.zacks.com/stock/news/2126345/mirati-mrtx-down-7-on-chmps-opinion-on-krazati-filing", "time_published": "20230724T152300", "authors": ["Zacks Equity Research"], "summary": "Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.072549, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.097259", "ticker_sentiment_score": "0.176669", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOWL", "relevance_score": "0.286082", "ticker_sentiment_score": "0.103494", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.145437", "ticker_sentiment_score": "-0.041229", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMGA", "relevance_score": "0.286082", "ticker_sentiment_score": "0.072312", "ticker_sentiment_label": "Neutral"}]}, {"title": "Horizon's  ( HZNP )  Daxdilimab Fails to Meet Goal in Lupus Study", "url": "https://www.zacks.com/stock/news/2126230/horizons-hznp-daxdilimab-fails-to-meet-goal-in-lupus-study", "time_published": "20230724T151200", "authors": ["Zacks Equity Research"], "summary": "Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.016817, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADCT", "relevance_score": "0.337811", "ticker_sentiment_score": "0.046462", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACAD", "relevance_score": "0.337811", "ticker_sentiment_score": "0.063333", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.172919", "ticker_sentiment_score": "0.063711", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.389744", "ticker_sentiment_score": "-0.192868", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Amgen Inc.  ( AMGN )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2126003/amgen-inc-amgn-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20230724T130006", "authors": ["Zacks Equity Research"], "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default336.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.217779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.484798", "ticker_sentiment_score": "0.098122", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2125862/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230724T102008", "authors": ["Zacks Equity Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default147.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999953"}], "overall_sentiment_score": 0.282717, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061159", "ticker_sentiment_score": "0.109012", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.121959", "ticker_sentiment_score": "0.061385", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires - Genelux  ( NASDAQ:GNLX ) ", "url": "https://www.benzinga.com/pressreleases/23/07/g33312361/genelux-corporation-strengthens-senior-management-and-clinical-team-with-promotions-and-new-hires", "time_published": "20230720T204500", "authors": ["Globe Newswire"], "summary": "WESTLAKE VILLAGE, Calif., July 20, 2023 ( GLOBE NEWSWIRE ) -- Genelux Corporation GNLX, a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of two new members to its leadership team.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.069723, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.059488", "ticker_sentiment_score": "0.007009", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLX", "relevance_score": "0.449503", "ticker_sentiment_score": "0.138277", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires", "url": "https://www.globenewswire.com/news-release/2023/07/20/2708618/0/en/Genelux-Corporation-Strengthens-Senior-Management-and-Clinical-Team-with-Promotions-and-New-Hires.html", "time_published": "20230720T204500", "authors": ["Genelux Corporation"], "summary": "WESTLAKE VILLAGE, Calif., July 20, 2023 ( GLOBE NEWSWIRE ) -- Genelux Corporation ( NASDAQ: GNLX ) , a late clinical-stage immuno-oncology company, today announced two key management promotions, as well as the addition of two new members to its leadership team.", "banner_image": "https://ml.globenewswire.com/Resource/Download/a4117c65-91cf-479d-9a61-b3edfddde26f", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.076676, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.045482", "ticker_sentiment_score": "0.00795", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLX", "relevance_score": "0.431554", "ticker_sentiment_score": "0.130966", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Is the Nasdaq?", "url": "https://www.kiplinger.com/investing/stocks/what-is-the-nasdaq", "time_published": "20230719T202804", "authors": ["Tom Taulli"], "summary": "\"The Nasdaq\" is a term market participants hear several times a day, but what exactly is \"the Nasdaq\"? Typically, when an investor says \"the Nasdaq,\" they're referring to the Nasdaq Composite, or IXIC. This is an index that tracks the performance of the Nasdaq Stock Market, an electronic platform ...", "banner_image": "https://cdn.mos.cms.futurecdn.net/V5bwoDADBb3z3nyMfkHFef-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.213677, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.134339", "ticker_sentiment_score": "0.100175", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.178459", "ticker_sentiment_score": "0.086592", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.089797", "ticker_sentiment_score": "0.028913", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.04497", "ticker_sentiment_score": "0.269086", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.089797", "ticker_sentiment_score": "0.086968", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer", "url": "https://www.globenewswire.com/news-release/2023/07/19/2707172/0/en/Autolus-Therapeutics-announces-appointment-of-Robert-F-Dolski-as-Chief-Financial-Officer.html", "time_published": "20230719T110000", "authors": ["Autolus Inc."], "summary": "- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/680b5e1a-9aba-4e38-b280-e43036561ef1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.079382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IONS", "relevance_score": "0.024775", "ticker_sentiment_score": "0.011725", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUTL", "relevance_score": "0.049526", "ticker_sentiment_score": "0.080276", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.024775", "ticker_sentiment_score": "0.011725", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.024775", "ticker_sentiment_score": "0.063853", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.024775", "ticker_sentiment_score": "0.011725", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.049526", "ticker_sentiment_score": "-0.087686", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2123401/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230719T102007", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default167.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.164146, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.068896", "ticker_sentiment_score": "0.034085", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.137278", "ticker_sentiment_score": "0.072244", "ticker_sentiment_label": "Neutral"}]}, {"title": "Softbank, Amgen-Backed Neumora Therapeutics Unveils Plans For Three Phase 3 Studies For Major Depressive Disorder - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/07/33271456/softbank-amgen-backed-neumora-therapeutics-unveils-plans-for-three-phase-3-studies-for-major-depr", "time_published": "20230718T182356", "authors": ["Vandana Singh"], "summary": "Neumora Therapeutics unveiled plans for three late-stage studies for its major depressive disorder ( MDD ) candidate Navacaprant. The U.S.-based clinical-stage biopharmaceutical is backed by Softbank Group Corp SFTBY SFTBF and Amgen Inc AMGN via a $100 million equity investment.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/18/aapharma_12.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.031057, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.331765", "ticker_sentiment_score": "0.134183", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.169676", "ticker_sentiment_score": "0.174468", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SFTBF", "relevance_score": "0.331765", "ticker_sentiment_score": "0.134183", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2122411/amgen-amgn-gains-but-lags-market-what-you-should-know", "time_published": "20230717T215021", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $227.84, marking a +0.18% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default209.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.18684, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.553265", "ticker_sentiment_score": "0.244339", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Venturing Beyond The Magic Kingdom: Former Disney CFO And Fortune 500 Veteran Takes The Reins At Lucy Scientific - Lucy Scientific Discovery  ( NASDAQ:LSDI ) ", "url": "https://www.benzinga.com/markets/cannabis/23/07/33235401/venturing-beyond-the-magic-kingdom-former-disney-cfo-and-fortune-500-veteran-takes-the-reins-at-", "time_published": "20230714T201706", "authors": ["Lara Goldstein"], "summary": "As of July 13, Lucy Scientific Discovery LSDI has a new principal. Current executive chairman, Richard Nanula, will retain this role while succeeding Chris McElvany as the company's CEO toward bringing \"significant strategic focus and leadership\" to Lucy.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/14/psychedelics_ma_pexels.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.494937, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.036027", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIS", "relevance_score": "0.195814", "ticker_sentiment_score": "0.036027", "ticker_sentiment_label": "Neutral"}, {"ticker": "LSDI", "relevance_score": "0.290033", "ticker_sentiment_score": "0.200941", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "MOORE KUEHN ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM", "url": "https://www.prnewswire.com/news-releases/moore-kuehn-encourages-amgen-inc-investors-to-contact-law-firm-301877809.html", "time_published": "20230714T195900", "authors": ["PLLC", "Moore Kuehn"], "summary": "NEW YORK, July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: ** Please only contact if shares purchased before July 29, 2020", "banner_image": "https://mma.prnewswire.com/media/698123/Moore_Kuehn_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.012183, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.909649", "ticker_sentiment_score": "-0.135717", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( AMGN )  - Analyzing Amgen's Short Interest - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/07/33233732/amgn-analyzing-amgens-short-interest", "time_published": "20230714T164546", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has fallen 3.7% since its last report. The company recently reported that it has 6.95 million shares sold short, which is 1.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.37 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.241618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Best Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/07/14/2-best-biotech-stocks-to-buy-right-now/", "time_published": "20230714T125000", "authors": ["Kody Kester"], "summary": "These two pharmaceutical titans look like convincing buys for income investors.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F739330%2Fa-doctor-consults-with-their-patient.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.192255, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.191675", "ticker_sentiment_score": "0.059056", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.064449", "ticker_sentiment_score": "0.068531", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.314017", "ticker_sentiment_score": "0.212918", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( AMGN )  Outpaces Stock Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2120958/amgen-amgn-outpaces-stock-market-gains-what-you-should-know", "time_published": "20230713T220020", "authors": ["Zacks Investment Research"], "summary": "Amgen (AMGN) closed the most recent trading day at $227.66, moving +0.88% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default358.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.203849, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.624172", "ticker_sentiment_score": "0.286109", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is Amgen's Dividend Safe?", "url": "https://www.fool.com/investing/2023/07/13/is-amgens-dividend-safe/", "time_published": "20230713T181053", "authors": ["George Budwell"], "summary": "Despite multiple headwinds, the biotech's dividend appears to be a safe play for income investors.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F739641%2Fpiggybank.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999858"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.293716, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.360098", "ticker_sentiment_score": "0.343252", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Get Ready For A Slew Of New Weight-Loss Drugs", "url": "https://www.investors.com/news/technology/weight-loss-drugs-to-watch-rivals-ramp-up-to-unseat-the-undisputed-leaders/", "time_published": "20230713T173700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Weight Loss Drugs To Watch: New Rivals Are Ramping Up To Unseat The Undisputed Leaders Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-Ozempic-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.069257, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAC", "relevance_score": "0.05387", "ticker_sentiment_score": "-0.014998", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.013477", "ticker_sentiment_score": "-0.158", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVO", "relevance_score": "0.120834", "ticker_sentiment_score": "0.105707", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLDAF", "relevance_score": "0.013477", "ticker_sentiment_score": "0.017854", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.067309", "ticker_sentiment_score": "-0.005041", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.094125", "ticker_sentiment_score": "0.044119", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.02695", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.02695", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.147407", "ticker_sentiment_score": "0.12034", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.040416", "ticker_sentiment_score": "-0.03469", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPCR", "relevance_score": "0.02695", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.040416", "ticker_sentiment_score": "0.023243", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPUH", "relevance_score": "0.013477", "ticker_sentiment_score": "0.146003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies", "url": "https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/", "time_published": "20230713T120600", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "One minute Dow Jones industrial average component Merck ( MRK ) might be doing battle with fellow drugmaker Bristol Myers Squibb ( BMY ) over drugs that can ward off cancer. The next, biotech giants like Amgen ( AMGN ) and Sanofi ( SNY ) are tussling in court over the fate of ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/05/JUMP-moderna-050820-newscom-300x169.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.083353, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.381253", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMGN", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.366061", "ticker_sentiment_score": "-0.549433", "ticker_sentiment_label": "Bearish"}, {"ticker": "SNY", "relevance_score": "0.366061", "ticker_sentiment_score": "0.043641", "ticker_sentiment_label": "Neutral"}]}, {"title": "Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say", "url": "https://www.marketwatch.com/story/drugmakers-deal-making-will-plow-ahead-despite-antitrust-scrutiny-analysts-say-eb36f41b", "time_published": "20230712T195900", "authors": ["Eleanor Laise"], "summary": "Big pharma goes shopping as \"patent cliff\" puts more than $225 billion in revenues at risk.", "banner_image": "https://images.mktw.net/im-470122/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.087055, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.100729", "ticker_sentiment_score": "0.135449", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.100729", "ticker_sentiment_score": "-0.018454", "ticker_sentiment_label": "Neutral"}, {"ticker": "DICE", "relevance_score": "0.100729", "ticker_sentiment_score": "0.049391", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.100729", "ticker_sentiment_score": "0.135449", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.100729", "ticker_sentiment_score": "0.049391", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.100729", "ticker_sentiment_score": "0.108243", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.199859", "ticker_sentiment_score": "0.04998", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.100729", "ticker_sentiment_score": "-0.018454", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Now the Right Time to Embrace Biotech ETFs?", "url": "https://www.zacks.com/stock/news/2120021/is-now-the-right-time-to-embrace-biotech-etfs", "time_published": "20230712T150900", "authors": ["Zacks Investment Research"], "summary": "Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/2266.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.986413"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.182418, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.124164", "ticker_sentiment_score": "0.04872", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.041538", "ticker_sentiment_score": "-0.027545", "ticker_sentiment_label": "Neutral"}]}, {"title": "Investors Heavily Search Amgen Inc.  ( AMGN ) : Here is What You Need to Know", "url": "https://www.zacks.com/stock/news/2119772/investors-heavily-search-amgen-inc-amgn-here-is-what-you-need-to-know", "time_published": "20230712T130007", "authors": ["Zacks Investment Research"], "summary": "Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default61.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.217533, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.482078", "ticker_sentiment_score": "0.094731", "ticker_sentiment_label": "Neutral"}]}, {"title": "European Regulator Expands Ozempic Probe To Include Other Weight Loss Drugs Over Suicide Risks - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) , Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/news/23/07/33192661/european-regulator-expands-ozempic-probe-to-include-other-weight-loss-drugs-over-suicide-risks", "time_published": "20230712T023347", "authors": ["Benzinga Newsbot"], "summary": "On Tuesday, the European Union's drug regulator expanded its investigation into the risk of suicidal thoughts and self-injury among patients taking weight loss and diabetes medications, including those produced by Novo Nordisk NVO.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Ozempic_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.143226, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.310843", "ticker_sentiment_score": "-0.337658", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.210274", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Activision Stock Jumps As U.S. Judge Clears Hurdle To Microsoft Buyout", "url": "https://www.investors.com/news/technology/activision-stock-jumps-as-judge-clears-hurdle-to-microsoft-buyout/", "time_published": "20230711T174300", "authors": ["PATRICK SEITZ", "Investor's Business Daily"], "summary": "Activision Blizzard ( ATVI ) shares rocketed Tuesday after a federal court allowed Microsoft ( MSFT ) to proceed with its $69 billion acquisition of the video game publisher. Activision stock surged to a two-year high on the news. U.S.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/07/Stock-Activision-89-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.014334, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.660632", "ticker_sentiment_score": "-0.033654", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.151539", "ticker_sentiment_score": "-0.195448", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HZNP", "relevance_score": "0.151539", "ticker_sentiment_score": "0.067473", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.785778", "ticker_sentiment_score": "-0.016054", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.2256", "ticker_sentiment_score": "0.089948", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.151539", "ticker_sentiment_score": "0.067473", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.151539", "ticker_sentiment_score": "0.067473", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.151539", "ticker_sentiment_score": "0.067473", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why This Biotech's Effort To Take On Horizon Fell Flat", "url": "https://www.investors.com/news/technology/vrdn-stock-collapses-why-this-horizon-rivaling-update-fell-flat/", "time_published": "20230711T142500", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "VRDN Stock Collapses. Why This Horizon-Rivaling Update Fell Flat | Investor's Business Daily Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/10/Stock-DrugSpill-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.004774, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.165031", "ticker_sentiment_score": "0.160937", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.165031", "ticker_sentiment_score": "0.160937", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRDN", "relevance_score": "0.651499", "ticker_sentiment_score": "-0.181991", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Stock Market Today: Stocks Tick Higher Ahead of June CPI, Q2 Earnings Season", "url": "https://www.kiplinger.com/investing/stocks/stock-market-today-stocks-tick-higher-ahead-of-june-cpi-q2-earnings-season", "time_published": "20230710T201520", "authors": ["Karee Venema"], "summary": "Stocks failed to make any major moves Monday as investors looked ahead to this week's inflation data and the start of second-quarter earnings season.", "banner_image": "https://cdn.mos.cms.futurecdn.net/hVsMLXTchmtqSgxTUjQEU9-415-80.jpg", "source": "Kiplinger", "category_within_source": "n/a", "source_domain": "www.kiplinger.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.838487"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}, {"topic": "Earnings", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.219813, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.127795", "ticker_sentiment_score": "-0.167242", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AAPL", "relevance_score": "0.127795", "ticker_sentiment_score": "-0.167242", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CME", "relevance_score": "0.064104", "ticker_sentiment_score": "-0.015069", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.127795", "ticker_sentiment_score": "0.144623", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Gains As Microsoft Stock Lags; Carl Icahn Stock Explodes Amid These Moves", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-gains-as-microsoft-stock-lags-carl-icahn-stock-explodes-amid-these-moves/", "time_published": "20230710T191800", "authors": ["Investor's Business Daily", "MICHAEL LARKIN"], "summary": "Dow Jones Gains As Microsoft Stock Lags. Carl Icahn Stock Explodes Amid These Moves Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/SMT-CarlIcahn-0502-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.247845, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.293841", "ticker_sentiment_score": "0.288484", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.170576", "ticker_sentiment_score": "0.124962", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.085782", "ticker_sentiment_score": "-0.002201", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.128363", "ticker_sentiment_score": "0.093245", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.085782", "ticker_sentiment_score": "0.093458", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.128363", "ticker_sentiment_score": "0.140223", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.085782", "ticker_sentiment_score": "0.1039", "ticker_sentiment_label": "Neutral"}, {"ticker": "FLS", "relevance_score": "0.128363", "ticker_sentiment_score": "0.050748", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.085782", "ticker_sentiment_score": "0.093458", "ticker_sentiment_label": "Neutral"}, {"ticker": "OII", "relevance_score": "0.128363", "ticker_sentiment_score": "0.17788", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "These companies have beaten the Rule of 40 year after year", "url": "https://www.marketwatch.com/story/these-companies-have-beaten-the-rule-of-40-year-after-year-8804d0e", "time_published": "20230710T140800", "authors": ["Steve Goldstein"], "summary": "Morgan Stanley applied a VC filter to the stock market. Here's what it found.", "banner_image": "https://images.mktw.net/im-814193/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.062006, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.285526", "ticker_sentiment_score": "0.025659", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.285526", "ticker_sentiment_score": "0.025659", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.285526", "ticker_sentiment_score": "0.025659", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANSS", "relevance_score": "0.285526", "ticker_sentiment_score": "0.025659", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.285526", "ticker_sentiment_score": "0.025659", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.145145", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Downgraded by StockNews.com to Buy", "url": "https://www.defenseworld.net/2023/07/08/amgen-nasdaqamgn-downgraded-by-stocknews-com-to-buy-2.html", "time_published": "20230708T074243", "authors": ["Defense World Staff"], "summary": "StockNews.com cut shares of Amgen ( NASDAQ:AMGN - Free Report ) from a strong-buy rating to a buy rating in a research note released on Friday morning.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.266372, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.823212", "ticker_sentiment_score": "0.436159", "ticker_sentiment_label": "Bullish"}, {"ticker": "JEF", "relevance_score": "0.056674", "ticker_sentiment_score": "0.077962", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.056674", "ticker_sentiment_score": "0.041132", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2118324/amgen-amgn-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230707T215022", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $218.65, marking a -1.94% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default113.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.126865, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.541943", "ticker_sentiment_score": "0.138865", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Does Amgen's Debt Look Like? - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/07/33150858/what-does-amgens-debt-look-like", "time_published": "20230707T171551", "authors": ["Benzinga Insights"], "summary": "Over the past three months, shares of Amgen Inc. AMGN moved lower by 12.70%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.116393, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.285526", "ticker_sentiment_score": "-0.088183", "ticker_sentiment_label": "Neutral"}]}, {"title": "$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/07/33150619/100-invested-in-this-stock-15-years-ago-would-be-worth-400-today", "time_published": "20230707T170025", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 10.23%. Currently, Amgen has a market capitalization of $117.46 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Global 2000 List 2023: The Top 200", "url": "https://www.forbes.com/sites/forbesstaff/2023/07/07/forbes-global-2000-list-2023-the-top-200/", "time_published": "20230707T154531", "authors": ["Forbes Staff"], "summary": "Two years after the start of the pandemic, Covid casualties like airlines and oil producers have reclaimed top spots among the largest companies in the world.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/627c094c98ab473ddd8ee821/0x0.jpg?format=jpg&crop=3840,2160,x0,y0,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.346538, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MPC", "relevance_score": "0.010247", "ticker_sentiment_score": "0.26442", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.010247", "ticker_sentiment_score": "0.119438", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBD", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEBNF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSUAY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBSDF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFC", "relevance_score": "0.010247", "ticker_sentiment_score": "0.077624", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.010247", "ticker_sentiment_score": "0.184116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DPSTF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CBAUF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AIG", "relevance_score": "0.010247", "ticker_sentiment_score": "-0.042787", "ticker_sentiment_label": "Neutral"}, {"ticker": "MFGI", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "HON", "relevance_score": "0.010247", "ticker_sentiment_score": "0.074214", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.010247", "ticker_sentiment_score": "0.053246", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBKFF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.171113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.010247", "ticker_sentiment_score": "0.220933", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACHY", "relevance_score": "0.051199", "ticker_sentiment_score": "0.097863", "ticker_sentiment_label": "Neutral"}, {"ticker": "MALRF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.293952", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.020491", "ticker_sentiment_score": "0.081801", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSBHF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.119438", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLCNF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.208567", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PCCYF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LRLCF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.310862", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANEWF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "POAHY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVS", "relevance_score": "0.010247", "ticker_sentiment_score": "0.218071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDLZ", "relevance_score": "0.010247", "ticker_sentiment_score": "0.119438", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIHKY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "C", "relevance_score": "0.010247", "ticker_sentiment_score": "0.103567", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRWOF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NPPXF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.119438", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EQNR", "relevance_score": "0.010247", "ticker_sentiment_score": "0.295935", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSNLF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARZGF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABT", "relevance_score": "0.010247", "ticker_sentiment_score": "0.171113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CEBCF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBN", "relevance_score": "0.010247", "ticker_sentiment_score": "0.155484", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.230508", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QCOM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.110593", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.010247", "ticker_sentiment_score": "0.191598", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "V", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "RTX", "relevance_score": "0.010247", "ticker_sentiment_score": "0.151833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VLO", "relevance_score": "0.010247", "ticker_sentiment_score": "0.110593", "ticker_sentiment_label": "Neutral"}, {"ticker": "COF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.010247", "ticker_sentiment_score": "0.081902", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYG", "relevance_score": "0.010247", "ticker_sentiment_score": "0.077624", "ticker_sentiment_label": "Neutral"}, {"ticker": "SO", "relevance_score": "0.010247", "ticker_sentiment_score": "0.110593", "ticker_sentiment_label": "Neutral"}, {"ticker": "CB", "relevance_score": "0.010247", "ticker_sentiment_score": "-0.110503", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.010247", "ticker_sentiment_score": "0.217118", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COP", "relevance_score": "0.010247", "ticker_sentiment_score": "0.203375", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAYZF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.193474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.238205", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACN", "relevance_score": "0.010247", "ticker_sentiment_score": "0.129245", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.103567", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIS", "relevance_score": "0.010247", "ticker_sentiment_score": "0.340987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEE", "relevance_score": "0.010247", "ticker_sentiment_score": "0.178529", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LIN", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TD", "relevance_score": "0.010247", "ticker_sentiment_score": "0.171113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.010247", "ticker_sentiment_score": "0.243999", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTPCF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.185049", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VWAGY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.110593", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.010247", "ticker_sentiment_score": "0.296927", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.129245", "ticker_sentiment_label": "Neutral"}, {"ticker": "DB", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "CEVIF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "DE", "relevance_score": "0.010247", "ticker_sentiment_score": "0.224757", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMAWF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.102691", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPHLF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.145468", "ticker_sentiment_label": "Neutral"}, {"ticker": "POST", "relevance_score": "0.010247", "ticker_sentiment_score": "0.145468", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNS", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.010247", "ticker_sentiment_score": "0.074214", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "EADSF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "OXY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.38269", "ticker_sentiment_label": "Bullish"}, {"ticker": "TKOMF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.103567", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDORY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.093112", "ticker_sentiment_label": "Neutral"}, {"ticker": "UL", "relevance_score": "0.010247", "ticker_sentiment_score": "0.213312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAMXF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHCJY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.010247", "ticker_sentiment_score": "0.074214", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALIZF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.010247", "ticker_sentiment_score": "0.110593", "ticker_sentiment_label": "Neutral"}, {"ticker": "IITSF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCA", "relevance_score": "0.010247", "ticker_sentiment_score": "0.293285", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSBC", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.010247", "ticker_sentiment_score": "0.218071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NAUBF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.191598", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CILJF", "relevance_score": "0.010247", "ticker_sentiment_score": "-0.062078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRARF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNEJF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.062375", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSX", "relevance_score": "0.010247", "ticker_sentiment_score": "0.103567", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENB", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PSTVY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "OVCHF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHTR", "relevance_score": "0.010247", "ticker_sentiment_score": "0.171113", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CICHY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMFG", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSRGF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.161898", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PINXY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAN", "relevance_score": "0.010247", "ticker_sentiment_score": "0.077624", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.010247", "ticker_sentiment_score": "0.083619", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0649", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYDDF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTHIF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VZ", "relevance_score": "0.010247", "ticker_sentiment_score": "0.151833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HDB", "relevance_score": "0.010247", "ticker_sentiment_score": "0.183183", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BHP", "relevance_score": "0.010247", "ticker_sentiment_score": "0.187852", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITOCF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.010247", "ticker_sentiment_score": "0.268334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACGBY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.129245", "ticker_sentiment_label": "Neutral"}, {"ticker": "MFG", "relevance_score": "0.010247", "ticker_sentiment_score": "0.240134", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.010247", "ticker_sentiment_score": "0.356177", "ticker_sentiment_label": "Bullish"}, {"ticker": "COST", "relevance_score": "0.010247", "ticker_sentiment_score": "0.191598", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MITSF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNP", "relevance_score": "0.010247", "ticker_sentiment_score": "0.14094", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNCFF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.136429", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITUB", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUK", "relevance_score": "0.010247", "ticker_sentiment_score": "0.419748", "ticker_sentiment_label": "Bullish"}, {"ticker": "HMC", "relevance_score": "0.010247", "ticker_sentiment_score": "0.119438", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.010247", "ticker_sentiment_score": "0.081902", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBCPF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.28209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCMXY", "relevance_score": "0.010247", "ticker_sentiment_score": "0.129245", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.010247", "ticker_sentiment_score": "0.226672", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BAM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.111474", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMT", "relevance_score": "0.010247", "ticker_sentiment_score": "0.059857", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBVA", "relevance_score": "0.010247", "ticker_sentiment_score": "0.151833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HYMLF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.110593", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSUMF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.010247", "ticker_sentiment_score": "0.15457", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.010247", "ticker_sentiment_score": "0.074214", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.010247", "ticker_sentiment_score": "0.243999", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIO", "relevance_score": "0.010247", "ticker_sentiment_score": "0.293952", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PEP", "relevance_score": "0.010247", "ticker_sentiment_score": "0.110593", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.010247", "ticker_sentiment_score": "0.189724", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IDCBY", "relevance_score": "0.020491", "ticker_sentiment_score": "0.067976", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.010247", "ticker_sentiment_score": "0.218071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBDSF", "relevance_score": "0.010247", "ticker_sentiment_score": "0.097456", "ticker_sentiment_label": "Neutral"}, {"ticker": "PM", "relevance_score": "0.010247", "ticker_sentiment_score": "0.091379", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Struggling Dividend Growth Stocks That Could Make You Richer", "url": "https://www.fool.com/investing/2023/07/07/2-struggling-dividend-growth-stocks-could-make/", "time_published": "20230707T134500", "authors": ["Prosper Junior Bakiny"], "summary": "Let's look beyond these drugmakers' ongoing issues.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738459%2Fa-person-looking-at-graphs-and-data-on-a-see-though-computer-display.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}], "overall_sentiment_score": 0.077176, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.471943", "ticker_sentiment_score": "0.192796", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.31197", "ticker_sentiment_score": "0.136755", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.045743", "ticker_sentiment_score": "0.051964", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.045743", "ticker_sentiment_score": "-0.059902", "ticker_sentiment_label": "Neutral"}]}, {"title": "Treasury Yields Spiking As Market Looks Ahead To Jobs Data, Raising Valuation Concerns - Albertsons Companies  ( NYSE:ACI ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/23/07/33135737/treasury-yields-spiking-as-market-looks-ahead-to-jobs-data-raising-valuation-concerns", "time_published": "20230706T154858", "authors": ["Alex Coffey"], "summary": "( Thursday market open ) Things are heating up, and we're not just talking about the July weather. A week from the start of Q2 earnings season, Wall Street is on tenterhooks awaiting tomorrow's crucial June Nonfarm Payrolls report. In the meantime, there's a host of labor data to digest today ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/07/06/shutterstock_1704099412.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.972193"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.999696"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.038282, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TSLA", "relevance_score": "0.065446", "ticker_sentiment_score": "0.083217", "ticker_sentiment_label": "Neutral"}, {"ticker": "GM", "relevance_score": "0.10886", "ticker_sentiment_score": "0.091287", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.033384", "ticker_sentiment_label": "Neutral"}, {"ticker": "KR", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.033384", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATVI", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.033384", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEP", "relevance_score": "0.043658", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.043658", "ticker_sentiment_score": "-0.033384", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Lactose Intolerance Treatment Market Forecast 2023-2032 - Market Size, Drivers, Trends, And Competitors As Per The Business Research Company's Lactose Intolerance Treatment Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/07/g33135424/global-lactose-intolerance-treatment-market-forecast-2023-2032-market-size-drivers-trends-and-comp", "time_published": "20230706T153000", "authors": ["Globe Newswire"], "summary": "LONDON, July 06, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Lactose Intolerance Treatment Global Market Report 2023, the market will grow from $28.3 billion in 2022 to $30.3 billion in 2023, with a compound annual growth rate ( CAGR ) of more than 7%.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.022012, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.053597", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.053597", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.053597", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCDTF", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.053597", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.053597", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.053597", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVZMY", "relevance_score": "0.102231", "ticker_sentiment_score": "-0.055328", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSRGF", "relevance_score": "0.051221", "ticker_sentiment_score": "-0.053597", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group", "url": "https://www.zacks.com/stock/news/2116904/the-zacks-analyst-blog-highlights-apple-verizon-communications-amgen-charles-schwab-and-the-cigna-group", "time_published": "20230705T122800", "authors": ["Zacks Investment Research"], "summary": "Apple, Verizon Communications, Amgen, Charles Schwab and The Cigna Group are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/30/115.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SCHW", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CI", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Analyst Reports for Apple, Verizon & Amgen", "url": "https://www.zacks.com/research-daily/2115929/top-analyst-reports-for-apple-verizon-amgen", "time_published": "20230703T164900", "authors": ["Zacks Investment Research"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Verizon Communications Inc. (VZ) and Amgen Inc. (AMGN).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default296.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.205468, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SCHW", "relevance_score": "0.122894", "ticker_sentiment_score": "0.102496", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.463792", "ticker_sentiment_score": "0.259726", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VZ", "relevance_score": "0.300946", "ticker_sentiment_score": "0.191875", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.357293", "ticker_sentiment_score": "0.218088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CI", "relevance_score": "0.122894", "ticker_sentiment_score": "0.102496", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2115804/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe", "time_published": "20230703T102009", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default330.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.236458, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.128478", "ticker_sentiment_score": "0.069872", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.253646", "ticker_sentiment_score": "0.156677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.128478", "ticker_sentiment_score": "0.069872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.128478", "ticker_sentiment_score": "0.069872", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sandoz launches rival version of AbbVie's arthritis drug Humira", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/", "time_published": "20230701T042000", "authors": ["Reuters"], "summary": "Sandoz launches rival version of AbbVie's arthritis drug ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/5DHA7FK4SRKA7K4CSVPZCIDJQ4.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.143754, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.141726", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.016269", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.082125", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.141726", "ticker_sentiment_score": "0.141368", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Gains But Lags Market: What You Should Know", "url": "https://www.zacks.com/stock/news/2115607/amgen-amgn-gains-but-lags-market-what-you-should-know", "time_published": "20230630T215019", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $222.02, marking a +0.39% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default315.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.152451, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.618922", "ticker_sentiment_score": "0.183569", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "For AbbVie's blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts say", "url": "https://www.marketwatch.com/story/for-abbvies-blockbuster-humira-cheaper-competitors-pose-surprisingly-little-threat-analysts-say-bf42114e", "time_published": "20230630T172800", "authors": ["Eleanor Laise"], "summary": "Lower-price biosimilar competition for top-selling drug launching this weekend.", "banner_image": "https://images.mktw.net/im-466413/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.03782, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.037504", "ticker_sentiment_score": "0.020192", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.074926", "ticker_sentiment_score": "-0.018187", "ticker_sentiment_label": "Neutral"}, {"ticker": "OGN", "relevance_score": "0.185876", "ticker_sentiment_score": "0.055793", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.074926", "ticker_sentiment_score": "-0.039548", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.25796", "ticker_sentiment_score": "0.003919", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.037504", "ticker_sentiment_score": "-0.002941", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.074926", "ticker_sentiment_score": "-0.039548", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck - Smith & Nephew  ( NYSE:SNN ) , TotalEnergies  ( NYSE:TTE ) , Morgan Stanley  ( NYSE:MS ) , iShares MSCI Hong Kong Index Fund  ( ARCA:EWH ) , Rio Tinto  ( NYSE:RIO ) , Novartis  ( NYSE:NVS ) , Amgen  ( NASDAQ:AMGN ) , WisdomTree Emerging Markets High Dividend Fund  ( ARCA:DEM ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/06/33063975/amgen-out-rio-tinto-in-as-morgan-stanley-shuffles-dividend-deck", "time_published": "20230629T170300", "authors": ["AJ Fabino"], "summary": "Industry giant Morgan Stanley MS is shaking up its model for income-focused investors, indicating a strategic move towards robust and resilient players. The multinational investment bank told investors Thursday that it added new positions and adjusted weights in its dividend portfolio.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Businessman.Cards.Shutterstock.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.145863, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SNN", "relevance_score": "0.211191", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTE", "relevance_score": "0.211191", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.211191", "ticker_sentiment_score": "0.116023", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.407844", "ticker_sentiment_score": "0.044247", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIO", "relevance_score": "0.312158", "ticker_sentiment_score": "0.224553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.211191", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.312158", "ticker_sentiment_score": "-0.094922", "ticker_sentiment_label": "Neutral"}, {"ticker": "WT", "relevance_score": "0.106541", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Will Amgen Buy Next?", "url": "https://www.fool.com/investing/2023/06/29/what-will-amgen-buy-next/", "time_published": "20230629T164500", "authors": ["George Budwell"], "summary": "The biotech could pursue these two budget-friendly targets.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F738041%2Fmna.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.14371, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.066047", "ticker_sentiment_score": "-0.074103", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.43816", "ticker_sentiment_score": "0.233553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.131643", "ticker_sentiment_score": "0.126483", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYTM", "relevance_score": "0.196344", "ticker_sentiment_score": "0.299473", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.380978", "ticker_sentiment_score": "0.206762", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "5 High-Yielding Dividend Stocks That Are Bargain Buys", "url": "https://www.fool.com/investing/2023/06/29/5-high-yielding-dividend-stocks-that-are-bargain/", "time_published": "20230629T140000", "authors": ["David Jagielski"], "summary": "This is a good time for investors to load up on healthcare companies.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F737733%2Ftesla.png&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.972756"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.160988, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.042496", "ticker_sentiment_score": "0.104615", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.042496", "ticker_sentiment_score": "-0.033773", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.210092", "ticker_sentiment_score": "0.215259", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.250816", "ticker_sentiment_score": "0.105485", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.042496", "ticker_sentiment_score": "0.037667", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.210092", "ticker_sentiment_score": "0.166981", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.250816", "ticker_sentiment_score": "0.232948", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.210092", "ticker_sentiment_score": "0.060321", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Is The Market Feeling About Amgen? - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/06/33049519/how-is-the-market-feeling-about-amgen", "time_published": "20230628T194535", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has fallen 4.93% since its last report. The company recently reported that it has 7.20 million shares sold short, which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.0 days to cover their ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.241618, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.085754", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Welcomed 60 IPOs in the First Half of 2023 - Nasdaq  ( NASDAQ:NDAQ ) ", "url": "https://www.benzinga.com/pressreleases/23/06/g33038980/nasdaq-welcomed-60-ipos-in-the-first-half-of-2023", "time_published": "20230628T110500", "authors": ["Globe Newswire"], "summary": "NEW YORK, June 28, 2023 ( GLOBE NEWSWIRE ) -- Nasdaq NDAQ announced today that in the first half of 2023, it welcomed 60 initial public offerings ( IPOs ) , raising a total of $3.71 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.281115, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WDFC", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGNC", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSGP", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENLT", "relevance_score": "0.051003", "ticker_sentiment_score": "0.065521", "ticker_sentiment_label": "Neutral"}, {"ticker": "COST", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSAI", "relevance_score": "0.051003", "ticker_sentiment_score": "0.065521", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROP", "relevance_score": "0.051003", "ticker_sentiment_score": "0.056563", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.051003", "ticker_sentiment_score": "0.065521", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBX", "relevance_score": "0.051003", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLYS", "relevance_score": "0.051003", "ticker_sentiment_score": "0.065521", "ticker_sentiment_label": "Neutral"}, {"ticker": "IZQVF", "relevance_score": "0.051003", "ticker_sentiment_score": "0.151379", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NXT(EXP20091224)", "relevance_score": "0.051003", "ticker_sentiment_score": "0.151379", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Nasdaq Welcomed 60 IPOs in the First Half of 2023", "url": "https://www.globenewswire.com/news-release/2023/06/28/2696058/6948/en/Nasdaq-Welcomed-60-IPOs-in-the-First-Half-of-2023.html", "time_published": "20230628T110500", "authors": ["Nasdaq", "Inc."], "summary": "Secured an 88% Win-Rate for Listings in the U.S. Market ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a00d1214-f7e8-4665-89e0-dcfda84f5fc8", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.281157, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WDFC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AGNC", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSGP", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENLT", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COST", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSAI", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ROP", "relevance_score": "0.049939", "ticker_sentiment_score": "0.059442", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLRN", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBX", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MLYS", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IZQVF", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NXT(EXP20091224)", "relevance_score": "0.049939", "ticker_sentiment_score": "0.157355", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Next-Gen Weight-Loss Drugs Set To Up The Game From Ozempic And Mounjaro: WSJ - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/06/33018678/next-gen-weight-loss-drugs-set-to-up-the-game-from-ozempic-and-mounjaro-wsj", "time_published": "20230627T094927", "authors": ["Benzinga Newsbot"], "summary": "The race to develop weight-loss drugs more potent than the popular Ozempic is heating up, with several promising contenders on the horizon, The Wall Street Journal reports.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Ozempic_and_other_drugs_for_weight_loss_2.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.227714, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.228073", "ticker_sentiment_score": "0.198843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.228073", "ticker_sentiment_score": "0.331016", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.228073", "ticker_sentiment_score": "0.198843", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Downgraded by StockNews.com to Buy", "url": "https://www.defenseworld.net/2023/06/27/amgen-nasdaqamgn-downgraded-by-stocknews-com-to-buy.html", "time_published": "20230627T051642", "authors": ["Defense World Staff"], "summary": "Amgen ( NASDAQ:AMGN - Get Rating ) was downgraded by analysts at StockNews.com from a \"strong-buy\" rating to a \"buy\" rating in a research note issued on Tuesday. A number of other equities analysts have also weighed in on AMGN. Argus lowered their price target on shares of Amgen from $270.00 to ...", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.143663, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MDB", "relevance_score": "0.064449", "ticker_sentiment_score": "0.044533", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.894176", "ticker_sentiment_score": "0.249798", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.128478", "ticker_sentiment_score": "0.201513", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.064449", "ticker_sentiment_score": "0.002006", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Viking Therapeutics Stock Is Crashing Today", "url": "https://www.fool.com/investing/2023/06/26/why-viking-therapeutics-stock-is-crashing-today/", "time_published": "20230627T033911", "authors": ["George Budwell"], "summary": "Investors seem concerned about the company's competitive positioning in weight loss.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F737406%2Fwoman-hijabi-eating-apple-on-phone-online-banking.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.154635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.146025", "ticker_sentiment_score": "0.130021", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.2872", "ticker_sentiment_score": "-0.065441", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.146025", "ticker_sentiment_score": "0.130021", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.146025", "ticker_sentiment_score": "0.130021", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.2872", "ticker_sentiment_score": "0.059924", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Amgen Stock Slumped on Monday", "url": "https://www.fool.com/investing/2023/06/26/why-amgen-stock-slumped-on-monday/", "time_published": "20230626T210300", "authors": ["Eric Volkman"], "summary": "Already under fire on the regulatory front, the company is hit with a price-target cut.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F737615%2Felectronic-circuit-board.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.033624, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.636698", "ticker_sentiment_score": "-0.076903", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.28387", "ticker_sentiment_score": "-0.18281", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "A Look Into Amgen Inc's Price Over Earnings - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/06/33009180/a-look-into-amgen-incs-price-over-earnings", "time_published": "20230626T161600", "authors": ["Benzinga Insights"], "summary": "In the current market session, Amgen Inc. AMGN share price is at $224.21, after a 1.28% decrease. Over the past month, the stock went up by 2.60%, but over the past year, it actually decreased by 7.93%.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": -0.045067, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.426225", "ticker_sentiment_score": "0.051898", "ticker_sentiment_label": "Neutral"}]}, {"title": "Russian Insurrection Crushed: 5 Stocks That Continue To Have Exposure To The Country - Procter & Gamble  ( NYSE:PG ) , Align Tech  ( NASDAQ:ALGN ) , Cloudflare  ( NYSE:NET ) , Amgen  ( NASDAQ:AMGN ) , Philip Morris Intl  ( NYSE:PM ) ", "url": "https://www.benzinga.com/markets/equities/23/06/32999737/russian-insurrection-crushed-5-stocks-that-continue-to-have-exposure-to-the-country", "time_published": "20230625T215241", "authors": ["Shanthi Rexaline"], "summary": "The political development in Russia over the weekend created a flutter in the international community, as Yevgeny Prigozhin, a close confidant of President Vladimir Putin and the leader of the paramilitary organization Wagner Group, revolted against the Russian military.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/War,Russia,And,The,Us,In,Ukraine,And,The,Middle.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.158523, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ALGN", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0636", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.144708", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.215574", "ticker_sentiment_score": "-0.16371", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PM", "relevance_score": "0.284696", "ticker_sentiment_score": "0.089589", "ticker_sentiment_label": "Neutral"}, {"ticker": "PG", "relevance_score": "0.144708", "ticker_sentiment_score": "-0.09122", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire", "url": "https://www.fool.com/investing/2023/06/24/4-growth-stocks-for-retirement/", "time_published": "20230624T112000", "authors": ["James Brumley"], "summary": "Buy 'em and then just get out of the way. Time and these companies' long-term strength will take care of the rest.", "banner_image": "https://media.ycharts.com/charts/8502f7300cfafeb147c49344620f6fb9.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.194514, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.205225", "ticker_sentiment_score": "0.07456", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTST", "relevance_score": "0.03458", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.103479", "ticker_sentiment_score": "0.049823", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.205225", "ticker_sentiment_score": "0.062416", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.137671", "ticker_sentiment_score": "0.105649", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.103479", "ticker_sentiment_score": "0.181498", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.171607", "ticker_sentiment_score": "0.093262", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Dips More Than Broader Markets: What You Should Know", "url": "https://www.zacks.com/stock/news/2112634/amgen-amgn-dips-more-than-broader-markets-what-you-should-know", "time_published": "20230623T215023", "authors": ["Zacks Investment Research"], "summary": "Amgen (AMGN) closed the most recent trading day at $227.11, moving -1.11% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default120.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.141322, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.606946", "ticker_sentiment_score": "0.092777", "ticker_sentiment_label": "Neutral"}]}, {"title": "UnitedHealth unit to add Boehringer's Humira biosimilar to reimbursement list", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/unitedhealth-unit-add-boehringers-humira-biosimilar-reimbursement-list-2023-06-23/", "time_published": "20230623T162300", "authors": ["Reuters"], "summary": "June 23 ( Reuters ) - Boehringer Ingelheim's biosimilar of AbbVie Inc's ( ABBV.N ) blockbuster arthritis drug Humira will be included in the reimbursement list of UnitedHealth Group Inc's ( UNH.N ) OptumRx unit, the German drugmaker said on Friday.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/GH27N2ZGX5NMVD2SH6YJKUERXA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.204093, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.211191", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.211191", "ticker_sentiment_score": "0.17076", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABBV", "relevance_score": "0.407844", "ticker_sentiment_score": "0.183739", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Horizon's  ( HZNP )  Tepezza Study in Japan for TED Meets Goal", "url": "https://www.zacks.com/stock/news/2112421/horizons-hznp-tepezza-study-in-japan-for-ted-meets-goal", "time_published": "20230623T131500", "authors": ["Zacks Investment Research"], "summary": "Horizon (HZNP) announces positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.033563, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AKRO", "relevance_score": "0.283323", "ticker_sentiment_score": "0.120198", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.283323", "ticker_sentiment_score": "0.073998", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.143987", "ticker_sentiment_score": "0.056615", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.283323", "ticker_sentiment_score": "0.025355", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderating Inflation, a Tasty IPO, Bull Market Talk, and More", "url": "https://www.fool.com/investing/2023/06/22/the-new-bull-market/", "time_published": "20230622T170600", "authors": ["Motley Fool Staff"], "summary": "We've also got two stocks worth watching: Chevron and Burford Capital.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F736674%2Fretired-woman-investing-laptop-401k-ira.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.998626"}, {"topic": "IPO", "relevance_score": "0.890401"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.990893"}], "overall_sentiment_score": 0.142808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.006075", "ticker_sentiment_score": "0.105762", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.01215", "ticker_sentiment_score": "-0.014509", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.006075", "ticker_sentiment_score": "0.026028", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVX", "relevance_score": "0.030369", "ticker_sentiment_score": "0.127219", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.018224", "ticker_sentiment_score": "0.132267", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.01215", "ticker_sentiment_score": "-0.034131", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORCL", "relevance_score": "0.030369", "ticker_sentiment_score": "0.028825", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPTX", "relevance_score": "0.006075", "ticker_sentiment_score": "-0.055728", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.006075", "ticker_sentiment_score": "0.049589", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.006075", "ticker_sentiment_score": "-0.055728", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.006075", "ticker_sentiment_score": "-0.055728", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.006075", "ticker_sentiment_score": "0.026028", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHOP", "relevance_score": "0.01215", "ticker_sentiment_score": "0.077929", "ticker_sentiment_label": "Neutral"}, {"ticker": "SG", "relevance_score": "0.006075", "ticker_sentiment_score": "-0.061808", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.006075", "ticker_sentiment_score": "0.026028", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVUE", "relevance_score": "0.006075", "ticker_sentiment_score": "-0.019171", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMG", "relevance_score": "0.01215", "ticker_sentiment_score": "-0.064915", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.01215", "ticker_sentiment_score": "0.048545", "ticker_sentiment_label": "Neutral"}, {"ticker": "BUR", "relevance_score": "0.01215", "ticker_sentiment_score": "0.069937", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.018224", "ticker_sentiment_score": "0.090434", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's  ( AMGN )  Blincyto sBLA Gets FDA Nod in Treating Leukemia", "url": "https://www.zacks.com/stock/news/2111850/amgens-amgn-blincyto-sbla-gets-fda-nod-in-treating-leukemia", "time_published": "20230622T134000", "authors": ["Zacks Investment Research"], "summary": "Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.241279, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ADMA", "relevance_score": "0.306963", "ticker_sentiment_score": "0.201547", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AKRO", "relevance_score": "0.364275", "ticker_sentiment_score": "0.137893", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADAP", "relevance_score": "0.364275", "ticker_sentiment_score": "0.087124", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.570165", "ticker_sentiment_score": "0.411882", "ticker_sentiment_label": "Bullish"}]}, {"title": "Alleged Industrial Espionage Makes an Interesting Story", "url": "https://www.fool.com/investing/2023/06/21/alleged-industrial-espionage-makes-an-interesting/", "time_published": "20230622T010900", "authors": ["Motley Fool Staff"], "summary": "We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F736716%2Fa-person-riding-in-a-futuristic-self-driving-robotaxi.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.083512, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SSNLF", "relevance_score": "0.02979", "ticker_sentiment_score": "-0.034297", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.118744", "ticker_sentiment_score": "0.033705", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.009932", "ticker_sentiment_score": "-0.012494", "ticker_sentiment_label": "Neutral"}, {"ticker": "KO", "relevance_score": "0.049629", "ticker_sentiment_score": "-0.017001", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.049629", "ticker_sentiment_score": "0.067792", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.009932", "ticker_sentiment_score": "0.00082", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.02979", "ticker_sentiment_score": "0.102635", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.009932", "ticker_sentiment_score": "0.057189", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32952860/if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-4-900-today", "time_published": "20230621T173023", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 2.74% on an annualized basis producing an average annual return of 11.22%. Currently, Amgen has a market capitalization of $122.17 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Amgen's Debt Overview - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/06/32930253/amgens-debt-overview", "time_published": "20230620T170108", "authors": ["Benzinga Insights"], "summary": "Over the past three months, shares of Amgen Inc. AMGN moved lower by 3.17%. Before having a look at the importance of debt, let's look at how much debt Amgen has.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": -0.135199, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.395012", "ticker_sentiment_score": "-0.014024", "ticker_sentiment_label": "Neutral"}]}, {"title": "Don't Judge The Tax Cuts And Jobs Act's Anti-Profit-Shifting Measures Yet", "url": "https://www.forbes.com/sites/taxnotes/2023/06/20/dont-judge-the-tax-cuts-and-jobs-acts-anti-profit-shifting-measures-yet/", "time_published": "20230620T134211", "authors": ["Ryan Finley"], "summary": "Ryan Finley explains that casting the 2017 Tax Cuts and Jobs Act's anti-base-erosion measures as a failure is premature.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6179aa6eee939e5da0847603/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.106246, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.031119", "ticker_sentiment_score": "0.109032", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDT", "relevance_score": "0.046664", "ticker_sentiment_score": "0.056898", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.031119", "ticker_sentiment_score": "0.02602", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.031119", "ticker_sentiment_score": "0.109032", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( NASDAQ:AMGN )  Downgraded by StockNews.com to Buy", "url": "https://www.defenseworld.net/2023/06/17/amgen-nasdaqamgn-downgraded-by-stocknews-com-to-buy-2.html", "time_published": "20230617T083256", "authors": ["Defense World Staff"], "summary": "StockNews.com lowered shares of Amgen ( NASDAQ:AMGN - Get Rating ) from a strong-buy rating to a buy rating in a research note issued to investors on Friday morning. Several other equities research analysts have also issued reports on the company.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.459462"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.154789, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVGO", "relevance_score": "0.061473", "ticker_sentiment_score": "0.053302", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.061473", "ticker_sentiment_score": "0.003", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.85716", "ticker_sentiment_score": "0.265167", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.061473", "ticker_sentiment_score": "0.003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Gains As Market Dips: What You Should Know", "url": "https://www.zacks.com/stock/news/2109682/amgen-amgn-gains-as-market-dips-what-you-should-know", "time_published": "20230616T215018", "authors": ["Zacks Investment Research"], "summary": "In the latest trading session, Amgen (AMGN) closed at $229.66, marking a +0.53% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default241.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.150813, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.479683", "ticker_sentiment_score": "0.134003", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie's  ( ABBV )  Skyrizi Meets Ulcerative Colitis Study Goals", "url": "https://www.zacks.com/stock/news/2109293/abbvies-abbv-skyrizi-meets-ulcerative-colitis-study-goals", "time_published": "20230616T114500", "authors": ["Zacks Investment Research"], "summary": "AbbVie's (ABBV) Skyrizi achieves statistical significance with its primary endpoint of clinical remission in a late-stage study as a maintenance treatment for ulcerative colitis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.192402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.489394", "ticker_sentiment_score": "0.261914", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.306963", "ticker_sentiment_score": "0.101135", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.052455", "ticker_sentiment_score": "0.10259", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.156461", "ticker_sentiment_score": "0.060314", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.104683", "ticker_sentiment_score": "0.072563", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Jumps As Market Shrugs Off Powell; Cava Stock Explodes On Trading Debut", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-jumps-as-stock-market-shrugs-off-fed-chair-jerome-powell-cava-stock-explodes-on-trading-debut/", "time_published": "20230615T191400", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Jumps As Market Shrugs Off Powell. Cava Stock ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/SMT_powell_061523_news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.083824, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.129052", "ticker_sentiment_score": "-0.031251", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVS", "relevance_score": "0.086245", "ticker_sentiment_score": "0.143161", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMPZF", "relevance_score": "0.043186", "ticker_sentiment_score": "0.029584", "ticker_sentiment_label": "Neutral"}, {"ticker": "EHC", "relevance_score": "0.129052", "ticker_sentiment_score": "-0.064162", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRWD", "relevance_score": "0.086245", "ticker_sentiment_score": "0.089417", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXP", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.093434", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.093434", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPLK", "relevance_score": "0.129052", "ticker_sentiment_score": "-0.060648", "ticker_sentiment_label": "Neutral"}, {"ticker": "LDNXF", "relevance_score": "0.043186", "ticker_sentiment_score": "0.073245", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.086245", "ticker_sentiment_score": "0.349248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UNH", "relevance_score": "0.086245", "ticker_sentiment_score": "0.349248", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DPZ", "relevance_score": "0.129052", "ticker_sentiment_score": "0.060456", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Big Pharma, Including Lilly, Is Lending Cachet To Gene Editing", "url": "https://www.investors.com/news/technology/verv-stock-soars-as-eli-lilly-adds-pharma-cachet-to-gene-editing-program/", "time_published": "20230615T181300", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "VERV Stock Soars As Eli Lilly Adds Pharma Cachet To Gene-Editing ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/10/Stock-vervetherapeutics-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.085713, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ARWR", "relevance_score": "0.182506", "ticker_sentiment_score": "0.160378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LLY", "relevance_score": "0.436009", "ticker_sentiment_score": "0.119693", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONS", "relevance_score": "0.182506", "ticker_sentiment_score": "0.160378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VERV", "relevance_score": "0.580732", "ticker_sentiment_score": "0.092561", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.182506", "ticker_sentiment_score": "0.160378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VSTM", "relevance_score": "0.09186", "ticker_sentiment_score": "0.20908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXSM", "relevance_score": "0.09186", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Anaemia Drugs Market to Grow Exponentially by 2029 Says Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/anaemia-drugs-market-to-grow-exponentially-by-2029-says-brandessence-market-research-301851868.html", "time_published": "20230615T102200", "authors": ["Brandessence Market Research And Consulting Private Limited"], "summary": "LONDON, June 15, 2023 /PRNewswire/ -- Anaemia is a disorder occurrence by the deficiency of red blood cells or decreasing amount of haemoglobin in the blood. It often leads to extreme weakness, fatigue, pale skin and irregular heartbeat, among others.", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.204001, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.028626", "ticker_sentiment_score": "0.100156", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028626", "ticker_sentiment_score": "0.100156", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.057215", "ticker_sentiment_score": "0.116057", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.028626", "ticker_sentiment_score": "0.100156", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biosimilars Market worth $66.9 billion | MarketsandMarkets", "url": "https://www.prnewswire.com/news-releases/biosimilars-market-worth-66-9-billion--marketsandmarkets-301851755.html", "time_published": "20230615T100000", "authors": ["MarketsandMarkets"], "summary": "CHICAGO, June 15, 2023 /PRNewswire/ -- The biosimilars industry is poised for significant growth and innovation in the near future.", "banner_image": "https://mma.prnewswire.com/media/1951202/MarketsandMarkets.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.365926"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.3889, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.026299", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.026299", "ticker_sentiment_score": "0.076496", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.05257", "ticker_sentiment_score": "0.218011", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.026299", "ticker_sentiment_score": "0.217101", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.026299", "ticker_sentiment_score": "0.076496", "ticker_sentiment_label": "Neutral"}]}, {"title": "Longeveron Welcomes Three New Prominent Board Members", "url": "https://www.globenewswire.com/news-release/2023/06/13/2687120/0/en/Longeveron-Welcomes-Three-New-Prominent-Board-Members.html", "time_published": "20230613T123000", "authors": ["Longeveron"], "summary": "Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa'el Hashad, Elected to Board at Annual Meeting of Stockholders ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/a6d6e61c-2a7d-4b22-954b-04b9841fbc38", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.140435, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGVN", "relevance_score": "0.281584", "ticker_sentiment_score": "0.124943", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRMD", "relevance_score": "0.028764", "ticker_sentiment_score": "0.008242", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCSA", "relevance_score": "0.05749", "ticker_sentiment_score": "0.008996", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.028764", "ticker_sentiment_score": "-0.024573", "ticker_sentiment_label": "Neutral"}, {"ticker": "UCBJF", "relevance_score": "0.028764", "ticker_sentiment_score": "0.008242", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2106648/amgen-amgn-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20230609T215023", "authors": ["Zacks Investment Research"], "summary": "Amgen (AMGN) closed at $218.82 in the latest trading session, marking a -0.88% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default214.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.122753, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.615462", "ticker_sentiment_score": "0.180086", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is AbbVie or Amgen the Better Bargain Buy Right Now?", "url": "https://www.fool.com/investing/2023/06/08/is-abbvie-or-amgen-the-better-bargain-buy-right-no/", "time_published": "20230608T161500", "authors": ["George Budwell"], "summary": "These elite drugmakers are both working through a number of headwinds.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F735173%2Fa-digital-brain-on-a-circuit-board-with-an-ai-chip-at-the-base.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.089747, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.334978", "ticker_sentiment_score": "0.105665", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.098456", "ticker_sentiment_score": "0.136691", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.463792", "ticker_sentiment_score": "0.040423", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/06/32778040/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields", "time_published": "20230608T130735", "authors": ["Lisa Levin"], "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/06/08/image41.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.087048, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.110973", "ticker_sentiment_score": "0.131969", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.110973", "ticker_sentiment_score": "-0.07675", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.110973", "ticker_sentiment_score": "-0.07675", "ticker_sentiment_label": "Neutral"}, {"ticker": "OGN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Upgrades Amgen  ( NASDAQ:AMGN )  to \"Strong-Buy\"", "url": "https://www.defenseworld.net/2023/06/08/stocknews-com-upgrades-amgen-nasdaqamgn-to-strong-buy.html", "time_published": "20230608T053245", "authors": ["Defense World Staff"], "summary": "Amgen ( NASDAQ:AMGN - Get Rating ) was upgraded by equities research analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a report released on Thursday. AMGN has been the topic of a number of other reports.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.204006, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.068896", "ticker_sentiment_score": "0.040257", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.068896", "ticker_sentiment_score": "-0.026062", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.068896", "ticker_sentiment_score": "0.040257", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.899545", "ticker_sentiment_score": "0.351278", "ticker_sentiment_label": "Bullish"}, {"ticker": "WFC", "relevance_score": "0.068896", "ticker_sentiment_score": "0.040257", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Zacks Analyst Blog Highlights JPMorgan Chase, McDonald's, Comcast, T-Mobile US and Amgen", "url": "https://www.zacks.com/stock/news/2105108/the-zacks-analyst-blog-highlights-jpmorgan-chase-mcdonalds-comcast-t-mobile-us-and-amgen", "time_published": "20230607T130700", "authors": ["Zacks Investment Research"], "summary": "JPMorgan Chase, McDonald's, Comcast, T-Mobile US and Amgen are part of the Zacks top Analyst Blog.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/81.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.0, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TMUS", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCZ", "relevance_score": "0.414559", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.414559", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCD", "relevance_score": "0.724687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2104843/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now", "time_published": "20230607T102006", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default320.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999994"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.26551, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.11894", "ticker_sentiment_score": "0.061867", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.177584", "ticker_sentiment_score": "0.265381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.11894", "ticker_sentiment_score": "0.061867", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.11894", "ticker_sentiment_score": "0.061867", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Analyst Reports for JPMorgan Chase, McDonald's & Comcast", "url": "https://www.zacks.com/research-daily/2104505/top-analyst-reports-for-jpmorgan-chase-mcdonalds-comcast", "time_published": "20230606T192300", "authors": ["Zacks Investment Research"], "summary": "Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), McDonald's Corporation (MCD) and Comcast Corporation (CMCSA).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default171.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.398644, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "TMUS", "relevance_score": "0.12645", "ticker_sentiment_score": "0.20905", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCZ", "relevance_score": "0.249744", "ticker_sentiment_score": "0.326645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.249744", "ticker_sentiment_score": "0.326645", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.12645", "ticker_sentiment_score": "0.20905", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FRC", "relevance_score": "0.063425", "ticker_sentiment_score": "0.177588", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.249744", "ticker_sentiment_score": "0.326645", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick", "url": "https://www.zacks.com/stock/news/2104424/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick", "time_published": "20230606T134007", "authors": ["Zacks Investment Research"], "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default231.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.858979"}], "overall_sentiment_score": 0.375551, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.383905", "ticker_sentiment_score": "0.202066", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Dow Stocks Like Microsoft, Apple, Disney, and Verizon Reveal Two Sides of the Market", "url": "https://www.fool.com/investing/2023/06/06/dow-stocks-microsoft-apple-disney-verizon-buy-sell/", "time_published": "20230606T130000", "authors": ["Daniel Foelber"], "summary": "Many well-known stocks are missing out on the market's epic 2023 rally.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F734317%2Fgettyimages-469382396.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.034423, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.069697", "ticker_sentiment_score": "0.097399", "ticker_sentiment_label": "Neutral"}, {"ticker": "NFLX", "relevance_score": "0.034882", "ticker_sentiment_score": "0.110458", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGT", "relevance_score": "0.104379", "ticker_sentiment_score": "0.02558", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.034882", "ticker_sentiment_score": "0.188265", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDNDF", "relevance_score": "0.034882", "ticker_sentiment_score": "-0.045009", "ticker_sentiment_label": "Neutral"}, {"ticker": "T", "relevance_score": "0.034882", "ticker_sentiment_score": "0.036901", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZ", "relevance_score": "0.034882", "ticker_sentiment_score": "0.036901", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.034882", "ticker_sentiment_score": "-0.045009", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.034882", "ticker_sentiment_score": "-0.035597", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.034882", "ticker_sentiment_score": "-0.045009", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.069697", "ticker_sentiment_score": "0.023351", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma", "url": "https://www.globenewswire.com/news-release/2023/06/05/2682408/33333/en/Coherus-Announces-Positive-Final-Overall-Survival-Results-of-JUPITER-02-Phase-3-Trial-Evaluating-Toripalimab-in-Nasopharyngeal-Carcinoma.html", "time_published": "20230605T213000", "authors": ["Inc.", "Coherus BioSciences"], "summary": "- Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/1c6824a5-8c2a-43f8-bd14-ee90d8f1ce5d", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.096029, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CHRS", "relevance_score": "0.054524", "ticker_sentiment_score": "0.023903", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHJBF", "relevance_score": "0.018187", "ticker_sentiment_score": "0.088777", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.018187", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.018187", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Jones Falls As Apple Unveils These Products; This Stock Soars After Cathie Wood Sells It", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-even-as-apple-unveils-ios-17-vr-headset-vision-pro-this-stock-soars-after-cathie-wood-sells-it/", "time_published": "20230605T191500", "authors": ["MICHAEL LARKIN", "Investor's Business Daily"], "summary": "Dow Jones Falls As Apple Unveils These Products. This Stock Soars ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/SMT-cathiewood-0605-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.222938, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.197413", "ticker_sentiment_score": "0.003186", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.049835", "ticker_sentiment_score": "0.117203", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTNT", "relevance_score": "0.148731", "ticker_sentiment_score": "0.160553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INTC", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.078554", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPAM", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.137989", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZS", "relevance_score": "0.099476", "ticker_sentiment_score": "0.452585", "ticker_sentiment_label": "Bullish"}, {"ticker": "DISH", "relevance_score": "0.099476", "ticker_sentiment_score": "0.058326", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDGR", "relevance_score": "0.245339", "ticker_sentiment_score": "0.058344", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.099476", "ticker_sentiment_score": "-0.078554", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.245339", "ticker_sentiment_score": "0.220675", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSL", "relevance_score": "0.148731", "ticker_sentiment_score": "0.240416", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PANW", "relevance_score": "0.245339", "ticker_sentiment_score": "0.256946", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.", "url": "https://www.marketwatch.com/story/biotech-stocks-could-soon-get-a-m-a-boost-here-are-3-likely-takeover-plays-206b79c3", "time_published": "20230605T190500", "authors": ["Michael Brush"], "summary": "Big pharma will be looking to acquire companies with promsing new medicines.", "banner_image": "https://images.mktw.net/im-273079/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.682689"}, {"topic": "Earnings", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.014455, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HZNP", "relevance_score": "0.097193", "ticker_sentiment_score": "0.031463", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.097193", "ticker_sentiment_score": "0.061044", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.097193", "ticker_sentiment_score": "0.053307", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMRN", "relevance_score": "0.097193", "ticker_sentiment_score": "0.053307", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.129342", "ticker_sentiment_score": "-0.065386", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.129342", "ticker_sentiment_score": "0.025247", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.064885", "ticker_sentiment_score": "-0.178347", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.19295", "ticker_sentiment_score": "0.065446", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.064885", "ticker_sentiment_score": "0.058044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.097193", "ticker_sentiment_score": "0.061044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.129342", "ticker_sentiment_score": "-0.065386", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much $1000 Invested In Amgen 15 Years Ago Would Be Worth Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/06/32721151/heres-how-much-1000-invested-in-amgen-15-years-ago-would-be-worth-today", "time_published": "20230605T173020", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 3.48% on an annualized basis producing an average annual return of 11.44%. Currently, Amgen has a market capitalization of $118.92 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "3 Top Dividend Stocks to Maximize Your Retirement Income", "url": "https://www.zacks.com/stock/news/2103755/3-top-dividend-stocks-to-maximize-your-retirement-income", "time_published": "20230605T131004", "authors": ["Zacks Investment Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default52.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.20712, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HRBK", "relevance_score": "0.106305", "ticker_sentiment_score": "0.079983", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.053271", "ticker_sentiment_score": "-0.036", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.210731", "ticker_sentiment_score": "0.115826", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGM", "relevance_score": "0.210731", "ticker_sentiment_score": "0.115826", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analysis: Stelara patent deal puts J&J back on path to $57 bln 2025 revenue forecast", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/stelara-patent-deal-puts-jj-back-path-57-bln-2025-revenue-forecast-2023-06-05/", "time_published": "20230605T101400", "authors": ["Patrick Wingrove"], "summary": "Analysis: Stelara patent deal puts J&J back on path to $57 bln 2025 ... ...", "banner_image": "https://graphics.reuters.com/JOHNSONANDJOHNSON-STELARA/byvrlwykove/chart.png", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.045265, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.06697", "ticker_sentiment_score": "0.064437", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.13347", "ticker_sentiment_score": "0.021723", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why The Biotech Buying Bonanza Will Likely Continue", "url": "https://www.investors.com/news/technology/biotech-stocks-are-in-blistering-ma-climate-ftc-could-change-that/", "time_published": "20230602T171700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Biotech Stocks Are In A 'Blistering' M&A Climate. The FTC Could ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/wJumpB060523.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "0.962106"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.993781"}], "overall_sentiment_score": 0.055036, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.031529", "ticker_sentiment_score": "0.163574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLU", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.045458", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROIV", "relevance_score": "0.031529", "ticker_sentiment_score": "0.161618", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.110028", "ticker_sentiment_score": "-0.017979", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.172097", "ticker_sentiment_score": "0.001427", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRWD", "relevance_score": "0.031529", "ticker_sentiment_score": "0.117903", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRTC", "relevance_score": "0.015767", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.063008", "ticker_sentiment_score": "0.016034", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCCC", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.058796", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.047278", "ticker_sentiment_score": "0.036401", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPRX", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.047278", "ticker_sentiment_score": "-0.146624", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALNY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APLS", "relevance_score": "0.031529", "ticker_sentiment_score": "0.066264", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISEE", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.045458", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALPMF", "relevance_score": "0.015767", "ticker_sentiment_score": "0.089075", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.078714", "ticker_sentiment_score": "-0.025629", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.031529", "ticker_sentiment_score": "0.012717", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.047297", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.031529", "ticker_sentiment_score": "-0.058796", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.031529", "ticker_sentiment_score": "0.032413", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.031529", "ticker_sentiment_score": "0.089095", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARGX", "relevance_score": "0.015767", "ticker_sentiment_score": "0.110607", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.031529", "ticker_sentiment_score": "0.012628", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.031529", "ticker_sentiment_score": "0.022789", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.031529", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autoinjectors Market worth $1.7 billion | MarketsandMarkets", "url": "https://www.prnewswire.com/news-releases/autoinjectors-market-worth-1-7-billion--marketsandmarkets-301840949.html", "time_published": "20230602T170000", "authors": ["MarketsandMarkets"], "summary": "CHICAGO, June 2, 2023 /PRNewswire/ -- The autoinjectors industry is set to experience significant growth in the near future as a result of several factors. With the rise in chronic diseases and the increasing need for self-administration of medication, autoinjectors have emerged as a convenient ...", "banner_image": "https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.413559"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.351754, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.021937", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLTX", "relevance_score": "0.021937", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTRS", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.021937", "ticker_sentiment_score": "0.013872", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coherus BioSciences to launch Humira biosimilar at 85% discount", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/coherus-biosciences-launch-humira-biosimilar-995-per-carton-2023-06-01/", "time_published": "20230601T141500", "authors": ["Reuters"], "summary": "June 1 ( Reuters ) - Coherus BioSciences Inc ( CHRS.O ) said on Thursday it plans to launch a biosimilar of AbbVie Inc's ( ABBV.N ) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug.", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=143", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.065728, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.156461", "ticker_sentiment_score": "-0.015915", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.156461", "ticker_sentiment_score": "0.118454", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.306963", "ticker_sentiment_score": "0.114419", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Large Cap Biotech Stocks To Watch Right Now", "url": "https://stockmarket.com/featured/2-large-cap-biotech-stocks-to-watch-right-now-2023-05-31", "time_published": "20230531T202915", "authors": ["Brandon Michael"], "summary": "The biotechnology sector is a rapidly evolving and highly exciting area of the market. The sector focuses on the use of living organisms to make products or run processes. This sector is at the forefront of scientific advancement.", "banner_image": "https://u3j7m9h7.rocketcdn.me/wp-content/uploads/2023/05/AMGN-stock.jpg", "source": "StockMarket.com", "category_within_source": "n/a", "source_domain": "stockmarket.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997874"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.244748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.319933", "ticker_sentiment_score": "0.27745", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.24289", "ticker_sentiment_score": "0.026505", "ticker_sentiment_label": "Neutral"}]}, {"title": "Should You Invest in the VanEck Biotech ETF  ( BBH ) ?", "url": "https://www.zacks.com/stock/news/2101737/should-you-invest-in-the-vaneck-biotech-etf-bbh", "time_published": "20230531T102006", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default142.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.1363, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.134968", "ticker_sentiment_score": "0.071604", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pain Relief Therapeutics Market to Grow Significantly by 2029- Brandessence Market Research", "url": "https://www.prnewswire.com/news-releases/pain-relief-therapeutics-market-to-grow-significantly-by-2029--brandessence-market-research-301836608.html", "time_published": "20230529T151500", "authors": ["Brandessence Market Research and Consulting Private Limited"], "summary": "Pain Relief Therapeutics Market to Grow Significantly by 2029 ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1392316/BEMR_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.214378"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.046836, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CARA", "relevance_score": "0.023487", "ticker_sentiment_score": "0.099264", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.023487", "ticker_sentiment_score": "0.099264", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.023487", "ticker_sentiment_score": "0.099264", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.046953", "ticker_sentiment_score": "0.122326", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.023487", "ticker_sentiment_score": "0.099264", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.046953", "ticker_sentiment_score": "0.130099", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.023487", "ticker_sentiment_score": "0.099264", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UZS", "relevance_score": "0.023487", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income", "url": "https://www.zacks.com/stock/news/2100835/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income", "time_published": "20230529T131004", "authors": ["Zacks Investment Research"], "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default42.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.134456, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AXS", "relevance_score": "0.20279", "ticker_sentiment_score": "0.032268", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.20279", "ticker_sentiment_score": "0.112432", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGM", "relevance_score": "0.20279", "ticker_sentiment_score": "0.112432", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Recombinant DNA Technology Market Report 2023: Increasing Number of Chronic Diseases Drives Growth", "url": "https://www.prnewswire.com/news-releases/global-recombinant-dna-technology-market-report-2023-increasing-number-of-chronic-diseases-drives-growth-301835829.html", "time_published": "20230527T014500", "authors": ["Research and Markets"], "summary": "Global Recombinant DNA Technology Market Report 2023 ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.152528, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.065957", "ticker_sentiment_score": "0.116556", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.033006", "ticker_sentiment_score": "0.110153", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT", "url": "https://investingnews.com/amgen-to-present-at-the-td-cowen-4th-annual-oncology-innovation-summit/", "time_published": "20230526T211114", "authors": [], "summary": "Amgen ( NASDAQ: AMGN ) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday May 31, 2023. David M. Reese M.D., executive vice president of Research and Development at Amgen will present at the conference.", "banner_image": "https://investingnews.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNTg1ODg1NS9vcmlnaW4ucG5nIiwiZXhwaXJlc19hdCI6MTcwODY4MTIxOX0.Phin9ClvosnPNpkGRdBWHz_VFepTco5fqEYZcXCsZIQ/image.png?width=210", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.150453, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.856646", "ticker_sentiment_score": "0.251172", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.116348", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is the Options Market Predicting a Spike in Amgen  ( AMGN )  Stock?", "url": "https://www.zacks.com/stock/news/2100115/is-the-options-market-predicting-a-spike-in-amgen-amgn-stock", "time_published": "20230526T123400", "authors": ["Zacks Investment Research"], "summary": "Investors need to pay close attention to Amgen (AMGN) stock based on the movements in the options market lately.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/13/816.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.07152, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.558244", "ticker_sentiment_score": "0.108528", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.", "url": "https://www.fool.com/investing/2023/05/26/a-challenger-to-jjs-top-blockbuster-is-on-the-way/", "time_published": "20230526T093000", "authors": ["Adria Cimino"], "summary": "Biotech-giant Amgen aims to launch a rival.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F733741%2Fgettyimages-1056449108.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.989041"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.095581, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KVUE", "relevance_score": "0.055492", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.165409", "ticker_sentiment_score": "0.019369", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.110717", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA", "url": "https://www.globenewswire.com/news-release/2023/05/25/2675804/0/en/Sandoz-Marketing-Authorization-Applications-for-proposed-biosimilar-denosumab-accepted-by-EMA.html", "time_published": "20230525T051500", "authors": ["Novartis Pharma AG"], "summary": "Basel, May 25, 2023 - Sandoz, a global leader in off-patent ( generic and biosimilar ) medicines, today announced that the European Medicines Agency ( EMA ) has accepted the marketing authorization applications ( MAA ) for proposed biosimilar denosumab for regulatory review.", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/5d242013-5d1f-440c-8ba6-3b5d3799b035", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.141934, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.03178", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?", "url": "https://www.fool.com/investing/2023/05/24/ftc-block-amgen-horizon-deal-pfizer-seagen-risk/", "time_published": "20230524T091500", "authors": ["David Jagielski"], "summary": "Should Pfizer and Seagen investors be worried?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F733344%2Fbuy-low-sell-high-stock-market-chart-investing-retirement-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.05082, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.720339", "ticker_sentiment_score": "-0.08185", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.471718", "ticker_sentiment_score": "-0.068107", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.213048", "ticker_sentiment_score": "0.040495", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.582526", "ticker_sentiment_score": "-0.031813", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.071784", "ticker_sentiment_score": "0.003075", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/05/32537932/check-out-what-whales-are-doing-with-amgn", "time_published": "20230523T181639", "authors": ["Benzinga Insights"], "summary": "A whale with a lot of money to spend has taken a noticeably bullish stance on Amgen. Looking at options history for Amgen AMGN we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.14324, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.864442", "ticker_sentiment_score": "0.313977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "There's An Overlooked Caveat To Pfizer's Ozempic Rival", "url": "https://www.investors.com/news/technology/pfizer-stock-the-one-caveat-investors-missed-with-its-ozempic-rival/", "time_published": "20230523T144300", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Pfizer Stock: The One Caveat Investors Missed With Its Ozempic Rival Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/08/stock-Pfizer-03-shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.153938, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "EVR", "relevance_score": "0.075161", "ticker_sentiment_score": "-0.039323", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.222838", "ticker_sentiment_score": "0.124397", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.149656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.149656", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.149656", "ticker_sentiment_score": "0.09497", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.654522", "ticker_sentiment_score": "0.218294", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AMGN: 4 Best Biotech Stocks According to POWR Ratings", "url": "https://stocknews.com/news/amgn-regn-uthr-vnda-4-best-biotech-stocks-according-to-powr-ratings/", "time_published": "20230523T143104", "authors": [], "summary": "The biotech industry has diversified and thrived, especially during the pandemic, owing to the advanced innovations and incessant efforts to curb the deadly virus. Moreover, the inelastic demand enjoyed by the industry makes it well-grounded to maintain its buoyancy in the upcoming times.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_517925923-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}], "overall_sentiment_score": 0.174501, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TCRX", "relevance_score": "0.025139", "ticker_sentiment_score": "-0.054824", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.149966", "ticker_sentiment_score": "0.086737", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.247334", "ticker_sentiment_score": "0.09851", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.100308", "ticker_sentiment_score": "0.049217", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTHR", "relevance_score": "0.149966", "ticker_sentiment_score": "0.010723", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?", "url": "https://www.zacks.com/stock/news/2098310/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now", "time_published": "20230523T102008", "authors": ["Zacks Investment Research"], "summary": "Smart Beta ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default322.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999892"}], "overall_sentiment_score": 0.272138, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.061949", "ticker_sentiment_score": "0.11403", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.123526", "ticker_sentiment_score": "0.068619", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer Next Blockbuster Act? It Might Be In Obesity", "url": "https://www.investors.com/news/technology/pfizer-stock-jumps-after-oral-drug-outperforms-novo-superstar-ozempic-in-weight-loss/", "time_published": "20230522T165800", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Pfizer Stock Jumps After Oral Drug Outperforms Novo Superstar ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/05/Stock-Ozempic-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999186"}], "overall_sentiment_score": 0.150596, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.160633", "ticker_sentiment_score": "0.067338", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.160633", "ticker_sentiment_score": "0.067338", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.160633", "ticker_sentiment_score": "0.067338", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.31482", "ticker_sentiment_score": "0.161389", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.521961", "ticker_sentiment_score": "0.062192", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen's Debt Overview - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/05/32510537/amgens-debt-overview", "time_published": "20230522T150100", "authors": ["Benzinga Insights"], "summary": "Shares of Amgen Inc. AMGN moved lower by 6.11% in the past three months. Before having a look at the importance of debt, let's look at how much debt Amgen has.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": -0.137136, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.304428", "ticker_sentiment_score": "-0.158499", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks", "url": "https://www.zacks.com/stock/news/2097899/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks", "time_published": "20230522T131004", "authors": ["Zacks Investment Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default172.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}], "overall_sentiment_score": 0.206457, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.219312", "ticker_sentiment_score": "0.121176", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIPC", "relevance_score": "0.110717", "ticker_sentiment_score": "0.119699", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMN", "relevance_score": "0.219312", "ticker_sentiment_score": "0.177479", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the Invesco Dynamic Pharmaceuticals ETF  ( PJP ) ?", "url": "https://www.zacks.com/stock/news/2097783/should-you-invest-in-the-invesco-dynamic-pharmaceuticals-etf-pjp", "time_published": "20230522T102007", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default134.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187565, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.129516", "ticker_sentiment_score": "0.063099", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.129516", "ticker_sentiment_score": "0.063099", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.193207", "ticker_sentiment_score": "0.127714", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.129516", "ticker_sentiment_score": "0.063099", "ticker_sentiment_label": "Neutral"}]}, {"title": "Autoimmune Drugs Market size to grow by USD 29,314.5 million between 2022 and 2027; AbbVie Inc., and AdvaCare Pharma among others, identified as key vendors - Technavio", "url": "https://www.prnewswire.com/news-releases/autoimmune-drugs-market-size-to-grow-by-usd-29-314-5-million-between-2022-and-2027-abbvie-inc-and-advacare-pharma-among-others-identified-as-key-vendors--technavio-301828870.html", "time_published": "20230519T231500", "authors": ["Technavio"], "summary": "Autoimmune Drugs Market size to grow by USD 29,314.5 million ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2080550/Technavio_Logo_Logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.200974, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOALF", "relevance_score": "0.037622", "ticker_sentiment_score": "0.140333", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKMPF", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}, {"ticker": "TAK", "relevance_score": "0.075161", "ticker_sentiment_score": "0.137715", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/05/32489034/heres-how-much-you-would-have-made-owning-amgen-stock-in-the-last-15-years", "time_published": "20230519T160030", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 4.01% on an annualized basis producing an average annual return of 11.64%. Currently, Amgen has a market capitalization of $119.97 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Market Rally Hits 2023 Highs As Big Techs Lead: Weekly Review", "url": "https://www.investors.com/news/stock-market-rally-hits-2023-highs-as-big-techs-lead-tesla-walmart-on-holding-in-focus-weekly-review/", "time_published": "20230519T154900", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally gained momentum, with the Nasdaq and S&P 500 hitting 2023 highs. The Nasdaq 100 rallied to a 52-week high, as big techs dominate the uptrend. The Dow Jones rose modestly, after briefly undercutting the 50-day line. The small-cap Russell 2000 also rebounded, helped by bank ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/09/Stock-BullHead-91-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.051771, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.099683", "ticker_sentiment_score": "-0.040052", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAT", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.02596", "ticker_sentiment_label": "Neutral"}, {"ticker": "DE", "relevance_score": "0.049939", "ticker_sentiment_score": "0.007999", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.02596", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.049939", "ticker_sentiment_score": "0.16906", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FL", "relevance_score": "0.074848", "ticker_sentiment_score": "-0.049084", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.049939", "ticker_sentiment_score": "0.107209", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.047108", "ticker_sentiment_label": "Neutral"}, {"ticker": "NU", "relevance_score": "0.074848", "ticker_sentiment_score": "0.142566", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.024982", "ticker_sentiment_score": "-0.118228", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.099683", "ticker_sentiment_score": "0.001122", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.024982", "ticker_sentiment_score": "0.104014", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.099683", "ticker_sentiment_score": "0.021838", "ticker_sentiment_label": "Neutral"}, {"ticker": "SE", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.130938", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.221932", "ticker_sentiment_score": "0.038425", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.02596", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.024982", "ticker_sentiment_score": "0.104014", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.099683", "ticker_sentiment_score": "-0.001099", "ticker_sentiment_label": "Neutral"}, {"ticker": "NKE", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.047108", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBS", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.02596", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPRT", "relevance_score": "0.049939", "ticker_sentiment_score": "0.025001", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.049939", "ticker_sentiment_score": "0.001001", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEWR", "relevance_score": "0.074848", "ticker_sentiment_score": "0.021298", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACLS", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.02596", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.024982", "ticker_sentiment_score": "0.019034", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROST", "relevance_score": "0.099683", "ticker_sentiment_score": "-0.043635", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPS", "relevance_score": "0.049939", "ticker_sentiment_score": "0.051988", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.049939", "ticker_sentiment_score": "-0.197057", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "STNE", "relevance_score": "0.049939", "ticker_sentiment_score": "0.138999", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTWO", "relevance_score": "0.049939", "ticker_sentiment_score": "0.290484", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WMT", "relevance_score": "0.221932", "ticker_sentiment_score": "0.050571", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.024982", "ticker_sentiment_score": "0.186093", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Safe Dividend Stocks to Beat Inflation", "url": "https://www.fool.com/investing/2023/05/19/3-safe-dividend-stocks-to-beat-inflation/", "time_published": "20230519T093500", "authors": ["James Brumley"], "summary": "Look for businesses that thrive in any economic environment.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732505%2Fgettyimages-1366649768.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.218976, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AAP", "relevance_score": "0.163631", "ticker_sentiment_score": "0.133328", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.243295", "ticker_sentiment_score": "0.096757", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.203729", "ticker_sentiment_score": "0.213009", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.041181", "ticker_sentiment_score": "-0.021989", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/05/19/2672401/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230519T090000", "authors": ["Alvotech"], "summary": "\u2022 Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 \u2022 Confirmatory patient study for AVT05, a proposed biosimilar for Simponi\u00ae and Simponi Aria\u00ae ( golimumab ) initiated, marking the fifth internally developed portfolio ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Earnings", "relevance_score": "0.989041"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.145891, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.012545", "ticker_sentiment_score": "0.054213", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.385137", "ticker_sentiment_score": "0.215528", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.012545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.025087", "ticker_sentiment_score": "0.034814", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.012545", "ticker_sentiment_score": "0.054213", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.012545", "ticker_sentiment_score": "0.054213", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.012545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.012545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.012545", "ticker_sentiment_score": "0.051698", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ISK", "relevance_score": "0.037622", "ticker_sentiment_score": "0.154174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:SEK", "relevance_score": "0.037622", "ticker_sentiment_score": "0.154174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.037622", "ticker_sentiment_score": "0.154174", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update", "url": "https://www.globenewswire.com/news-release/2023/05/19/2672402/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html", "time_published": "20230519T090000", "authors": ["Alvotech"], "summary": "REYKJAVIK, Iceland, May 19, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the \"Company\" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Earnings", "relevance_score": "0.989041"}, {"topic": "Economy - Macro", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.143537, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LTUS", "relevance_score": "0.012512", "ticker_sentiment_score": "0.054198", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALVO", "relevance_score": "0.384213", "ticker_sentiment_score": "0.212589", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVS", "relevance_score": "0.012512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.025021", "ticker_sentiment_score": "0.0348", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEVA", "relevance_score": "0.012512", "ticker_sentiment_score": "0.054198", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.012512", "ticker_sentiment_score": "0.054198", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.012512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.012512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.012512", "ticker_sentiment_score": "0.051684", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:ISK", "relevance_score": "0.037524", "ticker_sentiment_score": "0.154138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:SEK", "relevance_score": "0.037524", "ticker_sentiment_score": "0.154138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.037524", "ticker_sentiment_score": "0.154138", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Buy The Dip On The FTC's Latest Victim", "url": "https://www.forbes.com/sites/greatspeculations/2023/05/18/buy-the-dip-on-the-ftcs-latest-victim/", "time_published": "20230518T142840", "authors": ["Schaeffer's Investment Research"], "summary": "Shares of Horizon Therapeutics (HZNP) are fresh off their lowest level since November, after the Federal Trade Commission (FTC) yesterday said it will block the acquis...", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/646634f4e7cf787202c92c25/0x0.jpg?format=jpg&width=1200", "source": "Forbes", "category_within_source": "Money", "source_domain": "www.forbes.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.002443, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.271274", "ticker_sentiment_score": "-0.21303", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HZNP", "relevance_score": "0.701875", "ticker_sentiment_score": "0.003884", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Jump On Debt-Ceiling Hopes. These 6 Flash Buy Signals.", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-jumps-on-debt-ceiling-deal-hopes-six-stocks-flash-buy-signals/", "time_published": "20230517T205900", "authors": ["Investor's Business Daily", "ED CARSON"], "summary": "Dow Jones futures were steady after hours, along with S&P 500 futures and Nasdaq futures. Synopsys ( SNPS ) and Cisco Systems ( CSCO ) reported late Wednesday with Walmart ( WMT ) and Alibaba ( BABA ) due early Thursday.", "banner_image": "https://www.investors.com/wp-content/uploads/2019/11/stock-Bull-arena-01-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.144442, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.070935", "ticker_sentiment_score": "0.048204", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACW", "relevance_score": "0.047324", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGT", "relevance_score": "0.047324", "ticker_sentiment_score": "0.047868", "ticker_sentiment_label": "Neutral"}, {"ticker": "UAL", "relevance_score": "0.070935", "ticker_sentiment_score": "0.093809", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVGO", "relevance_score": "0.164549", "ticker_sentiment_score": "0.004184", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.14131", "ticker_sentiment_score": "0.087165", "ticker_sentiment_label": "Neutral"}, {"ticker": "WAL", "relevance_score": "0.070935", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.047324", "ticker_sentiment_score": "0.003994", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023673", "ticker_sentiment_score": "0.07532", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.047324", "ticker_sentiment_score": "-0.232697", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CCL", "relevance_score": "0.047324", "ticker_sentiment_score": "0.003994", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.047324", "ticker_sentiment_score": "0.003994", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.210579", "ticker_sentiment_score": "0.187975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.047324", "ticker_sentiment_score": "-0.232697", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NEWR", "relevance_score": "0.117948", "ticker_sentiment_score": "-0.036594", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.047324", "ticker_sentiment_score": "0.112537", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPS", "relevance_score": "0.164549", "ticker_sentiment_score": "0.028606", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.070935", "ticker_sentiment_score": "0.017169", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRI", "relevance_score": "0.070935", "ticker_sentiment_score": "0.057609", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCL", "relevance_score": "0.14131", "ticker_sentiment_score": "0.073712", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMT", "relevance_score": "0.117948", "ticker_sentiment_score": "0.095758", "ticker_sentiment_label": "Neutral"}]}, {"title": "TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients - TScan Therapeutics  ( NASDAQ:TCRX ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32450160/tscan-therapeutics-shares-fall-after-preliminary-data-highlight-in-leukemia-patients", "time_published": "20230517T183505", "authors": ["Vandana Singh"], "summary": "TScan Therapeutics Inc TCRX announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor histocompatibility antigens to prevent relapse after hematopoietic cell transplantation in leukemia patients.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/17/tcrx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.009364, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.325208", "ticker_sentiment_score": "-0.14117", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRX", "relevance_score": "0.598621", "ticker_sentiment_score": "-0.070101", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC Challenges Amgen's  ( AMGN )  $28B Acquisition of Horizon", "url": "https://www.zacks.com/stock/news/2096505/ftc-challenges-amgens-amgn-28b-acquisition-of-horizon", "time_published": "20230517T181000", "authors": ["Zacks Investment Research"], "summary": "Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.038326, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ANIP", "relevance_score": "0.432818", "ticker_sentiment_score": "0.242347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OCUP", "relevance_score": "0.317254", "ticker_sentiment_score": "0.107635", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.538084", "ticker_sentiment_score": "0.006673", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.631445", "ticker_sentiment_score": "-0.094048", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Turnaround For Weight Watchers Is Taking Shape - WW International  ( NASDAQ:WW ) ", "url": "https://www.benzinga.com/news/earnings/23/05/32441821/the-turnaround-for-weight-watchers-is-taking-shape", "time_published": "20230517T143554", "authors": ["MarketBeat"], "summary": "Weight management meals and services provider WW International Inc. WW stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed ( 26% ) as Artal Group S.A. sold its remaining 14.8 million share stake.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/17/jannis-brandt-mmsqugmlquo-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.043097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WW", "relevance_score": "0.592904", "ticker_sentiment_score": "0.105323", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDOC", "relevance_score": "0.082535", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.082535", "ticker_sentiment_score": "0.048345", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.082535", "ticker_sentiment_score": "0.048345", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.082535", "ticker_sentiment_score": "0.048345", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pfizer  ( PFE )  to Raise $31B in Debt to Fund Seagen  ( SGEN )  Deal", "url": "https://www.zacks.com/stock/news/2096263/pfizer-pfe-to-raise-31b-in-debt-to-fund-seagen-sgen-deal", "time_published": "20230517T133600", "authors": ["Zacks Investment Research"], "summary": "Pfizer (PFE) offers bonds worth $31 billion to fund its pending acquisition of cancer drugmaker, Seagen (SGEN).", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.101412, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.0699", "ticker_sentiment_score": "0.039444", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.570165", "ticker_sentiment_score": "0.045714", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.0699", "ticker_sentiment_score": "0.039444", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.339046", "ticker_sentiment_score": "0.21045", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.207571", "ticker_sentiment_score": "0.028444", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.570165", "ticker_sentiment_score": "0.075942", "ticker_sentiment_label": "Neutral"}]}, {"title": "FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal - Pfizer  ( NYSE:PFE ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32440200/fda-signals-support-for-pfizers-maternal-rsv-shot-ahead-of-adcomm-pfizer-raises-31b-in-debt-to-fu", "time_published": "20230517T121734", "authors": ["Vandana Singh"], "summary": "Pfizer Inc PFE plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc SGEN for $43 billion. The debt offering, which would be in eight tranches, is expected to close on May 19.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/17/pfe.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.107158, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.502207", "ticker_sentiment_score": "-0.100332", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.265378", "ticker_sentiment_score": "-0.284839", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HZNP", "relevance_score": "0.265378", "ticker_sentiment_score": "-0.284839", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PFE", "relevance_score": "0.502207", "ticker_sentiment_score": "0.207303", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?", "url": "https://www.fool.com/investing/2023/05/17/ftc-seeks-to-block-amgens-acquisition-of-horizon-t/", "time_published": "20230517T091300", "authors": ["Keith Speights"], "summary": "Don't bank on the FTC winning in its attempt to stop Amgen's buyout of Horizon just yet.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732461%2Fpercentage-interest-rate-growth-rate-mortgage-savings.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.007304, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.753867", "ticker_sentiment_score": "0.035968", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.18343", "ticker_sentiment_score": "-0.071609", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.061631", "ticker_sentiment_score": "0.006099", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.061631", "ticker_sentiment_score": "0.006099", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is This Dow Jones Stock a Buy for Income Investors?", "url": "https://www.fool.com/investing/2023/05/17/is-this-dow-jones-stock-a-buy-for-income-investors/", "time_published": "20230517T090600", "authors": ["Kody Kester"], "summary": "This pharmaceutical company is dedicated to maintaining its track record of innovation.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732584%2Fa-doctor-examines-a-patient.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997902"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}], "overall_sentiment_score": 0.201572, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.587133", "ticker_sentiment_score": "0.309801", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.118354", "ticker_sentiment_score": "-0.017436", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.118354", "ticker_sentiment_score": "0.24216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.059341", "ticker_sentiment_score": "0.063992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Skid On Biden's Debt-Limit Move; Tesla Will 'Try' This", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-breaks-support-as-president-biden-makes-debt-ceiling-move-elon-musk-tesla-cybertruck/", "time_published": "20230517T003700", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Dow Jones Breaks Support As President Biden Makes This Debt ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/01/Stock-biden-03-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.046016, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TGT", "relevance_score": "0.073247", "ticker_sentiment_score": "-0.033376", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAT", "relevance_score": "0.073247", "ticker_sentiment_score": "0.296841", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.048869", "ticker_sentiment_score": "-0.017999", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.193658", "ticker_sentiment_score": "0.159211", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVGO", "relevance_score": "0.048869", "ticker_sentiment_score": "0.291765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVZ", "relevance_score": "0.024446", "ticker_sentiment_score": "-0.292065", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.073247", "ticker_sentiment_score": "-0.145825", "ticker_sentiment_label": "Neutral"}, {"ticker": "DT", "relevance_score": "0.145878", "ticker_sentiment_score": "0.032021", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.193658", "ticker_sentiment_score": "0.027082", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.332083", "ticker_sentiment_score": "0.059857", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.048869", "ticker_sentiment_score": "-0.196007", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ACLS", "relevance_score": "0.073247", "ticker_sentiment_score": "0.246533", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOW", "relevance_score": "0.048869", "ticker_sentiment_score": "0.081948", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMD", "relevance_score": "0.169846", "ticker_sentiment_score": "0.125767", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRCX", "relevance_score": "0.048869", "ticker_sentiment_score": "0.291765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.073247", "ticker_sentiment_score": "0.006146", "ticker_sentiment_label": "Neutral"}, {"ticker": "ON", "relevance_score": "0.024446", "ticker_sentiment_score": "0.278756", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why These 3 Nasdaq Stocks Buckled Today", "url": "https://www.fool.com/investing/2023/05/16/why-these-3-nasdaq-stocks-buckled-today/", "time_published": "20230516T194200", "authors": ["George Budwell"], "summary": "The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732760%2Fmicrochip-technology-computer-chip-data-processing.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": -0.026487, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "APLS", "relevance_score": "0.16117", "ticker_sentiment_score": "0.070317", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDGL", "relevance_score": "0.16117", "ticker_sentiment_score": "0.070317", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.239698", "ticker_sentiment_score": "-0.105509", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRPT", "relevance_score": "0.16117", "ticker_sentiment_score": "0.070317", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.16117", "ticker_sentiment_score": "-0.137442", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC May Reportedly Block Amgen's  ( AMGN )  $28B Horizon Buyout", "url": "https://www.zacks.com/stock/news/2096013/ftc-may-reportedly-block-amgens-amgn-28b-horizon-buyout", "time_published": "20230516T191600", "authors": ["Zacks Investment Research"], "summary": "Unconfirmed reports suggest that the FTC may challenge the $28-billion buyout of Horizon Therapeutics (HZNP) by Amgen.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.074505, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.400052", "ticker_sentiment_score": "0.226511", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.654859", "ticker_sentiment_score": "0.022301", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.705799", "ticker_sentiment_score": "-0.076951", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.400052", "ticker_sentiment_score": "0.226511", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A - Horizon Therapeutics  ( NASDAQ:HZNP ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32428869/ftc-files-lawsuit-to-stop-amgen-buying-horizon-therapeutics-sending-shockwaves-through-biopharma-", "time_published": "20230516T183711", "authors": ["Vandana Singh"], "summary": "In a rare move to block a large pharma deal, the U.S. Federal Trade Commission would sue to stop Amgen Inc's AMGN $28 billion takeover of Horizon Therapeutics PLC HZNP.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/amgn-hznp_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.012361, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.246582", "ticker_sentiment_score": "0.087309", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.246582", "ticker_sentiment_score": "0.23582", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.72844", "ticker_sentiment_score": "-0.03577", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.246582", "ticker_sentiment_score": "-0.403854", "ticker_sentiment_label": "Bearish"}, {"ticker": "PFE", "relevance_score": "0.246582", "ticker_sentiment_score": "0.087309", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC sues to block Amgen's acquisition of Horizon Therapeutics", "url": "https://www.marketwatch.com/story/ftc-sues-to-block-amgens-acquisition-of-horizon-therapeutics-39a5cd1", "time_published": "20230516T174400", "authors": ["Eleanor Laise"], "summary": "Deal could allow Amgen to \"entrench the monopoly positions\" of two Horizon medications, regulators say.", "banner_image": "https://images.mktw.net/im-428023/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.087099, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.160099", "ticker_sentiment_score": "0.128818", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.160099", "ticker_sentiment_score": "0.128818", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.636698", "ticker_sentiment_score": "0.099875", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.160099", "ticker_sentiment_score": "-0.145872", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.160099", "ticker_sentiment_score": "0.128818", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks Dip, Nasdaq Bull Run Continues With Big Tech Speculation: Investors Eye Biden-McCarthy Debt Ceiling Talk - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Horizon Therapeutics  ( NASDAQ:HZNP ) , Baidu  ( NASDAQ:BIDU ) , Capital One Finl  ( NYSE:COF ) , Home Depot  ( NYSE:HD ) , Amgen  ( NASDAQ:AMGN ) , SPDR S&P 500  ( ARCA:SPY ) , Tencent Music Enter Gr  ( NYSE:TME ) , Tupperware Brands  ( NYSE:TUP ) ", "url": "https://www.benzinga.com/news/23/05/32417598/s-amp-p-500-futures-slip-after-home-depots-q1-print-analyst-says-retest-of-october-lows-likely-1", "time_published": "20230516T172600", "authors": ["Shanthi Rexaline"], "summary": "The markets were overall weaker on Tuesday, with a significant exception stemming from big gains reported by tech giants following 13F disclosures by hedge funds, which indicated that speculators raised their exposure to major tech firms. Alphabet, Inc. GOOG GOOGL, Advanced Micro Devices, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/wall_street4.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999975"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.070302, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.089295", "ticker_sentiment_score": "0.180636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.089295", "ticker_sentiment_score": "0.180636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.089295", "ticker_sentiment_score": "0.143055", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.044718", "ticker_sentiment_score": "0.042991", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.089295", "ticker_sentiment_score": "0.130549", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.133593", "ticker_sentiment_score": "0.157594", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.089295", "ticker_sentiment_score": "-0.243452", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HZNP", "relevance_score": "0.089295", "ticker_sentiment_score": "-0.243452", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMD", "relevance_score": "0.089295", "ticker_sentiment_score": "0.180636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CME", "relevance_score": "0.044718", "ticker_sentiment_score": "0.015965", "ticker_sentiment_label": "Neutral"}, {"ticker": "COF", "relevance_score": "0.177475", "ticker_sentiment_score": "0.1785", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HD", "relevance_score": "0.089295", "ticker_sentiment_score": "0.189977", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMZN", "relevance_score": "0.089295", "ticker_sentiment_score": "0.180636", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PSHZF", "relevance_score": "0.044718", "ticker_sentiment_score": "0.106188", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.089295", "ticker_sentiment_score": "0.213066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.220809", "ticker_sentiment_score": "0.267316", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.089295", "ticker_sentiment_score": "0.113192", "ticker_sentiment_label": "Neutral"}]}, {"title": "Trade commission fights Amgen's $28B purchase of Horizon Therapeutics - .com", "url": "https://www.upi.com/Top_News/US/2023/05/16/FTC-Amgen-Horizon-monopoly/4331684252329/", "time_published": "20230516T165815", "authors": [], "summary": "Trade commission fights Amgen's $28B purchase of Horizon Therapeutics UPI News ...", "banner_image": "https://cdnph.upi.com/ph/st/th/4331684252329/2023/upi_com/cbf506e055676671a962de01a4e58ff9/v1.5/Trade-commission-fights-Amgens-28B-purchase-of-Horizon-Therapeutics.jpg?lg=5", "source": "UPI Business", "category_within_source": "n/a", "source_domain": "www.upi.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.187277, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.004313", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.098255", "ticker_sentiment_score": "-0.004313", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why These 2 Large-Cap Stocks Dropped 10%-Plus on Tuesday", "url": "https://www.fool.com/investing/2023/05/16/why-these-2-large-cap-stocks-dropped-10-plus-on-tu/", "time_published": "20230516T163600", "authors": ["Dan Caplinger"], "summary": "Their declines weighed on the broader market.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732534%2Finvestors-looking-at-stock-chart.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.051404, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.265378", "ticker_sentiment_score": "-0.004154", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.200688", "ticker_sentiment_score": "-0.073756", "ticker_sentiment_label": "Neutral"}, {"ticker": "SE", "relevance_score": "0.265378", "ticker_sentiment_score": "0.044025", "ticker_sentiment_label": "Neutral"}]}, {"title": "FTC Suing To Stop Amgen's $27.8 Billion Purchase Of Horizon Therapeutics", "url": "https://www.forbes.com/sites/mollybohannon/2023/05/16/ftc-suing-to-stop-amgens-278-billion-purchase-of-horizon-therapeutics/", "time_published": "20230516T162141", "authors": ["Molly Bohannon"], "summary": "The FTC is attempting to stop the sale out of fears it will give the company too much power over rare disease treatments.", "banner_image": "https://imageio.forbes.com/specials-images/imageserve/6463ad3eb90c53927a65a233/0x0.jpg?format=jpg&crop=2521,1417,x0,y1,safe&width=1200", "source": "Forbes", "category_within_source": "Business", "source_domain": "www.forbes.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.002469, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.642977", "ticker_sentiment_score": "0.003752", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.104683", "ticker_sentiment_score": "-0.181631", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "JNJ", "relevance_score": "0.104683", "ticker_sentiment_score": "0.07514", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.104683", "ticker_sentiment_score": "0.07514", "ticker_sentiment_label": "Neutral"}]}, {"title": "Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon", "url": "https://apnews.com/article/amgen-horizon-ftc-antitrust-monopoly-regulators-d20c418b2c5b0684fabb9cc22c2432b0", "time_published": "20230516T155720", "authors": [], "summary": "Monopoly concerns push FTC to sue to block Amgen's more than ... The Associated Press ...", "banner_image": "https://storage.googleapis.com/afs-prod/media/5304fc5a6a9f41b294dcbbc05bb65c83/2860.webp", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.039021, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.09186", "ticker_sentiment_score": "0.051832", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.182506", "ticker_sentiment_score": "-0.020208", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Horizon Therapeutics Stock Is Crashing Today", "url": "https://www.fool.com/investing/2023/05/16/why-horizon-therapeutics-stock-is-crashing-today/", "time_published": "20230516T151401", "authors": ["George Budwell"], "summary": "The FTC is reportedly gearing up to block the drugmaker's takeover by Amgen.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F732420%2Fascending-bar-chart-line-invest-financial-newspaper-stock-market-quote-rally-bull-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.014738, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.736015", "ticker_sentiment_score": "-0.141426", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.250386", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stock Market Awaits Debt Ceiling Talks. Home Depot Tanks After Sales Miss.", "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-awaits-debt-ceiling-talks-home-depot-tanks-after-sales-miss-and-gloomy-guidance/", "time_published": "20230516T145100", "authors": ["Investor's Business Daily", "KIMBERLEY KOENIG"], "summary": "Stock Market Awaits Debt Ceiling Talks. Home Depot Tanks After ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/02/Stock-Home-Depot-05-IBD.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.997902"}, {"topic": "Earnings", "relevance_score": "0.77141"}], "overall_sentiment_score": -0.103949, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HZNP", "relevance_score": "0.100941", "ticker_sentiment_score": "-0.301597", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIDU", "relevance_score": "0.150906", "ticker_sentiment_score": "0.363387", "ticker_sentiment_label": "Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.050572", "ticker_sentiment_score": "0.098357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.100941", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.150906", "ticker_sentiment_score": "-0.302037", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.050572", "ticker_sentiment_score": "0.120318", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.150906", "ticker_sentiment_score": "-0.229939", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.050572", "ticker_sentiment_score": "-0.129001", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top Stories Tuesday, May 16: Former SVB CEO Blames Fed & Media Hype For Collapse, FTC Plans Lawsuit to Block Horizon Therapeutics $28B Takeover, Home Depot Lowers Annual Outlook - Amgen  ( NASDAQ:AMGN ) , Delta Air Lines  ( NYSE:DAL ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32422751/former-svb-ceo-blames-fed-media-hype-for-collapse-ftc-plans-lawsuit-to-block-horizon-therapeutics", "time_published": "20230516T135640", "authors": ["Vandana Singh"], "summary": "Greg Becker, the former CEO of SVB Financial Group, the parent company of Silicon Valley Bank, attributed the bank's collapse to a combination of factors, including rapid rate hikes by the Federal Reserve and negative sentiment amplified by social media.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/svb_gguy_on_shutterstock.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.94762"}], "overall_sentiment_score": -0.043655, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EADSF", "relevance_score": "0.084871", "ticker_sentiment_score": "0.233878", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.168785", "ticker_sentiment_score": "-0.122164", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.084871", "ticker_sentiment_score": "-0.19137", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.084871", "ticker_sentiment_score": "-0.106676", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.127007", "ticker_sentiment_score": "0.044419", "ticker_sentiment_label": "Neutral"}, {"ticker": "VOD", "relevance_score": "0.168785", "ticker_sentiment_score": "0.0342", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.042496", "ticker_sentiment_score": "0.073065", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.084871", "ticker_sentiment_score": "-0.077248", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMM", "relevance_score": "0.084871", "ticker_sentiment_score": "-0.32848", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.168785", "ticker_sentiment_score": "-0.128259", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAL", "relevance_score": "0.084871", "ticker_sentiment_score": "0.233878", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jim Cramer's top things to watch in the stock market Tuesday", "url": "https://www.cnbc.com/2023/05/16/jim-cramers-top-things-to-watch-in-the-stock-market-tuesday.html", "time_published": "20230516T131345", "authors": ["Jim Cramer"], "summary": "Dow component Home Depot's decline on big revenue miss and guidance cut sets up the 30-stock average for a modestly lower open.", "banner_image": "https://image.cnbcfm.com/api/v1/image/107061782-1652723845923-GettyImages-1240707144.jpg?v=1684242825&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.041286, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AAPL", "relevance_score": "0.163909", "ticker_sentiment_score": "0.085707", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.073373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.082393", "ticker_sentiment_score": "0.065253", "ticker_sentiment_label": "Neutral"}, {"ticker": "COF", "relevance_score": "0.163909", "ticker_sentiment_score": "0.085707", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.035123", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.163909", "ticker_sentiment_score": "-0.073373", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSHZF", "relevance_score": "0.082393", "ticker_sentiment_score": "0.065253", "ticker_sentiment_label": "Neutral"}]}, {"title": "Horizon Crashes - Taking Others With It - On Scrutiny In Amgen Deal", "url": "https://www.investors.com/news/technology/hznp-stock-crashes-on-reports-the-ftc-could-block-its-takeover-by-amgen/", "time_published": "20230516T130300", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "HZNP Stock Crashes On Reports The FTC Could Block Its Takeover ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2019/02/Stock-HorizonPharma-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.112015, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGEN", "relevance_score": "0.325208", "ticker_sentiment_score": "0.364806", "ticker_sentiment_label": "Bullish"}, {"ticker": "RXDX", "relevance_score": "0.325208", "ticker_sentiment_score": "0.364806", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMGN", "relevance_score": "0.470894", "ticker_sentiment_score": "0.154791", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.470894", "ticker_sentiment_score": "-0.351453", "ticker_sentiment_label": "Bearish"}]}, {"title": "Why Horizon Therapeutics  ( HZNP )  Stock is Tanking Today? - Horizon Therapeutics  ( NASDAQ:HZNP ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32417018/amgen-horizon-therapeutics-deal-regulatory-overhang-ftc-plans-lawsuit-to-block-28b-takeover", "time_published": "20230516T120626", "authors": ["Vandana Singh"], "summary": "The Federal Trade Commission is expected to file a lawsuit in a bid to block Amgen Inc's AMGN $28 billion takeover of Horizon Therapeutics PLC HZNP. In December, Amgen agreed to buy Horizon Therapeutics at $116.50/share, implying an enterprise value of approximately $28.3 billion, marking the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/amgn-hznp.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.016789, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.810649", "ticker_sentiment_score": "0.016314", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.651499", "ticker_sentiment_score": "0.059469", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Futures Slip After Home Depot's Q1 Print: Analyst Says Retest Of October Lows Likely - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , Horizon Therapeutics  ( NASDAQ:HZNP ) , Baidu  ( NASDAQ:BIDU ) , Capital One Finl  ( NYSE:COF ) , Home Depot  ( NYSE:HD ) , Amgen  ( NASDAQ:AMGN ) , SPDR S&P 500  ( ARCA:SPY ) , Tencent Music Enter Gr  ( NYSE:TME ) , Tupperware Brands  ( NYSE:TUP ) ", "url": "https://www.benzinga.com/news/23/05/32417598/s-amp-p-500-futures-slip-after-home-depots-q1-print-analyst-says-retest-of-october-lows-likely", "time_published": "20230516T110313", "authors": ["Shanthi Rexaline"], "summary": "The see-sawing mood and tight trading ranges that have been characteristic of recent sessions will likely hold in the near term. The major stock futures point to a mostly lower opening on Tuesday as Home Depot, Inc.'s HD disappointing first-quarter results cast a cloud on the economic outlook.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Stock_market_analysis_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.999864"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.026446, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CMA", "relevance_score": "0.043499", "ticker_sentiment_score": "0.175436", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.08687", "ticker_sentiment_score": "-0.242151", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BIDU", "relevance_score": "0.08687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.043499", "ticker_sentiment_score": "0.093027", "ticker_sentiment_label": "Neutral"}, {"ticker": "COF", "relevance_score": "0.08687", "ticker_sentiment_score": "0.097795", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.172713", "ticker_sentiment_score": "0.005835", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.043499", "ticker_sentiment_score": "0.062784", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.08687", "ticker_sentiment_score": "-0.242151", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TME", "relevance_score": "0.08687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.043499", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TUP", "relevance_score": "0.08687", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's the big thing holding up the stock market, says Bank of America", "url": "https://www.marketwatch.com/story/heres-the-big-thing-holding-up-the-stock-market-says-bank-of-america-e5a2d2c5", "time_published": "20230516T110000", "authors": ["Barbara Kollmeyer"], "summary": "Investors want to see the economy land softly softly, and that is the main thing that will keep assets resilient, say BofA managers.", "banner_image": "https://images.mktw.net/im-782457?width=700&height=413", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.026673, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.180764", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVDA", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.180764", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BAC", "relevance_score": "0.036812", "ticker_sentiment_score": "0.02381", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRK-A", "relevance_score": "0.036812", "ticker_sentiment_score": "0.034719", "ticker_sentiment_label": "Neutral"}, {"ticker": "BK", "relevance_score": "0.073546", "ticker_sentiment_score": "0.036411", "ticker_sentiment_label": "Neutral"}, {"ticker": "VOD", "relevance_score": "0.110124", "ticker_sentiment_score": "-0.139841", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.073259", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSM", "relevance_score": "0.073546", "ticker_sentiment_score": "0.036411", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLT", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.180764", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.110124", "ticker_sentiment_score": "-0.15853", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HZNP", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.073259", "ticker_sentiment_label": "Neutral"}, {"ticker": "RH", "relevance_score": "0.110124", "ticker_sentiment_score": "0.039858", "ticker_sentiment_label": "Neutral"}, {"ticker": "FDX", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.180764", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMG", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.180764", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HD", "relevance_score": "0.073546", "ticker_sentiment_score": "0.007201", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.073546", "ticker_sentiment_score": "-0.180764", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PSHZF", "relevance_score": "0.036812", "ticker_sentiment_score": "-0.173506", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FOREX:TRY", "relevance_score": "0.036812", "ticker_sentiment_score": "-0.049316", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.036812", "ticker_sentiment_score": "-0.049316", "ticker_sentiment_label": "Neutral"}]}, {"title": "Capital One stock rallies and Home Depot shares dip, and other companies on the move", "url": "https://www.marketwatch.com/story/capital-one-stock-rallies-and-home-depot-shares-dips-and-other-companies-on-the-move-fb5b254e", "time_published": "20230516T102300", "authors": ["Jamie Chisholm"], "summary": "Capital One Financial Corp.'s shares rose 6% after Warren Buffett's Berkshire Hathaway Inc. took a near $1 billion bet on the credit card and banking group ...", "banner_image": "https://images.mktw.net/im-763017/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.061476, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COF", "relevance_score": "0.42503", "ticker_sentiment_score": "0.449303", "ticker_sentiment_label": "Bullish"}, {"ticker": "WAL", "relevance_score": "0.42503", "ticker_sentiment_score": "-0.249202", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HD", "relevance_score": "0.42503", "ticker_sentiment_score": "-0.249202", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.42503", "ticker_sentiment_score": "-0.249202", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BRK-A", "relevance_score": "0.220809", "ticker_sentiment_score": "0.283255", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Horizon shares sink on report that FTC will sue to block takeover by Amgen", "url": "https://www.marketwatch.com/story/horizon-shares-sink-on-report-that-ftc-will-sue-to-block-takeover-by-amgen-544909b0", "time_published": "20230516T015100", "authors": ["Mike Murphy"], "summary": "Shares of Horizon Therapeutics Inc. plunged 15% in extended trading Monday after Bloomberg News reported the FTC is expected to file a lawsuit to block Amgen Inc.'s $27.8 billion acquisition of Horizon.", "banner_image": "https://images.mktw.net/im-724754/social", "source": "MarketWatch", "category_within_source": "Top Stories", "source_domain": "www.marketwatch.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": -0.069375, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.933751", "ticker_sentiment_score": "0.025643", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.459624", "ticker_sentiment_score": "0.018265", "ticker_sentiment_label": "Neutral"}]}, {"title": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks", "url": "https://www.zacks.com/stock/news/2095203/improve-your-retirement-income-with-these-3-top-ranked-dividend-stocks", "time_published": "20230515T131004", "authors": ["Zacks Investment Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default271.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.235159, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.214462", "ticker_sentiment_score": "0.11906", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIPC", "relevance_score": "0.108222", "ticker_sentiment_score": "0.118756", "ticker_sentiment_label": "Neutral"}, {"ticker": "CFG", "relevance_score": "0.214462", "ticker_sentiment_score": "0.167928", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?", "url": "https://www.zacks.com/stock/news/2095065/should-you-invest-in-the-ishares-biotechnology-etf-ibb", "time_published": "20230515T102009", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default205.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}], "overall_sentiment_score": 0.191498, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.069094", "ticker_sentiment_score": "0.03409", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.137671", "ticker_sentiment_score": "0.072354", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32376443/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-amgen-inc-amgn", "time_published": "20230512T231655", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 12, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ( \"Amgen\" or the \"Company\" ) AMGN. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.012133, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.658003", "ticker_sentiment_score": "-0.100244", "ticker_sentiment_label": "Neutral"}]}, {"title": "Biotech ETFs Pop on M&A Resurgence", "url": "https://www.zacks.com/stock/news/2093665/biotech-etfs-pop-on-ma-resurgence", "time_published": "20230510T163300", "authors": ["Zacks Investment Research"], "summary": "2023 could be a year of heightened biotech dealmaking activity ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.682689"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.084975, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.199859", "ticker_sentiment_score": "0.13748", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLU", "relevance_score": "0.199859", "ticker_sentiment_score": "0.244943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.199859", "ticker_sentiment_score": "0.13748", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.325294", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IVZ", "relevance_score": "0.100729", "ticker_sentiment_score": "0.010937", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXDX", "relevance_score": "0.199859", "ticker_sentiment_score": "0.244943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.199859", "ticker_sentiment_score": "0.13748", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.295867", "ticker_sentiment_score": "-0.173328", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Looking Into Amgen's Recent Short Interest - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/short-sellers/23/05/32319933/looking-into-amgens-recent-short-interest", "time_published": "20230510T153030", "authors": ["Benzinga Insights"], "summary": "Amgen's AMGN short percent of float has risen 8.7% since its last report. The company recently reported that it has 7.99 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.3 days to cover their short ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.267375, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.224903", "ticker_sentiment_score": "0.158881", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Jacmel Growth Partners Appoints Mark Hardaway as Chief Financial Officer", "url": "https://www.prnewswire.com/news-releases/jacmel-growth-partners-appoints-mark-hardaway-as-chief-financial-officer-301820127.html", "time_published": "20230510T120100", "authors": ["Jacmel Growth Partners"], "summary": "Jacmel Growth Partners Appoints Mark Hardaway as Chief Financial ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1917658/Jacmel_Growth_Partners.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.357751, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.083833", "ticker_sentiment_score": "0.113663", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Inc.: Please contact the Portnoy Law Firm to recover your losses; May 2, 2023 deadline - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32307676/amgen-inc-please-contact-the-portnoy-law-firm-to-recover-your-losses-may-2-2023-deadline", "time_published": "20230510T033001", "authors": ["Globe Newswire"], "summary": "Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 09, 2023 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Amgen Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.068003, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.744646", "ticker_sentiment_score": "-0.203884", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Are TScan Therapeutics  ( TCRX )  Shares Are Shooting Higher Today - TScan Therapeutics  ( NASDAQ:TCRX ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32290080/why-are-tscan-therapeutics-shares-are-shooting-higher-today", "time_published": "20230509T152920", "authors": ["Vandana Singh"], "summary": "Amgen Inc AMGN and TScan Therapeutics Inc TCRX announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/09/tcrx.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.19724, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.608634", "ticker_sentiment_score": "0.433651", "ticker_sentiment_label": "Bullish"}, {"ticker": "TCRX", "relevance_score": "0.608634", "ticker_sentiment_score": "0.148636", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts - AbbVie  ( NYSE:ABBV ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/05/32289782/check-out-3-health-care-stocks-with-over-3-dividend-yields-from-wall-streets-most-accurate-analysts", "time_published": "20230509T131655", "authors": ["Lisa Levin"], "summary": "During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/09/image19.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.016709, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.118064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.118064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.233556", "ticker_sentiment_score": "-0.16002", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.118064", "ticker_sentiment_score": "-0.078586", "ticker_sentiment_label": "Neutral"}, {"ticker": "OGN", "relevance_score": "0.118064", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm - Signature Bank  ( OTC:SBNY ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32278887/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-svb-a", "time_published": "20230509T013000", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 08, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SVB Financial Group SIVB SIVBP ) ) ) , Amgen Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.198365, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SBNY", "relevance_score": "0.174272", "ticker_sentiment_score": "-0.143319", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.752304", "ticker_sentiment_score": "-0.179602", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "DEADLINE ALERT for SIVBQ, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Alphabet  ( NASDAQ:GOOG ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32274952/deadline-alert-for-sivbq-amgn-sbnysbnyp-and-googgoogl-the-law-offices-of-frank-r-cruz-reminds-inve", "time_published": "20230508T204550", "authors": ["Globe Newswire"], "summary": "LOS ANGELES, May 08, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.106245, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SBNY", "relevance_score": "0.150592", "ticker_sentiment_score": "-0.197526", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "What Does Amgen's Debt Look Like? - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/05/32269590/what-does-amgens-debt-look-like", "time_published": "20230508T170049", "authors": ["Benzinga Insights"], "summary": "Over the past three months, shares of Amgen Inc. AMGN moved lower by 2.71%. Before having a look at the importance of debt, let's look at how much debt Amgen has. Based on Amgen's balance sheet as of April 28, 2023, long-term debt is at $60.76 billion and current debt is at $834.00 million, ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": -0.139479, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.395012", "ticker_sentiment_score": "-0.011209", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32268954/amgn-lawsuit-alert-levi-korsinsky-notifies-amgen-inc-investors-of-a-class-action-lawsuit-and-upcom", "time_published": "20230508T163000", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 08, 2023 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ( \"Amgen\" or the \"Company\" ) AMGN of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": -0.033999, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.76367", "ticker_sentiment_score": "-0.154628", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN", "url": "https://markets.businessinsider.com/news/stocks/rosen-globally-respected-investor-counsel-encourages-amgen-inc.-investors-to-secure-counsel-before-important-may-12-deadline-in-securities-class-action-amgn-1032299067", "time_published": "20230506T171000", "authors": [], "summary": "ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action ...", "banner_image": "https://api.newsfilecorp.com/newsinfo/165021/208", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.119759, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.554751", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.060848", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Best Biotech Stocks to Buy Right Now", "url": "https://www.fool.com/investing/2023/05/06/best-biotech-stocks-to-buy-right-now/", "time_published": "20230506T115500", "authors": ["Kody Kester"], "summary": "Buying pharmaceutical companies with all-around drug portfolios and pipelines is the key to success as an investor.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F731019%2Fhealthcare-professionals-talking-to-each-other.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.988787"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": 0.259399, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.273552", "ticker_sentiment_score": "0.153935", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.273552", "ticker_sentiment_score": "0.103106", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.069697", "ticker_sentiment_score": "-0.004056", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32248609/amgn-notice-top-ranked-rosen-law-firm-encourages-amgen-inc-investors-to-secure-counsel-before-impo", "time_published": "20230505T202700", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 05, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. AMGN between July 29, 2020 and April 27, 2022, both dates inclusive ( the \"Class Period\" ) , of the important May 12, 2023 lead plaintiff deadline.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.095828, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.491878", "ticker_sentiment_score": "-0.028876", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.058615", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc.  ( AMGN )  - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32240261/glancy-prongay-murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-agains", "time_published": "20230505T143000", "authors": ["Globe Newswire"], "summary": "LOS ANGELES, May 05, 2023 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP ( \"GPM\" ) reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Amgen Inc. ( \"Amgen\" or the \"Company\" ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.00485, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.699089", "ticker_sentiment_score": "-0.019312", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.054983", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Magnificent Dividend Stocks to Buy Before the Next Recession", "url": "https://www.fool.com/investing/2023/05/05/2-magnificent-dividend-stocks-to-buy-before-next/", "time_published": "20230505T134500", "authors": ["Prosper Junior Bakiny"], "summary": "The healthcare sector is a good place to find recession-proof stocks.", "banner_image": "https://media.ycharts.com/charts/c6c06687434d40c534e3cde623ea1a27.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.092594, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.318309", "ticker_sentiment_score": "0.274021", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.442082", "ticker_sentiment_score": "0.15084", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32231065/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-amgen-inc-amgn", "time_published": "20230505T025010", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 04, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ( \"Amgen\" or the \"Company\" ) AMGN. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.012133, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.658003", "ticker_sentiment_score": "-0.100244", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Look Into Amgen Inc's Price Over Earnings - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/23/05/32220966/a-look-into-amgen-incs-price-over-earnings", "time_published": "20230504T173026", "authors": ["Benzinga Insights"], "summary": "In the current market session, Amgen Inc. AMGN price is at $231.03, after a 0.75% spike. However, over the past month, the stock fell by 8.80%, and in the past year, by 2.31%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.130567, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.348919", "ticker_sentiment_score": "-0.126931", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novo Nordisk rivals see room to compete in $100 billion weight-loss drug market", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-rivals-see-room-compete-100-bln-weight-loss-drug-market-2023-05-04/", "time_published": "20230504T101700", "authors": ["Michael Erman"], "summary": "Novo Nordisk rivals see room to compete in $100 bln weight-loss ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/43AHBNO2U5JETK3AKEKYCI2WVA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.169768, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALT", "relevance_score": "0.089462", "ticker_sentiment_score": "0.289729", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MORN", "relevance_score": "0.044801", "ticker_sentiment_score": "0.051946", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.044801", "ticker_sentiment_score": "-0.098281", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.044801", "ticker_sentiment_score": "0.189864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.089462", "ticker_sentiment_score": "-0.034983", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.177802", "ticker_sentiment_score": "0.124933", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm - Signature Bank  ( OTC:SBNY ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32204027/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-svb-a", "time_published": "20230504T013000", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 03, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SVB Financial Group SIVPQ SIVBQ ) ) ) , Amgen Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.198406, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SBNY", "relevance_score": "0.175221", "ticker_sentiment_score": "-0.143863", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.754911", "ticker_sentiment_score": "-0.179853", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Why Amgen Stock Was Sickly Today", "url": "https://www.fool.com/investing/2023/05/03/why-amgen-stock-was-sickly-today/", "time_published": "20230503T222710", "authors": ["Eric Volkman"], "summary": "The company's asset-to-be reported underwhelming first-quarter results.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F728647%2Fgrowth-3.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.067634, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.639616", "ticker_sentiment_score": "0.185032", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.285526", "ticker_sentiment_score": "0.186357", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023 - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32201704/amgn-shareholder-alert-jakubowitz-law-reminds-amgen-shareholders-of-a-lead-plaintiff-deadline-of-m", "time_published": "20230503T215307", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 03, 2023 ( GLOBE NEWSWIRE ) -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. AMGN. This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": -0.087295, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.810034", "ticker_sentiment_score": "-0.321671", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "AMGN NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN", "url": "https://markets.businessinsider.com/news/stocks/amgn-notice-rosen-trusted-investor-counsel-encourages-amgen-inc.-investors-to-secure-counsel-before-important-may-12-deadline-in-securities-class-action-amgn-1032288763", "time_published": "20230503T180900", "authors": [], "summary": "AMGN NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action ...", "banner_image": "https://api.newsfilecorp.com/newsinfo/164688/208", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.119759, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.554751", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.060848", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/05/32194490/heres-how-much-you-would-have-made-owning-amgen-stock-in-the-last-15-years", "time_published": "20230503T180022", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 12.1%. Currently, Amgen has a market capitalization of $124.51 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Horizon  ( HZNP )  Q1 Earnings and Revenues Miss Estimates", "url": "https://www.zacks.com/stock/news/2089213/horizon-hznp-q1-earnings-and-revenues-miss-estimates", "time_published": "20230503T155500", "authors": ["Zacks Investment Research"], "summary": "Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.014305, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ADMA", "relevance_score": "0.374875", "ticker_sentiment_score": "0.16059", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.154951", "ticker_sentiment_score": "0.198341", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APTX", "relevance_score": "0.304114", "ticker_sentiment_score": "0.097741", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.304114", "ticker_sentiment_score": "-0.068219", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents - Novartis  ( NYSE:NVS ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/05/32184876/amgen-vs-sandoz-legal-battle-erupts-over-bone-strengthening-drug-patents", "time_published": "20230503T130025", "authors": ["Vandana Singh"], "summary": "Amgen Inc AMGN has reportedly sued Novartis AG's NVS Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several patents. Amgen said the proposed biosimilars infringe 21 patents covering Prolia and Xgeva.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/03/amgn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.13636, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.758753", "ticker_sentiment_score": "-0.34764", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?", "url": "https://www.zacks.com/stock/news/2088704/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe", "time_published": "20230503T102007", "authors": ["Zacks Investment Research"], "summary": "Sector ETF report for ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default65.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.18305, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.130571", "ticker_sentiment_score": "0.07042", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.194763", "ticker_sentiment_score": "0.124689", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.130571", "ticker_sentiment_score": "0.07042", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.130571", "ticker_sentiment_score": "0.07042", "ticker_sentiment_label": "Neutral"}]}, {"title": "An investment chief who manages $1 billion in assets shares 10 investments that will reduce your portfolio's volatility while this bear market lasts longer than expected.", "url": "https://www.businessinsider.com/how-to-invest-q1-earnings-bear-stock-market-recession-risk-2023-5", "time_published": "20230503T100000", "authors": ["James Faris"], "summary": "10 Ways to Invest As Earnings Fall in a Bear Market: Landsberg - Business Insider ...", "banner_image": null, "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "www.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.977154"}, {"topic": "Earnings", "relevance_score": "0.999855"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.019808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IBKR", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.05179", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.044141", "ticker_sentiment_score": "-0.008", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDNDF", "relevance_score": "0.044141", "ticker_sentiment_score": "0.182204", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYK", "relevance_score": "0.088147", "ticker_sentiment_score": "0.159342", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JPM", "relevance_score": "0.044141", "ticker_sentiment_score": "0.167492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVO", "relevance_score": "0.088147", "ticker_sentiment_score": "0.104463", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.088147", "ticker_sentiment_score": "0.104463", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.088147", "ticker_sentiment_score": "0.104463", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEE", "relevance_score": "0.088147", "ticker_sentiment_score": "0.271074", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development", "url": "https://www.benzinga.com/pressreleases/23/05/g32180034/vaccentis-appoints-dr-ingrid-rauter-as-chief-medical-officer-and-head-of-research-development", "time_published": "20230503T070000", "authors": ["Globe Newswire"], "summary": "Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life science executive Ingrid Rauter as Head of R&D and Chief Medical Officer.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.270606, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.05749", "ticker_sentiment_score": "0.162041", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SDGR", "relevance_score": "0.05749", "ticker_sentiment_score": "0.162041", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Amgen sues Sandoz to block generic version of bone cancer and osteoporosis drugs | The Financial Express", "url": "https://www.financialexpress.com/healthcare/pharma-healthcare/amgen-sues-sandoz-to-block-generic-version-of-bone-cancer-and-osteoporosis-drugs/3072497/", "time_published": "20230503T063500", "authors": [], "summary": "Amgen sues Sandoz to block generic version of bone cancer and ... The Financial Express ...", "banner_image": "https://www.financialexpress.com/wp-content/uploads/2023/04/pills-rp.jpg", "source": "The Financial Express", "category_within_source": "n/a", "source_domain": "www.financialexpress.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.033979, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.401331", "ticker_sentiment_score": "-0.39275", "ticker_sentiment_label": "Bearish"}]}, {"title": "AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32170885/amgn-lawsuit-alert-levi-korsinsky-reminds-amgen-inc-investors-of-a-class-action-lawsuit-and-upcomi", "time_published": "20230502T193047", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 02, 2023 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ( \"Amgen\" or the \"Company\" ) AMGN of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": -0.034001, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.765213", "ticker_sentiment_score": "-0.154751", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pfizer  ( PFE )  Q1 Earnings Beat, COVID Jab Sales Down as Expected", "url": "https://www.zacks.com/stock/news/2088433/pfizer-pfe-q1-earnings-beat-covid-jab-sales-down-as-expected", "time_published": "20230502T175000", "authors": ["Zacks Investment Research"], "summary": "Pfizer (PFE) beats estimates for Q1 earnings and sales. Revenues from its COVID-19 vaccine, Comirnaty declined, as expected.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/89/447.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.998645"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.413559"}], "overall_sentiment_score": -0.007234, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BHVN", "relevance_score": "0.02786", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.165978", "ticker_sentiment_score": "-0.035776", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.055686", "ticker_sentiment_score": "0.080008", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.423694", "ticker_sentiment_score": "0.063717", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.055686", "ticker_sentiment_score": "-0.132036", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Incredibly Cheap Dividend Stocks to Buy in May", "url": "https://www.fool.com/investing/2023/05/02/2-incredibly-cheap-dividend-stocks-to-buy-in-may/", "time_published": "20230502T134500", "authors": ["George Budwell"], "summary": "These two dividend-paying pharma stocks both screen as significantly undervalued right now.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F730203%2Fpaper-certificate-shares-invest-stock-split-market-reverse-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}, {"topic": "Earnings", "relevance_score": "0.995921"}], "overall_sentiment_score": 0.378169, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "ICNB", "relevance_score": "0.050148", "ticker_sentiment_score": "0.111698", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.149656", "ticker_sentiment_score": "0.232116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JNJ", "relevance_score": "0.100099", "ticker_sentiment_score": "0.177057", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "AMGEN DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Amgen Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32132689/amgen-deadline-reminder-kessler-topaz-meltzer-check-llp-reminds-investors-of-amgen-inc-of-deadline", "time_published": "20230501T195600", "authors": ["Globe Newswire"], "summary": "RADNOR, Pa., May 01, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ( \"Amgen\" ) ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.009824, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.680543", "ticker_sentiment_score": "-0.177187", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business' - Coherus BioSciences  ( NASDAQ:CHRS ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32128185/analyst-sees-a-multibagger-initiates-coverage-on-this-top-notch-biosimilar-business", "time_published": "20230501T183648", "authors": ["Vandana Singh"], "summary": "Truist initiated coverage on Coherus BioSciences Inc CHRS with a Buy rating and a price target of $24. The analyst notes the company's growing biosimilar franchise with a track record of taking share in competitive markets such as Amgen Inc's AMGN Neulasta.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/01/chrs.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.220919, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.345674", "ticker_sentiment_score": "0.474661", "ticker_sentiment_label": "Bullish"}, {"ticker": "CHRS", "relevance_score": "0.498188", "ticker_sentiment_score": "0.217525", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DEADLINE ALERT for SIVB, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Alphabet  ( NASDAQ:GOOG ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32124666/deadline-alert-for-sivb-amgn-sbnysbnyp-and-googgoogl-the-law-offices-of-frank-r-cruz-reminds-inves", "time_published": "20230501T154300", "authors": ["Globe Newswire"], "summary": "LOS ANGELES, May 01, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.106245, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SBNY", "relevance_score": "0.150592", "ticker_sentiment_score": "-0.197526", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.075635", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Targeted Therapy Market Is Projected To Grow At An 8% Rate Through The Forecast Period As Per The Business Research Company's Targeted Therapy Global Market Report 2023", "url": "https://www.benzinga.com/pressreleases/23/05/g32124311/the-targeted-therapy-market-is-projected-to-grow-at-an-8-rate-through-the-forecast-period-as-per-t", "time_published": "20230501T153000", "authors": ["Globe Newswire"], "summary": "LONDON, May 01, 2023 ( GLOBE NEWSWIRE ) -- The Business Research Company's research on the targeted therapy market forecasts that the market is expected to expand from $97.3 billion in 2022 to $106.7 billion in 2023, at a compound annual growth rate ( CAGR ) of more than 9%.The targeted therapy ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.055098, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVS", "relevance_score": "0.066047", "ticker_sentiment_score": "0.143315", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.066047", "ticker_sentiment_score": "0.087133", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.066047", "ticker_sentiment_score": "0.087133", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.066047", "ticker_sentiment_score": "0.087133", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.066047", "ticker_sentiment_score": "0.087133", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top Dividend Stocks to Maximize Your Retirement Income", "url": "https://www.zacks.com/stock/news/2087394/3-top-dividend-stocks-to-maximize-your-retirement-income", "time_published": "20230501T131004", "authors": ["Zacks Investment Research"], "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default344.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.222674, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAG", "relevance_score": "0.215415", "ticker_sentiment_score": "0.071809", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.215415", "ticker_sentiment_score": "0.119475", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.054483", "ticker_sentiment_score": "0.044028", "ticker_sentiment_label": "Neutral"}]}, {"title": "Galera Expands Commercial Leadership Team", "url": "https://www.globenewswire.com/news-release/2023/05/01/2658164/0/en/Galera-Expands-Commercial-Leadership-Team.html", "time_published": "20230501T110000", "authors": ["Galera Therapeutics"], "summary": "Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/d4232a7c-0097-427f-af68-18288ab26fa6", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.214378"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.055384, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ARWR", "relevance_score": "0.019193", "ticker_sentiment_score": "0.047241", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADPT", "relevance_score": "0.019193", "ticker_sentiment_score": "0.047241", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTTX", "relevance_score": "0.038376", "ticker_sentiment_score": "0.052198", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.057536", "ticker_sentiment_score": "0.069003", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTX", "relevance_score": "0.057536", "ticker_sentiment_score": "-0.025054", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.057536", "ticker_sentiment_score": "0.058", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.019193", "ticker_sentiment_score": "-0.011309", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.019193", "ticker_sentiment_score": "0.104429", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:UZS", "relevance_score": "0.019193", "ticker_sentiment_score": "-0.000931", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN INC.  ( NASDAQ: AMGN )  SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen Inc.  ( NASDAQ: AMGN )  - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/05/g32107516/amgen-inc-nasdaq-amgn-shareholder-class-action-alert-bernstein-liebhard-llp-reminds-investors-of-t", "time_published": "20230501T054500", "authors": ["Globe Newswire"], "summary": "Did you lose money on investments in Amgen Inc.? If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at ( 212 ) 951-2030 or pallocco@bernlieb.com to discuss your rights.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990893"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.038472, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.765818", "ticker_sentiment_score": "-0.035858", "ticker_sentiment_label": "Neutral"}]}, {"title": "StockNews.com Upgrades Amgen  ( NASDAQ:AMGN )  to \"Strong-Buy\"", "url": "https://www.defenseworld.net/2023/04/30/stocknews-com-upgrades-amgen-nasdaqamgn-to-strong-buy.html", "time_published": "20230430T054447", "authors": ["Defense World Staff"], "summary": "Amgen ( NASDAQ:AMGN - Get Rating ) was upgraded by analysts at StockNews.com from a \"buy\" rating to a \"strong-buy\" rating in a research report issued to clients and investors on Friday.", "banner_image": "https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&Symbol=AMGN", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.248066, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TFC", "relevance_score": "0.061315", "ticker_sentiment_score": "0.060017", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.876064", "ticker_sentiment_score": "0.418294", "ticker_sentiment_label": "Bullish"}]}, {"title": "ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g32100545/rosen-national-investor-counsel-encourages-amgen-inc-investors-to-secure-counsel-before-important-", "time_published": "20230429T200300", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 29, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. AMGN between July 29, 2020 and April 27, 2022, both dates inclusive ( the \"Class Period\" ) , of the important May 12, 2023.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.095889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.499254", "ticker_sentiment_score": "-0.045242", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.059636", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm - DraftKings  ( NASDAQ:DKNG ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g32098394/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-draft", "time_published": "20230429T010000", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 28, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DraftKings Inc. DKNG, SVB Financial Group SIVPQ SIVBQ ) ) ) , and Amgen Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}], "overall_sentiment_score": -0.196718, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.229604", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.770749", "ticker_sentiment_score": "-0.18134", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "DEADLINE ALERT for AMGN, SBNY, GOOG, NSC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - Alphabet  ( NASDAQ:GOOG ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g32097589/deadline-alert-for-amgn-sbny-goog-nsc-law-offices-of-howard-g-smith-reminds-investors-of-class-act", "time_published": "20230428T225319", "authors": ["Globe Newswire"], "summary": "BENSALEM, Pa., April 28, 2023 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.039252, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.035875", "ticker_sentiment_score": "0.080658", "ticker_sentiment_label": "Neutral"}, {"ticker": "SITS", "relevance_score": "0.035875", "ticker_sentiment_score": "0.004984", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBNY", "relevance_score": "0.071677", "ticker_sentiment_score": "-0.087323", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.314374", "ticker_sentiment_score": "-0.104683", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.177933", "ticker_sentiment_score": "0.051374", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSC", "relevance_score": "0.247119", "ticker_sentiment_score": "0.008062", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g32097480/amgn-lawsuit-alert-levi-korsinsky-reminds-amgen-inc-investors-of-a-class-action-lawsuit-and-upcomi", "time_published": "20230428T223452", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 28, 2023 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ( \"Amgen\" or the \"Company\" ) AMGN of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}], "overall_sentiment_score": -0.034001, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.765213", "ticker_sentiment_score": "-0.154751", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Amgen  ( AMGN )  Q1 Earnings Beat Estimates, 2023 View Raised", "url": "https://www.zacks.com/stock/news/2087027/amgen-amgn-q1-earnings-beat-estimates-2023-view-raised", "time_published": "20230428T155200", "authors": ["Zacks Investment Research"], "summary": "Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.079321, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.050148", "ticker_sentiment_score": "0.050873", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.428632", "ticker_sentiment_score": "0.286631", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZN", "relevance_score": "0.124939", "ticker_sentiment_score": "0.284938", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HZNP", "relevance_score": "0.075161", "ticker_sentiment_score": "0.154439", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Amgen  ( AMGN )  Shares Are Trading Lower Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/general/biotech/23/04/32080092/why-amgen-shares-are-trading-lower-today", "time_published": "20230428T125841", "authors": ["Vandana Singh"], "summary": "Amgen Inc AMGN reported Q1 FY23 sales of $6.11 billion, down 2% Y/Y, resulting from lower revenue from COVID-19 manufacturing collaboration, partially offset by a 2% increase in product sales. The consensus estimate stood at $6.17 billion.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/28/amgn.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.169633, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.757528", "ticker_sentiment_score": "-0.015734", "ticker_sentiment_label": "Neutral"}]}, {"title": "Government Drug Price Curbs Could Sound A Death Knell For Industry", "url": "https://www.investors.com/news/technology/biotech-stocks-brace-for-the-worst-as-government-drug-price-negotiations-loom/", "time_published": "20230428T120000", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "Biotech Stocks Brace For The Worst As Government Drug Price ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2022/09/Stock-humira-01-shutt.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.839681"}, {"topic": "Earnings", "relevance_score": "0.684621"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.024097, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NVO", "relevance_score": "0.040668", "ticker_sentiment_score": "-0.11222", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.027118", "ticker_sentiment_score": "0.044929", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.055277", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.076847", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.08123", "ticker_sentiment_score": "-0.011317", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.027118", "ticker_sentiment_score": "0.044929", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSSMY", "relevance_score": "0.013561", "ticker_sentiment_score": "0.077066", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.027118", "ticker_sentiment_score": "-0.076847", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVT", "relevance_score": "0.027118", "ticker_sentiment_score": "0.05187", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.067727", "ticker_sentiment_score": "-0.061364", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCO", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0266", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.027118", "ticker_sentiment_score": "0.052088", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.040668", "ticker_sentiment_score": "-0.064288", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.067727", "ticker_sentiment_score": "0.005039", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.027118", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.054205", "ticker_sentiment_score": "-0.077946", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen  ( AMGN )  Q1 Earnings Beat Estimates", "url": "https://www.zacks.com/stock/news/2086418/amgen-amgn-q1-earnings-beat-estimates", "time_published": "20230427T213514", "authors": ["Zacks Investment Research"], "summary": "Amgen (AMGN) delivered earnings and revenue surprises of 3.65% and 0.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.144118, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.406745", "ticker_sentiment_score": "0.120744", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVAX", "relevance_score": "0.14131", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Futures: Amazon Erases Gains On Cloud Fears; These Techs Dive", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-amazon-continues-earnings-surge-for-tech-titans-but-cloudflare-snap-plunge/", "time_published": "20230427T213200", "authors": ["ED CARSON", "Investor's Business Daily"], "summary": "Futures: Amazon Jumps On Earnings, But These Techs Plunge Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/07/stock-bull-charge-02-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.096773, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AYX", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ENPH", "relevance_score": "0.046184", "ticker_sentiment_score": "0.067013", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.023102", "ticker_sentiment_score": "0.217449", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.092213", "ticker_sentiment_score": "0.039533", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAPL", "relevance_score": "0.069227", "ticker_sentiment_score": "0.198088", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVX", "relevance_score": "0.069227", "ticker_sentiment_score": "0.079631", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.115121", "ticker_sentiment_score": "0.019396", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.023102", "ticker_sentiment_score": "0.042606", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MSFT", "relevance_score": "0.137934", "ticker_sentiment_score": "0.186854", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FSLR", "relevance_score": "0.137934", "ticker_sentiment_score": "0.003946", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PI", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.102237", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PINS", "relevance_score": "0.046184", "ticker_sentiment_score": "-0.156323", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NET", "relevance_score": "0.137934", "ticker_sentiment_score": "-0.109802", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.227859", "ticker_sentiment_score": "0.093466", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.183198", "ticker_sentiment_score": "-0.001522", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS", "url": "https://investingnews.com/amgen-reports-first-quarter-financial-results/", "time_published": "20230427T204313", "authors": [], "summary": "Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.121049, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.015675", "ticker_sentiment_score": "0.193262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNBWY", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.031343", "ticker_sentiment_score": "0.109564", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRVB", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.093836", "ticker_sentiment_score": "0.044844", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS", "url": "https://investingnews.com/amgen-reports-first-quarter-financial-results-2659922399/", "time_published": "20230427T204313", "authors": [], "summary": "Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg", "source": "Investing News Network", "category_within_source": "n/a", "source_domain": "investingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.121049, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.015675", "ticker_sentiment_score": "0.193262", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNBWY", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.031343", "ticker_sentiment_score": "0.109564", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRVB", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XNCR", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.093836", "ticker_sentiment_score": "0.044844", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYKOF", "relevance_score": "0.015675", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Gilead Posts Bullish Cancer Drug Sales, But Profit Questions Linger", "url": "https://www.investors.com/news/technology/gild-stock-gilead-earnings-amgen-stock-amgen-earnings-q1-2023/", "time_published": "20230427T201700", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "GILD Stock: Cancer Treatments Surge, But Profit Questions Linger Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-Gilead-07-adobe.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.989041"}], "overall_sentiment_score": -0.026446, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.398781", "ticker_sentiment_score": "-0.230628", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.469457", "ticker_sentiment_score": "-0.124062", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen 1st quarter profit falls as costs rise, sales up 2%", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-1st-quarter-profit-falls-costs-rise-sales-flatten-2023-04-27/", "time_published": "20230427T201211", "authors": ["Deena Beasley"], "summary": "Amgen 1st quarter profit falls as costs rise, sales flatten ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/6AGSR6G2LRKJFO5RCDBMUZ4HPU.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.94762"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.026455, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.089129", "ticker_sentiment_score": "0.017019", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.089129", "ticker_sentiment_score": "0.046439", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS", "url": "https://www.prnewswire.com/news-releases/amgen-reports-first-quarter-financial-results-301810090.html", "time_published": "20230427T200100", "authors": ["Amgen"], "summary": "THOUSAND OAKS, Calif., April 27, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.", "banner_image": "https://mma.prnewswire.com/media/152881/amgen_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.088516, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.006681", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.006681", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.006681", "ticker_sentiment_score": "0.182426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REGN", "relevance_score": "0.006681", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.013361", "ticker_sentiment_score": "0.05887", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.013361", "ticker_sentiment_score": "0.099235", "ticker_sentiment_label": "Neutral"}]}, {"title": "Check Out What Whales Are Doing With AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/markets/options/23/04/32057580/check-out-what-whales-are-doing-with-amgn", "time_published": "20230427T191607", "authors": ["Benzinga Insights"], "summary": "Someone with a lot of money to spend has taken a bullish stance on Amgen AMGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.205205, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.784481", "ticker_sentiment_score": "0.343713", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.109455", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie  ( ABBV )  Q1 Earnings Beat, Skyrizi Sales Underperform", "url": "https://www.zacks.com/stock/news/2086355/abbvie-abbv-q1-earnings-beat-skyrizi-sales-underperform", "time_published": "20230427T163300", "authors": ["Zacks Investment Research"], "summary": "AbbVie's (ABBV) first-quarter 2023 earnings and sales beat estimates. However, share price dives as some key drugs miss sales estimates.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/36/1919.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.085916, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.290361", "ticker_sentiment_score": "0.181809", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.16849", "ticker_sentiment_score": "0.078911", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.042421", "ticker_sentiment_score": "0.055312", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.042421", "ticker_sentiment_score": "0.055312", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.084722", "ticker_sentiment_score": "0.13344", "ticker_sentiment_label": "Neutral"}]}, {"title": "AbbVie's weak newer drug sales fan worries as Humira faces rivals", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-raises-annual-profit-forecast-humira-demand-holds-steady-2023-04-27/", "time_published": "20230427T125800", "authors": ["Reuters"], "summary": "April 27 ( Reuters ) - AbbVie Inc ( ABBV.N ) on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker's attempts to cushion the blow to sales from blockbuster Humira losing patent exclusivity.", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/VXP5FAFIRJOTZKPPV4FFRKSXYA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Earnings", "relevance_score": "0.875462"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.057619, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.110973", "ticker_sentiment_score": "0.064642", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.514619", "ticker_sentiment_score": "0.140816", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly's Obesity Treatment Hopeful Just Crushed Sales Estimates", "url": "https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q1-2023/", "time_published": "20230427T125700", "authors": ["ALLISON GATLIN", "Investor's Business Daily"], "summary": "Eli Lilly Stock Jumps As Diabetes Newcomer Crushes Sales ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2018/12/stock-Eli-Lilly-02-Shutter.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}], "overall_sentiment_score": 0.296207, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.937588", "ticker_sentiment_score": "0.553125", "ticker_sentiment_label": "Bullish"}, {"ticker": "VKTX", "relevance_score": "0.290607", "ticker_sentiment_score": "0.104201", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.290607", "ticker_sentiment_score": "0.104201", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.147818", "ticker_sentiment_score": "-0.008306", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why US Stocks Are Poised To Open Higher Thursday - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ", "url": "https://www.benzinga.com/news/earnings/23/04/32041361/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-card", "time_published": "20230427T110448", "authors": ["Shanthi Rexaline"], "summary": "Tech earnings could come to the market's rescue on Thursday, with all major index futures currently trading higher. Traders could also weigh in on the first-quarter GDP report to take stock of how the economy fared amid a housing market downturn, banking crisis, and rising rate environment.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/27/shutterstock_1321462400.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.045987, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MAT", "relevance_score": "0.092927", "ticker_sentiment_score": "-0.082361", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.184598", "ticker_sentiment_score": "-0.077057", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.046543", "ticker_sentiment_score": "0.22746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSFT", "relevance_score": "0.092927", "ticker_sentiment_score": "-0.045771", "ticker_sentiment_label": "Neutral"}, {"ticker": "MA", "relevance_score": "0.046543", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNO", "relevance_score": "0.092927", "ticker_sentiment_score": "-0.207512", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LLY", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COF", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLAC", "relevance_score": "0.092927", "ticker_sentiment_score": "-0.082361", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.184598", "ticker_sentiment_score": "0.081253", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAL", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNAP", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CP", "relevance_score": "0.092927", "ticker_sentiment_score": "-0.082361", "ticker_sentiment_label": "Neutral"}, {"ticker": "BZH", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.184598", "ticker_sentiment_score": "-0.077057", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAT", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WOLF", "relevance_score": "0.092927", "ticker_sentiment_score": "-0.262484", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CCZ", "relevance_score": "0.046543", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAS", "relevance_score": "0.046543", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.092927", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN ALERT: The Klein Law Firm Reminds Investors of a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g32018218/amgn-alert-the-klein-law-firm-reminds-investors-of-a-lead-plaintiff-deadline-of-may-12-2023-in-the", "time_published": "20230426T181641", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 26, 2023 ( GLOBE NEWSWIRE ) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. AMGN alleging that the Company violated federal securities laws.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": -0.038918, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.833329", "ticker_sentiment_score": "-0.091066", "ticker_sentiment_label": "Neutral"}]}, {"title": "If You Invested $100 In This Stock 15 Years Ago, You Would Have $600 Today - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/news/earnings/23/04/32015814/if-you-invested-100-in-this-stock-15-years-ago-you-would-have-600-today", "time_published": "20230426T163020", "authors": ["Benzinga Insights"], "summary": "Amgen AMGN has outperformed the market over the past 15 years by 4.78% on an annualized basis producing an average annual return of 12.1%. Currently, Amgen has a market capitalization of $128.19 billion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.983605", "ticker_sentiment_score": "0.387251", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now", "url": "https://www.zacks.com/stock/news/2084801/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now", "time_published": "20230426T125006", "authors": ["Zacks Investment Research"], "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999326"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}], "overall_sentiment_score": 0.344058, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.390904", "ticker_sentiment_score": "0.463929", "ticker_sentiment_label": "Bullish"}, {"ticker": "VTRS", "relevance_score": "0.329992", "ticker_sentiment_score": "0.401637", "ticker_sentiment_label": "Bullish"}]}, {"title": "ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31997354/rosen-a-global-and-leading-law-firm-encourages-amgen-inc-investors-to-secure-counsel-before-import", "time_published": "20230425T191500", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 25, 2023 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. AMGN between July 29, 2020 and April 27, 2022, both dates inclusive ( the \"Class Period\" ) , of the important May 12, 2023.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.091058, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.495015", "ticker_sentiment_score": "-0.04827", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.059049", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday", "url": "https://www.fool.com/investing/2023/04/25/why-shares-of-arrowhead-pharmaceuticals-are-up-tue/", "time_published": "20230425T152036", "authors": ["Jim Halley"], "summary": "The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F729185%2Fstack-of-one-hundred-dollar-bills-cash-money-invest-retire-getty.jpg&op=resize&h=340", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.085631, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.116348", "ticker_sentiment_score": "0.133218", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.230235", "ticker_sentiment_score": "0.1535", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TAK", "relevance_score": "0.116348", "ticker_sentiment_score": "0.025961", "ticker_sentiment_label": "Neutral"}]}, {"title": "DEADLINE ALERT for SIVBQ, AMGN, SBNY, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Alphabet  ( NASDAQ:GOOG ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31991941/deadline-alert-for-sivbq-amgn-sbny-and-googgoogl-the-law-offices-of-frank-r-cruz-reminds-investors", "time_published": "20230425T151500", "authors": ["Globe Newswire"], "summary": "LOS ANGELES, April 25, 2023 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.108668, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SBNY", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.215793", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMGN", "relevance_score": "0.075874", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.075874", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance", "url": "https://www.globenewswire.com/news-release/2023/04/25/2653492/0/en/Novartis-delivers-strong-sales-growth-robust-margin-expansion-and-major-innovation-milestones-Raises-FY-guidance.html", "time_published": "20230425T050000", "authors": ["Novartis Pharma AG"], "summary": "Ad hoc announcement pursuant to Art. 53 LR ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/5d242013-5d1f-440c-8ba6-3b5d3799b035", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.992549"}], "overall_sentiment_score": 0.254524, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCO", "relevance_score": "0.015512", "ticker_sentiment_score": "0.094236", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.015512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.015512", "ticker_sentiment_score": "0.094236", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABBV", "relevance_score": "0.015512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCYC", "relevance_score": "0.015512", "ticker_sentiment_score": "0.006259", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.015512", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Will Humana's  ( HUM )  Q1 Earnings Beat on Insurance Unit Strength?", "url": "https://www.zacks.com/stock/news/2083626/will-humanas-hum-q1-earnings-beat-on-insurance-unit-strength", "time_published": "20230424T165800", "authors": ["Zacks Investment Research"], "summary": "Humana's (HUM) first-quarter results are likely to reflect surging premiums and investment income.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/55/1345.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.239209, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BIO", "relevance_score": "0.149346", "ticker_sentiment_score": "0.034626", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUM", "relevance_score": "0.384397", "ticker_sentiment_score": "0.282687", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.149346", "ticker_sentiment_score": "0.044102", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.149346", "ticker_sentiment_score": "0.078296", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can Rising Expenses Hurt Teladoc Health's  ( TDOC )  Q1 Earnings?", "url": "https://www.zacks.com/stock/news/2083617/can-rising-expenses-hurt-teladoc-healths-tdoc-q1-earnings", "time_published": "20230424T164700", "authors": ["Zacks Investment Research"], "summary": "Teladoc Health's (TDOC) first-quarter results are likely to reflect growth in Access Fees revenues and total visits.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6c/1876.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.105826, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BIO", "relevance_score": "0.13873", "ticker_sentiment_score": "0.033176", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDOC", "relevance_score": "0.399911", "ticker_sentiment_score": "0.228364", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.13873", "ticker_sentiment_score": "0.042294", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.13873", "ticker_sentiment_score": "0.075084", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.046452", "ticker_sentiment_score": "-0.033009", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bristol-Myers  ( BMY )  to Report Q1 Earnings: What+'s in Store?", "url": "https://www.zacks.com/stock/news/2083607/bristol-myers-bmy-to-report-q1-earnings-what-s-in-store", "time_published": "20230424T155700", "authors": ["Zacks Investment Research"], "summary": "Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b7/2106.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.148123, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.151858", "ticker_sentiment_score": "0.076523", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.151858", "ticker_sentiment_score": "0.06884", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.250386", "ticker_sentiment_score": "0.209747", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SNY", "relevance_score": "0.151858", "ticker_sentiment_score": "-0.0026", "ticker_sentiment_label": "Neutral"}]}, {"title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31961579/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-amgen-inc-amgn", "time_published": "20230424T155225", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 24, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ( \"Amgen\" or the \"Company\" ) AMGN. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.012133, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.658003", "ticker_sentiment_score": "-0.100244", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can Amgen  ( AMGN )  Keep the Earnings Streak Alive in Q1?", "url": "https://www.zacks.com/stock/news/2083497/can-amgen-amgn-keep-the-earnings-streak-alive-in-q1", "time_published": "20230424T145100", "authors": ["Zacks Investment Research"], "summary": "Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f4/2111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99915"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.055517, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABBV", "relevance_score": "0.095327", "ticker_sentiment_score": "0.179044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.598151", "ticker_sentiment_score": "0.506365", "ticker_sentiment_label": "Bullish"}, {"ticker": "AZN", "relevance_score": "0.280615", "ticker_sentiment_score": "0.378027", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVO", "relevance_score": "0.189298", "ticker_sentiment_score": "0.034599", "ticker_sentiment_label": "Neutral"}]}, {"title": "Eli Lilly  ( LLY )  to Report Q1 Earnings: Will It Beat Estimates?", "url": "https://www.zacks.com/stock/news/2083494/eli-lilly-lly-to-report-q1-earnings-will-it-beat-estimates", "time_published": "20230424T144000", "authors": ["Zacks Investment Research"], "summary": "Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999937"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.094861, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.315397", "ticker_sentiment_score": "0.060391", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.183546", "ticker_sentiment_score": "-0.02216", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.183546", "ticker_sentiment_score": "-0.002948", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.228287", "ticker_sentiment_score": "-0.00174", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income", "url": "https://www.zacks.com/stock/news/2083316/3-top-ranked-dividend-stocks-a-smarter-way-to-boost-your-retirement-income", "time_published": "20230424T131004", "authors": ["Zacks Investment Research"], "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default66.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.221435, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.215894", "ticker_sentiment_score": "0.119684", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.054607", "ticker_sentiment_score": "-0.036005", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSCO", "relevance_score": "0.215894", "ticker_sentiment_score": "0.121325", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates", "url": "https://www.zacks.com/stock/news/2083259/4-pharma-biotech-stocks-poised-to-beat-q1-earnings-estimates", "time_published": "20230424T123800", "authors": ["Zacks Investment Research"], "summary": "We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default175.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.178822, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ACAD", "relevance_score": "0.222022", "ticker_sentiment_score": "-0.046605", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.306963", "ticker_sentiment_score": "0.190761", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.348103", "ticker_sentiment_score": "0.075985", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.134339", "ticker_sentiment_score": "-0.001252", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.222022", "ticker_sentiment_score": "0.025583", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN Announcement: Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Amgen Inc. - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31950336/amgn-announcement-kessler-topaz-meltzer-check-llp-announces-investor-securities-fraud-class-action", "time_published": "20230424T022100", "authors": ["Globe Newswire"], "summary": "RADNOR, Pa., April 23, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ( \"Amgen\" ) ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": 0.009824, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.680543", "ticker_sentiment_score": "-0.177187", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm - Signature Bank  ( OTC:SBNY ) , Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31950236/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-svb-a", "time_published": "20230424T010000", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 23, 2023 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SVB Financial Group SIVPQ SIVBQ ) ) ) , Amgen Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.198406, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "SBNY", "relevance_score": "0.175221", "ticker_sentiment_score": "-0.143863", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.754911", "ticker_sentiment_score": "-0.179853", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Cancer Immunotherapy Market Size Worth USD 388.25 Billion in 2030 - Emergen Research", "url": "https://markets.businessinsider.com/news/stocks/cancer-immunotherapy-market-size-worth-usd-388-25-billion-in-2030-%E2%80%93-emergen-research-1032251605", "time_published": "20230423T132200", "authors": [], "summary": "The global Cancer Immunotherapy Market size was USD 119.39 Billion in 2021 and is expected to register a revenue CAGR of 14.0% during the forecast period, according to latest analysis by Emergen Research Cancer immunotherapy, also known as immuno-oncology, is a fast expanding specialty in cancer ...", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.929393"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.174698, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.034282", "ticker_sentiment_score": "-0.109525", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAYZF", "relevance_score": "0.034282", "ticker_sentiment_score": "-0.109525", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.034282", "ticker_sentiment_score": "-0.109525", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.034282", "ticker_sentiment_score": "-0.109525", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.034282", "ticker_sentiment_score": "-0.109525", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.034282", "ticker_sentiment_score": "-0.109525", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.034282", "ticker_sentiment_score": "-0.109525", "ticker_sentiment_label": "Neutral"}]}, {"title": "Amgen Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit", "url": "https://markets.businessinsider.com/news/stocks/amgen-investor-reminder-kessler-topaz-meltzer-check-llp-reminds-amgen-inc.-shareholders-of-deadline-in-securities-fraud-class-action-lawsuit-1032251075", "time_published": "20230422T140600", "authors": [], "summary": "Radnor, Pennsylvania-- ( Newsfile Corp. - April 22, 2023 ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed against Amgen Inc. ( \"Amgen\" ) ( NASDAQ: AMGN ) .", "banner_image": "https://api.newsfilecorp.com/newsinfo/163294/208", "source": "Business Insider", "category_within_source": "RSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.007395, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.741276", "ticker_sentiment_score": "-0.214139", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Will HIV and Oncology Propel Gilead's  ( GILD )  Q1 Earnings?", "url": "https://www.zacks.com/stock/news/2082974/will-hiv-and-oncology-propel-gileads-gild-q1-earnings", "time_published": "20230421T165500", "authors": ["Zacks Investment Research"], "summary": "Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default199.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999965"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.112432, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GILD", "relevance_score": "0.267315", "ticker_sentiment_score": "0.203694", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMGN", "relevance_score": "0.135602", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVO", "relevance_score": "0.135602", "ticker_sentiment_score": "0.060969", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.135602", "ticker_sentiment_score": "-0.002433", "ticker_sentiment_label": "Neutral"}]}, {"title": "CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023 - Amgen  ( NASDAQ:AMGN ) ", "url": "https://www.benzinga.com/pressreleases/23/04/g31937601/class-action-alert-the-law-offices-of-vincent-wong-remind-amgen-investors-of-a-lead-plaintiff-dead", "time_published": "20230421T152147", "authors": ["Globe Newswire"], "summary": "NEW YORK, April 21, 2023 ( GLOBE NEWSWIRE ) -- Attention Amgen Inc. ( \"Amgen\" ) AMGN shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.77141"}], "overall_sentiment_score": -0.15951, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.879272", "ticker_sentiment_score": "-0.242665", "ticker_sentiment_label": "Somewhat-Bearish"}]}]}